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Previous literature showed contradictory evidence on the subject of predictors 
of chemotherapy-induced Palmar Plantar Erythrodysesthesia (PPE). While 
there is evidence to suggest that dose and schedule of the drugs play a large 
role, the fact that many still go on to develop severe PPE following dose 
reduction would indicate that there are other factors involved. Since the 
incidence of PPE is more prevalent during the first three cycles of treatment 
this would also indicate that there are factors other than a cumulative effect. 
The contradictory evidence in the literature relates to biographical factors, 
performance status, co-morbidities and renal function. There is a lack of 
empirical evidence to support the theory that PPE is caused by damage to the 
microcapillaries due to everyday activities that cause friction or pressure to 
the hands or feet.  
 
Purpose 
The aim of this exploratory study was to identify pre-treatment risk factors for 
the development of PPE prior to cycle four.  
 
Patients and methods 
The study was made up of two phases, a retrospective phase and a 
prospective phase, using mixed strategies to collect data. Thus providing two 
independent samples to compare and validate or refute results. 
Phase I 
A retrospective notes review of patients who had received Infusional 5FU or 
capecitabine containing regimes over a 1 year period (n=392).  
Phase II 
Prospective data collection from participants receiving capecitabine 
monotherapy (n = 125). Data was collected during semi-structured interviews, 
from participant’s diaries, physical examination of the hands and feet and 
notes review. Data relating to activities that cause friction, pressure or heat 





Data from both samples were analysed independently using bivariate (chi-
square and t-test) tests where each independent variable was analysed 
against PPE. The variables which achieved statistical significance were 
entered into a multivariate (binary logistic regression) model. The multivariate 
analysis employed a specific modelling algorithm using a relaxed alpha value 
applied to various entry methods to produce multiple models. The outcomes 
from these models were entered into a ROC curve test to establish which 




The bivariate analysis demonstrated that those at most risk of developing 
PPE prior to cycle 4 of capecitabine monotherapy were males with non-
metastatic colorectal cancer, who had either developed PPE with previous 
chemotherapy regimes or not had previous chemotherapy and who started 
their treatment during the winter months. 
When variables were combined in a multivariate logistic regression model, 
those that were associated with an increased risk of PPE were male, no 
metastatic spread, no inflammatory condition as co morbidity, smoked, did not 
drink, had weight loss prior to treatment, a low/normal pre treatment ALP level 
and started their treatment during the winter. 
 
Phase II 
The bivariate analysis demonstrated that those at most risk of developing 
PPE prior to cycle 4 of capecitabine monotherapy were those with no 
metastatic disease, had an inflammatory condition as co morbidity, were 
receiving capecitabine as adjuvant treatment, had a good performance status 
(0-1) and had a tendency to have warm hands. 
When variables were combined in a multivariate logistic regression model, 
those that were associated with an increased risk of PPE were younger (< 65) 
had no metastatic disease, an inflammatory condition as co morbidity, drank 




radiotherapy, were overweight or obese, had a pre treatment creatinine 
clearance of 30-50mls/min and had a tendency to have warm hands. 
 
Conclusions 
Similarly to the literature, contradictory findings were seen between the two 
samples within this study. There was only one variable that was associated 
with the development of PPE prior to cycle 4, which was the absence of 
metastatic disease. Limitations of retrospective data may explain variation in 
some variables which may have been underreported; however it is likely that it 
is not possible to identify specific factors that increase the risk of PPE.  
This is the first study to have collected and analysed data related to friction, 
pressure and heat causing activities. These activities have been suggested as 
increasing the risk of developing PPE and form the basis of patient education 
to avoid these activities. Data from this study indicates that only a tendency to 
have warm hands is associated with an increased risk of PPE. Whilst this 
finding would need validating in larger studies, it is a unique contribution to the 
body of knowledge of PPE. This finding indicates that avoidance of activities 
that cause friction and pressure has no evidence base. Patients may therefore 
be avoiding activities that add to their enjoyment which at this stressful time in 
their lives may add to any psychological distress.  
Despite limitations of this study, the importance of the findings presented here 
lie in its usefulness in shaping future research to investigate identified 
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GLOSSARY OF TERMS 
ABCB1 gene The membrane-associated protein encoded by this 
gene is a member of the super family of ATP-binding 
cassette (ABC) transporters. ABC proteins transport 
various molecules across extra- and intra-cellular 
membranes. This protein is a member of the 
MDR/TAP subfamily. Members of the MDR/TAP 
subfamily are involved in multidrug resistance.  
Acral Acral distribution of a dermatosis means it affects 
distal portions of limbs (hand, foot) and head (ears, 
nose) 
Acrodynia Scaly dermatitis due to vitamin B6 deficiency in rats 
Actinic Keratosis Small rough areas on skin exposed to the sun, 





Adjuvant Additional cancer treatment given after the primary 
treatment to lower the risk that the cancer will come 
back. Adjuvant therapy may include chemotherapy, 
radiation therapy, hormone therapy, targeted therapy, 
or biological therapy. 
Alanine 
aminotransferase 
Blood test to detect or monitor liver disease 
Albumin The main protein of plasma. Its main function is to 
regulate osmotic pressure. Also binds cations 
(Calcium, sodium and potassium), bilirubin, drugs and 
hormones. Normal level 35-55g/L 
α-fluoro-β-alanine Major catabolite of 5-FU 
Alkaline 
phosphatase 
An enzyme in the cells lining the biliary ducts of the 
liver. ALP levels in plasma will rise with large bile duct 
obstruction, and diseases of the liver. ALP is also 
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present in bone, so it is higher in patients with bone 
metastases. 
Allopurinol A purine analog. The primary use of allopurinol is to 
treat hyperuricemia and its complications such as 
chronic gout. Also commonly used in chemotherapy 
treatments to both reduce side effects (some regimes 
can rapidly produce tumour lysis syndrome of which 
severe hyperuricemia is a feature) and to increase 
their effectiveness (allopurinol inhibits the breakdown 
of mercaptopurine, therefore increasing its effect).  
alpha level of 
significance 
Risk of type I error (falsely rejecting a Ho when it is in 
fact true) recorded in findings as p value. (A type II 
error, also known as a false negative, occurs when 
the test fails to reject a false null hypothesis. 




A reaction that occurs when an antigen combines 
with a corresponding antibody to produce an immune 
complex. 
Angiogenic Induction of blood vessel growth 
Anthracycline A type of antibiotic that comes from certain types 
of Streptomyces bacteria. Anthracyclines are used to 
treat many types of cancer. Anthracyclines damage 
the DNA in cancer cells, causing them to die. 
daunorubicin, doxorubicin, and epirubicin are 
examples of anthracyclines. 
Antimetabolite A drug that is very similar to natural chemicals in a 
normal biochemical reaction in cells but different 
enough to interfere with the normal division and 
functions of cells. 3 groups of antimetabolites; folate 
antagonists (methotrexate, pemetrexed); purine 
antagonists (6-mercaptopurine, dacarbazine, 
fludarabine) and pyrimidine antagonists (5-FU, 




Anti-neoplastic Inhibiting or preventing the development of 
neoplasms 
Antioxidant Antioxidants are substances that may protect your 
cells against the effects of free radicals. Free radicals 
are molecules produced when your body breaks 
down food, or by environmental exposures like 
tobacco smoke and radiation. Free radicals can 
damage cells, and may play a role in heart disease, 
cancer and other diseases.  
Aquaphor A petroleum based ointment, containing mineral oils, 
ceresin and lanolin 
Autosomal recessive Autosomal recessive is one of several ways that a 
trait, disorder, or disease can be passed down 
through families.  
Bag Balm® A lanolin based cream originally used to treat cow’s 
sore udders. 
Bevacizumab Monoclonal antibody. Blocks Vascular Endothelial 
Growth Factor – anti-angiogenic 
Bilirubin Yellow pigment of bile. Produced during the 
breakdown of red blood cells. Normal values 3-17 
umol/L 
Bleomycin An anti-tumour antibiotic 
Body Mass Index Measure of body fat based on height and weight. 
Underweight < 18.5; Normal weight 18.5-24.9; 
Overweight 25-29.9; Obesity ≥ 30 
Body Surface Area Calculated surface of the human body used to 
calculate drug doses 
Brivudin Anti-viral agent to treat Herpes Zoster infection 
Bullous Blister 
Cachexia Cancer cachexia describes a syndrome of 
progressive weight loss, anorexia, and persistent 
erosion of host body cell mass in response to a 




Caelyx Liposomal encapsulated form of doxorubicin 
Capecitabine Capecitabine is a prodrug, that is enzymatically 
converted to 5-fluorouracil in the tumour, where it 
inhibits DNA synthesis and slows growth of tumour 
tissue. 
Catabolism The process involving a series of degradative 
chemical reactions that breaks down complex 
molecules into smaller units, usually releasing 
energy in the process. 
Celecoxib Non-steroidal anti-inflammatory and selective Cox-2 
inhibitor 
Cetuximab Monoclonal antibody. Epidermal growth factor 
receptor inhibitor. 
Chlorphenhydramine Anti-histamine 
Chronomodulation Delivery of chemotherapy at a time of day where the 
maximum dose can be given with the minimum 
toxicity.  
Cimetidine Histamine H2 receptor antagonist inhibits production 
of stomach acid 
Circadian rhythm A roughly-24-hour cycle in the biochemical, 
physiological or behavioural processes of living 
beings. Regular changes in mental and physical 
characteristics that occur in the course of a day 
(circadian is Latin for "around a day"). Most circadian 
rhythms are controlled by the body’s biological 
"clock." 




A formula to calculate plasma creatinine clearance 
Coefficient A number or symbol multiplied with a variable or an 
unknown quantity in an algebraic term  
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Collagen Naturally occurring protein mainly found in connective 
tissues 
Correlation Expresses the strength of a relationship in a single 
figure  
Cox-2 Isoenzyme of cyclooxygenase (Cox) enzyme 
responsible for the formation of prostanoids such as 
prostaglandins 
Cyclophosphamide Nitrogen mustard alkylating agent Intercalates with 
DNA 
Cytidine deaminase Enzyme with helps maintain the cellular pyrimidine 
pool 
Cytokine Cell signalling proteins 
Cytosine 
arabinoside 
Also known as cytarabine. Combinations of cytosine 
and arabinoside which inhibits DNA synthesis 
Cytostatic Inhibiting or suppressing cellular growth and 
multiplication 
Dactylitis A painful swelling of the hands and feet (dactylitis) in 
very young patients with Sickle Cell Disease 
Daunorubicin Anthracycline. Intercalates with DNA 
Degrees of freedom A calculation of standard deviation – calculating how 
many scores vary around the sample mean 
5’-deoxy-5-
fluorouridine 




Questionnaire to assess the quality of life of a variety 
of skin conditions 
Desquamation Peeling of skin 
Dihydropyrimidine 
dehydrogenase 
Enzyme involved in the metabolism of uracil and 
thymine.  
Diphenhydramine Anti-histamine 
Dipyramidol Inhibits thrombus formation 
Disease progression Worsening of disease over time 
Docetaxel Taxane. Antimitotic agent. 
Dorsum The back of a structure e.g. back of the hand 
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Dose intensity Refers to the interval and dose level of the 
chemotherapy regimen. When treatment intention is 
cure the aim is for the patient to receive the maximum 
tolerated dose at the recommended interval to 
achieve the best possible survival advantage. 
Doxorubicin Anthracyline antibiotic. Intercalates with DNA 
Dysesthesia Impairment of sensation, especially that of touch. 
characterized by sensations of numbness, tingling, 
burning, or pain 
Dysgeusia Taste changes 
Eccrine glands Sweat glands 
Effect size A measure of the strength of a relationship between 2 
variables 
Epirubicin Anthracyline antibiotic. Intercalates with DNA 
Erlotinib Tyrosine kinase inhibitor which acts on the epidermal 
growth factor receptor 
Erysipelas a type of skin infection usually caused by group A 
Streptococcus bacteria 
Erythrodysesthesia Tingling sensation of the palms and soles of the feet 
eta-squared  Provides an indication of the magnitude of the 
differences between the groups. Ranges from 0 to 1 
and represents the proportion of variance in the 
dependent variable that is explained by the 
independent variable 
External validity When the tools used or the findings from a study can 
be used in another setting to the one where the 
original research was carried out. Generalisability. 
Folic acid One of the vitamin B group. Works with vitamin B12 to 
form healthy red blood cells 
Focus 2 trial Oral capecitabine versus infusional 5-FU in elderly 
patients with colorectal cancer 
Folate Naturally occurring folic acid in the body. Required for 
DNA synthesis and repair  
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Fluorouracil (5-FU) Pyrimidine analogue. A suicide inhibitor and works 
through irreversible inhibition of thymidylate synthase  
G2 phase Stage of the cell cycle which lasts until the cell enters 
mitosis. Significant biosynthesis occurs during this 
phase, mainly involving the production of 
microtubules, which are required during the process 
of mitosis. Inhibition of protein synthesis during 
G2 phase prevents the cell from undergoing mitosis. 
Gemcitabine A nucleoside analog. The triphosphate analogue of 
gemcitabine replaces one of the building blocks of 
nucleic acids (cytidine), during DNA replication. 
Graft versus host 
disease 
Complication after a stem cell or bone marrow 
transplant where the newly transplanted material 
attacks the transplant recipient’s body 
Granulocyte colony 
stimulating factor 
G-CSF is a substance produced naturally by the body 
that stimulates the bone marrow to produce white 
blood cells particularly neutrophils. GCSF is given to 
try to prevent neutropenic episodes during treatment, 
and thus allowing dose intensity to be maintained in 
patients where the treatment intention is cure. 
Hazard ratio A measure of how often a particular event happens in 
one group compared to how often it happens in 
another group, over time. In cancer research, hazard 
ratios are often used in clinical trials to measure 
survival at any point in time in a group of patients who 
have been given a specific treatment compared to a 
control group given another treatment or a placebo. A 
hazard ratio of one means that there is no difference 
in survival between the two groups. A hazard ratio of 
greater than one or less than one means that survival 
was better in one of the groups. 
Henna A flowering plant used as a dye 
Hyperpigmentation Darkening of the skin or nails caused by an increased 
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production of melanin 
Hypothesis A proposed explanation of a phenomenon 
Hyperhydrosis Abnormally increased perspiration, more than what is 
normally required for the regulation of body 
temperature. 
Hyperkeratosis Thickening of the skin due to excessive accumulation 
of keratinin in the outer layers of the skin 
Ibandronic acid Bisphosphonate used to treat osteoporosis, 
hypercalcaemia or pain from bone metastases 
Inflammatory 
response 
The inflammatory response (inflammation) occurs 
when tissues are injured by bacteria, trauma, toxins, 
heat, or any other cause. The damaged cells release 
chemicals including histamine, bradykinin, and 
prostaglandins. These chemicals cause blood vessels 
to leak fluid into the tissues, causing swelling. This 
helps isolate the foreign substance from further 
contact with body tissues. 
International 
Normalised Ratio 
A test to assess the clotting ability of blood 
Inter-triginous Where 2 skin areas touch or rub together 
Irinotecan Topoisomerase inhibitor 
Isoniazid Anti tuberculis drug 
Kaposi’s Sarcoma A tumour caused by the human herpes virus but more 
commonly now caused by HIV 
Keratinocytes Skin cells which produce keratin. Keratin strengthens 
skin, hair and nails. 
Keratoderma Diffuse thickening on hands and feet and 
hyperpigmentation 
Keratolytic Thickening of the skin due to an excess accumulation 
of keratin in the outer layers of the skin 
Lac-hydrin Lactic acid based moisturising cream 
Lapatinib Tyrosine kinase inhibitor which interrupts the HER2 
growth receptor pathway 
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Lentigo Maligna Non-invasive melanoma which presents as blue/black 
in colour 
Leucovorin A reduced folic acid and used in combination with 
other chemotherapy drugs to either enhance 
effectiveness or as a chemoprotectant 
Lipophilic Having an affinity for, tending to combine with, or 
capable of dissolving in lipids. 
Melanocyte A cell in the skin that produces and contains melanin 
Metabolite Any substance produced during metabolism 
Metastases Spread of disease from one part of the body to 
another 
Methotrexate Antimetabolite. Inhibits the metabolism of folic acid 
Microtubules Important for maintaining cell structure 
Mitomycin Antitumour antibiotic 
Mitotane Antineoplastic agent usually given to treat a rare 
cancer of the adrenal glands, adrenal cortical 
carcinoma, either in its advanced stage or relapsed. 
Mucositis Inflammation of the mucosa lining the gastrointestinal 
tract commonly as a side effect of chemotherapy. 
Often used to refer to inflammation of the oral 
mucosa although the correct name is stomatitis 
Multiple Myeloma Cancer of the plasma cells of the bone marrow 
Myxoedema Hypothyroidism 
Neuritis Inflammation of the nerves 
Neurotoxic Exposure to toxic substances that cause damage to 
nerves 
Neutropenia A reduction in the number of circulating neutrophils 
often seen after chemotherapy and renders the 
patient susceptible to life-threatening infections. 
Nominal Variables coded numerically but number does not 
Have a value. Also known as categorical 
Nonagenarian Aged between 90 and 99 years of age 
Octogenarian Aged between 80 and 89 years of age 
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Ondansetron 5HT3 receptor antagonist anti-emetic 
Onycholysis  Detachment of the nail from the nail bed 
Onychomadesis Total separation of the nail plate from the nail bed 
that begins at the proximal area and then progresses 
to the free edge with the nail shedding. It may be due 
to systemic illness or drug-induced. 
Ordinal Hierarchical ranking e.g. Likert. No equal distance 
between numbers 
Overall survival A term used to describe the chances of survival from 
cancer. Often described as the 5 year survival in trials 
which is the number of people still alive 5 years after 
participating in the trial  
Oxaliplatin Platinum agent which inhibits DNA synthesis 
Paclitaxel Taxane. Mitotic inhibitor 
Palliation To relieve symptoms of a disease or disorder 
Paraneoplastic 
syndrome 
The collective signs and symptoms caused by a 
substance originating from a tumour or in reaction to 
a tumour. Paraneoplastic syndromes can be due to a 
number of causes including hormones or other 
biologically active products made by the tumour. 
Paronychia Inflammation of tissue surrounding a nail 
Parsimony Adoption of the simplest assumption in the 
formulation of a theory or in the interpretation of data, 
especially in accordance with the rule of Ockham's 
razor. (A rule in science and philosophy stating that 
entities should not be multiplied needlessly. This rule 
is interpreted to mean that the simplest of two or 
more competing theories is preferable and that an 
explanation for unknown phenomena should first be 
attempted in terms of what is already known. Also 
called law of parsimony.) 
Pathogenesis Mechanism by which a disease is caused 
Pegylation Process of covalent attachment of poly (ethylene 
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glycol) polymer chains to another molecule, normally 
a drug or therapeutic protein that can help to meet the 
challenges of improving the safety and efficiency of 
many treatments. 
Pegylated G-CSF ‘pegylated’ form of G-CSF, which means it is attached 
to a substance called polyethylene glycol. This 
increases the length of time that the G-CSF works for. 
Performance status Relative scale used to describe a patient's overall 
physical well-being, based upon his or her ability to 
do everyday tasks. Clinical trials often specify a 
minimum performance status level for entry in order 
to make sure that patients are well enough to receive 
certain chemotherapy drugs given at necessary 
dosages and Oncologists use this as a basis for their 
decisions on the appropriate type and dose of 
chemotherapy for individual patients. The scale used 




Redness particularly over the muscle mass at the 
base of the thumb on the palms of the hands 
Peripheral 
neuropathy 
Damage to the nerves of the peripheral nervous 
system 
Pharmacodynamics How the drug acts on the body 
Pharmacokinetics How the body acts on the drug 
Phase I study Earliest trials of a new drug to find the maximum 
tolerated dose and to test for side effects 
Phase II study To test efficacy of treatment and type of cancer it has 
an effect on. Finding more about side effects and how 
to manage them and more testing of the best dose 
Phase III study Compare a new treatment with standard treatment, or 
different doses or a new way of giving a standard 
treatment 
Predictive values The positive predictive value is the proportion of 
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subjects with PPE correctly diagnosed. 
The negative predictive values is the proportion of 
subjects without PPE who are correctly diagnosed 
Proliferation Cell growth including cell development and cell 
division 
Protein synthesis A process whereby DNA encodes for the production 
of amino acids and proteins 
Pyridoxine Pyridoxine (Vitamin B6) plays a vital role in the 
activities of many enzymes. It is essential for the 
breakdown and use of proteins, carbohydrates and 
fats from food and for the release of stored 
carbohydrates for energy. It is involved in the 
production of red blood cells and antibodies and in 
the maintenance of a healthy skin and healthy 
digestion. It is also important for normal function of 
the nervous system and several hormones. 
Quadriceps Large muscle group on the front of the thigh 
Radiation recall Occurs months to years after radiation treatment. A 
reaction that follows recent administration of 
chemotherapy where erythema occurs over a 
previously irradiated site 
Ratio Interval scale with an absolute zero. 
Reynard’s disease Reynard’s disease is a common condition that affects 
the blood supply to certain parts of the body, usually 
the fingers and toes. The condition occurs because 
blood vessels go into a temporary spasm which 
blocks the flow of blood. This causes the affected 
area to change colour to white, then blue and then 
finally red as the blood flow returns. Usually triggered 
by cold temperatures or by stress or anxiety. 
Sclerodactyl Localised thickening and tightness of the skin on the 
fingers or toes 
Seborrhoea Greasy skin 
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Sensitivity The proportion of actual positives who are correctly 
identified as such 
Septuagenarian Aged between 70 – 79 years 
sic erat scriptum 
(Sic) 
"thus was it written" added immediately after a quoted 
word or phrase, indicates that the quoted words have 
been transcribed exactly as spelled or presented in 
the original source, complete with any erroneous 
spelling or other presentation. 
Skindex-16 A questionnaire developed as a measure of 
dermatological health-related quality of life, including 
symptoms, emotions and functional aspects 
Sorafenib A small molecule inhibitor of several tyrosine protein 
kinases; Vascular endothelial growth factor receptor 
and Platelet-derived growth factor receptor (VEGFR 
and PDGFR) 
Specificity The proportion of negatives that are identified as such 
Spectroscopy Study of the interaction between matter and radiated 
energy 
Staphylococci Gram negative bacteria 
Sunitinib A small molecule, multi-targeted receptor tyrosine 
kinase inhibitor (VEGFR and PDGFR) 
Synergistic Acting together 
2-tailed  tails refer to ends of a normal distribution curve. 1-
tailed test used when directional hypothesis stated, 2-
tailed in other situations when it is possible for 
positive or negative association 
Taxane Chemotherapy produced by the plants of the genus 
Taxus (Yew tree) 
Temozolamide Oral alkylating agent. Interferes with DNA replication 
Thiotepa Alkylating agent 
Thymidine 
Phosphorylase 
An enzyme involved in the breakdown of thymidine, 
which helps maintain the pool of nucleosides in the 
cells 
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Time to progression A measure of time after a disease is diagnosed until 
the disease starts to get worse 
Troxacitabine A nucleoside analogue 
Tumour response Response evaluation criteria in solid tumours 
(RECIST) is a set of definitions when cancer patients 
improve (respond), stay the same (stabilize) or 
worsen (progression) 
Type I error A true null hypothesis incorrectly rejected 
Type II error Failure to reject a false null hypothesis 
Tyrosine Kinase 
Inhibitors (TKIs) 
Tyrosine kinases are domains of growth factor 
receptors. TKIs inhibit growth factors from attaching 
to these receptors 
Udderley Smooth® Greaseless water-based moisturiser 
Uracil One of the 4 nucleobases in RNA the others are 
adenine, cytosine and guanine 
Vincristine Vinka alkaloid. Mitotic inhibitor 
Vinorelbine Vinka alkaloid. Mitotic inhibitor  
X-ACT trial Capecitabine versus bolus 5-FU/LV as adjuvant 





CHAPTER  1 INTRODUCTION 
1.1  Introduction and research background 
There have been significant developments in the treatment of cancer as a 
result of scientific research leading to the use of multimodality therapy. 
Unfortunately, the use of chemotherapy is accompanied by substantial risks 
and can influence the quality of life of the individual. Palmar Plantar 
Erythrodysesthesia (PPE) is a distinctive and relatively frequent toxicity 
related to some anti-neoplastic agents. PPE appears to be dose dependent, 
as both peak drug concentration and total cumulative dose determine its 
occurrence. The areas affected become dry and peel, with numbness and 
tingling, progressing to painful erythema, blistering and ulceration (Burgdoff et 
al 1982, Nagore et al 2000). Although this presentation is common in the 
majority of cases, there have been reports of dissimilar and sometimes 
unusual presenting features in people with dark skin (Park et al 2003, 
Narasimhan et al 2004, Saif & Elfiky 2007) and between chemotherapy 
agents (Zimmerman et al 1995, Chu et al 2000, Lipworth et al 2009,). The 
pain and discomfort can interfere with the individual’s ability to carry out 
normal activities and can cause difficulty in walking when the soles of the feet 
are affected. This can result in delays in treatment, dose reduction or 
cessation of treatment in severe cases. This in turn can lead to anxiety in the 
patients who express concern that their cancer will return if unable to 
complete the full course of chemotherapy.  
 
The pathogenesis of PPE remains unclear, with two theories gaining 
consensus. The first that extravasation of the drug occurs from damaged 
microcapillaries due to trauma caused by everyday activities (Hoff et al 2000, 
Lotem et al 2000, Molpus et al 2004, Saif 2011). The second that the drug is 
carried to the surface of the skin by sweat, and with the hands and feet having 
a high concentration of sweat glands, explains why they are the most affected 





While there is evidence to show that dose and schedule of the drugs play a 
large role in the development of PPE, the fact that many still go on to develop 
severe PPE following dose reduction or who commence on a reduced dose, 
would indicate that there are other factors that influence the risk of developing 
PPE. Biographical data, performance status, co-morbidities and renal function 
have all been analysed as potential risk factors of PPE with contradictory 
results.  
 
Numerous approaches have been taken to prevent and/or reduce the severity 
of PPE. Two universally accepted methods to the management of PPE are, 
firstly for moderate to severe symptoms, treatment delay and dose reduction. 
Secondly, supportive care in conjunction with patient education, and it is this 
latter approach that has yet to be established in clinical trials. 
 
Personal experience, supported by Banfield et al (1995), is that the impact of 
PPE on the patient’s quality of life is greater than many think. In the past PPE 
has not been treated as a serious side effect, since it is not life-threatening. 
This often meant that patients were not questioned thoroughly about any 
symptoms of PPE that may have occurred between cycles, resulting in more 
severe PPE with subsequent cycles (Edwards 2003, Gerbrecht 2003).  Case 
reports have built up evidence that PPE can cause more serious problems. 
These include amputation, (Narasimhan et al 2004, Palaia et al 2006) and 
severe infections particularly in neutropenic patients, (Zimmerman et al 1995, 
Poikonen et al 2004). This evidence, suggesting that PPE can have potential 
serious and life-threatening consequences in a small number of patients and 
the increase in the number of PPE-inducing agents, has led to an increased 
understanding of the importance of a full assessment of symptoms between 
cycles. 
 
It is this personal experience, and the lack of empirical evidence to support 
the theory that PPE may be caused by damaged microcapillaries due to 




exploratory study to examine the role that patient activities may play in the 
development of PPE is unique and will add to the body of knowledge of risk 
factors for PPE. 
 
The initial intention was to include patients receiving pegylated liposomal 
doxorubicin (PLD), docetaxel, infusional 5-fluorouracil (5-FU) or capecitabine 
containing regimes. The rationale for this choice was that these agents 
appeared to have the highest incidence of PPE. Following discussions with 
consultant oncologists and chemotherapy nurses, PPE was seen infrequently 
with PLD and docetaxel in the unit where the study would be carried out. 
Collection of data in phase I was thus restricted to infusional 5-FU and 
capecitabine containing regimes. Following this phase, it was evident that 
capecitabine monotherapy had a significantly higher incidence of PPE than 
infusional 5-FU or capecitabine in combination regimes. Further analysis of 
the retrospective data using only those who had received capecitabine 
monotherapy was performed. Phase II of this study then focused only on 
patients prescribed capecitabine monotherapy. 
 
The term ‘patient’ is used to refer to potential recruits to the study before 
consent to participate was gained. It is also used when discussing evidence in 
the literature where the authors use this term. The term ‘participant’ is used 
throughout when referring to individuals participating in the current study.  
1.2    Purpose of the research 
The aim of this research is to identify factors that contribute to the occurrence 
of PPE using quantitative methodology. Empirical research is necessary to 
ensure that the outcomes of the study are relevant to, and can be applied to, 
a specific client group, namely patients receiving capecitabine known to cause 
PPE.  
 
Patient education strategies to minimise the severity of PPE are based on 
anecdotal evidence and consensus and is one of the mainstays in managing 




education, support and monitoring of patients receiving chemotherapy. The 
findings from this study will provide an evidence base for nurses caring for 
patients receiving PPE-inducing agents to enable them to provide focused 
education, supportive measures and monitoring for those most at risk of 
developing PPE. These strategies would aim to reduce the incidence and 
severity of PPE that would allow for the maximum dose to be administered, 
and reduce the impact on an individual’s quality of life. 
 
1.3   Research questions 
This thesis intends to answer the following questions; 
 Can risk factors be identified to predict the development of PPE? 
 Do individual patient activities that cause friction or exposure to 
heat, increase the risk of developing PPE? 
 
In order to answer these questions a statistical model was used to explore 
and assess the contribution of risk factors for the development of PPE. This 
model is based on one described by Hosmer and Lemeshow (2000) and 
demonstrated by Bursac et al (2007). The hypotheses and research model 
employed are described in detail in chapter 3. 
 
Addressing the gap in the literature in the next section will describe the 
contribution this research makes in terms of building upon existing literature. 
 
1.4    Research contribution 
This research explores numerous potential risk factors of PPE. The findings 
will add to the current evidence of biographical data, performance status, co-
morbidities and renal function as risk factors of PPE. Since this is the first time 
that individual activity related risk factors for PPE have been studied, this is 





Findings from this research will add to the literature by; 
 Contributing originality in the form of empirically tested activity-
related risk factors of PPE  
 Providing nurses with an evidence-base on which to base 
educational programmes 
 Providing valuable information to support future research and 
development 
 
1.5    Thesis outline 
The Introductory chapter establishes the focus of the study and provides the 
rationale for its choice. The purpose of the study based on its aims and 
objectives precedes the research questions to be answered. Gaps in the 
literature are identified to demonstrate how the findings from this study will 
make a unique contribution to the existing body of knowledge. An outline of 
the thesis is provided in figure 1.1. 
 
Chapter 2 provides a general literature review. It commences by detailing the 
search strategy used to identify relevant literature. Since PPE is known by 
many guises, the many definitions are discussed justifying the one used 
throughout this thesis. The overall scale of the problem (PPE) is presented, 
with subsections for 5-fluorouracil and capecitabine, the drugs to be studied. 
Existing knowledge on the presentation, pathogenesis and aetiology of PPE is 
discussed emphasising the controversial evidence and the difficulties in 
making comparisons between studies. The wide variety of suggested 
strategies to manage or minimise the severity of PPE is included for 
completion of the subject, and to highlight the lack of empirical evidence to 
support these strategies. The chapter concludes with the nurses’ role in the 
assessment, monitoring and education of patients receiving PPE-inducing 
agents. 
 
Chapter 3 describes the theoretical framework on which the research is 




data. The research hypotheses which provide the basis for the formulation of 
the research questions are presented. The process of data analysis using 
bivariate statistical tests and single and multivariate regression is explained. A 
rationale for the choice of the multivariate logistic regression modelling 
algorithm is given and the chapter concludes by identifying limitations in the 
study design. 
 
Chapter 4 outlines the results of the data analysis. It is set out in three 
sections, one for each sample, each presented in the same order and format 
for consistency. A substantial amount of data were gathered and analysed, 
therefore data are presented in tabular form within the text and appendices to 
illustrate the findings. Individual cases with unusual presentation of PPE 
linked to co-morbidities are discussed. 
 
Chapter 5 provides a discussion of the findings based on the data analysis in 
chapter 4. This chapter is divided into sections similar in order to those in 
chapter 2. Graphs and photographs are provided to illustrate some of the 
comparisons made between the samples in this study and those in the 
literature. The emphasis is placed on risk factors for capecitabine-induced 
PPE since this was the agent of choice following the data analysis from phase 
1 of the study. The chapter concludes with a summary of the key findings 
emphasising the original contribution these findings make to the existing 
literature. 
 
Chapter 6 commences with a summary of the research to remind the reader 
of the methods employed to collect the data. The process of data analysis is 
described including the rationale for the choice of the modelling algorithm 
applied to the selection and retention of variables in the multivariate logistic 
regression. This is followed by an outline of the conclusions to answer the 
research questions, focusing on the more accurate and richer data collected 
from the prospective sample. The contribution the research has made to the 




the limitations of the study. The chapter concludes with recommendations for 
future research.  
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CHAPTER  2 REVIEW OF THE LITERATURE 
2.1  Search strategy 
The approach employed to explore the literature surrounding Palmar Plantar 
Erythrodysesthesia (PPE) was to initially identify the search terms to be used. 
The universally recognised hand-foot syndrome (HFS) was the preliminary 
term used, expanding to include other key words as identified from articles 
and database MESH (Medical Subject Headings) terms. Table 2.1 outlines 
the findings of the search and terms used to explore four databases, Allied 
and Complementary Medicine; British Nursing Index (BNI); Cumulative Index 
to Nursing and Allied Health (CINAHL) and Medline. 
 










1 Hand-foot syndrome 468 20 79 27 
2 Palmar Plantar 
Erythrodysesthesia 
139 0 12 4 
3 Plantar Palmar 
Erythrodysesthesia 
6 1 0 0 
4 Palmar Plantar Erythema 17 0 8 1 
5 Plantar Palmar Erythema 5 0 0 0 
6 Acral Erythema 97 4 37 8 
7 Acral Erythrodysesthesia 3 0 0 1 
8 Palmar Plantar Keratoderma 485 1 473 1 
9 Peculiar Acral Erythema 3 1 0 0 
10 Burgdorf reaction 2 0 0 1 
*Articles that did not include chemotherapy-induced cutaneous reaction 
Table 2-1 Search strategy 
 
There was no mention of this cutaneous reaction in the published literature 
before 1974; little attention was paid to it until the 1980s; it was not mentioned 
in common toxicity classifications until the 1990s; and the evidence for risk 
Review of the literature 
Page | 9 
 
factors of this reaction is based on case reports and consensus. Given these 
facts, the search of the databases had no restrictions applied such as date or 
research based articles only. 
 
Since the terms Hand-foot syndrome and Palmar Plantar Erythrodysesthesia 
revealed the largest number of articles, these two terms were entered into 
ZETOC and SCOPUS alert services which e-mailed details of new literature 
as it was published throughout the time this study was carried out.  
 
Of necessity only English literature articles were selected. The reference list 
of each article obtained was examined for any literature not identified from the 
searches of the databases. 
 
A further search of the two databases CINAHL and medline was carried out to 
identify evidence from phase III trials of capecitabine monotherapy. The 
purpose of this additional search was to be able to compare the findings of the 










CINAHL 47 13 18 0 
Medline 22 13 0 0 
Table 2-2 Search strategy capecitabine Monotherapy 
 
Articles available electronically from De Montfort University, University of 
Leicester, NHS evidence or the Royal College of Nursing were obtained. 
Journals not available electronically but held as a hard copy at other 
universities in the East Midlands were identified and visits were made to 
obtain this material. The final source used to obtain published articles was via 
the inter-library loan service. 
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2.2   Introduction 
Palmar-Plantar Erythrodysesthesia (PPE) is rarely serious and never life-
threatening; however, the pain and discomfort it causes can have a significant 
impact on the patient’s ability to carry out normal daily activities and on their 
quality of life (Webster-Gandy 2007). A literature search revealed multiple 
definitions of this side effect to anti-neoplastic agents. The multiple definitions 
will be briefly discussed to support the rationale for the one used throughout 
this piece of work. An attempt will be made to identify the incidence, followed 
by the symptoms of PPE and theories of the pathophysiological mechanisms 
involved. An analysis of the risk factors identified in the literature and which 
has informed the development of the hypotheses and data collection tools 
used in this study will be presented. Reference to risk factors for PPE caused 
by agents other than 5-FU and capecitabine have been included since many 
of these factors have not yet been tested with 5FU or capecitabine and cannot 
therefore be excluded as possibilities. Strategies to prevent and manage PPE 
are briefly discussed and are useful to complete the whole picture to show the 
difficulties in identifying effective interventions even though this does not form 
part of the current study. The nurses’ role in the assessment and recognition 
of PPE and patient education needs will conclude this chapter. 
 
2.3  Definitions and common causative chemotherapeutic agents 
Described as a painful, erythematous skin lesion of the palms and soles, 
(Alley et al 2002), this local cutaneous reaction to certain systemic anti-
neoplastic agents was first described as Palmer Planter Erythrodysesthesia in 
1974 by Zuehlke in patients with hypernephroma (renal cell carcinoma) 
receiving mitotane. In the early 1980s it was referred to as chemotherapy-
induced acral erythema (Nagore et el 2000, Lassere & Hoff 2004). The term 
palmar-plantar erythema was first used in 1984 (Laack et al 2001). Other 
terms used include acral erythema (Arias et al 1997, Bhasin et al 2005); 
acrauding erythema; Burgdorf’s reaction (Bardia et al 2006); toxic acral 
erythema (Lotem et al 2000); toxic erythema of palms and soles (Nagore et el 
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2000); or hand-foot syndrome (HFS) (Lotem et al 2000, Alley et al 2002). 
Rosner (1998) appears to take exception to the use of HFS to describe this 
side effect since haematologists have used this term for decades to describe 
a painful swelling of the hands and feet (dactylitis) in very young patients with 
Sickle Cell Disease. He suggests that HFS should be reserved for this 
condition and that acral erythema or Palmar Plantar Erythema should be used 
for the chemotherapy-induced side effect. It is for this reason and the 
increasing use in more recent publications that Palmar-Plantar 
Erythrodysesthesia (PPE) will be used throughout this piece of work. In 
response to this criticism, Hoff et al (1998a) while acknowledging Rosner’s 
concerns, pointed out that the HFS used to describe dactylitis in Sickle Cell 
Disease is very different in pathogenesis and presentation to chemotherapy-
related HFS and that although Palmar Plantar Erythema may be the preferred 
name, HFS is well established and has wide acceptance within the oncology 
community and is doubtful that there will be any confusion in using the same 
name. 
 
As the term PPE would indicate, the hands (palmar) are most commonly 
affected followed by the soles of the feet (plantar), although the sides and 
dorsal surfaces of these can also be affected (Wood 2004). There have been 
reports of other areas of the body also being affected, particularly inter-
triginous sites and those areas where body heat is greatest. These include the 
axilla (Jacobi et al 2005), groin, vulva (Sharma & Chan 2003) and perineal 
areas (Cady et al 2006). Similarly at pressure points (elbows, scapula, 
sacrum) and where tight fitting clothing (Sharma & Chan 2003) or belts press 
against the skin (Lotem et al 2000). It has even been reported at the site of 
recently applied electrocardiograph (ECG) pads (Zimmerman et al 1995). 
There have been reports of the trunk, neck, chest and scalp being affected 
(Gerbrecht 2003), as well as scars anywhere on the body (Von Moos et al 
2008) and a few reported cases of penile and scrotal involvement in men 
receiving infusional 5-FU or capecitabine (Sorscher 2004, Sapp and 
Desimone 2007, Lee et al 2009). Because of the severity of the symptoms of 
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PPE in penile and scrotal involvement, Sapp and Desimone (2007) suggest 
that this should be graded as grade 4 toxicity.  
 
Alongside 5-FU, the first agent to be identified as the main causative agent for 
PPE (Lokich & Moore 1984, Lassere & Hoff 2004), the other agents 
commonly implicated are capecitabine; pegylated liposomal doxorubicin 
(caelyx®) (Molpus et al 2004, Bareggi et al 2005); docetaxel and cytarabine 
(Waltzer & Flowers 1993, Hoff et al 2000). PPE has also been reported with 
the use of vincristine; cyclophosphamide (Komamura et al 1995); bleomycin; 
thiotepa (Alley et al 2002); methotrexate (Hellier et al 1996); gemcitabine 
(Laack et al 2001); high dose vinorelbine; (Edwards 2003), paclitaxel; 
(DeArgila et al 1996), temozolomide (Kanat et al 2007), and hydroxyurea 
(Bhasin et al 2005). PPE is known to be caused by many cytostatics and it is 
for this reason that monitoring of PPE is included in protocols for many clinical 
trials for these agents (Van Cutsem et al 2004). Many novel agents that target 
specific pathways crucial to the growth and development of tumours have 
emerged and are used to treat a variety of cancers. Skin toxicity, including 
PPE, is the principal side effect associated with many of these agents 
especially those that target the epidermal growth factor receptor (EGFR) 
signal transduction pathway. The true incidence rates are not yet known 
(Robert et al 2005, Lacouture et al 2007), but, could potentially be used as a 
marker for the efficacy of treatment (Perez-Soler 2003). Examples of these 
novel agents include cetuximab (Monoclonal antibody targeting EGFR) for 
colorectal cancer (Monti et al 2003), sunitinib and sorafenib (tyrosine kinase 
inhibitors (TKI)) for renal cell cancer (Dasanu et al 2007), and lapatinib (EGFR 
and HER-2 inhibitor) (Cancerbackup 2009). The incidence of PPE in these 
TKIs have been reported as between 10-28% with sunitinib and 10-62% with 
sorafenib, with grade 3 reported as between  4-12% and 2-36% respectively 
(Lipworth et al 2009). The EGFR is upregulated in several cancers and it is 
also important for normal skin development and function.  
 
Toxicities that have been suggested as markers of efficacy of treatment with 
the newer novel therapies include the rash seen with erlotinib and cetuximab 
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(Gurney 2005). There have been similar findings in patients receiving 
capecitabine either as monotherapy or in combination with other agents. A 
correlation (p = 0.01) between severity of PPE and tumour response was 
reported in a study by Chua et al (2003). However, this finding was based on 
a small sample of ten who developed PPE from a total sample of 17 Chinese 
patients receiving capecitabine. In another study (Kaufmann et al 2010) of 
161 patients taking capecitabine monotherapy, the incidence of PPE, median 
time to progression (TTP) and median overall survival (OS) rates were 
compared with those who did not develop PPE. The participants that 
developed PPE had a longer TTP and OS. In the same study, a multivariate 
analysis showed that, patients aged over 65 years and PPE were found to be 
the only independent predictors of TTP and PPE was the only independent 
predictor of OS. The study concluded that PPE and age > 65 years were 
correlated with improved activity outcomes. Since this study was carried out 
on women with breast cancer the older age as a predictor of OS is to be 
expected given that breast cancer in younger patients tends to be more 
aggressive with a poorer outcome in terms of TTP and OS. (BreastCancer 
2006). This positive correlation between the occurrence of PPE and longer 
OS was also observed in a meta-analysis of 13 retrospective studies of 
patients receiving capecitabine monotherapy for colon, gastric and breast 
cancer (Roche 2010), and in the results from the X-Act trial (Twelves et al 
2008). Correlation between severe PPE and clinical outcome was reported in 
a retrospective study in patients with metastatic breast cancer which found 
that those with grade 3 PPE had a longer TTP and OS compared to those 
with grade 1 or 2, thus suggesting that PPE may be a valuable tool that could 
help appraise and monitor the efficacy of capecitabine, although further 
studies are required to confirm this finding (Kurt et al 2006). 
 
Some reports of PPE with tyrosine kinase inhibitors (TKI) were found in 
patients who had previously received pegylated liposomal doxorubicin. 
Lacouture et al (2007) propose that this is a ‘recall reaction’ and that doctors 
and nurses treating patients with these new agents should be aware of the 
possibility of this reaction. This recall reaction has also been reported by Hui 
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et al (2002). In their report, 6 patients who developed PPE with previous 
troxacitabine treatment was recalled with later treatments of a variety of 
regimes. Although the PPE could be related to the direct effect of the current 
drug being administered, they felt that the common denominator of previous 
exposure to troxacitabine suggested a recall reaction. Until large numbers 
have been treated with these agents (TKIs) as first line treatment we will not 
be able to establish whether PPE is due to ‘recall’ from previous 
chemotherapy or if PPE is caused directly by the TKIs. The increasing size of 
the problem would indicate that PPE is an area worthy of further investigation 
and therefore an attempt will now be made to define the incidence.  
 
2.4  Incidence 
Formulation of the drugs and period of exposure can impact on the incidence 
of PPE. Examples include pegylated-liposomal doxorubicin which has a 
higher incidence of PPE that the standard formulation of doxorubicin (Lotem 
et al 2000). Fluorouracil (5-FU) administered by intermittent bolus injection 
has a low incidence of PPE, but, when given as a continuous infusion, PPE is 
common (Alley et al 2002). Capecitabine, which is converted to 5-FU, 
provides prolonged exposure to tissue and has an incidence of PPE of 
between 50–69% with approximately 10-22% having severe PPE (Blum et al 
1999, Abushullaih et al 2002, Cassidy et al 2002, Twelves et al 2005, and 
Roche 2010). Whilst the overall incidence of PPE reported in the literature 
was easily interpreted, the reporting of severe PPE proved more difficult.    
 
A substantial amount of literature was retrieved that either made reference to 
PPE within the text or specifically contained PPE (or other associated term) in 
the title. This showed that although there was the occasional mention that the 
onset of PPE between cycles was possibly underreported, only one study was 
identified that specifically collected and analysed this type of data. A 
prospective study of 1470 patients receiving continuous infusion 5-FU 
300mg/m2/day alone or with bolus mitomycin 7mg/m2 every six weeks. Data 
were examined in detail to measure whether the time of onset of grade 1 PPE 
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had any predictive significance for the development of more severe toxicity in 
subsequent cycles (Tebbutt et al 2003). Their findings showed that 55.1% of 
patients who developed grade 1 PPE early went on to develop grade 2 or 
worse compared with 27.3% who did not develop early grade 1 PPE (p < 
0.001). The data were then tested by univariate Cox regression analysis 
which revealed that for every extra day after the commencement of 
chemotherapy before any symptoms of grade 1 PPE were reported, there was 
a lower risk of developing grade 2 or worse in subsequent cycles (hazard ratio 
0.99, 95% CI 0.98-0.99; p < 0.001). Other factors were analysed by 
multivariate Cox regression to assess their predictive ability for PPE. Older, 
females with a good performance status (Appendix 2.1); increased bilirubin 
levels and early grade 1 diarrhoea were identified as independent risk factors 
for grade 2 or worse PPE in following cycles of chemotherapy. They suggest 
that the timing of the appearance of grade 1 toxicities could be used to identify 
patients who have a higher risk of later presenting with more severe grades of 
toxicity. Recommending that older females with a good performance status, 
impaired liver and renal function, and early grade 1 PPE alone or in 
conjunction with grade 1 diarrhoea should be considered for early dose 
reduction, since this group are at an increased risk of going on to develop 
grade 2 or worse PPE. 
 
Very few studies have examined any association between PPE and tumour 
type, but a systematic review of 4883 patients from eleven trials receiving 
sorafenib found an increased rate of PPE in those with renal cell carcinoma 
(RCC) compared to any other malignancy (Chu et al 2008). However, it is 
possible that this may be due to other factors or a unique link between the 
pathophysiology of PPE and RCC which would need confirming in further 
studies.  
 
Whilst reviewing the literature it became evident that there are several 
difficulties in determining the true incidence of PPE. Many studies are small 
scale or isolated case reports. The larger studies are often based on a 
retrospective meta-analysis or medical notes review, provide little detail of 
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cutaneous reaction and used different PPE grading systems (Appendix 2.2). 
Since PPE is often subjectively reported, standardisation is difficult and cross-
study comparison a challenge. These observations were also reflected by 
Janusch et al (2006) and Nagore et al (2000) in their review articles. 
Incidence by grade of PPE is often not reported in studies or only the severe 
grades (2-4) presented as an overall figure. The overall incidence of PPE from 
the literature has been quoted in a review paper as being between 6 – 64% 
across the full range of chemotherapy regimes with 80% of these patients 
experiencing less severe grades (Nagore et el 2000).  
 
While it is acknowledged that PPE can occur in patients receiving many 
different anti-neoplastic agents, since this study collected data from patients 
receiving 5-FU or capecitabine, it is the incidence of PPE with these agents as 
monotherapy or in combination that will now be presented.  
 
2.4.1 Fluorouracil (5-FU) 
5-FU is an antimetabolite and acts as a false pyrimidine base (uracil), 
interfering with the synthesis of DNA by blocking the action of the enzyme 
thymidylate synthetase. Approximately 22-45% is metabolized in the liver, 
with its catabolites excreted in urine and 7-20% excreted unchanged in the 
urine (Perry 2006, EMC 2011). Reduction of the dose is advisable in patients 
with any of the following: cachexia; reduced bone marrow function and 
impaired hepatic or renal function (EMC 2011). Common side effects include 
stomatitis, diarrhoea, mild nausea and vomiting, anorexia, hyperuricaemia, 
epistaxis, fatigue, however, PPE is the side effect of interest, and it is this that 
will be discussed further. 
 
There were some consistent findings indicating a higher incidence with 
infusional (27-34%) rather than bolus 5-FU (7-13%) (Feldman & Ajani 1985, 
Chiara et al 1997, Meta-analysis group in cancer 1998, Elasmer et al 2001, 
Laack et al 2001, Chabner & Longo 2006), with some evidence to suggest 
that PPE toxicity with 5-FU is cumulative (Bareggi et al 2005). A meta-
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analysis of 1219 patients from 6 randomised controlled trials comparing the 
toxicities of 5-FU bolus versus continuous infusion confirmed that PPE is 
more frequent with continuous infusional 5-FU (13% bolus and 34% 
continuous infusion p <.0001). The adjusted risk ratio for PPE was 1.87 (95% 
CI; 1.50-2.34) which indicates that there is almost twice the risk of developing 
PPE when 5-FU is given by continuous infusion (Meta-analysis group in 
cancer 1998). In 1989 Curran and Luce presented a series of 9 cases of PPE 
reported to the 5-FU manufacturers, which they suggested, indicated that the 
likelihood of PPE in association with 5-FU bolus is greater than previously 
thought. Of the 9 cases 44% (4 of 9) received continuous infusional 5-FU and 
55% (5 of 9) received 5-FU as a bolus regime. The article did not provide 
details of the dose or interval of the regimes and since the number of patients 
is very small consideration has to be given that these findings could have 
occurred by chance. The rationale for the use of continuous infusion of 5-FU 
is that it has a short half-life which makes high dose intensity achievable. 
Tumour response rates are high and the range of side effects differs to those 
seen with bolus regimes, however, PPE emerges as one of the most frequent 
problems (Chiara et al 1997). 
 
The circadian rhythm in plasma concentration of drugs may also contribute to 
the toxicity profile of some drugs suggesting that chronomodulation of drugs 
may be a means of managing the incidence and severity of PPE (Bjarnason 
et al 1993, Milano & Chamorey 2002, Tan & McLeod 2005, Chabner & Longo 
2006). The optimal time for 5-FU infusion achieving low toxicity and better 
efficacy is between 2200 and 1000 hours with the peak delivery at 0400 hours 
(Coudert et al 2008). Some studies have shown that modifying continuous 
infusion rates to plasma concentrations of oxaliplatin and 5-FU limited the 
incidence of adverse events allowing for dose escalation (Caussanel et al 
1990, Metzger et al 1994, Bochicchio et al 1999). Problems that have 
prevented the implementation of this in practice include practical and 
economic reasons (Jansman et al 2001). 
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2.4.2 Capecitabine 
Capecitabine is a fluoropyrimidine carbamate and interferes with RNA 
processing and protein synthesis. It is converted to 5-FU initially in the liver 
with the final conversion by the enzymes cytidine deaminase and thymidine 
phosphorylase. 54% of capecitabine is bound to protein, in particular albumin 
(35%) with a half-life of 0.5 to 0.7 hours. 96% is excreted in urine most as 
FBAL (a metabolite of capecitabine) (61%) with only 2.6% excreted in faeces 
which indicates that the majority is absorbed via the gastrointestinal tract 
which may impact on co-medications (discussed elsewhere) (Roche 2011). 
 
PPE was the only adverse event occurring in 45%-68% of patients, with grade 
3 occurring in up to 17% and is more frequent than with 5-FU (Cox et al 1999, 
Twelves et al 1999,  2001 & 2005,  Elasmer et al 2001, Hoff et al 2001, 
McGavin & Goa 2001, Van Cutsem et al 2001, Abushullaih et al 2002, 
Cassidy et al 2002, O’Shaughnessy et al 2002, Gerbrecht 2003, Scheithauer 
et al 2003, Lassere & Hoff 2004, Marse et al 2004, Van Cutsem et al 2004, 
Walko & Lindley 2005, Wiseman & Lyseng-Williamson 2005). A large pool of 
safety data from phase II and III clinical trials of pre-treated breast cancer 
patients and first line colorectal cancer patients (n = 875) receiving 
capecitabine 2500 mg/m2/day intermittent regimen found PPE and diarrhoea 
to be the most common adverse events (52.2% and 48.8% respectively). 
Patients who experienced grade 2-4 PPE/diarrhoea received a reduced dose 
in subsequent cycles. A small proportion (13% and 12% respectively) 
experienced a recurrence of grade 3 symptoms (Blum 2001). This raises the 
possibility that PPE is not solely dose related. Studies have demonstrated that 
this reduced dose had no statistically significant difference in outcome such 
as disease recurrence or 2-3 year survival (El-Helw & Coleman 2005, Yun et 
al 2010).  
 
Toxicity due to capecitabine may be managed by symptomatic treatment, 
interruption of treatment and dose reduction. The manufacturer’s 
recommendations for interruption or reduction are given in table 2.3 
Review of the literature 
Page | 19 
 
 
Toxicity grades* Dose changes within a 
treatment cycle 
Dose adjustment 
for next cycle/dose 
(% of starting dose) 
• Grade 1 Maintain dose level Maintain dose level 
• Grade 2 
-1st appearance Interrupt until resolved to 
grade 0-1 
100% 
-2nd appearance 75% 
-3rd appearance 50% 
-4th appearance Discontinue treatment 
permanently 
Not applicable 
• Grade 3 
-1st appearance Interrupt until resolved to 
grade 0-1 
75% 
-2nd appearance 50% 
-3rd appearance Discontinue treatment 
permanently 
Not applicable 
• Grade 4 
-1st appearance Discontinue permanently 
or 
If physician deems it to be in 
the patient's best interest to 
continue, interrupt until 
resolved to grade 0-1 
50% 
-2nd appearance Discontinue permanently Not applicable 
Table 2-3 Manufacturers guidelines for interruption or dose reduction 
(EMC 2012) 
 
Pooled data from four prospective trials of capecitabine in combination with 
other agents showed that combined use of docetaxel was the only 
independent risk factor for capecitabine-induced PPE (p = .001) (Heo et al 
2004). This confirms findings from other studies and suggests that the 
addition of other neurotoxic agents enhance this toxicity of capecitabine (Park 
et al 2003, Giordano et al 2006). This finding is not surprising given that 
docetaxel is recognised as an agent which has also been implicated in the 
development of PPE. In a phase III trial of docetaxel combined with epirubicin 
compared with docetaxel combined with capecitabine as first line adjuvant 
therapy for breast cancer, grade 3 PPE was higher in the capecitabine 
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combination group (4%) with none in the epirubicin group p = .024 (Mavroudis 
et al 2010). 
 
There is a gradual move to replace infusional 5-FU with oral capecitabine in 
combination regimes, since capecitabine is simpler and more convenient to 
administer. The patient does not require insertion of a long term central 
venous catheter or cope with the presence of an ambulatory chemotherapy 
pump for several days (Aisner 2007). In phase III studies of capecitabine in 
combination with oxaliplatin or irinotecan the incidence of PPE is shown to be 
lower (36% and 41% respectively) than that seen in capecitabine as 
monotherapy (54%) and could be explained by the lower dose of capecitabine 
administered in these regimes (Cassidy et al 2004, Patt et al 2004a). This 
contradicts the theory that PPE is not merely related to dose. However, a 
retrospective analysis of toxicities before and after a dose change of 
capecitabine (reduction from 2000mg/m2/day to 1700mg/m/day) in 
combination with oxaliplatin reported no statistically significant difference in 
gastrointestinal and cutaneous toxicities. However, a difference in neutropenia 
and hyperbilirubinaemia (p = .03 and p < .001 respectively) (Baird et al 2011), 
again throws doubt that dose alone is a factor in the development of PPE and 
so the debate continues with contradictory findings.  
 
When a comparison is made between oxaliplatin in combination with either 
infusional 5-FU (folfox) or capecitabine (capox) an increased incidence of 
grade 3 PPE is seen in the capox group (OR = 3.90; 95% CI 2.13 – 7.12) 
(Cao et al 2010). Similarly, in a large meta-analysis of 10 randomised 
controlled trials n = 3208 (RR = 3.40; 95% CI 2.25 – 5.15; p < .001), no 
significant difference in time to progression and overall survival between the 
folfox and capox groups was found, indicating that capecitabine can be used 
safely as a substitute for infusional 5-FU (Zhao et al 2010). Cassidy et al 
(2011) reported an increased incidence of PPE in the capecitabine/oxaliplatin 
group compared with the 5-FU/oxaliplatin group (31% versus 11%) and an 
even higher incidence when bevacizumab was added to both combinations 
(40% versus 14%). In combination with cisplatin a higher incidence was found 
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in the capecitabine group compared with the infusional 5-FU group (Kang et al 
2009). These findings mirror those found in comparisons between infusional 
5-FU and capecitabine monotherapy with an incidence of PPE 6.2% and 
53.3% respectively (Walko and Lindley 2005). 
 
Phase II and III trials evaluated the addition of leucovorin (LV) to capecitabine, 
which is commonly used with 5-FU. However, the addition of LV was found to 
increase the incidence of toxicity especially PPE and diarrhoea without any 
increase in anti-tumour efficacy, and it is therefore not recommended (Van 
Cutsem et al 2000).  
 
In section 2.4.1 it was shown that circadian rhythm of plasma concentration of 
drugs influences the toxicity profile of that drug. A nonblinded study (Qvortrup 
et al 2010) of 139 patients were randomized to receive standard XELOX 
(capecitabine and oxaliplatin) with short-time infusion (30 minutes) of 
oxaliplatin or chronomodulated XELOX (80% capecitabine administered in the 
evening and oxaliplatin in the afternoon).There was no significant difference in 
toxicity and severe toxicity between the two groups or in overall response 
rate. Another small study (Santini et al 2006) of 36 patients receiving 
oxaliplatin as a continuous infusion over 12 hours and chronomodulated 
capecitabine (25% at 0800 hours, 25% at 1800 hours and the remaining 50% 
at 2300 hours). With a good safety profile and high tumour growth control, this 
schedule may be of interest but would require further study in a large 
randomized trial to confirm these findings (Qvortrup et al 2010). 
 
One of the factors that may influence this difference is the circadian variation 
in the activity of many enzymes, involved in the anabolism and catabolism 
drugs. Dehydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of 
capecitabine has its peak activity between 0100 (Harris et al 1990) and 0230 
hours (Zeng et al 2005).  
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2.5  Presentation, grading and impact on the patient 
PPE was not mentioned in common toxicity classifications until the 1990s, 
(Chiara et al 1997) and many of the published clinical trials of agents 
associated with PPE were initiated prior to the introduction of a standard 
grading system (Gressett et al 2006). There are several different toxicity 
classification systems currently in use; WHO (1979); NCI (NCI 2006); 
capecitabine clinical trial criteria (Blum et al 1999) (Appendix 2.2). Von Moos 
et al (2008) states that these classification systems may be useful in clinical 
trials, but may not accurately reflect the clinical severity of PPE, and that it is 
difficult to differentiate between the grades making their use in clinical practice 
questionable. In a study to establish the consistency in the use of two toxicity 
scales (NCI and WHO) Brundage et al (1993) used 7 experienced data 
managers and 12 simulated patients. They found that there was variability 
between the application of the toxicity criteria, the interpretation of the data 
and interviewing skills, which although there was no difference between the 
two scales, this variability makes interpretation of toxicity frequency and 
severity difficult.  
 
Having discussed some of the difficulties in establishing the incidence, the 
presenting features are much clearer in most instances. Common presenting 
features include a tingling and numbness in a glove and sock distribution 
pattern with or without erythema (Akash & Bhounsule 2011). This is followed 
by pain, marked erythema and swelling (Nagore et al 2000, Lassere & Hoff 
2004). Finally progressing to blisters, ulceration, severe pain and moist 
desquamation, this can result, rarely, in full thickness necrosis (Burgdoff et al 
1982, Laack et al 2001, Von Moos et al 2008). This adversely effects the 
patient’s quality of life, interfering with general activities of daily living (Lassere 
& Hoff 2004). In a study of patients with PPE, 47% of all patients and 78% of 
those with grade 3 identified it as the most unpleasant side effect of 
chemotherapy (Webster-Gandy et al 2007). Other features which may occur 
at any stage include dryness, rash, pruritus and skin breaks particularly on the 
finger tips (Hoff et al 2000).  
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The symptom which distinguishes PPE from other erythematous diseases of 
the hands and feet is the dysesthesia (impairment of sensation) (Janusch et al 
2006). Neurologically, strength, and reflexes are generally not compromised, 
however, light touch may induce burning, tingling or pain, while pin prick and 
temperature sensation may be reduced or absent (Von Moos et al 2008). A 
diffuse rash on the trunk, limbs and sometimes the face can also accompany 
the severe grades of PPE (Cady et al 2006). If left untreated the symptoms 
will progress rapidly and will require more aggressive management and 
necessitate prolonged cessation of chemotherapy until resolved completely 
(Gordon et al 1995, Edwards 2003). In the majority of cases skin regeneration 
following cessation of the causative agent occurs within 1 to 2 weeks 
(Gressett et al 2006). Banfield et al (1995) present a case report of a patient 
who developed PPE during 5-FU treatment and whose symptoms of abnormal 
sensation and appearance of the affected digits persisted for many months 
following cessation of treatment despite the administration of pyridoxine, 
which is thought to reduce the severity of PPE and will be discussed later. 
They suggested that this case implies that in some instances the impact on a 
patient’s quality of life may be greater than first thought. Another case that 
supports this suggestion is presented by Palaia et al (2006) where they report 
a 53 year old female treated with pegylated liposomal doxorubicin for 
advanced ovarian cancer that developed severe grade 3 PPE with ulceration 
of the tip of one finger which became necrotic and required amputation. A 
possible explanation for this is that the absence of pain sensation, probably 
due to the neuropathy from her previous chemotherapy, led to an 
underestimation of the onset of PPE in this patient. Conversely symptoms 
may resolve between cycles particularly 3-4 weekly schedules, and, if not 
reported by the patient subsequent episodes of PPE may be more severe, 
therefore highlighting the importance of questioning the patient carefully 
before each cycle (Edwards 2003). PPE is rarely serious and never life-
threatening, or so it is alleged in the literature. A multivariate analysis in a 
phase III trial of docetaxel identified PPE as the only independent predictive 
factor for severe infections in neutropenic patients (Poikonen et al 2004). 
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Infections with Staphylococci, gram-negative bacteria or erysipelas have been 
observed as complications in patients with PPE which may prolong healing 
time (Janusch et al 2006). Hoff et al (2000) provides a four stage continuum 
along which symptoms of PPE progress with stage 4 including infectious 
complications and hospitalisation. An example of a patient treated with 
docetaxel who required hospitalisation secondary to infected ulcerated skin 
lesions in the groin and other areas of the body is presented by Zimmerman 
et al (1995). These findings suggest that PPE can have potentially serious 
and life-threatening consequences in a small number of patients.  
 
Some authors have observed that black patients treated with capecitabine 
develop PPE more often, although no actual figures were presented, and 
more importantly, that their presenting features and incidence of serious 
manifestations (grade 2 and 3 PPE) are different to those seen in white 
patients (Narasimhan et al 2004). The term ‘black’ here includes people with 
naturally dark skin, for example, Afro-Caribbean, Philipino, and Korean. A 
study of 23 patients receiving a combination of capecitabine and docetaxel for 
advanced gastric cancer revealed an incidence of 52% (12) of grade 3 PPE 
which is higher that the previously reported figure of 24%. Ethnicity (Korean) 
was suspected to underlay this significant difference, although it is 
acknowledged that there may be other reasons (Park et al 2003). 
 
The conventional signs of grade 1 PPE are hidden in black patients who 
instead develop a progressive hyperpigmentation of the palms and soles 
(Hood and Reeck 2006, Saif & Elfiky 2007). Simultaneous gradual thickening 
of the skin (keratoderma) of the palms and soles leads to stiffness of the 
hands and soles with pain and loss of function (Narasimhan et al 2004, 
Schellens et al 2005,). This difference in presentation may not be recognised 
widely which may have led to the under reporting of PPE in dark skinned 
individuals. In a study (Bjarnason et al 1993) of infusional 5-FU, darkening of 
the nails and hyperpigmentation in 3 dark skinned patients was documented. 
However, this was not defined as PPE and was not, therefore, included in the 
incidence figures for PPE. In black patients with diabetes, PPE may worsen 
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rapidly into a severe form of grade 3 resulting in life-threatening 
complications, such as infection affecting the underlying bones and a 
compromised circulation, which could lead to the possibility of amputation of a 
limb (Narasimhan et al 2004). The latter statement is, however, based on a 
single case report of a black patient with diabetes who had already lost one 
leg due to complications of his diabetes and a larger number of reported 
cases would be required to support the suggestion that black patients have a 
higher incidence of the more serious grade 3 PPE. 
 
Since presentation of PPE in black patients differs from that of white patients, 
suggestions have been made that the definition of grade 1 PPE should be 
amended to include hyperpigmentation instead of erythema and that 
progression to grade 2 PPE should include palmar-plantar keratoderma (PPK) 
(Narasimhan et al 2004, Saif & Elfiky 2007). 
 
Do & Kim (2007) present two cases of palmar-plantar keratoderma following 
the administration of capecitabine for breast cancer. Acquired PPK is 
associated with pre-existing inflammatory skin conditions, infections, 
circulatory problems (e.g. lymphoedema), metabolic abnormalities (e.g. 
myxoedema), malignancies and toxic agents (NZ dermatological society 
2009). Both cases presented by Do & Kim (2007) had metastatic breast 
cancer and it is possible that the keratoderma might be paraneoplastic. Since 
the keratoderma progressed rapidly following signs of PPE during treatment 
with capecitabine, and resolved spontaneously after discontinuing treatment, 
it is more likely to be a result of the capecitabine rather than any other factors. 
The authors reported these cases from Korea, although the ethnic origin of 
the two cases was not defined. 
 
Having said that there can be differences in presentation between ethnic 
groups, there appears also to be variation in the presentation of PPE between 
different agents. Bullous (blister) variants have been described with cisplatin, 
methotrexate, TKIs and the monoclonal antibody bevacizumab. PPE induced 
by TKIs presents more often as localised patches in weight bearing areas and 
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areas that rub against each other (Fife et al 2009), and usually occurs within 
the first 6 weeks of treatment (Lipworth et al 2009). Docetaxel-induced PPE 
has been reported to present as discrete patches of erythema and not always 
limited to the hands and feet (Zimmerman et al 1995). Because of this unique 
and clinically distinct presentation Childress and Lokich (2003) propose that 
this cutaneous toxicity associated with docetaxel should be renamed as 
Periarticular Thenar Erythema and Onycholysis (PATEO), or fixed 
erythrodysesthesia plaque (Chu et al 2000).  There are occasional reports of 
unusual presentations with capecitabine monotherapy. One case report of a 
56 year old man with colorectal cancer, developed cutaneous lesions 
resembling sclerodactyl-like changes after the seventh cycle (Trindade et al 
2008).  
 
Presentation of skin eruptions in haematology patients following stem cell 
transplantation can cause difficulties in diagnosis as chemotherapy-induced 
PPE and acute graft versus host disease are difficult to distinguish apart 
(Azurdia et al 1999). So, having initially stated that presenting features are 
clearer than incidence, it would seem that in some instances it is not. These 
include; dark skinned individuals; the anti-neoplastic agent being administered 
and those who have received stem cell transplants.  
  
An understanding of the pathophysiological mechanism of PPE is necessary 
to be able to identify potential risk factors. 
 
2.6  Pathogenesis 
The exact mechanism involved in the cause of PPE is unclear but occurrence 
appears to be related to prolonged exposure as with infusional drugs, daily 
ingestion or liposomal encapsulation which extends the drug half-life resulting 
in drug accumulation in the skin (Gordon et al 1995, Molpus et al 2004). Two 
theories have emerged from the literature; the first that extravasation of the 
drugs occur from damaged microcapillaries due to trauma caused by normal 
daily activities such as walking, exposure to heat and grasping objects which 
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results in an inflammatory response (Molpus et al 2004, Saif 2011); secondly 
many chemotherapy agents concentrate in eccrine sweat glands such as 
those found in the hands and feet and sweat acts as a carrier of the drug to 
the skin surface (Azurdia et al 1999, Molpus et al 2004, Lorusso et al 2007). 
The latter theory would explain the areas of the body commonly affected by 
PPE and is supported by the presence of the drugs in sweat (Jacobi et al 
2005, Gressett et al 2006, Martschick et al 2009). This theory reminds 
healthcare professionals that penile involvement in male patients with PPE 
should be considered since this is an area with a high concentration of eccrine 
sweat glands and may be under reported by patients until it becomes severe, 
due to their embarrassment (Sorscher 2004, Lee et al 2009). 
 
No clear correlation between plasma levels of metabolites from capecitabine 
and incidence of PPE has been seen (Gieschke et al 2002, Jeung and Chung 
2010). A suggested cause of PPE by capecitabine is that keratinocytes in the 
skin have high levels of the enzyme thymidine phosphorylase (TP) involved in 
the conversion of capecitabine to 5-FU which could result in metabolite 
accumulation in the skin (Asgari et al 1999, Fischel et al 2004). similar to 5-FU 
itself (Jeung and Chung 2010). Biopsies taken from the palms and backs of 4 
patients receiving capecitabine monotherapy found a marked expression of 
TP in both sites but a paucity of the dihydropyrimidine dehydrogenase 
enzyme (DPD) in the samples from the palms of the hands. Since DPD 
catabolizes 5-FU, the dearth of this enzyme in the palms may explain the 
localised accumulation of 5-FU causing PPE (Ferrero et al 2006). A similar 
picture for TP levels in the palm (p = .04) was found in a pilot study by Milano 
et al (2008) in 12 healthy volunteers. However they found a higher level of 
DPD in the palms than the back (p = .01), the opposite of the previous report. 
Milano et al (2008) found a significantly higher proliferation rate in the palms 
than the back (p = .008) and suggested that it was this that could make them 
more susceptible to the localised action of chemotherapy. Furthermore, a 
significant association between high levels of TP in tumour cells and the 
development of PPE (p = 0.01) with tumour response (p = 0.004) has been 
demonstrated in a phase II study of 30 patients receiving capecitabine in 
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combination with docetaxel for non-small cell lung cancer (Han et al 2005). 
This poses the question of whether it is the TP level in tumour cells (which is 
not routinely measured) that influences the efficacy of the treatment thus 
indicating that PPE is a clinical sign of these raised levels. Further research is 
warranted to compare TP levels and efficacy with the incidence of PPE. 
 
Schedule-dependent PPE has been demonstrated in the use of caelyx and is 
thought to be linked to the turnover time of keratinocytes and epidermal transit 
time (3-4 weeks). A three weekly schedule may hit the skin during its sensitive 
repair time causing an inflammatory response which increases the 
permeability of the microcapillaries leading to extravasation and further 
damage (Lotem et al 2000, Lyass et al 2000). This is supported by Markman 
et al (2004) who presented a case report of a patient who became sunburnt 
between courses of caelyx whereby even with a dose delay and visual 
resolution of the sunburn, severe PPE developed with the subsequent dose 
highlighting the skin’s sensitivity to multiple insults. A photo-enhanced 
melanocyte-based reaction is suggested as the reason for extensive 
hyperpigmentation of normal sun exposed areas of the face (despite strict 
precautions) which accompanied severe painful PPE in one Portuguese 
patient (Tavares-Bello 2007). If we accept these theories as probable, 
potential risk factors can be identified. 
 
2.7  Aetiology and risk factors 
There is variability in the frequency and severity of PPE which appear to be 
determined by pharmacokinetic and pharmacodynamic properties of the 
individual drugs (Lyass et al 2000, Lorusso et al 2007) and/or patient-related 
factors (Lassere & Hoff 2004). The properties of 5FU and capecitabine were 
addressed in section 2.4. In this section a review of the literature of other 
factors will be presented. These factors include biographical details, past 
medical and drug history, health status, organ function, genetics and activities 
of living. 
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2.7.1 Age and Gender 
Age and gender have been suggested as risk factors for PPE, with some 
evidence that older, female patients have an increased risk of PPE (Meta-
analysis group in cancer 1998, Schellens et al 2005, Chabner & Longo 2006), 
while others found no significant difference in age and gender (Comandone et 
al 1993, Chiara et al 1997, Abushullaih et al 2002, Heo et al 2004, Feliu et al 
2005, Sun et al 2009).  
 
Normal physiological changes associated with ageing are known to affect the 
pharmacokinetics and dynamics of drugs often leading to slower metabolism 
and excretion, therefore, it is no surprise that the older patient would be at risk 
of developing chemotherapy-induced toxicities (Jansman et al 2000). When 
analysing the significance of age as a risk factor it is important to note that 
despite the incidence of cancer in the over 70s, there has in the past, been a 
lack of data addressing toxicities in this age group, possibly due to a 
reluctance to treat the very elderly and the age limit (70 years) for entry into 
trials (Zalcberg et al 1998).  
 
An increase risk of PPE has been reported in older patients (p = .009) and 
females receiving 5-FU (p = 0.04) (Meta-analysis group in cancer 1998), and 
may be due to a lower capacity to clear 5-FU in women (Milano et al 1992), 
but not in association with capecitabine (Abushullaih et al 2002, Cassidy et al 
2002). A small study of 41 older (> 65 years) Chinese women receiving a 
combination of capecitabine and docetaxel for metastatic breast cancer 
reported an incidence of PPE grade 1 and 2 of 22% (9) with no grade 3 PPE, 
suggesting this is an effective treatment in elderly women (Wang et al 2010). 
One study comparing the incidence of toxicities between those under the age 
of 65 years and those above 65 years found a similar incidence for PPE of 
any grade and for severe PPE in patients receiving capecitabine monotherapy 
(Scheithauer et al 2003). Stein et al (1995) collapsed age into two categories 
below 70 years and above 70 yrs and found a statistically significant 
association between the older age group and any severe toxicity (p < .001) in 
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patients receiving 5-FU treatment. This finding was not replicated with 
capecitabine monotherapy in patients under 75 years compared with over 75 
years, although only 18 out of a sample of 178 fell into the over 75 year age 
group (Jensen et al 2006). In a small Spanish study of 17 patients with 
metastatic breast cancer who were older than 70 years, PPE grade 3 
occurred in 18% at the standard dose and reduced to 7% when the dose was 
reduced to 1000 mg/m2 (Zamora et al 2004). In another study, carried out in 
China, of 45 patients with advanced gastric cancer, treated with a fixed dose 
of capecitabine 1000mg/day continuously for four weeks followed by one 
week's rest, PPE of all grades occurred in 35.5% with only 2.2% developing 
grade 3 PPE (He et al 2011). The authors of both of these two studies 
concluded that capecitabine was tolerable in patients over the age of 70 if 
given a reduced dose and no difference in efficacy was seen. Oral therapy is 
thought to be preferred by patients, either because of the convenience of this, 
or assuming that there will be reduced toxicities (Labianca et al 2001, Saif & 
Elfiky 2007). However, the Focus 2 trial which recruited elderly and frail 
patients with advanced colorectal cancer from 61 UK centres, found there was 
increased toxicity with capecitabine monotherapy and no evidence of 
improved quality-of-life. The scores used for measuring whether treatment 
interfered with the patient's normal activities indicated a preference for 5 FU 
rather than capecitabine. However the difference was not significant 
(Seymour et al 2011). Having said that there is little difference between the 
incidence of PPE in older patients in the studies above. Reddy & Fakih (2007) 
suggests that patients over 80 years old require substantial dose reduction to 
avoid severe toxicities of capecitabine or 5-FU since they appear to behave 
differently to those in their 70s. 
 
One factor linked to gender which appeared to occur more frequently in 
patients who developed capecitabine-induced PPE for metastatic breast 
cancer was the hormone receptor status of the tumour. There was a 
significant difference between progesterone receptor positive and negative 
tumours (p = 0.003), but no difference in oestrogen receptor status (Kurt et al 
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2006). Since only one study has reported this association further study is 
required to confirm this finding. 
 
2.7.2 Ethnicity 
No evidence has been found in the literature prior to 2005 to indicate that PPE 
prefers a particular race or ethnicity (Janusch et al 2006). However, since the 
presentation of PPE in people with dark skin differs from the white population 
(as previously discussed in section 2.5), the incidence may have been under 
reported. More recently a higher incidence of PPE has been seen in 
Japanese (Hyodo et al 2006) and Korean patients (Yun et al 2010), but with a 
lower incidence in grade 3 PPE which was also seen in Asian patients 
compared to other ethnic groups (Haller et al 2008, Lee et al 2008). 
 
2.7.3 Past Medical History 
Other patient-related factors linked to the development of PPE include; a pre-
existing peripheral vascular disease; compromised peripheral nervous 
system; (e.g. carpal tunnel syndrome) (Zimmerman et al 1995), peripheral 
neuropathy from previous chemotherapy (Palaia et al 2006), diabetes 
(Narasimhan et al 2004, Wilkes & Doyle 2005) dermatological disorders; and 
previous irradiation therapy (Hood & Reeck 2006). Previous exposure to 
chemotherapy especially if the patient experienced toxicities such as 
mucositis (Heo et al 2004), diarrhoea (Wagstaff et al 2003) and neutropenia 
(Jansman et al 2000) have been linked to the development of PPE. Whether 
these factors are statistically significant is unclear in some of the literature and 
are mostly based on case reports, and small scale studies and would require 
validation in larger studies.  
 
There have been some reports that patients with diabetes may have an 
increased risk of developing PPE due to the presence of diabetic neuropathy 
which may reduce sensory perception of the early symptoms of PPE 
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(Narasimhan et al 2004, Goutos et al 2009), although, this finding has only 
been described in single case reports. 
 
The prime aim of one study of 179 patients receiving capecitabine-containing 
combination chemotherapy from 4 prospective clinical trials which reported an 
incidence of PPE in 64.8% (116) and grade 3 in 4.5% (8) was to analyse 
prognostic factors for PPE (Heo et al 2004). They assessed baseline clinical 
factors including age, sex, pre-treatment performance status, regimen and 
combined use of drugs, also performance status per cycle and other toxicities. 
Their findings suggested that docetaxel in combination with capecitabine 
(multivariate Cox regression p = .001) and previous occurrence of mucositis 
(time-dependent Cox regression p = .029) were the only factors that were 
significant prognostic indicators for the development of PPE. Interestingly they 
also found that the occurrence of docetaxel-induced nail toxicity (45.1%, 23 of 
51) was significantly associated with the incidence of PPE (p = .022, chi-
square test). Another study by Chiara et al (1997) of PPE in patients receiving 
infusional 5-FU (n = 70) found that previous exposure to 5-FU was 
significantly associated with the development of PPE in subsequent 
chemotherapy (p = 0.003). Of the 70 patients, 36 developed PPE, 15 with 
PPE alone and the remaining 21 PPE and other toxicities; diarrhoea (58.3%); 
mucositis (50%), nausea and vomiting (41.6%) and conjunctivitis (25%). The 
latter were only presented as descriptive statistics and no significance testing 
or correlation between grade of PPE and additional toxicities were presented. 
 
Disel et al (2010) reported a 65 year old Turkish man with advanced gastric 
cancer who had had a previous stroke leaving him with a right-sided 
hemiplegia. He developed grade 2 PPE 10 days after the start of cycle 4 of 
capecitabine treatment. The PPE developed in his left hand and foot and they 
state that this is the first reported case of unilateral PPE. They hypothesised 
that changes in the skin due to vascular insufficiency led to capecitabine 
metabolites having reduced access to the skin in the extremities affected by 
the hemiplegia and were unable to accumulate and cause PPE. Whilst this 
hypothesis seems plausible unilateral PPE may be partly due to the lack of 
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exposure to other factors, such as friction and heat implicated in the 
development of PPE, due to reliance on using his left side for day to day 
activities.  
 
Another case report in the literature was of a 53 year old Italian female with 
ovarian cancer receiving PLD every 4 weeks who had persistent peripheral 
neuropathy following previous chemotherapy treatment. A past medical 
history of poliomyelitis had left her with a right quadriceps paralysis. She 
developed grade 3 PPE after cycle 3 with a dark, cold and ulcerated area of 
the distal phalange of the 2nd finger on the left hand which led to amputation of 
that part of the digit. This is the first reported case of irreversible skin toxicity 
probably due to the absence of pain sensation caused by the peripheral 
neuropathy. This may have led to an underestimation of the severity of the 
erythema seen after cycle 2 as the patient reported no pain or burning (Palaia 
et al 2006). This finding is support by Tanyi et al (2009) who found that those 
with peripheral neuropathy were twice as likely to develop PPE than those 
who did not have peripheral neuropathy from previous treatment (p = .0001) 
and suggested that peripheral neuropathy damages the nerves of the blood 
vessel walls causing them to lose their ability to respond to temperature 
changes which enhances the mechanism of PPE. 
 
2.7.4 Drug to Drug Interaction 
Concomitant medications may lead to drug-drug interactions resulting in 
increased toxicity of anti-neoplastic agents or affect the efficacy of the co-
medication (Jansman et al 2000, Chabner & Longo 2006). There have been 
case reports of an increased incidence of PPE in patients who receive 
pegylated G-CSF (PG-CSF) with each cycle of docetaxel, where the PPE 
resolved without dose reduction after the PG-CSF was stopped (Bardia et al 
2006). This association is supported by Burnstein et al (2005) who report 
grade 2 or 3 PPE in 4% of patients who received PG-CSF in a prospective 
clinical trial of dose dense docetaxel chemotherapy, although exact details of 
sample size or alterations to treatment were not provided. The absence of 
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PPE in a large trial of patients receiving docetaxel supported with non PG-
CSF suggests that it is the pegylation of G-CSF contributes to PPE toxicity 
(Citron et al 2003). In addition, the substitution for non-pegylated G-CSF in 
patients who developed PPE following PG-CSF support while receiving 
doxorubicin and cyclophosphamide (AC) resulted in resolution of the PPE 
without any alterations to treatment (Lee & Lynch 2007). PG-CSF has a 
longer half life and therefore increased tissue concentration than non-
pegylated G-CSF and is cleared through a mechanism controlled by 
neutrophils (Kotto-Kome et al 2004). One of the histological features of PPE is 
the infiltration of the lesions by white blood cells and it is possible that 
pegylation of G-CSF enhances and increases neutrophil infiltration in some 
patients, provoking the inflammation observed with PPE (Bardia et al 2006, 
Lee & Lynch 2007).   
 
Other concomitant medications that increase the toxicity of 5-FU or 
capecitabine are allopurinol, dipyramidol, metronidazole and cimetidine 
(Jansman et al 2000), with a single case report of severe PPE when 
capecitabine is administered concurrently with brivudin, an anti-viral agent to 
treat Herpes Zoster infection (Baena-Canada et al 2010). Capecitabine 
causes an increase in phenytoin levels and the close monitoring of phenytoin 
levels or the use of alternative antiepileptic medication is recommended (Berg 
2006, Privitera and de los Rios La Rosa 2011, Roche 2011). Capecitabine 
increases the effect of warfarin and leads to raised International Normalised 
Ratio (INR) levels and can fluctuate during 3-weekly cycles. Suggestions have 
been made that the patient should be transferred to low-molecular weight 
heparin during treatment with capecitabine (McGavin & Goa 2001, Berg 2006, 
Giunta 2010, Roche 2011).  
 
Finally, antacids interfere with the absorption of capecitabine and should 
either be avoided or taken 2 hrs before or after taking capecitabine (Van 
Cutsem et al 2000, McGavin & Goa 2001). 
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2.7.5 Performance status 
Surprisingly unlike other toxicities, PPE had a higher incidence in patients with 
a good performance status (n = 70, p = 0.053) (Chiara et al 1997) (n = 41, p = 
0.03) (Abushullaih et al 2002). Contradictory findings are presented by others 
who found no significant association with performance status (Comandone et 
al 1993, Heo et al 2004). Comandone et al (1993) based their findings on just 
12 cases of patients receiving 5FU who developed PPE, whereas, Heo et al 
(2004) used a larger sample of pooled data from four trials (n = 179) of 
Korean patients who received capecitabine-containing regimes. One study, in 
patients with leukaemia receiving a combination of cytosine arabinoside and 
daunorubicin, indicated a correlation between poor performance status and 
the development of severe PPE which also resolved slowly (Demirçay et al 
1997), though again this was based on small numbers with only 2 out of the 
15 who developed PPE having poor performance status.  
 
2.7.6 Nutrition and weight 
A risk factor identified in the literature which could include both drug and 
patient factors is the role that malnutrition plays in the development of PPE.  
Nutritional deficit has been implicated particularly since pyridoxine (Vit B6) 
has been shown as a possible treatment of PPE (Lassere & Hoff 2004). 
Decreased serum albumin and increased bilirubin levels could contribute to 
an increased risk of toxicity, particularly related to drugs that are at least 90% 
protein-bound (Jansman et al 2000). A reduction in this carriage mechanism 
or an increase in bilirubin (as bilirubin is also protein bound and competes 
with the drug for attachment) results in an increase of free circulating drug 
which is partly responsible for the development of toxicities (Jansman et al 
2000). A study of prognostic factors for the toxicity of 5-FU in 130 patients 
revealed that baseline serum albumin was not predictive of toxicity and since 
5-FU is only 10% protein-bound, this result is not surprising (Steinberg et al 
1992). With capecitabine, the amount bound to protein is low, although higher 
than 5-FU at 54%, mostly bound to albumin (35%) (McGavin and Goa 2001, 
Review of the literature 
Page | 36 
 
Reigner et al 2001). In a study by Sharma et al (2006) high levels of dietary 
folate have been linked to increased tumour response but also resulted in 
development of toxicities with Capecitabine. Folate is required for the binding 
between 5FU metabolites to the enzyme thymidine phosphorylase (TP) during 
the metabolism of capecitabine. They found that high levels of pre treatment 
serum folate levels were significantly associated with increased toxicity during 
cycle 1 and over the entire treatment period (p = 0.02), particularly grade 2/3 
diarrhoea (p = 0.001) and grade 2/3 nausea and vomiting (p = 0.032) when 
compared with grade 0 and 1. These results are based on a sample of 38 
patients, thereby lacking sufficient power to draw firm conclusions. The USA 
has had voluntary addition of vitamins (including folates) and minerals to 
foods such as bread, flour, spreadable fats, milk and milk products since 1924 
which became mandatory in 1943. In the UK it has been mandatory to fortify 
flour and margarine since the 1940s. However, the addition of folates is still 
subject to debate (DH 2011). The presence of fortified foods in the diet of 
those from the USA in Haller et al’s (2008) study may partly explain the higher 
incidence of grade 3/4 toxicities, although this is not proven.  
 
Weight loss prior to a diagnosis of cancer was linked to an increased 
incidence of severe PPE compared to those who had not lost weight (p < 
0.002). This is thought to be due to altered response to chemotherapy in 
patients with weight loss, since even 5% weight loss can alter measurable 
physiological values such as immune response (Andreyev et al 1998). Data in 
their study, however, did not establish how much weight loss was significant 
and the accuracy of the weight loss was doubtful. Weight was not recorded 
prior to the diagnosis of cancer, was based on subjective reporting by the 
patient, and was not validated independently.  
 
The influence of cachexia (a common presenting feature of cancer), on the 
pharmacology of chemotherapy agents is unclear and has not been evaluated 
as a risk factor for toxicities (Jansman et al 2000).  Conversely, some doctors 
are reluctant to prescribe PLD to overweight patients as they suggest that 
being overweight intensifies the risk of PPE due to increased friction in the 
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inter-triginous areas especially the axilla, breast and waist areas (Griggs et al 
2005 & 2007). There are several physiological changes that occur in 
overweight individuals that may affect the way drugs are processed by the 
body. These include alterations in lean body mass, adipose tissue mass, 
organ size, blood volume and cardiac output. However, prospective 
pharmacokinetic studies are required to demonstrate whether increased body 
weight is a risk factor for toxicities from chemotherapy agents (Jansman et al 
2000). Gordinier et al (2006) tested this hypothesis in a retrospective analysis 
of patients records over 7 years (n = 103). They found that there was no 
significant difference in body mass index (BMI) between those that developed 
PPE and those that did not, suggesting that BMI is not a risk factor for PPE.  
 
Individual patient chemotherapy doses are based on calculated Body Surface 
Area (BSA) because of convention rather than scientific research (Gurney et 
al 1998). Being first described to scale the doses from lower mammals such 
as rodents to humans, this led to the myth that BSA based dosing provides 
safe and effective administration schedules of chemotherapy (Pinkel 1958, 
Gurney et al 1998, Ratain 1998). Two small studies have challenged the 
convention of using BSA to calculate dosage. The first evaluated patients who 
received epirubicin of the same dose regardless of BSA, organ function or 
other factors, finding no correlation between BSA or weight and toxicity 
(Gurney et al 1998). The second with a fixed dose of capecitabine 1000mg/m2 
twice a day for 14 days every 3 weeks, again finding no difference in the 
frequency of adverse events and BSA (Sun et al 2009). It has been suggested 
that Lean Body Mass (LBM) correlates better to drug clearance than BSA, but 
has been tested in too few studies to draw conclusions (Ratain 1998). An 
analysis of 5FU and LBM found the latter to be a significant predictor of 
toxicity in female patients (Prado et al 2007), which can be partially explained 
by the difference between men and women, since women have a lower 
proportion of LBM (Jansman et al 2000, Prado et al 2007). Zalcberg et al 
(1998) in a bivariate analysis of toxicity and LBM found a statistically 
significant association between low LBM and grade 3/4 neutropenia in 
patients receiving 5FU (p = 0.009). However, the significance disappeared in 
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a multivariate analysis suggesting that the bivariate effect was caused by 
gender reflecting the fact that females have lower LBM than males. The LBM 
compartments in the body include metabolic tissues such as the kidneys and 
liver, bone and intra and extracellular water. Since 5FU is fairly hydrophilic, it 
will be distributed in and metabolized by the LBM, which would explain the 
higher incidence of toxicity seen in patients with a low LBM (Gusella et al 
2002, Prado et al 2007). Until a simple standard and accurate method to 
calculate LBM is available practice cannot change (Ratain 1998). 
 
2.7.7 Organ function 
A link between renal impairment and an increased incidence of severe 
toxicities with capecitabine have been demonstrated due to a reduction in the 
excretion of its metabolites (Gieschke et al 2002, Poole et al 2002) suggesting 
that capecitabine should not be given to patients with severe renal 
impairment.  Another study comparing pre-treatment creatinine clearance 
(CrCl) values with the incidence of PPE determined that for every 10 
millilitres/minute reduction in CrCl the risk of developing PPE increased by 7% 
(95% CI: 2 – 11) (Hénin et al 2009). A dose reduction of 25% of capecitabine 
is required in moderate renal failure (CrCl 30-50 mls/min) and is 
contraindicated in severe renal failure (CrCl below 30mls/min) (EMC 2012). 
For elevations of bilirubin levels of three times the upper limit of normal, 
capecitabine should be interrupted until bilirubin falls below this level. The 
effect of severe hepatic dysfunction on capecitabine is not known (EMC 
2012). Likewise a dose reduction of 5-FU is required with impaired renal and 
hepatic function (EMC 2011).  
 
An investigative model Gieschke et al (2002) of pharmacokinetics of 
capecitabine identified that a 50% decrease in CrCl was associated with a 
30% reduction in the clearance of α-fluoro-β-alanine (FBAL), a metabolite of 
capecitabine. This is an unsurprising find given that the majority of FBAL is 
excreted via the kidneys. In addition, the study reported that this was a 
predictor of dose-limiting toxicities. A similar effect of CrCl values and FBAL 
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clearance was seen in a study by Poole et al (2002) who also found that those 
with moderate or severe renal impairment experienced an increased 
incidence of grade 3/4 toxicities. However, no relationship between FBAL and 
these toxicities was found. There was, however a strong association between 
severe toxicities and another metabolite of capecitabine, 5’-DFUR (5’-deoxy-
5-fluorouridine) whose clearance is also affected by the kidneys. They 
recommend that capecitabine should not be given to patients with severe 
renal impairment. A study of pooled data from two large phase III trials using 
pre-treatment CrCl values determined that for every 10 millilitres/minute 
reduction in CrCl the risk of developing PPE increased by 7% (95% CI: 2 – 
11) (Hénin et al 2009). 
 
2.7.8 Genetics 
Other factors that have been linked to increased incidence of toxicities from 
5FU are genetic polymorphisms of the enzymes DPD (dihydropyrimidine 
dehydrogenase the rate limiting enzyme of 5FU catabolism) (Diasio & 
Johnson 1999) and TP (Thymidine Phosphorylase the main activating 
enzyme of capecitabine) (Caronia et al 2011).  
DPD activity has been shown to be circadian dependent with increased 
activity in the evening which corresponds with findings that 5-FU is 
metabolised faster in the evening (Bjarnason et al 1993). Alteration in genes 
regulating drug transport and metabolism have been shown to play a 
significant role in the development of severe PPE. This has been seen 
particularly in 5-FU (Johnson et al 1999, Van Kuilenburg et al 2002) and 
capecitabine (Mattison et al 2006) containing regimes where there was 
mutation of the gene (DPYD) (Van Kuilenburg et al 2002, Loganayagam et al 
2010). This gene encodes for the enzyme DPD and a mutation leads to 
complete or partial loss of DPD enzyme (Johnson et al 1999). This results in 
delayed or incomplete catabolism of the drug resulting in severe and 
sometimes fatal side effects (Johnson et al 1999, Johnson & Diasio 2001, 
Loganayagam et al 2010). African Americans with colorectal cancer had a 
high incidence of 5FU toxicities in one study (Mattison et al 2006), which 
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motivated them to evaluate DPD enzyme activity in healthy African Americans 
compared with Caucasians [sic]. DPD deficiency was found to be three times 
greater in African Americans (p = 0.07), and the women in this group were 
found to have a higher incidence of DPD deficiency than the men in the same 
ethnic group (p ≤ 0.001). The opposite was seen in the Caucasian [sic] group 
with men having a higher rate of DPD deficiency than women (p = ≤ 0.003) 
Testing for DPD activity prior to commencing treatment with 5-FU or 
capecitabine has been suggested (Lu et al 1993). Point mutation in the DPD 
gene, resulting in deficiency in gene production, has been seen in German, 
Finnish, Turkish and Taiwanese populations (in < 3%) but not seen in 
Japanese and African American populations (Van Kuilenburg 2004). Because 
of this low prevalence there is doubt as to the usefulness of pre-treatment 
genetic testing to individualise doses (Etienne et al 1994), although 
Loganayagam et al (2010) found that the UK population deficit in the DPD 
gene accounts for approximately 19% of severe toxicities from 5FU. A further 
study five years later demonstrated that there was a significant difference in 
DPD levels between patients with breast cancer and healthy females (p < .01) 
suggesting that patients with breast cancer have an increased risk of toxicity 
from 5-FU (Lu et al 1998). PPE is not mentioned specifically in any of the 
studies of DPD deficiency, as it is not considered a life threatening toxicity; 
therefore it is unclear whether PPE occurs more frequently or severely in 
these patients.  
 
Park et al (2003) found a high incidence of grade 3 PPE (52%) in 23 patients 
receiving combination therapy of capecitabine and docetaxel for advanced 
gastric cancer, who also received pyridoxine in an attempt to reduce the 
incidence of PPE. They suspected that ethnicity may be a factor (details not 
given) and analysed the DPD gene in those that developed PPE grade 3, 
finding no evidence of DPD deficiency, therefore suggesting that severe PPE 
is not associated with gene mutation. This is contrary to the findings by Harris 
et al (1991) and Milano et al (1999) who suggest an association in patients 
receiving 5FU therapy. The testing for DPD deficiency in all the studies cited 
above appear to have been on serum. Interestingly, Ferrero et al (2006) took 
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biopsies from the palms of the hands and the back (control), finding increased 
expression of TP, but a relative absence of DPD in the skin. They concluded 
that capecitabine may be activated in the skin due to this high level of TP in 
conjunction with the absence of DPD explaining the specificity of PPE to the 
palms of the hands and soles of the feet. They also suggested that this may 
be an area for pharmacological research to limit the development of PPE.   
 
Gender differences have been reported, with females having lower levels of 
DPD than males, which may partly explain the increase in toxicity of 5-FU in 
females. However, the DPYD mutation has an autosomal recessive pattern of 
inheritance; therefore, it is difficult to explain this phenomenon since it is not 
sex-linked (Milano et al 1999).  
 
Gene mutation of TP has been associated with death due to severe toxicities 
of 5FU (Caronia et al 2011). The presence of mutated genes is twice as 
common in Chinese people as in Caucasian [sic] people. However, similar 
incidence is seen between Caucasians [sic] and south-west Asians. It is 
unclear whether this same link is made with capecitabine (Tan & McLeod 
2005). A third gene that has been shown to be associated with PPE is the 
cytidine deaminase (CDD) gene (p = 0.04) and may gives new insights into 
discovering the mechanisms of PPE (Caronia et al 2011). Gonzales-Haba et 
al (2010) examined mutations in the ABCB1 gene and suggested this could 
be a biomarker for toxicity in colorectal cancer, particularly for neutropenia, 
diarrhoea and PPE. However, the study appears to suggest that a mutation in 
this gene is significantly associated with a reduced risk of these toxicities. 
 
2.7.9 Patient activities 
Since PPE may result from increased vascularity, pressure and temperature 
(Arias et al 1997) in the hands and feet, patient risk factors may include 
strenuous physical activity (Lassere & Hoff 2004), trauma and friction (Baer et 
al 1985) caused by normal activities such as walking or grasping objects, and 
long-term alcohol intake (Lassere & Hoff 2004).  
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Some studies, predominantly with patients receiving PLD, have suggested 
that active cooling reduces the risk of developing PPE (Baer et al 1985, 
Zimmerman et al 1994, Molpus et al 2004, Scotte et al 2005, Sayer et al 
2006, Mangili et al 2008). Others have found the opposite with an increased 
incidence of PPE in those who used active cooling measures (Tanyi et al 
2009).  
 
As previously alluded to (section 2.6), chemotherapy has been isolated in the 
sweat glands of patients who developed PPE. It would, therefore, seem 
logical that individual sweat patterns may play a role in the development of 
PPE. In a small study (n = 10) of patients receiving PLD, 5 patients had 
hyperhydrosis and all 5 developed PPE (Jacobi et al 2005). PLD presence in 
sweat was confirmed by spectroscopy in 12 patients in a study to understand 
the pathogenesis of PPE (Lademann et al 2005). Exposure to heat and 
sweating may be more prevalent during hot weather, which calls into question 
whether the time of year when chemotherapy is administered has any 
association with the development of PPE, although this notion was refuted by 
Tanyi et al (2009) who found no association between the incidence of PPE 
and time of the year treatment was given. Son et al (2009) however, stated 
that changes in the skin, due to environmental factors such as humidity and 
the increased use of central heating in the winter may make the skin more 
sensitive to PPE inducing agents. Regular exposure to the sun, even with 
sunscreen precautions has been linked to the development of PPE 
(Zimmerman et al 1995, Peramiquel et al 2006), with one report of a patient 
severely sunburnt during treatment who developed PPE despite resolution of 
the sun damage to the naked eye (Markman et al 2004). 
 
Alcohol abuse has been associated with the development of PPE in patients 
receiving 5-FU or capecitabine with a suggestion that this group of patients 
should be prescribed pyridoxine from the start of treatment to reduce the 
severity of PPE (Vukelja et al 1989). 
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Whilst biographical, health status, organ function and genetics as risk factors 
for PPE have been tested as part of large phase III trials this has 
demonstrated contradictory findings for some factors. There is consistency in 
the literature to suggest that impaired renal function and DPD deficiency are 
risk factors for PPE. Potential risk factors related to patient activities that lead 
to increased trauma, pressure or temperature to the hands and feet have not 
been subjected to rigorous testing. 
 
2.8  Strategies to manage or minimise the severity of PPE 
Numerous approaches have been suggested to prevent and/or reduce the 
severity of PPE. Two universally accepted approaches to the management of 
PPE are, for moderate to severe symptoms, treatment delay with/without a 
reduction in the dose (EMC 2011 & 2012). The second accepted approach 
being supportive care in conjunction with patient education (Webster-Gandy 
2007). Pharmacological and non-pharmacological supportive care strategies 
proposed in the literature will be presented in this section. Patient education 
strategies will be discussed in section 2.9. 
 
2.8.1 Pyridoxine (Vitamin B6) 
The interest in pyridoxine to prevent or treat PPE stems from its similarity to 
acrodynia (a condition observed in pyridoxine phosphate depleted rats) 
(Gyorgy & Eckardt 1939).  
 
Early reports on the use of pyridoxine to treat PPE are based on single case 
reports or small uncontrolled studies, with a few examples given below.  
 
Vukelja et al (1989) present a 63 year old man with metastatic pancreatic 
cancer who was given bolus 5-FU 900mg/week escalating to 1150mg/week. 
After 11 weeks of treatment he developed PPE with cracking to his finger tips, 
severe pain and difficulty holding objects. Pyridoxine 100mg daily was 
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prescribed with no change in the 5-FU dose resulting in complete resolution of 
his pain. To test whether this result was a coincidence, his skin was tested 
with topical 5-FU for 72 hours, during which time pyridoxine was stopped. 
Within 24 hours there was a recurrence of PPE with swelling and pain of the 
fingers. Pyridoxine was recommenced and within 24 hours the pain and 
swelling had resolved. 
 
Vukelja et al (1993) reported two further cases, one male and one female, 
who received docetaxel monotherapy. Both patients developed PPE and were 
commenced on pyridoxine 50mg three times a day with an improvement in 
their pain within 24 hours. The female patient occasionally forgot to take the 
pyridoxine and when that happened she developed tingling of her fingers 
which prevented her from using her computer. 
 
One patient with Kaposi’s sarcoma who had previously been treated with PLD 
and which had been discontinued due to grade 3 PPE, presented with 
progression of the disease. She was retreated with PLD at a lower (50%) 
dose than previously given. She again developed PPE and was prescribed 
100mg pyridoxine three times a day for one week, then reduced to 50mg 
three times a day. There was complete resolution of the symptoms of PPE 
and PLD treatment with pyridoxine was continued resulting in a good tumour 
response and no further PPE (Gordon et al 1995). 
 
A 56 year old female with metastatic breast cancer was treated with a 
combination of capecitabine and docetaxel. She developed severe PPE and 
treatment was discontinued. Despite attempts to treat with other 
chemotherapy agents her disease progressed. Capecitabine and docetaxel 
were recommenced with pyridoxine (dose unknown) in an attempt to prevent 
the development of PPE. Her PPE was completely controlled and she was 
able to continue her treatment. Her liver metastases disappeared on scan 
images (Umeda et al 2010). 
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A controlled study of patients receiving continuous infusional 5-FU who were 
commenced on either 50mg or 150mg of pyridoxine per day once they 
developed moderate PPE showed a partial reversal of PPE and allowed 
continuation of treatment without delay in 4 out of the 5 patients who received 
pyridoxine. Based on this observation it was recommended that randomised 
trials be undertaken to evaluate whether pyridoxine reduces the incidence of 
PPE without affecting response (Fabian et al 1990). 
 
Patients with multiple myeloma were administered a combination regime of 
vincristine, PLD and dexamethasone every 4 weeks. After a high incidence of 
grade 3 PPE in the first 9 patients pyridoxine 200mg/day was added to the 
regime. Following this addition of pyridoxine the incidence of grade 3 PPE 
reduced (Hussein et al 2002). The actual figures demonstrating the reduced 
incidence were not evident in their study nor was any statistical analysis. They 
stated that the result should be treated with caution since the decrease in 
PPE may be due to the medical teams’ increased expertise with this regime 
particularly the detailed instructions given to patients to minimise the risk of 
PPE.  
 
The cases reported above all suggest that pyridoxine does indeed play a role 
in treating PPE since all authors reported a reduction in the symptoms 
experienced by the patients enabling them to continue with their therapy. 
Several randomised trials have been carried out to assess the efficacy of 
pyridoxine to either prevent or treat PPE. 
 
A preclinical randomised study in 41 dogs to establish the effectiveness of 
pyridoxine given with PLD to prevent the development of PPE found that the 
placebo group were over 4 times more likely to develop severe PPE than the 
pyridoxine group (p = .03). Although pyridoxine did not completely prevent 
PPE, it occurred later and with less severity resulting in fewer delays or 
discontinuation of treatment (Vail et al 1998). 
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During a phase II study of PLD in combination with paclitaxel, the first 15 
patients developed grade 2 or 3 PPE. The next 20 patients were commenced 
on pyridoxine 300mg/day; however a reduction in the incidence of PPE was 
not seen demonstrating that high-dose pyridoxine has no effect on the 
frequency and severity of PLD-induced PPE (Rossi and Catalono 2007). 
Although a different dose of pyridoxine was used, another trial found similar 
results. A randomised controlled trial (n = 34) with 18 patients allocated to the 
pyridoxine group and 16 to the placebo group. Any patients who developed 
PPE grade 2/3 were unblinded and if taking the placebo they were changed to 
pyridoxine 100mg twice a day, if on pyridoxine they were removed from the 
trial. No statistical difference was found between the groups, indicating that 
pyridoxine was not effective in preventing or treating PPE (Von Gruenigen et 
al 2010). 
 
The two studies above were carried out on patients receiving PLD therapy 
and it is possible that pyridoxine may be effective with different PPE-inducing 
agents. The following three trials report variable findings when pyridoxine is 
added to capecitabine. 
  
A multicentre retrospective notes review was carried out to determine the 
incidence and severity of PPE in patients receiving capecitabine monotherapy 
and to assess the efficacy of pyridoxine as prophylaxis or treatment of PPE 
(Mortimer et al 2003). There were two groups of patients; those taking 
capecitabine alone (n = 99); and those who received pyridoxine (n = 99). Out 
of the 99 who received pyridoxine, 73 (74%) were prescribed this 
prophylactically with the remaining 26 receiving pyridoxine as treatment once 
PPE occurred. They found no statistically significant difference in the 
incidence of PPE between those who received capecitabine alone compared 
to those who received pyridoxine as prophylaxis. The conclusions drawn from 
this study were that the data did not support the use of pyridoxine as 
prophylaxis to prevent PPE. However, when used as treatment once PPE 
occurs, pyridoxine may provide some relief of symptoms (p < .001). Although, 
prospective randomised controlled trials to test this hypothesis would be 
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required. It is unclear from this study whether the patients who received 
pyridoxine once PPE occurred also had a delay in their treatment. It cannot 
therefore be established with any certainty if the positive effect seen was due 
to the pyridoxine or a delay in treatment. 
 
A randomised controlled trial by Chalmerchai et al (2010) carried out in 
Thailand compared two doses of pyridoxine, 200mg versus 400mg daily to 
prevent capecitabine-induced PPE.  A sample of 56 (28 in each group), found 
less grade 2 or 3 PPE in the high dose group 11 (39%) compared with 20 
(71%) p = .03 with no cases of grade 3 in the high dose group compared with 
3 (10.7%) in the lower dose group, but was not statistically different p = .24. A 
multivariate analysis demonstrated that 400mg of pyridoxine was the only 
independent factor for a reduction in the incidence of PPE. However, they 
found that the group receiving the higher dose of pyridoxine had worsened 
tumour response with an increased incidence of disease progression and a 
shorter time to progression. Limitations of their study include the lack of a 
placebo group, a small sample size and it did not meet the preplanned 
statistical power. 
 
Another randomised double-blinded placebo controlled study (Kang et al 
2010) was performed to examine the effectiveness of pyridoxine to prevent 
PPE. Chemo-naïve patients received capecitabine containing regimes and 
pyridoxine 200mg/day (n = 180) or a placebo (n = 180). If those in the placebo 
group developed PPE, they were further randomised to either the pyridoxine 
or the placebo group. The results showed no significant difference in the 
incidence of PPE between the two groups was found and concluding that 
pyridoxine is not effective to prevent or treat PPE associated with 
capecitabine containing regimes. 
 
A final study (Yoshimoto et al 2010) to assess the impact of prophylactic 
pyridoxine (60mg/day) on the incidence of PPE with capecitabine 
monotherapy or in combination with cyclophosphamide (n = 38) compared 
historical data in 40 patients who had not received pyridoxine. The incidence 
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of PPE in the pyridoxine group was 52.6% compared with 82.8% in the 
capecitabine only group (p < .01). They suggest that pyridoxine is effective in 
reducing the rate of PPE. Limitations of this study include a small sample, 
gender biased (all women), and no data presented to show the difference 
between those who received capecitabine monotherapy and those who 
received a combination regime.  
 
Pyridoxine has been reported anecdotally to be useful to both prevent and 
treat PPE induced by various anti-neoplastic agents. The trials that have been 
carried out, report findings on small samples and use different doses of 
pyridoxine making comparison difficult. As a safe nutritional supplement, its 
prophylactic use is attractive; however, its efficacy needs to be proven in large 
prospective randomised controlled trials (Lassere and Hoff 2004). These 
studies would also need to include data on the outcome of treatment 
comparing those who received pyridoxine with those who did not. Time to 
disease progression and overall survival data should be measured, 
particularly in the light of the worrying report by Chalmerchai et al (2010) 
mentioned above. The debate on the usefulness of pyridoxine in the 




Moisturising creams are recommended for use before and during treatment to 
the hands and feet to reduce the severity of PPE (Bush & Smith 2001, 
Gressett et al 2006, Grenon & Chan 2009). Particular attention should be 
given to the creases of the hands and wearing cotton gloves and socks at 
night will aid absorption of the cream (Pike 2001, Von Moos et al 2008). 
Udderly smooth®, bag balm®, lanolin-containing creams, ammonium lactate 
(Lac-hydrin), have all been used and some patients have reported success 
with George’s Special Dry Skin cream, hemp-based creams and Aquaphor 
(Gerbrecht 2003).  
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A case report of a 61 year old man receiving gemcitabine and vinorelbine 
combination every 3 weeks, developed PPE (hands only) three days after the 
start of cycle 2. He was treated with topical urea 10% and able to continue 
with his treatment. With his next cycle he developed PPE on his feet, again 
treated with topical urea. By cycle 4 the PPE had completely resolved on both 
his hands & feet and he continued with treatment with no recurrence of PPE 
(Laack et al 2001). 
 
Urea & lactic acid are known to have keratolytic and hydrating properties and 
since hyperkeratosis is a feature of PPE, this provided support to study the 
role of a cream containing these substances (Gressett et al 2006, Grenon & 
Chan 2009). A Multicentre randomised controlled trial (n = 137) of cotaryl 
cream (12% urea and 6% lactic acid) compared with a placebo was carried 
out on patients taking capecitabine. From the start of treatment ½ - 1 
teaspoon of the cream or placebo was applied to the palms of the hands and 
soles of the feet, twice a day. No statistically significant difference between 
the groups and grade 2 or 3 PPE was found. In fact there was an increased 
incidence of severe PPE in the cream group, concluding that there is no 
evidence to support the use of urea and lactic acid cream to prevent PPE. 
There was some concern that the cream itself may have caused some of the 
skin toxicity (Wolf et al 2010). 
 
Bag Balm®, and Udderley Smooth cream® are petroleum-lanolin containing 
ointments intended for veterinary use to sooth cows udders. Bag Balm® also 
contains an antiseptic ingredient hydroxyquinoline sulphate (Bush and Smith 
2001). A study by Chin et al (2001) described the effect of Bag Balm® as 
topical treatment for PPE caused by a variety of agents. 13 patients 
developed PPE with 9 assessed as grade 2 or 3. All 13 used Bag Balm® and 
12 of the 13 reported improvement in their PPE. There were no 
discontinuations of treatment due to PPE, showing promising results for this 
emollient. To enhance the effectiveness of these creams Saif & Elfiky (2007) 
suggest soaking hands in lukewarm water for 10 minutes and then apply 
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petroleum jelly onto the wet skin, as this traps the water on the surface and 
also protects injured or blistered skin.  
 
Topical antioxidant creams have also been shown to have promising results in 
the prevention and treatment of PPE. An observational study of 12 chemo-
naïve patients who applied antioxidant cream to the hands and feet did not 
develop PPE of any grade. 4 patients who interrupted the application of the 
antioxidant ointment developed grade 1 or 2 PPE, which resolved with the re-
application of the ointment. 3 other patients who had developed PPE with 
previous chemotherapy treatment developed very mild reactions while using 
the cream (Lademann et al 2006). The primary results of a pilot non-
randomized study of 20 patients who received a specially designed topical 
antioxidant ointment for PPE was also very promising (Von Moos et al 2008).  
 
2.8.3 Steroids 
Since steroids are known to reduce inflammation, it is this property that has 
led to their use to prevent or treat PPE, although the known dangers of steroid 
use have to be considered (Lassere & Hoff 2004, Von Moos et al 2008). 
 
Single or small group case reports have suggested that corticosteroids 
administered topically (Esteve et al 1995, Gordon et al 1995, Komamura et al 
1995, Valkalis et al 1998) or systemically (Brown et al 1991, Hellier et al 1996, 
Titgan 1997, Hoff et al 1998b) are effective in the prevention and 
management of PPE induced by a range of agents but has yet to be proven 
with capecitabine (Lassere & Hoff 2004). 
 
A 64 year old female received PLD with pre medications of intravenous 
dexamethasone 20mg, diphenhydramine 50mg, cimetidine 300mg and 
ondansetron 10mg. After cycle 3 she developed a general rash and severe 
desquamation and dermatitis in a stocking-glove distribution. She was started 
on oral dexamethasone 8mg twice a day starting 24 hours pre treatment and 
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for 5 days following treatment. This appeared to prevent further PPE without 
treatment delay or dose reduction (Titgan 1997). 
 
A second case report of a 67 year old man with gliobastoma multiforme 
received temozolamide 200 mg/m2 for 5 days every 4 weeks. After his fifth 
cycle he developed grade 3 PPE (WHO criteria) which was treated with 
intravenous dexamethasone (no dose and frequency given). The signs and 
symptoms of PPE disappeared within one week compared with the normal 
course of the side effect of 5-6 weeks (Kanat et al 2007). 
 
In a phase I/II study of high-dose vinorelbine 8mg bolus followed by 96 hr 
continuous infusion of the same drug 7-14 mg/m2 /day, 4 out of 60 patients 
developed PPE. One of these was given dexamethasone 8mg orally twice a 
day for 5 days starting prior to the vinorelbine bolus and resulted in no further 
PPE (Hoff et al 1998a). 
 
Conversely in 12 patients with 5-FU induced PPE who were treated with 
topical steroids or systemic anti-inflammatory agents no significant activity 
was found. 5-FU was withheld in all the patients for up to 4 weeks with 
gradual relief, however, when 5-FU was restarted, PPE recurred. Of the 12, 6 
tolerated the treatment without dose reduction, 4 required a dose reduction 
and 2 had to discontinue 5-FU due to PPE (Comandone et al 1993). In this 
small study no information was given about which steroids or anti-
inflammatory agents were prescribed or the dose and frequency. The 
incidence of each grade of PPE or the toxicity criteria used was not included. 
 
A prospective study (Drake et al 2004) of the effect of dexamethasone on 
PLD-induced PPE was carried out in 9 patients who developed grades 2-4 
PPE. Of these 9 patients, 6 were given dexamethasone and were able to 
continue with treatment with no dose modification. The remaining 3 had no 
dexamethasone and required treatment delays and dose reduction. The 
conclusion was that dexamethasone is effective in managing PPE and has 
now become standard practice in one unit who have seen no dose reductions 
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due to PPE or any grade 3 or 4 PPE since introducing this practice. The 
findings from this study are limited by the small sample size, the lack of 
randomisation or statistical testing of the differences and are therefore 
inconclusive at this time. 
 
2.8.4 Celecoxib 
Celecoxib is a Cox-2 inhibitor used for the relief of acute pain and symptoms 
of chronic inflammatory conditions (Lassere & Hoff 2004). In a retrospective 
study of 67 patients receiving capecitabine monotherapy the addition of 
celecoxib appeared to reduce the incidence of PPE grade 2 or above from 
34% with capecitabine alone to 13% when celecoxib was added (Lin et al 
2002). This potential effect needs testing in a large prospective randomised 
trial to provide sufficient evidence to recommend its use for prophylaxis of 
PPE. 
 
In a prospective randomised study, 16 patients were given capecitabine 
monotherapy and another 15 given capecitabine with celecoxib. The 
celecoxib group showed a significant reduction in the frequency of grade 1 
PPE (29% versus 72%; p < .001) and for grade 2 PPE (11.76% versus 30%; p 
= .02), but no significant difference for grade 3 PPE. In the capecitabine only 
group, 5 patients refused to continue treatment and 1 required a dose 
reduction due to PPE, whereas, there were none in the celecoxib group 
(Zhang et al 2011). An earlier study by Lin et al (2002) also found a significant 
difference between the two groups for grade 1 PPE (12.5% versus 34.3%; p = 
.04), but not for grade 2 (3.1% versus 17.1%; p = .11). From this study they 
also suggested that the combination of celecoxib and capecitabine may 
enhance anti-tumour activity by inhibiting cox-2 expression, which they later 
confirmed (Lin et al 2006a). Survival and tumour response rates have not yet 
been identified in Kang et al’s (2010) study, but may be published late 2012. 
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2.8.5 Other 
Pyridoxine, emollients, corticosteroids and celecoxib have been the main 
areas of interest to prevent or treat PPE, although there have been reports of 
other substances that have shown some effect, although in most cases in only 
a single case report. 
 
2.8.5.1 Cod Liver Oil (CLO) 
A retrospective notes review (Kanis et al 2009) of 18 patients who had taken 
CLO (1 capsule three times a day) while receiving PLD (40mg/m2 as 
monotherapy and 30mg/m2 in combination regimes every 28 days), found no 
grade 2 PPE or above. There were no dose reductions, interruptions or 
discontinuations due to PPE. They suggest that CLO may alleviate PPE via 
reduced extravasation of PLD and/or by blunting of local inflammatory 
response since the active ingredients of CLO reduce the production of 
inflammatory cytokines. 
 
2.8.5.2 Vitamin E 
Vitamin E is added to many skin products and is known to be a major 
lipophilic antioxidant stabilising cell membranes. When administered 
systemically vitamin E promotes collagen synthesis and inhibits the 
inflammatory response, providing the basis for the following study (Kara et al 
2006). Their study examined five patients with metastatic breast cancer who 
received docetaxel and capecitabine in combination, and were prescribed 
vitamin E 300mg per day when they developed PPE grade 2 or 3. Within 7-10 
days the PPE resolved and they were all able to continue without a dose 
reduction of either docetaxel or capecitabine. They state that further studies 
are required to evaluate the use of vitamin E but initial findings suggest 
considering vitamin E as a preventive drug when receiving PPE-inducing 
drugs. 
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A retrospective multicentre study (Yamamoto et al 2010) examined the role of 
vitamin E in the management of capecitabine-induced PPE of 32 Her-2 
negative patients with breast cancer. Capecitabine 828 mg/m2 twice a day for 
21 days every 4 weeks was prescribed. If a patient developed grade 2 PPE, 
they were prescribed vitamin E 100mg per day as a starting dose with no 
reduction in the capecitabine dose. A marked effect was seen within 7 days of 
commencing vitamin E with 17 patients requiring an increase of vitamin E to 
400mg per day to reduce the pain of PPE, and 4 of these requiring a 
reduction in the dose of capecitabine. Their findings indicate that those taking 
vitamin E who managed to continue on the full dose of capecitabine had a 




Henna is a plant which is thought to have anti-inflammatory, antipyretic and 
analgesic properties. It is used as a topical medicine to treat seborrhoea 
(greasy skin) or fungal infections or for decorative purposes in some parts of 
the world (Yucel and Guzin 2008). These authors present the case of a 
female patient who develop grade 3 PPE on her feet only, had used henna on 
her hands and she was subsequently advised to use it on her feet as well. 
The symptoms resolved within 48 hours and completely disappeared after 1 
week without any reduction in the dose of chemotherapy. This led on to an 
observational study on 10 Turkish women who after developing grade 2 or 3 
PPE, applied henna to their hands and feet. They were instructed to wrap 
them in cloth and then wash them after 5-6 hours. They achieved a complete 
response in all 10 with no dose reduction. They conclude by stating that this 
coincidental discovery of henna dye for the treatment of PPE seems 
promising and is an area of future pharmacological research to identify the 
substance present in henna and develop it as a cream or lotion without the 
dying effect.  
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2.8.5.4 Nicotine patch 
Kingsley (1994) reported a single case of a 65 year old female who received 
5-FU and leucovorin continuous infusion over 24 hours every week. She 
presented with hyperpigmentation of the hands which progressed to 
desquamating erythema. A nicotine patch (7mg) was applied to the skin 
(location not stated) 1 hour pre infusion and removed 1 hour after completion 
resulting in complete resolution of the PPE. The effect of the nicotine may be 
due to vasoconstriction reducing the amount of 5-FU delivered to the skin. 
 
2.8.5.5 Dimethyl Sulfoxide (DMSO) 
First used as a solvent for chemical reactions, in medicine, DMSO is 
predominantly used as a topical analgesic; a vehicle for topical application of 
pharmaceuticals; an anti-inflammatory; and an antioxidant. It was there 
properties that led to a study by Lopez et al (1999). In their study, 10 (29%) 
out of 35 patients receiving PLD developed grade 3 PPE. Of these 10 
patients, 2 patients developed grade 3 PPE after 3 cycles and applied topical 
DMSO 99% four times a day for 2 weeks. PPE resolved over a period of 1-3 
weeks and shows promising results but requires prospective studies to 
definitively evaluate its therapeutic effectiveness. In the 2 cases mentioned 
above, treatment with PLD was interrupted during the time DMSO was 
applied which questions its effectiveness since the PPE could have resolved 
with an interruption in treatment. There are also some concerns about the 
toxicity of DMSO itself which need to be resolved before its use is considered 
for evaluation in the treatment of PPE (Von Moos et al 2008). 
 
The interventions discussed above are predominately based on single case 
reports or small samples in uncontrolled trials. The safety and efficacy of 
these interventions have yet to be tested and proven in large randomised 
placebo controlled clinical trials for definitive recommendations to be made 
(Bush & Smith 2001). 
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2.9  The nurses’ role in the assessment and recognition of PPE  
The role of the oncology nurse is to educate the patient on how to recognise 
the signs and symptoms of PPE; when to report this to the hospital; dose 
modifications as required and strategies to reduce the risk and severity of 
PPE (Gerbrecht 2003).  
 
Patient education strategies have developed from anecdotal evidence and are 
based on level 4 and 5 evidence (case series and expert opinion) and include 
the following advice; 
 
 Use of emollient creams to hands and feet (Bush & Smith 2001) – but do 
not rub vigorously (Janusch et al 2006) 
 Avoid skin irritants (Janusch et al 2006, Von Moos et al 2008) 
 Wear cotton gloves and socks to aid absorption of the cream (Pike 2001, 
Von Moos et al 2008) 
 Avoid tight fitting, clothes (Alza Pharmaceuticals 1999), jewellery and 
shoes (Bush & Smith 2001) 
 Avoid adhesive dressings (Von Moos et al 2008) 
 Avoid repetitive activity or remaining in the same position for long periods 
(Von Moos et al 2008) 
 Avoid anything that causes sweating (Von Moos et al 2008) 
 Pat the skin when drying do not rub (Von Moos et al 2008) 
 Avoid extremes of temperature, pressure or friction (Alza Pharmaceuticals 
1999, Gerbrecht 2003) 
 Restrict the use of hot baths, hot showers, hot tubs and saunas (Alza 
Pharmaceuticals 1999, Pike 2001) 
 Avoid hot foods and liquids (Mangili et al 2008) 
 Avoid contact with hot water or steam such as seen in dishwashers or 
laundry (Alza Pharmaceuticals 1999) 
 Avoid mechanical manual work (Janusch et al 2006) 
 Avoid use of tools where squeezing of the hand onto a hard surface is 
required (DIY, gardening) (Von Moos et al 2008) 
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 Avoid excessive exercise (Alza Pharmaceuticals 1999) such as jogging, 
walking or aerobics (Von Moos et al 2008) 
 Restrict exposure to strong sunlight (Pike 2001, Mangili et al 2008) 
 
Signs and symptoms of PPE may resolve between cycles and some patients 
may be reluctant to report them. Patients sometimes believe that side effects 
of chemotherapy are inevitable and are to be tolerated. Others might hide 
symptoms as they fear that their cancer will grow and they may die if 
treatment is delayed or reduced (Mrozek-Orlowski & Sanborn 1999). To 
overcome these beliefs the nurse must emphasise that a dose reduction does 
not necessarily diminish the efficacy of treatment (particularly with 
capecitabine) (Gerbrecht 2003, Marse et al 2004). Tolerating side effects 
could compromise treatment, as allowing development of severe side effects 
will result in longer delays to allow them to resolve (Marse et al 2004). It is 
therefore important that the nurse questions the patient carefully, as 
subsequent episodes may be more severe and could be avoided with 
appropriate dose modification (Edwards 2003, Wood 2004). Figure 2.1 is a 
suggested PPE symptom assessment form which can be used by nurses 
during each consultation with a patient prior to each cycle of Capecitabine 
(Edwards 2003).  
 
A prospective multicentre study (Grenier et al 2007) evaluated the impact of a 
nurse-led education and support programme on toxicity and adherence to 
treatment. The sample n = 112 consisted of women receiving PLD for 
recurrent ovarian cancer. All patients received education on the potential 
toxicities and how to manage them. They were issued with an education kit to 
take home which included; a patient booklet on PPE; a symptom diary; a list 
of hints to reduce the incidence or severity of PPE; and emollient creams to 
minimise the severity of PPE. At each visit the nurse reviewed the patient’s 
symptom diary and re-emphasised actions to prevent, minimise or treat 
toxicities. Their findings suggested that the incidence of PPE (50%) was 
similar to phase III studies, however severe PPE and mucositis was 
substantially reduced with fewer discontinuations. There were however, 
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several limitations of this study, it lacked randomisation, and comparison was 
made with phase III studies rather than incidence of toxicities in the centres 
prior to the implementation of the programme. The patients in this study were 
receiving PLD as second, third, or fourth line treatment and may have had 
more advanced disease then those in other studies and some toxicities may 
still occur despite any interventions. 
 
PPE SYMPTOM ASSESSMENT  
Routine examination 
Examine palms of the hands and soles of feet and toes, heels, bunion 
areas 
 
Examine tops of feet and toes, heels  
Examine skin exposed to pressure (waistline. Bra line, elbows, knees)  
Examine skin exposed to warmth/moisture (axilla, inner thigh, under 
breasts, perineum) 
 
Examine pressure points if patient is bed ridden  
Patient questionnaire 
Have you experienced any tingling, redness, rash, swelling, flaking, 
blisters, sores, cracks, or fissures in the palms of your hands or soles 
of your feet? 
 
Have any of these changes occurred in other parts of your body, such 
as your waistline, bra line, armpit, perineum, thighs, knees, heels, 
balls of feet etc? 
 
Have any of these changes to your skin been painful?  
Have any of these changes to your skin interfered with your normal 
activities? 
 
Have changes to the skin of your feet made walking uncomfortable or 
difficult? 
 
When did you first experience these symptoms and how did they 
develop? 
 
Have your symptoms resolved?  
How long did the symptoms take to resolve?  




(Edwards 2003 p 29) 
Figure 2-1 PPE symptom assessment 
 
The impact of PPE on the patient’s quality of life is often underestimated. A 
valid and reliable tool to assess this impact would help health professionals to 
assess the effectiveness of treatments to relieve PPE and to make decisions 
on the appropriate actions to take when patients develop PPE. Sibaud et al 
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(2011) developed such a tool containing 14 items (HFS14) and tested its 
clinical validity by comparing its score to the NCI CTCAE criteria version 3 
(2006). They also measured correlation with other know and validated tools 
which included the Dermatology Life Quality Index (DLQI); Skindex-16; short 
term 12 health-related questionnaires and pain measurement. They 
concluded that the HFS14 scale was easy to use and measured quality of life 
comparable to other tools, but needed further testing in longitudinal studies. 
Limitations of the study included small sample size (n = 43), gender 
imbalance (74% female) and lack of testing of other factors that may affect 
quality of life such as performance status and psychological well-being. 
 
With the advent of more oral treatments, where the patient self administers 
the drugs and monitors their own side effects at home, assessing compliance 
and toxicity from a distance becomes a challenge. The role of the oncology 
nurse in ensuring the patient and their family understands how to take the 
drugs safely and the importance of recognising and reporting side effects 
immediately is more important than ever (Berg 2006).   
 
2.10  Summary 
In conclusion, although for most patients PPE is rarely serious, for a small 
number it can have serious consequences since it increases the risk of 
developing infection if neutropenic, amputation has been reported in a small 
number of cases and in circumstances such as DPD deficiency it can prove 
fatal. It is difficult to establish the true incidence of these serious 
consequences of PPE, since it relies on the reporting of single cases in the 
literature. Little attention in the literature was paid to this fairly common side 
effect until relatively recently and is generally only the subject of case reports, 
retrospective and small scale studies. The results of a few prospective trials 
are now emerging. While the theories of the pathophysiological mechanisms 
presented seem plausible, they are yet to be proven definitively. Age and 
gender as risk factors for PPE have been investigated in several large phase 
III studies of PPE causing agents and findings reported are contradictory. 
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Only small numbers of patients over 70 years old receiving 5FU or 
capecitabine have been studied thus far with no indication that this group has 
a higher incidence of PPE than younger patients. There is some evidence 
however that suggests that patients over the age of 80 receiving capecitabine 
have a high incidence of PPE and should be treated with caution. These older 
age groups require larger studies to establish the true incidence and impact of 
PPE. Another risk factor reported in a small number of studies is the 
association between performance status and PPE. This association is 
contradictory and has been reported in small samples only. Evidence is 
emerging to indicate that presentation of PPE varies between agents and 
ethnicity, particularly in people with dark skin. The incidence of PPE in people 
with dark skin may have been under reported in the past due to the symptoms 
not being diagnosed as PPE. The fact that severe PPE has been seen in 
patients following a reduction in dose would indicate that there are other 
factors rather than dose alone implicated in the development of PPE. The 
complexity in establishing these factors is that there is contradictory evidence; 
risk factors may vary for each family of anti-neoplastic agents; some are only 
subjectively reported and many have yet to be tested in patients receiving 
capecitabine. One factor that is gaining consensus in the use of capecitabine 
is the early onset of grade 1 PPE, which is associated with an increased risk 
of developing more severe PPE in later cycles. An interesting finding that has 
been reported in a few studies is that PPE may be a marker of efficacy of 
treatment. Larger studies of this finding are required to establish the reliability 
of this finding. Prevention and treatment of PPE is based on consensus, case 
reports and small scale studies and is often contradictory. There have been 
no large randomised controlled trials (RCTs) to test the effectiveness of 
emollients; steroids; celecoxib; cod liver oil; vitamin E; henna; nicotine patch 
or DMSO. Pyridoxine is the only preventative or treatment agent that has 
been subjected to analysis is several trials. The majority of these trials are 
case reports or small sample studies. However, the largest RCT of these 
studies reported no significant difference between the pyridoxine group and 
the placebo group to prevent or treat PPE. The one study that did show 
evidence in favour of high-dose pyridoxine also reported a poorer tumour 
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response. With the balance of the evidence and the unfavourable tumour 
response pyridoxine cannot be recommended to prevent or treat PPE. 
 
There have been no studies to analyse patient activities such as exposure of 
the hands and feet to heat, friction and pressure as risk factors of PPE and 
there has yet been no attempt to develop and validate a PPE risk assessment 
tool. The advice given to patients receiving PPE causing agents is based on 
consensus rather than controlled trials. The current advice given to patients 
often results in them making changes to their lifestyle and temporary 
cessation of activities such as hobbies that they enjoy. These changes can 
impact on the patient’s quality of life which may have already been affected by 
a diagnosis of cancer and the effects of treatment. Large trials to examine 
these activities rigorously would ensure that advice given is based on the best 
possible evidence.  
 
The following chapter described the methodology used to collect and analyse 
data on these factors to make a unique contribution to the current body of 
knowledge on the subject of PPE. 
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CHAPTER  3  RESEARCH METHODOLOGY, STUDY DESIGN 
   AND DATA COLLECTION METHODS 
3.1  Introduction 
The preceding chapter provided a systematic review of the literature. A deficit 
in knowledge, particularly related to the evidence to support advising patients 
to avoid certain activities to reduce the risk of PPE, was identified. This 
demonstrated a need to provide further insight into factors that increase the 
risk of developing PPE. This chapter describes how the research was 
conducted and presents the rationale for the choice of philosophical 
framework, study design and the analytical approach that was used 
throughout this systematic enquiry.  
 
All research involving human subjects poses ethical dilemmas which must be 
considered during the research design and conduct of the study and these are 
clearly presented for the reader to examine. A note of importance is the 
tension that can occur when acting as researcher in ones own area of clinical 
practice. The chapter concludes by presenting limitations of the study design 
and methodology. 
 
Research without theory does little to advance knowledge. Similarly, a study 
that lacks theoretical justification lacks substance. A theory is simply an 
interpretation of a phenomenon; it is not definitive and may be rejected or 
modified over time and there may even be competing theories to explain the 
same phenomenon (Parahoo 2006). A paradigm is a school of thought. 
Positivism is one such paradigm which has greatly influenced research in the 
health field. The most important characteristic of positivism is empiricism 
which implies that only what is observed can be called fact (Parahoo 2006). A 
theory must predict that each time the variables happen to be in the same 
relationship, the same results are obtained (Bowling 2002). 
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Quantitative research has its origins in positivism, maintaining that reality can 
be observed, measured and quantified in some way. This influences the 
questions posed, the type of data collected, how it is collected, analysed and 
interpreted (Seers & Critelton 2001). Although the purpose of quantitative 
research is to discover an answer to a particular problem, the link with 
previous knowledge is important to enable the researcher to learn from it and 
in return, contribute to it (Parahoo 2006). Without alluding to existing 
knowledge, the study and its findings will exist in isolation from other similar 
studies. A review of relevant literature and theories aided the decision of how 
to approach this study. The collection of data to support or refute hypotheses 
and data collection tools was based on existing literature.  Analysis of the data 
collected in this study aimed to explain the relationship between variables that 
have been suggested in the literature to be linked with the development of 
PPE. This will result in the generation of a theoretical model containing risk 
factors for developing PPE. It is not possible within the confines of this study 
to test this theory as this would require further research. Since this study 
makes no attempt to intervene or change outcomes it can be defined as an 
observational or exploratory study. This is one of the two broad classes of 
quantitative research, the other being experimental studies which seek to 
intervene or alter care or treatment and consequently assess its effectiveness 
(Seers & Critelton 2001). 
 
There was no intention in this study to qualitatively measure the impact of 
PPE on a participant’s quality of life, physically or psychologically. Other 
studies have explored this and the primary intention in this study was to 
identify risk factors that predispose a patient to develop PPE. 
 
In contrast to randomised controlled trials which can provide valid estimates of 
the underlying effect of the intervention being studied, surveys can only yield 
estimates of association, rather than whether one variable caused another, 
which may deviate from the true underlying relationships due to the effects of 
confounding variables (Bowling 2002). Methods to attempt to take into 
account these confounding variables will be discussed later. 
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Figure 3.1 summarises the research design applied to this study and is 








Figure 3-1 Research design 
 
3.2  Research design 
The study consists of two phases. Phase I is a retrospective notes review of 
patients who received infusional 5FU or capecitabine containing 
chemotherapy regimes over a one year period. The purpose was to establish 
which regime carried an increased risk of PPE to refine the sample selection 
for phase II. Participants in phase I were not included in the sample used in 
phase II thereby providing two independent samples to compare findings. The 
following sections will describe how the research was carried out in each 
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3.2.1 Phase I - Retrospective notes review 
A retrospective analysis of patients records, who had completed 
chemotherapy treatment (specified in the sample group) during the previous 
year formed the first phase of this study. Details of patients who had received 
the specified regimes were obtained from the oncology pharmacist. Data were 
collected using the medical notes data extraction form (Appendix 3.1) and 
included; tumour-related information; patient demographic and social data; co-
morbidities; laboratory results; chemotherapy regime information and toxicities 
developed as a result of the chemotherapy. Toxicities were graded using the 
NCI CTCAE (version 3.0 2006) except for PPE which was graded according 
to the capecitabine clinical trial criteria (Blum et al 1999) (Figure 3.2). 
 
Grade Clinical domain Functional domain 
1 Numbness, dysesthesia/ 
paraesthesia, tingling, painless 
swelling or erythema 
Discomfort that does not 
disrupt normal activities 
2 Painful erythema, with swelling Discomfort that affects 
activities of daily living 
3 Moist desquamation, ulceration, 
blistering, severe pain 
Severe discomfort, unable 
to work or perform 
activities of daily living 
Figure 3-2 Capecitabine Clinical Trials toxicity criteria (Blum et al 1999)  
 
3.2.1.1 Sample selection and sample size estimation  
The sample was taken from patients who had received oxaliplatin and 
infusional 5-FU (folfox) or capecitabine containing regimes, since infusional 
5FU and capecitabine have been reported to have a high incidence of PPE. 
Details provided by the oncology pharmacist of patients who had received 
these regimes between April 2008 and March 2009 provided a potential 
sample of 415. However, due to difficulties locating several sets of notes and 
excluding those patients who received only 1 cycle of chemotherapy (unless 
stopped due to PPE) resulted in an actual sample size of 392 (n=145 folfox 
and n=247 capecitabine containing regimes).  
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As data were collected from participants receiving different chemotherapy 
regimes, the data were analysed as a whole sample and by chemotherapy 
agent (infusional 5FU, capecitabine containing regimes and capecitabine 
monotherapy) to ascertain whether there were any differences in risk factors 
between those regimes. 
 
The widely accepted 80% power estimation (Munro 2005), an effect size of 
0.3 (medium) and the significance level of 0.05 were used in this study and 
sample size estimated using G* Power version 3.1 priori analysis program 
(Faul et al 2007). A sample size of 108 participants was determined for a 
bivariate analysis. The actual size used was 392 in the retrospective sample 
as this represented all participants who received either capecitabine 
containing regimes or oxaliplatin and infusional 5FU and would enable a focus 
to be placed on one regime if this proved necessary. The capecitabine 
monotherapy sample from the retrospective data (n = 151) exceeded the 108 
required to achieve 80% power in a bivariate analysis. Post hoc G* Power 
analysis of the capecitabine monotherapy sample from the retrospective data 
using the same parameters as above with n = 151 provided a power of 72% in 
a multivariate regression analysis. 
 
3.2.1.2 Process of data analysis  
To answer the research question; 
Can risk factors of PPE be identified to predict the development of PPE? 
The null hypothesis (H0) for each variable was statistically tested. 31 variables 
were tested in this retrospective sample (table 3.1) 
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Variables tested in phase I retrospective sample 
Gender Peripheral 
neuropathy 
Aim of treatment CrCl 
Marital status Skin conditions Tumour type ALT 
Ethnicity Inflammatory 
diseases 
Recent weight loss ALP 
Employment Previous cancer 
diagnosis 
Start season Bilirubin 
Smoker Metastatic spread Age Albumin 
Alcohol PPE with previous 
chemotherapy 





PVD Regime Creatinine  
Table 3-1 Variables tested in phase I 
Note: Inflammatory conditions are defined as a range of immune system 
disorders and include asthma; coeliac disease; rheumatoid arthritis; 
inflammatory bowel disorder; pelvic inflammatory disease and vasculitis. 
Coding of data 
 
The dependent variable being dichotomous was coded 0 and 1 with the 
category of most importance to the research question taking the coding of 1 
(Marston 2010). In this study participants who developed PPE were coded 1 
since the research question is to identify factors that may increase the risk of 





The data were checked for errors following input into SPSS through 
examining frequencies for each variable and spurious data checked against 
the original forms and corrected if an error found.  A random sample of 10% 
was subsequently generated in SPSS 16.0, 17.0 & 18.0 (IBM SPSS Chicago 
2008, 2009 & 2010) and checked against the original forms and corrections 
made if necessary. 
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Various statistic tests were applied to the data. Firstly each variable was 
tested in a bivariate analysis with the dependent factor PPE. Secondly the 
variables that reached statistical significance in the bivariate analysis were 
entered into a logistic regression model using various entry methods. Finally 
the various models from the logistic regression were entered into receiver 
operating characteristics (ROC) curves. Each of these stages will now be 
described further and the rationale for choice of the statistical tests will follow 
in section 3.5 
 
Descriptive statistics were first employed to explain frequencies, measure of 
central tendency (mean, mode and median), dispersion of personal & 
demographic characteristics and to check for any skewness of the data. The 
distributions identified any variables that required recoding or collapsing into 
fewer categories and the variables that had sufficient spread of responses for 




Frequency, severity, clinical course and consequences of PPE were 
determined by descriptive statistics. Between group differences were 
assessed using the chi-square (X 2) test for categorical data and independent-
samples t-test for continuous data. The α value p < .05, 2-tailed for all tests 
was used throughout this bivariate analysis to answer the question of whether 
there is a difference between the groups and the outcome measure in either 
direction (Bland 1995). 
 
Since the aim of this study is to identify factors other than the drug itself that 
may influence the development of PPE, the sample used for inferential 
statistical analysis was restricted to those who developed PPE within the first 
3 cycles and those who did not develop it, based on the assumption that PPE 
developing in later cycles is more likely to be due to accumulation of the drug. 
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This assumption is supported by Lipworth et al (2009) who stated that studies 
show that nearly all cases of PPE occur within the first two or three cycles of 
capecitabine, thus suggesting that the total cumulative dose does not affect 
the incidence of PPE. Each grade of PPE was analysed separately because 
they carry a different clinical significance and treatment decision for 
subsequent doses, a recommendation made by Heo et al (2004). 
 
Variables significant by bivariate analysis were further tested by multivariate 
logistic regression to seek to examine any relationship between variables and 
the nature of that relationship with the aim to make predictions (Parahoo 
2006). The criteria for selection and retention of variables into the logistic 
regression are explained next. 
 
Multivariate logistic regression - Modelling technique used 
 
The following stages describe the method used for the manual purposeful 
selection of variables for inclusion and retention in the chosen model; 
 
1. A bivariate model was fitted to each variable 
2. Variables achieving p < .25 in the bivariate analysis were entered 
into the model and the logistic regression test applied 
3. Variables achieving p < .1 were retained as significant and the 
variable with the largest p value above .1 then removed.  
Rather than removing all non-significant variables at once it is 
sensible to remove the variable with the largest p value and refit the 
model. This is because when one variable is removed from a 
model, the significance of those left in the model changes. This 
process is repeated until all variables in the model are significant at 
p < .1 (Marston 2010). For assessing whether a variable is 
significant overall in the model, the overall significance of the 
variable is more important than the significance of individual 
categories within the variable (Marston 2010). The reference 
category within each variable provides the overall significance of 
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the variable and it was this figure that was used to assess the 
significance level. 
4. The β coefficient value for each variable was imported into excel 
and the percentage difference between the current step in the 
model and the previous one calculated 
5. If this difference was greater than 20% for any variable remaining in 
the model, the p value of that variable was then examined and the 
following rules applied 
a. If the p value became < .1 when previously > .1 the variable 
that had been removed was returned to the model as a 
confounder 
b. If the p value remained < .1 the variable that had been 
removed was returned to the model as a confounder 
c. If the p value became > .1 when previously < .1the variable 
that had been removed was returned to the model as a 
confounder 
d. If the p value remained  > .1 the variable that was removed 
was left out of the model 
6. Stages 3 – 5 were repeated until only variables that had a p value 
of < .1 or confounders were left 
7. This same model was then re-run using the forward and backward 
entry methods to make comparisons with the purposeful entry and 
retention model, to see if indeed the analyst selects a richer model 
compared with the computer which has no idea of the theory which 
determines the importance of each variable. 
8. Variables that were not originally included into the model (p > .25 in 
the bivariate tests) were added one at a time and logistic regression 
applied. Any where the p value became < .25 were then entered 
into the model from stage 6 and the model reduced as before. 
Although these variables have no effect on PPE incidence they may 
have an effect with a group of variables, as logistic regression 
analysis shows those variables that best explain the occurrence of 
PPE (Marston 2010). 
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Figure 3.3 presents this model diagrammatically. 
 
Figure 3-3 Algorithm for selection and retention of variables in logistic 
regression models 
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Once a model has been generated the question of whether it can be 
generalised to other samples is asked. If assumptions have been broken, 
accurate conclusions cannot be drawn from the model. However, even if the 
assumptions are met the belief that the model from the sample will be the 
same as the population from which the sample was drawn is questionable but 
the likelihood of this is increased. Cross-validation could be used to assess 
how well the model can predict the outcome in a different sample (Field 
2005). In this study this was possible by comparing the model using cases 
from the retrospective notes review that had received capecitabine 
monotherapy with the prospective data. The results of this are presented in 
chapter 4. 
 
Receiver operating characteristic (ROC) curve 
 
Once all logistic regression models were completed the predictive values of 
each was calculated in SPSS. A ROC curve was created to compare the 
purposeful, forward and backward entry models and to compare the 
purposeful entry model with the same model containing additional variables 
as described in step 8 above. The area under the curve was examined to 
establish which model best predicted which combination of variables were 
more likely to increase the risk of developing PPE. 
  
3.2.2 Phase II - Survey 
Mixed strategies to collect data were used within the semi-structured 
interviews. These strategies included an interview schedule, documentation 
review, a self reporting instrument (symptom record) and visual inspection of 
the participant’s hands and feet. 
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A pilot study is a smaller version of the study being proposed. Its purpose is to 
discover any problems with the data collection tools and the ability of the data 
to answer the research question(s) (Burns and Grove 1999). Any problems 
identified would enable the tools to be refined prior to undertaking the actual 
study. 
 
Subjects used in the pilot study are not normally reused again in the actual 
study, since it may have an effect on these subjects during the study (Brink & 
Wood 1998). This is true in studies involving direct contact with participants; 
however, due to the retrospective nature of phase I, participants involved in 
the pilot study could also be included in the actual study without exerting any 
effect. 
 
The data collection tool used in phase 2 was tested on 6 participants to 
assess ease and ability to collect the data required. No amendments were 
made following this pilot. The tool was tested on participants who received 
capecitabine monotherapy treatment prior to commencing treatment and 
when attending to receive cycle 2 of their treatment, to ensure the subjects 
chosen for the pilot test resembled the sample tested during phase 2 of the 
actual study (de Vaus 2002). In this phase, since direct contact was made 
with the participants, those used for the pilot study were not included in the 
actual study. 
 
The symptom record and the participant information sheet were developed in 
conjunction with two patients who have received chemotherapy in the past to 
check that they were written in a patient friendly language. Interestingly, both 
of these patients contacted me at the hospital after reading about the planned 
research in the local newspaper. 
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Each participant was interviewed prior to commencement of their treatment 
and at each subsequent visit for 6 cycles of treatment. These participants 
attended for a planned hospital appointment at the time of each interview and 
much of the data collected are routinely asked as part of the usual 
chemotherapy process. Every attempt was made to ask the additional 
questions while the patient was waiting either to see their doctor or to receive 
their treatment, thereby keeping any inconvenience to a minimum. 
 
The interviews were conducted in a private room in the clinical area to 
maintain privacy and confidentiality. The interview schedule (appendix 3.3) 
was designed to collect the same data as the data extraction form used in 
phase I. In addition other factors identified in the literature that may influence 
the development of PPE were included. These included patient characteristics 
such as skin type or activities such as those causing friction to the hands or 
feet. These factors could not be collected in phase I since they were not 
recorded nor routinely asked.  Demographic, tumour-related information, 
chemotherapy regime and laboratory data were extracted from the patient’s 
medical records and recorded on the interview schedule. 
 
Attrition from this study due to drug toxicity or disease progression is 
unavoidable and details of this will be presented in chapter 4. There was the 
possibility of attrition if the participant was inconvenienced due to the 
interviews or if they felt uncomfortable in their relationship with the interviewer. 
This did not occur during the study, in fact, one patient who had initially 
declined to participate, later requested recruitment to the study once he 
developed PPE. Other patients recruited to the study went above and beyond 
what was asked of them; they rang the researcher between cycles to report 
symptoms of PPE and even photographed their own feet and/or hands and 
provided the researcher with copies at their next visit. 
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Self report instrument (symptom record) 
 
A structured self report instrument (appendix 3.4) was designed to collect data 
between visits to hospital. The purpose of this instrument was to ascertain 
whether the participant developed PPE or other toxicities which had resolved 
prior to attending hospital to begin the next cycle of capecitabine. A few 
months after the start of phase II, the clinical area introduced the use of 
patient diaries produced by the drug manufacturer which collected the same 
data as the self report instrument designed for this study. The latter was 
therefore abandoned to avoid duplication and data were taken from the 
manufacturer’s diary.  
 
As with any diary, completion varied ranging from those that kept no records 
to those who kept very detailed accounts of what occurred between cycles. 
Approximately 50% of the participants maintained the symptom record or 
manufacturer’s diary and although this did not affect collection of data about 
the incidence of toxicities, since participants were interviewed at each visit, 
the collection of the precise timing and frequency of some toxicities proved 
more difficult as it relied upon the participant’s recall of the previous three 
weeks. This did not affect the findings of this study; rather it added a richness 
to the information provided by those who did maintain records. 
 
Data obtained from these self report instruments or diaries was transferred to 
the interview schedule at each visit and therefore not reported separately in 
chapter 4. If a patient did not complete the self report instrument or diary they 
were questioned on the development of any toxicities between cycles.  
 
Visual inspection of hands and feet 
 
Participant’s hands and feet were inspected at each visit to assess for signs of 
PPE. If any signs or symptoms were experienced they were grade according 
to the capecitabine clinical trials toxicity criteria (Blum et al 1999) and 
recorded on the interview schedule. Photographic evidence was taken with 
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the participant’s permission for use to illustrate the variety of presentations of 
PPE.  
 
3.2.2.1 Sample selection and sample size estimation  
Based on the findings from phase I, the study design was refined and the 
prospective sample was restricted to participants receiving capecitabine 
monotherapy. This enabled comparison between the retrospective and 
prospective data and possible validation of the findings from the retrospective 
sample.  
 
Population sampling was the method of choice for this phase of the study. All 
patients prior to commencing capecitabine monotherapy between 11th June 
2009 and 31st December 2010, were offered recruitment into the study and 
followed for 6 cycles of treatment. The rationale for this sampling method is 
that each group should be representative of the total population in terms of 
age, gender and ethnicity. Since PPE most commonly occurs within the first 6 
cycles of the treatment, it was not felt necessary to gather data beyond this 
point. 
 
Details of patients commencing treatment were identified from the ‘new case’ 
diary (a diary of dates and times when a patient will attend for a nurse-led 
education and information session prior to commencing chemotherapy) or 
from the consultants clinic lists.  
 
Patients attended a pre-chemotherapy nurse assessment clinic where they 
were provided with information and education about their proposed treatment. 
Each patient was given an information sheet, (appendix 3.5), by the 
chemotherapy nurse, about the study which also contained an invitation to 
participate. During the patient’s visit to receive their first treatment cycle they 
were asked by the researcher if they wished to participate in the study and if 
they agreed, consent was taken (appendix 3.6), the first part of the interview 
schedule completed, and a symptom record booklet issued to participants. 
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Since individuals were now participants in the study, this term will be used 
from this point forward  
 
Exclusion criteria included those participants who did not wish to participate 
and those who were unable to speak English where an interpreter was not 
available. Since the data being collected was not of a sensitive nature, family 
members could be used to interpret. Four patients declined but there were no 
patients excluded because of language difficulties. The reason for declining 
was that participants felt they had too much going on in their lives at present 
without an additional meeting with another health care professional. 
 
The widely accepted 80% power estimation (Munro 2005), an effect size of 
0.3 (medium) and the significance level of 0.05 were used in this study and 
sample size estimated using G* Power version 3.1 priori analysis program 
(Faul et al 2007). As in phase I the sample size of 108 participants was 
determined for a bivariate analysis. The actual size used was 125 in this 
sample. Post hoc G* Power analysis of the sample using the same 
parameters as above with n = 125 provided a power of 65% in a multivariate 
regression analysis. 
 
Unfortunately due to changes in circumstances of the researcher’s role within 
the trust it was not possible to collect further data to increase the size of the 
prospective sample.   
 
3.2.2.2 Process of data analysis  
To answer the research questions; 
Can risk factors of PPE be identified to predict the development of PPE? 
Do individual patient activities that cause friction or exposure to heat increase 
the risk of developing PPE? 
 
The null hypothesis (H0) for each variable was statistically tested. 41 variables 
were tested in this sample (table 3.2) 
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Variables tested in phase II retrospective sample 
Gender Previous cancer 
diagnosis 
BMI Hot water 
Marital status Metastatic spread Creatinine Dry skin 
Ethnicity PPE with previous 
chemotherapy 
CrCl Cool hands 
Employment Previous 
radiotherapy 
ALT Cool feet 
Smoker Regime ALP Sweaty hands 
Alcohol Aim of treatment Bilirubin Sweaty feet 
Diabetes Tumour type Albumin Hand cream 
PVD Recent weight loss Performance status Skin type 
Peripheral 
neuropathy 
Start season Other capecitabine-
induced toxicities 
 
Skin conditions Age Sunburn  
Inflammatory 
diseases 
BSA Hobbies  
Table 3-2 Variables tested in phase II 
Note: Inflammatory conditions are defined as a range of immune system 
disorders and include asthma; coeliac disease; rheumatoid arthritis; 
inflammatory bowel disorder; pelvic inflammatory disease and vasculitis. 
 
The data gathered during phase II was subjected to the same coding and data 
cleaning process as described in section 3.2.1.2 for phase I of this study. 
 
The various statistic tests applied to the data from phase I were repeated in 
phase II. Firstly each variable was tested in a bivariate analysis with the 
dependent factor PPE. Secondly the variables that reached statistical 
significance in the bivariate analysis were entered into a logistic regression 
model using various entry methods. Finally the various models from the 
logistic regression were entered into receiver operating characteristics (ROC) 




A patient identification sticker was placed on the front sheet of the interview 
schedule to ensure the correct patient record was used at each visit to 
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prevent any patient data being mixed up. This front sheet was shredded after 
the data collection phase. Each patient was allocated a trial number which 
was used to anonymise data during the analysis stage. No identifiable data 
was accessed by individuals outside of the direct healthcare team during the 
study. 
 
Data was stored on both a computer within the trust and on a memory stick as 
backup. The computer and memory stick that was used to store identifiable 
data have been encrypted and are therefore password protected and only 
accessible by the principal investigator. All identifiable material will be 
destroyed at the end of the study and only unidentifiable data will be archived 
in a secure office at the trust. 
 
3.3  Issues of the researcher and clinician in practice 
There are potential tensions that may exist when acting as a researcher in 
ones own area of clinical practice (Orb et al 2001). Since this is important in 
the context of phase II of this study this issue will be addressed here 
separately. The researcher as service provider is referred to as insider-
research and has unique challenges and ethical dilemmas to consider. 
 
The identification of the researcher as a nurse may influence the researcher-
participant interaction and quality of data shared. This may depend upon the 
participant’s perception of a nurse and previous experiences (Jack 2008). It 
could be argued that it is important for a nurse to become close to research 
participants to extract rich data (Wilkes & Beale 2005). Conversely one may 
elicit less information as participants feel coerced to participate and may limit 
information given (Orb et al 2001).  
 
Power imbalance can add an extra layer of complexity when the researcher 
interviews their own patients, who may feel compelled to participate or risk 
jeopardizing the care or treatment they are receiving (Jack 2008, Johnson & 
Long 2010). A noncoercive disclaimer would include the elements of voluntary 
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participation; confidentiality; freedom to withdraw (Fouka & Mantzorou 2011) 
and informed consent (Daugherty 1999). The invitation to participate in the 
study was administered by the chemotherapy nurse running the pre-
chemotherapy assessment clinic and not the researcher to prevent any 
possible coercion. Participation was voluntary, confidentiality was explained in 
the patient information sheet and all participants were free to withdraw without 
giving a reason. Informed consent was taken by the researcher and 
participants were given the opportunity to decline any stage of the study 
design, for example having photographs taken of their hands or feet. Others 
suggest that to avoid coercion the researcher should avoid direct contact with 
the participants when recruiting or interviewing (Yanos & Ziedonis 2006). The 
process of recruitment has been described above, but the interviewing was 
carried out by the researcher since it was not possible for anyone else to carry 
this out due to funding and workload issues. Yanos & Ziedonis (2006) equally 
state that it is possible to integrate the roles of clinician and researcher to 
develop a moral identity which promotes good ethical judgement. The key is 
to be aware of the possibility of exploitation and develop a relationship with 
participants that reduce the possibility of misconceptions of the role of 
researcher. 
 
Intervention made during the interview may affect the validity an objectivity of 
the data (Jack 2008) and some authors suggest that intervention should only 
occur if the participant is in a state of anxiety or in life-threatening situations 
(Cartwright & Limandi 1997). Although, standing by and not providing care or 
interventions is incongruent with the culture of nursing, which is the ethic of 
caring (Fouka & Mantzorou 2011). The nurse as a researcher needs to 
consider their own and others expectations, of whether they should 
sometimes act as a nurse and provide care or always remain as the 
researcher (Wilkes & Beale 2005). 
 
Strategies to address this include acknowledging requests for information but 
not addressing them until the end of the interview and referring to another 
health care professional if an intervention is required (Jack 2008). 
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An insider-researcher is in a prime position to investigate and encourage 
others to take the results of research seriously and to make changes in 
practice (Yanos & Ziedonis 2006). This type of researcher is in the unique 
situation of understanding the complexities of the work area, and how to 
navigate through these. Organisational, professional and personal contexts 
may influence the way a piece of research is undertaken. An additional 
dimension is the influence of the educational institute if undertaking the 
research as part of a programme of study (Costley et al 2010). 
 
There is no absolute answer to the issue of the influence the clinician as 
researcher may have on participants. This should be reflected upon, rather 
than ignored (Jack 2008). It is not intrinsically unethical in finding oneself in a 
conflict of interest, the key question is whether the clinician/researcher 
recognizes this and how it is dealt with (Lemmens & Singer 1998). 
 
It is a crucial role of the local research ethics committee to mediate between 
these conflicting interests (Kent 1997). The local ethics committee and the 
local R & D team at the trust were satisfied with the processes involved in 
conducting this research study. Neither of these bodies requested any 
guidelines prior to commencing the study to address any potential conflicts, 
therefore none were developed. 
 
During the interviews there was no apparent evidence that any of the 
participants felt uncomfortable talking to the researcher. Many participants 
asked the receptionist of the chemotherapy suite to inform the researcher that 
they had arrived to ensure the opportunity was not missed to collect data. As 
a nurse some interventions were carried out, others were referred to more 
appropriate health care professionals. It was not apparent that this unduly 
influenced participation in the research, rather created a relationship which 
allowed rich data to be collected which occurs when the participant feels 
confident in the researcher. 
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3.4  Rationale for research design 
Having described each stage of the data collection and analysis processes, 
the rationale for these is presented in this section. 
3.4.1 Phase I. Retrospective notes review 
Retrospective studies seek to understand the phenomenon as embedded in 
that particular period of history. It is a relatively inexpensive method of 
surveying a large number of people quickly and the data can be easily coded. 
The main disadvantages are that the researcher has to rely upon existing data 
that was not collected with the same rigor with which prospective research is 
carried out. Records may also be incomplete or difficult to decipher (Parahoo 
2006, McKenna et al 2010). Despite these reservations it was felt that this 
method would provide a simple method to obtain a sample and data that 
would help to identify an appropriate sample for phase II and for comparison 
and validation of results between the two sample. 
 
3.4.2 Phase II Survey 
Prospective surveys occur over the forward passage of time, often with more 
than one episode of data collection and seek to explore what is likely to 
happen or the outcome of an event. Prospective studies can be expensive 
and consume a great deal of time and often have a high attrition rate 
(McKenna et al 2010). Other potential effects of a prospective survey that the 
researcher needed to consider were that participants may become 
‘conditioned’ to the study. That is they learn the responses that they think are 
expected of them (McKenna et al 2010). In addition, there is the ‘Hawthorne 
effect’, a reactive effect of the study where people change their behaviour 
simply because they are being studied (Roethlisberger & Dickson 1939). It 
was not evident that responses were learned or that behaviour changed as a 
result of the research. Each participant openly revealed and described how 
they had felt between each cycle which was different for each individual and 
the only behaviours that changed were as a result of the discomfort caused by 
Study design and methodology 
Page | 83 
 
the PPE or the treatment provided to relieve the symptoms, for example, the 
regular use of emollients. The strengths and weaknesses of face-to-face 
interviews are presented in table 3.3. 
 
There are many factors to consider when conducting interviews; the 
development of an appropriate interview schedule; the environment where it 
occurs; the questioning and listening abilities of the interviewers; and 
managing the interview (Tod 2010). The interviews conducted within this 
study took place in a private room in the clinical area to maintain privacy and 
confidentiality. The interview schedule was formulated based on factors that 
may influence the development of PPE identified in the literature and from 
discussions with clinical experts. Since the qualities and training of 
interviewers are essential for the reliability and validity of the survey results, 
(Bowling 2002) training would have been provided to all data collection 
personnel by the principal investigator. However, due to staffing shortages 
and workload it was not possible for the specialist chemotherapy sisters to 
assist in the data collection as initially thought. Therefore the data were 
collected by a single interviewer, namely the principal investigator. 
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STRENGTHS WEAKNESSES 
 Can generate a large volume of data from 
a large sample (Tod 2010) 
 Longer and more complex questions are 
possible (McKenna et al 2010, Tod 2010) 
 High response rates (McKenna et al 
2010) 
 No literacy requirements for respondents 
(Tod 2010) 
 Facilitates cooperation from research 
subject (McKenna et al 2010) 
 Can use visual materials e.g. show cards 
(McKenna et al 2010) 
 Provides additional opportunities to clarify 
questions and responses (Hughes 2002, 
McKenna et al 2010) 
 Inconsistencies and misinterpretations can 
be checked (Bowling 2002) 
 Ability to observe body language and 
have eye contact to aid in interpretation of 
what is being said (Hughes 2002) 
 Enables the interviewer to ensure data are 
being collected from the correct sample 
(McKenna et al 2010) 
 Costly due to time-intensive nature 
(McKenna et al 2010) 
 Interviewee is not anonymous (McKenna 
et al 2010) 
 Can be subject to interviewer bias 
(Bowling 2002) 
 May be additional bias if interpreters are 
used (Tod 2010) 
 Data are open to  misinterpretation due to 
cultural differences (Hughes 2002) 
 Difficult to replicate(Hughes 2002) 
 Data are often subject to observer effect 
(Hughes 2002, Tod 2010) 
 
Many of the weaknesses are linked to 
accounts of people’s subjective experiences 
 
Table 3-3 Strengths and weaknesses of face-to-face interviews 
 
3.4.2.1 Symptom record 
The strength of self-report techniques is that they can yield information that 
would be difficult to obtain by other means such as feelings, retrospective 
activities and events. Their main weakness lies in the questionable validity 
and accuracy of self reports (Polit et al 2001, Parahoo 2006).  
 
3.5  Rationale for data analysis methods 
The research study generated a large amount of data which were analysed 
using parametric (X 2) and nonparametric tests (t –test) to identify factors that 
are significant in patients who develop PPE. Data were initially analysed using 
bivariate descriptive and inferential statistical techniques. This gathered 
information on the frequency of occurrence of the categories of each single 
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variable for the purpose of description and testing of significance of each 
variable for the development PPE (Polit et al 2001, Parahoo 2006). Items 
which occurred at a specified significance level (as described in section 
3.2.1.2 and figure 3.3) were then further analysed using multivariate statistical 
techniques (logistic regression and ROC curves) to analyse and infer 
relationships among three or more variables (Cormack 2000, Polit et al 2001, 
Parahoo 2006).  
 
The descriptive part of the study obtained data from the sample regarding the 
incidence and distribution of variables, whereas the analytical/correlational 
part investigated associations between variables (Bowling 2002, Parahoo 
2006). The rationale for multiple testing of data was firstly to test for any 
association between each individual variable and the development of PPE. 
This would allow comparison with findings in the literature. It would also 
establish those variables which achieved statistical significance to include in 
combination in the logistic regression model. Manual and automatic methods 
of entry and retention of variables into the regression model were employed to 
identify which method produced the most favourable model to predict the 
development of PPE (McNames 2005).   
 
Caution should be used in the clinical importance placed on the meaning of 
the α value p < .05. A ‘significant’ value purely means that the results are not 
likely to be due to chance i.e. at p < .05, 5 times out of a 100 a true Ho would 
be rejected (type I error). Conversely a ‘non-significant’ value means that the 
difference is probably due to chance (Polit et al 2001, Munro 2005).  
 
3.5.1 Sample size 
The power of a statistical test is the probability that the null hypothesis (Ho) 
will be rejected given that it is in fact false. Significance tests that lack 
statistical power are questionable in their usefulness because they cannot 
reliably distinguish between (Ho) and the alternative hypothesis (H1) of interest 
(Faul et al 2007). A priori power analysis is where the sample size (n) is 
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computed before the study begins using the 3 requirements for estimating 
sample size as defined by Cohen (1988); the power level required (1 – β); the 
prespecified significance level (α – the risk of type I error falsely rejecting a Ho 
when it is in fact true) and the population effect size. 
 
Cohen’s (1988) definition of effect size; 
Small = 0.10 
Medium = 0.30 
Large = 0.50 
 
3.5.2 Hypothesis testing 
A scientific hypothesis (H1) is one that states that there is a relationship 
between X and Y, conversely a null hypothesis (Ho) states that there is no 
relationship between X and Y. The process of testing the hypothesis 
statistically is one of disproof or rejection, since; proving that the H1 is true is 
not possible. However, it is possible to demonstrate that the Ho has a high 
possibility of being incorrect, which provides evidence to lend support to the 
H1. (Polit et al 2001). It is through statistical tests that the researcher then sets 
out to reject the Ho. 
 
3.5.3 Bivariate analysis  
3.5.3.1 Chi square (X2) test  
Chi square (X2) test is used to make inferences about the existence of 
significant relationships between the group variable and the incidence of PPE. 
PPE was at the nominal level of 1 for the presence of PPE and 0 for its 
absence; this implies that the X 2 test can be used to answer the core 
questions of this study concerning whether there is a significant effect for the 
group variable on PPE incidence. Of those nominal variables examined by the 
X 2 test of independence, the association between variables was tested by 
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descriptive cross-tabulation. The group or incidence variable was entered in 
rows and the recorded variables were entered in columns, and expected and 
observed counts were indicated. Pearson (or Yates’s correction for 2 x 2 
tables) X 2 value, d.f (degrees of freedom) and p value were calculated to 
decide the level of statistical significance of the association between 
variables. 
 
The effect size (a measure of the strength and direction of the relationship 
between two variables) for variables with a statistically significant association 
with PPE is presented.  
 
For two by two contingency tables in the X 2 test, effect size is interpreted 
according to Cohen (1988) criteria where; 
0.10 = small effect size 
0.30 = medium effect size 
0.50 = large effect size 
 
For tables larger than two by two, Cramer’s V is used and varies dependent 
on the degrees of freedom; 
 
For 3 categories within a variable; 
0.07 = small effect size 
0.21 = medium effect size 
0.35 = large effect size 
 
For 4 or more categories within a variable; 
0.06 = small effect size 
0.17 = medium effect size 
0.29 = large effect size 
 
Assumptions; 
1. Data are frequency data i.e. counts and categorical (nominal). 
Ordinal data will need to be categorized with a sound rationale for 
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doing so for example if the data are not normally distributed. An 
adequate sample for cross tabulation is one that ensures that no 
cell is empty and there should be > 5 participants in each expected 
count cell. If < 5 in any of these cells collapsing data to merge 
categories may be a solution. 
2. Measures should be independent of each other. That is that a 
subject cannot appear in more than one cell or be used more than 
once. 
3. There should be a theoretical reason for the categories 
(Munro 2005) 
 
These assumptions were met through categorizing some ordinal data or 
collapsing variables into fewer categories where there were counts of less 
than 5 in any cell. It is acknowledged that categorising a continuous variable 
may reduce the amount of information available, and that the statistical testing 
of this data may be less sensitive (less power). The choice of cut off points 
can lead to different conclusions about a set of data (Swinscow & Campbell 
2002). The cut off points selected in this study reflect those used in other 
studies for example Creatinine clearance (CrClC1) was categorized using the 
same parameters as Poole et al (2002).  
 
 
3.5.3.2 Independent-samples t-test for independent groups 
Independent samples t-test for independent groups are used to compare the 
mean scores, of continuous variables for two different groups of people 
(Pallant 2007). In this study it is used to compare the mean scores of age and 
laboratory values (continuous dependent variables) in patients who developed 
PPE and those who did not (categorical independent variable). 
 
The t value, d.f and p value were calculated to show any statistically 
significant differences in the mean scores of the two groups, and the mean 
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difference to show the magnitude of the differences in the means (Pallant 
2007). 
 
The effect size for continuous variables using eta-squared in the t-test is 
interpreted according to Cohen (1988); 
0.01 = small effect size 
0.06 = medium effect size 
0.14 = large effect size 
 
Assumptions 
1. Data should be normally distributed, however, with larger samples; 
major problems will not occur if this assumption is violated. 
2. The variances of the two groups are equal, although in reality this is 
not always possible and SPSS provides an alternative t-value that 
compensates for variances that are not equal 
3. Data should be from different participants 
(Pallant 2007, Marston 2010) 
 
These assumptions were met with data close to normal distribution and with 
similar variances and from different participants. Normal distribution was 
tested by producing histograms of the frequencies with the normal distribution 
curve included for each set of data. 
 
3.5.4  Multivariate analysis 
Multivariate tests are used to understand the complex relationship between 
variables. 
 
3.5.4.1 Logistic regression & Modelling 
When a result from previous statistical tests is accepted as significant, it does 
not mean a causal relationship has been established. There is still more to do 
to make the argument secure. Establishing whether an apparently causal or 
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predictive relationship is statistically significant is only the first stage of the 
argument. The researcher still has to ascertain that it is this independent 
variable and not some other which is also associated, that produces the 
effect. To do this the following information is required; 
1. Which of the influences are strong and which are weak 
2. To what extent the different independent variables are 
‘independent’ influences (or on the other hand, how much their 
influence overlaps) 
3. Whether there are interaction effects (whether the influence of two 
or more variables together is different from what would be predicted 
by any one alone)  
 
In the real world we are often comparing groups which differ in a number of 
elements. When design controls are not used, multivariate analysis 
techniques are employed for statistical control of these ‘unwanted’ differences 
and to show; 
1. Whether the effects of extraneous variables are larger than those of 
the influence(s) being studied 
2. Whether they are confounded by them (examined later) 
3. Whether they interact with them 
(Sapsford & Jupp 2006) 
 
Logistic regression is a statistical modelling technique to investigate 
relationships between independent variables and a dichotomous dependent 
variable (in this study PPE) from which to produce a predictive model 
containing variables that best explain the occurrence of PPE. The goal being 
to ascertain if the variables used were important in the population being 
served by the clinical area from which the data were collected. Results are 
presented as a series of summary statistics including, for each individual 
predictor; its significance; coefficient estimation (β); and odds ratio (OR). The 
Beta coefficient is an estimate of the nature of the relationship of each 
variable to the prediction, controlling the overlap with all the other variables in 
the model. The larger this is, the larger the effect of that particular 
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independent variable on the dependent variable. The odds ratio lends 
interpretability to the data and is a factor by which the ratio of odds of an 
event for those with a given characteristic is measured against the odds of an 
event for those without. It approximates how much more likely (or unlikely) it is 
for the outcome to be present given certain conditions and used to determine 
which variables affect the probability of a particular outcome. For continuous 
independent variables the OR is given for a 1 unit of change in the predictor 
variable. Unlike the mean the OR does not fall in the middle of the confidence 
interval. (Munro 2005, Sapsford & Jupp 2006, Marston 2010). 
 
Assessing the ‘goodness of fit’ of the model describes how well it fits a set of 
observations (variables). It is important to test the extent to which the model 
fits the data, since if a model is a poor fit of the observed data then it follows 
that predictions made from the model will also be poor (Field 2005). The 
Hosmer-Lemeshow test can be applied to any number of variables whether 
they are continuous or categorical and compares the values predicted 
(expected) by the model with those actually observed (Bewick et al 2005). 
Since the Hosmer-Lemeshow statistic is a test of the null hypothesis that the 
model is good, a p value of > .05 indicates a good fit and the null hypothesis 
that there is no difference between the observed and predicted (by the model) 
values can be accepted (Brake et al 2006). Caution should be applied when 
using this test as it is dependent on sample size and is not recommended for 
small samples (Chan 2004).  
 
Cox and Snell and Nagelkerke (an adjusted version of Cox & Snell R2) R 
square are used not to measure the goodness of fit but to measure 
usefulness of the predictor variables in predicting the response variable or as 
a measure of effect size (Bewick et al 2005). Or put another way it is the 
proportion of variability in a data set that is accounted for by the statistical 
model. It provides a measure of how well future outcomes are likely to be 
predicted by the model. R squared is the relative predictive power of a model 
with a descriptive measure between 0 and 1. The closer the value is to 1, the 
greater the ability of the model to predict the values of the variables within the 
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model. These are pseudo correlations, that is, not actual correlations but 
measures designed to emulate correlations. There is no agreed best measure 
and can be difficult to interpret. They may, however, be helpful in the model 
building state as a statistic to evaluate competing models. Hence the reason 
for reporting them (Hosmer & Lemeshow 2000). Since there is no agreed best 
method, the Nagelkerke figure will be reported within this study. 
 
The classification table in the logistic regression helps to measure the ability 
of the model to correctly predict which category each case fits into by cross 
tabulation of the observed response categories with the predicted response 
categories. 
 
Assumptions used in multivariate modelling procedures are more restrictive 
than bivariate analysis and if any of these assumptions are incorrect, the 
results may be seriously compromised. One solution to this problem is to fit a 
whole family of models to compare the conclusions or to validate the model 
results (Greenland 1989). Hence, the rationale for applying different entry 
methods to the same variables to establish whether different conclusions are 
reached with different modelling approaches. 
 
Assumptions 
1. Sample size and number of predictors must be considered. A large 
number of predictors, particularly if categorical with a small sample 
size can be problematic. 
2. There should be no correlation between variables. Multicollinearity 
diagnostic tests can be applied to data to check for high 
intercorrelations among the predictor variables and if found one of 
the variables should be removed. 
3. Outliers may affect the goodness of fit of the model and should be 
inspected for any where the model predicts that a case fits into one 
category where in reality it should be classified in the other.  
(Pallant 2007)  
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To ensure these assumptions were met, the problem of categorical predictors 
was addressed during the bivariate analysis by collapsing categories within 
variables. Collinearity diagnostics were carried out for all categorical 
predictors using the Coefficients table from a linear regression test and one of 
the intercorrelated variables removed if the tolerance value was less than 0.1 
Intercorrelation was evident between two variables, previous chemotherapy 
and PPE with previous chemotherapy therefore the variable previous 
chemotherapy was deleted from the data. On reflection this intercorrelation 
should have been blatantly obvious without running diagnostics since a 
patient could only have had PPE with previous chemotherapy if they had 
indeed had previous chemotherapy. However, running the diagnostic test 
confirmed this and provided a useful learning experience to increase 
knowledge of statistical testing. All outliers were checked against their original 
data to seek any obvious reasons why they did not fit the model well or if any 
error in data inputting had been made. As no obvious reason was found the 
outliers were not excluded from the analysis.  
 
There were certain considerations to make prior to executing logistic 
regression, these included; identifying the reference category; how missing 
data will be dealt with and recognizing confounders. Unlike linear regression, 
dummy variables do not have to be created explicitly, since SPSS creates 
these from nominal variables. However, thought should be given to the most 
appropriate category to be the reference category against which the other 
categories are compared (Marston 2010). The reference category was chosen 
as the one that appeared, following the bivariate analysis, to be the least likely 
to increase the risk of PPE which should provide a positive value for the odds 
ratio (OR), thus easing the interpretation of the data. 
 
There is always the problem of missing data and how it should be handled. A 
few missing observations are a minor nuisance, but a large amount of missing 
data are a major threat to a study’s reliability. Missing data are much more 
common in retrospective studies. Information sought from patient’s medical 
notes does not always provide certain life style information for example, 
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smoking habits. The simplest (but naïve) method is to use the complete cases 
only. However, this raises two important problems of its own; information is 
lost as the sample size is reduced and the results may be biased. In general it 
is advisable not to include in an analysis any variable that is not available for a 
large population of the sample (Altman & Bland 2007, Consentino & 
Claeskens 2011). One solution to this problem is to code the missing data as 
a category within the variable. However this code must not be used as a 
reference category since it has no influence on the dependent variable or take 
action on the resulting values for that category. This solution allows all the 
other data belonging to that case to be used in the analysis and avoids the 
problem of reducing the sample size. 
 
Confounding can be a major concern in causal studies. Anticipating the role of 
confounding variables, as positive or negative, on effect measures is 
important in interpreting results because it can lead to bias in the estimation of 
exposure effects (Mehio-Sibai et al 2005). In the extreme, this can mean that 
a causal effect is suggested where none exists, or that a true effect is hidden. 
Confounding commonly occurs when there are differences between the 
exposed and unexposed groups in respect of independent risk factors for the 
disease. Confounding can be reduced by matching in the study design but 
this can be difficult and/or wasteful of resources. In the past statistical 
correction methods have been applied but more recently this is being 
replaced by methods based on regression models (McNames 2005). It is 
widely accepted that there are multiple risk factors for any disease/condition 
of interest, and the question is often asked whether the apparent association 
may be due in whole or in part to a variable which was not measured or 
controlled in the study design or analysis.  Epidemiologists usually want to 
focus on the causal effect of one factor (exposure), although other factors 
may be considered only because they might be confounders rather than being 
of direct interest. The goal is to study the effect of the exposure on the 
disease/condition, ‘controlling’ or ‘adjusting’ for the others. The final choice of 
model form should be dictated by the need to eliminate confounding not 
parsimony (thriftiness in the number of variables in the final model). However 
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automated selection procedures should not be relied on to make decisions 
about confounders as they may result in inappropriate exclusions or 
inclusions in a model (Schlesselman 1978, McNames 2005).  
 
There is often a temptation to reduce the model in a stepwise fashion until all 
the remaining terms have “significant” coefficients. However this defeats the 
purpose of multivariate control of confounding, since “non-significance” does 
not mean lack of confounding. The deletion of many “non-significant variables 
from the model may lead to substantial confounding by the aggregate of the 
deleted factors (Miettinen 1976). Since stepwise regression, can easily lead to 
invalid estimates and tests of effect, variable selection is better approached by 
direct estimation of the degree of confounding produced by each variable than 
by significance-testing algorithms (Greenland 1989). 
 
How badly a covariable confounds the association between a disease and a 
primary trait depends on the strength of two other associations: between 
covariable and disease, and between covariable and primary trait. To assess 
the confounding potential by testing one of these associations for statistical 
significance, using a ‘traditional’ critical level of 0.05 or 0.01, is inadequate. 
Such a preliminary test places the burden of proof in the wrong direction, 
avoiding type I errors (True Ho incorrectly rejected). In evaluating confounding 
potential, the burden of proof should be in the opposite direction, type II error 
(fail to reject a false Ho) being more important. To identify any confounding 
effect of covariables with this backward burden of proof direction the 
significance level should be 0.25 or 0.50, possibly even higher (Dales & Ury 
1978) Mickey & Greenland’s (1989) study of several different models 
confirmed these findings. Hosmer & Lemeshow (1989), while supporting this 
approach do offer a word of caution in that variables of questionable 
importance might be included in the model and that it is important to critically 
review all variables added to the model before a decision is reached regarding 
the final model.  
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If one wishes to conduct a statistical test of a confounder, a logically sound 
approach would employ equivalence testing in place of significance testing. 
The most commonly proposed alternative to conventional algorithms is to 
base variable selection on a “proportional change-in-estimate” method at 
some arbitrary level such as 10% or 20% (Miettinen 1976, Greenland 1989, 
Hosmer & Lemeshow 1989, Mickey & Greenland 1989). 
 
3.5.4.2 Selection of variables for regression 
The purpose is to select a subset of variables that does the best job of 
predicting a particular outcome. We usually want to find the smallest group of 
variables that will account for the greatest proportion of variance in the 
dependent variable known as a parsimonious model (Munro 2005, Miles & 
Shelving 2008), which should also be biologically reasonable (Hosmer & 
Lemeshow 1989). Predictors included and the way they are entered into a 
model can have a great impact on the results. Ideally predictors should be 
selected based on statistical or clinical significance. Clinical significance 
based on previous studies can prove difficult due to the contradictory nature 
of the findings. For example, Jansman et al (2000), Schellens et al (2005), 
Tan & McLeod (2005) and Chabner & Longo (2006) suggest that age and 
gender were significant in relation to PPE occurrence, while others found no 
significant difference in age and gender (Comandone et al 1993, Chiara et al 
1997, Heo et al 2004, Gressett et al 2006, Janusch et al 2006, Webster-
Gandy et al 2007). If the predictors were uncorrelated the order of entry would 
have little effect on the results. However since this is a rarity the method of 
entry chosen in crucial (Field 2005, Bursac et al 2007). The Backward, 
forward, stepwise techniques of entering variables into the model presents a 
problem, in that we are asking the computer to make decisions regarding 
which variables are important, when the computer has no idea about the 
theory that may determine which variables are important (Miles & Shevlin 
2008). The analyst not the computer is ultimately responsible for the review 
and evaluation of the model (Hosmer & Lemeshow 1989). 
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3.5.4.3 Modelling technique used; 
Binary logistic regression was chosen as it suits models where the dependent 
variable is dichotomous. Parameters for inclusion and retention in the model 
were based on a model presented by Bursac et al (2007) and described by 
Hosmer and Lemeshow (2000). This modelling technique uses purposeful 
selection of variables and is advantageous when interested in risk factor 
modelling, rather than simply prediction. This modelling method allows 
confounding variables in addition to significant variables to be included 
resulting in a potentially richer model (Bursac et al 2008). Assumptions used 
in modelling procedures are more restrictive than bivariate analysis and if any 
of these assumptions are incorrect, the results may be seriously 
compromised. One solution to this problem is to fit a whole family of models to 
compare the conclusions or to validate the model results (Greenland 1989). 
Comparison of models using different variable entry methods (forward, 
backward and purposeful) was made using the area under the curve figure 
obtained by applying Receiver Operator Characteristics (ROC) tests to 
establish which method proved to be the better predictor of PPE.  
 
3.5.5 Receiver Operating Characteristic (ROC) Curves  
ROC is used in classification analysis either to compare two or more 
assessors, scales or techniques or to establish the accuracy of (the sensitivity 
and specificity) a model to predict, in this case PPE. The value of this 
statistical test is to assist healthcare professionals to decide an optimal 
threshold for making decisions in a given situation (Anthony 2011). Caution 
should be applied when using thresholds, since they do not state with 
absolute certainty that a person will develop a condition, but usually indicate 
that it is fairly confident/quite likely. The level that the threshold is set at 
depends on the merits of specificity and sensitivity. If it is important to get the 
diagnosis right and false positives are not problematic then the threshold is 
set low so that as the score increases the risk of getting the condition 
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increases (figure 3.4). This means the test is set to be more sensitive but with 
poorer specificity (Anthony 1999). 
 
 
Figure 3-4 ROC curve demonstrating effect of threshold levels 
(Braga & Oliveira 2003) 
 
A ROC plot is obtained by calculating the sensitivity (true positive) and 1-
specificity (false positive) of each observed data value. A model to perfectly 
discriminate between the two groups would produce a curve that coincided 
with the left and top sides of the plot (1.00) (Altman & Bland 1994). In 
practice, however, there is usually overlap between the values of the group 
with the condition (in this case PPE) and those without, meaning that the 
curve usually falls between the random diagonal line (left bottom to top right) 
and the perfect fit. The further the curve is from the diagonal line the better the 
classification. The area under the curve (AUC) indicates the probability that a 
random person with PPE has a higher value than a random person who does 
not develop PPE and is used to assess the performance of the model 
(Bowling 2002). AUC ranges from 0 to 1, thus AUC = 1 means all cases with 
PPE are higher than all without, and AUC = 0.5 means that half are higher 
and half are lower, or put another way, a model that is no better than guessing 
the outcome (Chan 2004). When comparing two or more curves, as with the 
comparison of the logistic regression models described above, the curve 
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above and to the left of the other(s) indicates a more accurate model (Anthony 
2011). 
 
3.6  Ethical considerations 
Since I (the researcher) am an employee of the acute NHS trust where the 
study took place and working clinically within the chemotherapy suite is a 
normal part of my role, access to the population and their records does not 
present the problems that would be faced by a researcher external to the 
organisation. Each NHS trust has a Caldecott guardian responsible for the 
safekeeping of patient’s records to protect their rights. Anyone (whether an 
insider researcher or external to the trust) wishing to carry out research 
requiring access to patients records, must gain approval from this guardian 
(Gelling 2010). Approval was given for the researcher to access patients 
notes for the purpose of this study.  This did not, however, mean that the 
study could proceed without gaining formal ethical committee and Research 
and Development (R & D) approval. Application for ethical approval was 
submitted on 17th October 2008 to the University Faculty Ethics Committee 
and approved on 13th November 2008 with no amendments required 
(appendix 3.7). Application for ethical approval was submitted to the NHS 
ethics committee on 21st January 2009 and was considered at their meeting 
on 19th February 2009, I attended to answer any questions they had. Approval 
was granted following minor amendments on 27th March 2009 (appendix 3.8). 
Research governance approval from the trust’s R & D lead was sought on 9 th 
March 2009 and approved 29th May 2009 (appendix 3.9). Lengthy discussions 
have been held with a member of the R & D team to assist in the ethical 
approval process and to identify requirements for research governance 
approval which included curriculum vitae of the principal investigator and 
attendance on Good Clinical Practice (GCP) and consent training. Support for 
the study was sought and agreed by key managers of the chemotherapy suite 
and included the general manager, clinical director, head of nursing, matron, 
lead chemotherapy clinician, and senior sister.    
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An amendment was submitted to the ethics committee on 17th February 2010 
requesting agreement to restrict the prospective sample to capecitabine 
monotherapy (Appendix 3.10), which was approved 1st March 2010 
 
 
This research study was carried out in adherence with the Nursing 
Professional Code of conduct (NMC 2008), the Nuremberg Code of 1947 
(National Institute for Health 2009), the Declaration of Helsinki 1964; 2002 
(WMA) and the Research Governance Framework for Health and Social Care 
(DH 2001; 2003).  
 
The ethical principles of beneficence and justice charges researchers to 
ensure that benefits outweigh risk (Polit et al 2001). The potential risk during 
the collection of data from these participants is one of emotional distress. If 
patients became distressed during an interview, the interview was terminated 
at once. If the patient wished to continue with the interview following recovery 
from their distress the interview was re-commenced. The chemotherapy 
specialist sister caring for the patient was informed of the patient’s distress 
and asked to assist if necessary. The researcher made referrals (based on 
clinical need and not as a result of participation in the study) to the palliative 
care team, counselling or psycho-oncology services when appropriate 
following discussion with the specialist sister. This occurred on 5 occasions. 
Other assistance was given to individual participants and included helping one 
participant to complete an application for financial benefits, one to apply for 
funding to have a special weekend away for herself and her partner after 
being given a poor prognosis, one participant with Reynaud’s disease to seek 
an appointment with a rheumatologist and another to seek information for his 
erectile dysfunction following colorectal surgery and radiotherapy.     
 
The participant’s right of self-determination is an essential ethical 
consideration and the researcher ensured that informed consent was given. 
Each participant was issued with an information sheet explaining the study 
and the right to refuse or withdraw at any time. Each participant was given the 
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opportunity to have any questions answered prior to giving or declining 
consent.  
 
Methods to protect the participant’s right to privacy included all data collected 
being treated with confidentiality and anonymity (McHaffie 2000). Information 
on the handling, use and storage of data were included in the participant 
information sheet.  
 
During the retrospective notes review, if information was found that indicated 
a breach of codes of professional practice e.g. unsafe practice, the trust’s 
policies would be followed and reported to the appropriate professional lead 
within the acute NHS Trust. During the collection of data in this phase this 
proved to be unnecessary. 
 
Participants were informed that if they disclosed any information that indicated 
someone was at risk of harm, was against the law, unprofessional behaviour 
or unsafe practice, this would have to be reported to the appropriate 
authorities. 
 
3.7   Research issues 
Strengths and weaknesses of the study design and methodology will be 
presented in this section and limitations of the data collected, analysis and 
findings will be discussed in chapter 6 along with identification of the 
contribution of the study to the current body of knowledge. 
 
3.7.1 Limitations of study design 
The aspiration of objectivity in quantitative research is used to keep the 
participants and the researcher at a distance (Topping 2006). This is often 
achieved by using a researcher to collect data rather than someone directly 
involved in the clinical care of the patient. As previously mentioned due to 
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staff shortages and workload the specialist chemotherapy sisters were unable 
to assist with the data collection and the researcher became the soul data 
collector.  
 
The strength of a single data collector lies in the consistency in the 
interpretation of the questions asked. However, the burden placed on one 
person to collect all of the data may limit the sample size that can be 
interviewed. 
 
Despite the inexpensive method of surveying a large number of people 
relatively quickly, the main limitation of a retrospective analysis is the reliability 
of the data which may not be collected with the rigor expected in a research 
study. For some variables, data were unavailable in the participant’s medical 
notes particularly performance status, history of weight loss, social history and 
ethnicity. Other difficulties included the inconsistency in the reporting method 
of toxicities of the treatment, with some doctors using the NCI CTCAE criteria 
v 3.0 (2006), others using terms such as mild, moderate or severe and a few 
only making reference to the presence of a toxicity with no history of its onset 
or severity.  
 
The data were collected from a single centre with the sample drawn from that 
geographical area which may introduce an element of bias and influence the 
generalisability of the findings to other populations.  
 
The size of the whole retrospective sample was sufficient to power the 
statistical tests to give a greater than 80% chance that a statistically 
significant effect would be detected. However, when this sample was 
restricted to those participants that received capecitabine monotherapy only 
the power was reduced to 72% and the power of the prospective data were 
65%. With 80% being the conventional level of power required to detect an 
effect as it actually exists, the lower power seen in the capecitabine 
monotherapy samples may call the study results into question, in that the 
study might have been too small to detect any differences.  
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3.7.2 Validity and reliability of the proposed study 
The variables entered and purposefully reduced in the logistic regression 
model applied to the retrospective capecitabine monotherapy sample were 
applied to the prospective data for the purpose of demonstrating validity and 
reliability of the findings. The result of this analysis is presented in chapter 4 
and discussed further in chapter 5.  
 
3.8  Summary 
 
The methodological approach to conducting this study is based on the 
positivist paradigm drawing on a quantitative approach of survey design. 
Details of each phase of the study using a multi-strategy approach to data 
collection in phase two were explained. Sample selection for both phases of 
this study was described including estimation of the statistical power 
achieved.  This was followed by an explanation of the process applied to the 
analysis of the data including details of the statistical tests used and the 
rationale for the use of the special algorithm employed for the selection and 
retention of variables in the multivariate modelling technique. The theoretical 
basis and subsequent research design used for this study has been 
presented. The issue of the potential role conflict when the researcher is also 
a clinician were discussed and ethical dilemmas were examined. Strategies to 
overcome these conflicts and challenges were identified. The chapter 
concluded by discussing limitations of the study design and methodology.  





CHAPTER  4   FINDINGS 
4.1  Introduction 
This chapter presents the findings from data collected from the two samples 
(retrospective and prospective). The findings are presented in three sections; 
the whole sample from the retrospective notes review, followed by the findings 
from the participants within this sample who received capecitabine 
monotherapy only. Capecitabine monotherapy was the focus for the 
prospective data collection phase of the study, the findings of which are 
presented in the third and final section of this chapter. The descriptive 
statistics are presented for the whole of each sample. The inferential statistics 
are restricted to those who developed PPE prior to cycle 4 versus those who 
did not so that risk factors for early development of PPE could be identified. A 
detailed description of each model applied to the three samples is given with a 
summary table (table 4.45) of the statistics from these models at the end of 
the chapter. Individual case reports are presented to illustrate previously 
unreported or unusual features of PPE. 
 
4.2  Retrospective data  
4.2.1 Descriptive statistics 
4.2.1.1  Sample characteristics 
The sample was drawn from patients who had received oxaliplatin and 
infusional 5-FU (folfox) or capecitabine containing regimes between April 
2008 and March 2009. A total of 392 participants of which men totalled 229 
(58.4%) and women 163 (41.6%), were included in the analysis. The median 
age across the sample was 66 (range 30-85 yrs), with men slightly older than 




63 yrs (35-85 yrs). The sample characteristics are presented in table 4.1. All 
participants received more than one cycle of chemotherapy, unless the 
treatment was stopped following the first cycle due to severe toxicities 
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a patients who developed PPE of any grade 
b patients who did not develop PPE during treatment 
c other tumour sites = Oesophageal; Gastric; Unknown primary; Cholangiocarcinoma; 
Pancreas; Pseudomyxoma peritonei; Neuroendocrine; Ovary 
d other cap = capecitabine/RTD; ECX; capox; Cisp/Cap/RTD; Cap/docetaxel; Bev/Cap; 
Gem/Cap; EOX = 12  





In relation to toxicity from both capecitabine containing regimes and infusional 
5FU, mild to severe adverse events were reported for 284 (72.4%) of the 392 
participants. Diarrhoea was the most common adverse side effect. The 
incidence of toxicity is listed in table 4.2; the figures reflect the development of 
multiple toxicities in many participants.  
 
Toxicity Sample With PPEa 
n (% )  
PPE pre 
cycle 4a 






Number (%) 392 (100) 109 (27.8) 82 (20.9) 27 (6.9) 283 (72.2) 
Diarrhoea 152 (38.8) 57 (52.3) 50 (61.0) 7 (25.9) 95 (33.6) 
Mucositis 107 (27.3) 37 (33.9) 30 (36.6) 7 (25.9) 70 (24.7) 
N & Vc 112 (28.6) 35 (32.1) 25(30.5) 10 (37.0) 77 (27.2) 
Rash 17 (4.3) 3 (2.8) 2 (2.4) 1 (3.7) 14 (4.9) 
Fatigue 101 (25.8) 32 (29.4) 21 (25.6) 11 (40.7) 69 (24.4) 
a participants who developed PPE of any grade 
b participants who did not develop PPE during treatment 
c Nausea and vomiting 
Table 4-2 Incidence of toxicity N (%) retrospective data 
 
Gastrointestinal adverse events were observed most frequently. 152 
participants reported diarrhoea (38.8%) and nausea and/or vomiting was 
recorded in 112 participants (28.6%). PPE developed in 109 participants 
(27.8%). The incidence of PPE was higher in those who received 
capecitabine monotherapy 50.3% (76 out of 151 participants) than in those 
receiving either other capecitabine containing regimes (22.9%) or infusional 
5FU (7.6%). Diarrhoea and mucositis had a higher incidence in participants 
receiving infusional 5FU (40% for each toxicity). However, nausea and/or 
vomiting had a higher incidence in those who received other capecitabine 
containing regimes 35.4% (34 out of 96 participants). These results are 


















PPE 76 (50.3) 22 (22.9) 11 (7.6) 
Diarrhoea 37 (24.5) 27 (28.1) 58 (40.0) 
Mucositis 34 (22.5) 15 (15.6) 58 (40.0) 
N & Vd 36 (23.8) 34 (35.4) 42 (29.0) 
Rash 4 (2.6) 4 (4.2) 9 (6.2) 
Fatigue 29 (19.2) 24 (25.0) 48 (33.1) 
a capecitabine monotherapy 
b Other capecitabine containing regimes = 
capecitabine/RTD; ECX; capox; Cisp/Cap/RTD; 
Cap/docetaxel; Bev/Cap; Gem/Cap; EOX = 12 
c Infusional 5FU 
d Nausea and vomiting 
Table 4-3 Incidence of toxicity by regime (n = 392) retrospective data 
 
Table 4.4 presents an examination of any association between these toxicities 
and the incidence of PPE at any cycle. A chi-square test for independence 
(with Yates continuity correction) indicated an association between diarrhoea 
and PPE, X 2 (1, n = 392) = 10.85 p = .001. This significant association 
between diarrhoea and PPE showed that for those with diarrhoea, there were 
more cases of PPE than would have been expected (observed cases = 57 
versus expected = 42) (table 4.5).  However, only a small effect size was 
detected with phi = .17. The test showed no association between mucositis, 
nausea and vomiting, rash or fatigue and development of PPE at any cycle.  
 
Variable X 2a df
b p phic 
Diarrhoea 10.85 1 .001 .17 
Mucositis 2.92 1 .09 .09 
N & Vd .70 1 .40 .05 
Rash  .46 1 .50a -.04 
Fatigue .78 1 .38 .05 
a  X 2 differences between observed and expected frequencies 
b df extent to which values are free to vary given a specific number of subjects and a total 
score (in 2 x 2 table always 1) 
c phi strength of any association (effect size or risk) 0-1 higher values indicate a stronger 
association (small effect = .10, medium effect = .30, large effect = .50 (Cohen 1988)) Can be 
+ve or -ve 
dNausea and vomiting 






p = .001 Diarrhoea 
Total No Yes 
PPE No Count 188 95 283 
Expected Count 173.3 109.7 283.0 
Yes Count 52 57 109 
Expected Count 66.7 42.3 109.0 
 
% of Total 61.2% 38.8% 100.0% 
Table 4-5 Cross tabulation of Chi-square test diarrhoea 
 
Since PPE is the toxicity of interest in this study a more detailed description of 
the severity of PPE will now be presented. 
 
4.2.1.3 Severity and time course of PPE 
For analysis of the severity of PPE, the grade (previously stated in figure 3.2 
page 65) and cycle at first presentation of PPE was recorded and the most 
severe episode of PPE experienced. The grade distribution, cycle of 
presentation and the worst episode are presented in table 4.6. Of the 109 
participants who developed PPE at any cycle, 82 (75.2%) presented with PPE 
before starting cycle 4 and  27 (24.8%) after starting cycle 4 of their treatment. 
PPE was evaluated at the time of the development of the first episode. Of the 
109 participants who had PPE, 20 participants (18.3%) had their first episode 
after the first cycle, 41 (37.6%) after the second cycle, 21 (19.3%) after the 
third cycle and 27 participants (24.8%) had their first episode following the 
fourth or more cycles. More participants presented with grade 1 PPE as their 
first episode for all regimes. Of the 59 (54.1%) participants whose first 
presentation at any cycle of PPE was grade 1, 25 developed grade 2 (9 
participants) or grade 3 (16 participants) following subsequent cycles. 34 
participants (31.2%) had grade 1 PPE, 35 participants (32.1%) had grade 2 
PPE and 40 participants (36.7%) had grade 3 PPE as their most severe 
episode. There were differences in the incidence of PPE prior to cycle 4 
between the different regimes. Out of those who developed PPE prior to cycle 




with 63.6% of other capecitabine containing regimes and 45.4% for infusional 





SEVERITY AND TIME COURSE OF PPE RETROSPECTIVE DATA FOR WHOLE SAMPLE AND BY REGIME 

















































































































































































































a cycle in which the first episode of PPE developed number and percentage of those with PPE 
b grade that participants presented with at first episode of PPE number and percentage of those with PPE 
c worst grade for each participant developing PPE number and percentage of those with PPE 




4.2.1.4 Treatment outcome. 
231 of the 392 (58.9%) participants completed all planned cycles. Details of 
completion rates including deferral of treatment and dose reductions are 
provided in Table 4.7.  
 
Outcome Sample 
Number (%) 392 (100) 
Completed all cycles  231 (58.9) 
Discontinued treatment  
due to PPEa 
due to other toxicities/adverse eventsa 
Dis prog/poor PSa 
Patient requesta 
Dieda 








Deferred due to PPE 47 (11.9) 
Deferred due to other toxicities 17 (4.3) 
Dose reduction at cycle 1 49 (12.5) 
Dose reduction due to PPE 49 (12.5) 
Dose reduction due to other toxicities 113 (28.8) 
a % of total number who discontinued treatment 
Table 4-7 Completion rates n (%) retrospective data 
 
161 participants (41.1%) discontinued treatment before completion of 6 
cycles. Of these 161 participants, the reasons for the discontinuation of 
treatment were PPE 17 (10.6%), other toxicities or adverse events 71 
(44.1%), disease progression or deteriorating performance status 38 (23.6%), 
patient request 10 (6.2%), died during treatment 15 (9.3%) or no reason given 
10 (6.2%). 
 
Of the 10 participants who chose to discontinue their treatment, 5 received 
capecitabine monotherapy, 2 received other capecitabine containing regimes 
and 3 infusional 5FU. Only 2 of these developed PPE, grade 1 (1) and grade 
3 (1). 9 of the 10 chose to discontinue treatment as they were feeling 
generally unwell due to the effects of the treatment and 1 due to psychological 
distress. None of the participants met the usual threshold to stop based on the 




included in the analysis as they chose to discontinue their treatment after 
receiving at least 3 cycles of treatment. 
 
Participants (49) who had a dose reduction at the start of their treatment did 
so for a variety of reasons; 19 due to moderate renal failure (creatinine 
clearance (CrCl) 30-50); 8 who had severe toxicities with previous 
chemotherapy; 1 receiving concurrent radiotherapy; 2 with delayed wound 
healing; 2 because of their age (80yrs); 3 with poor performance status (2-3) 
and 14 reason unknown. All of the 14 participants where the reason was 
unknown were female with metastatic breast cancer and the dose reduction 
consisted of a reduced length of administration time e.g. for 7 days with 2 
weeks rest rather than the usual regime of 14 days administration and 1 week 
rest. Although these participants had received previous chemotherapy they 
had not suffered from severe toxicities and their ages ranged from 46 – 70 
years. The only common feature of this group was that they were all under the 
care of one particular consultant. 64 participants had a delay between cycles 
due to the presence of toxicities, 47 of these was due to PPE (43.1% of the 
109 who developed PPE) and 17 due to other toxicities.  
 
Since the aim of this study is to identify factors other than the drug itself that 
may influence the development of PPE, the sample used for inferential 
statistical analysis was restricted to those who developed PPE within the first 
3 cycles and those who did not develop it, based on the assumption that PPE 
developing in later cycles is more likely to be due to accumulation of the drug.  
4.2.2 Inferential statistics 
4.2.2.1 Bivariate analysis (Chi-square) 
A chi-square test was applied to each individual variable and PPE and the 






Variable X 2 df P value Phi/Cramer’s V 
Gender .86b 1 .35 -.05 
Maritalstatus2gps .07b 1 .79 .02 
Ethnic2gps 2.86b 1 .09a -.12 
Job2gps .10b 1 .75 .03 
Smoker .79b 1 .37 .07 
Alcohol .72b 1 .39 -.07 
Recent wt loss 2.44b 1 .12 -.16 
BMI2gpsM .09b 1 .73 .02 
BMI2gpsF .12b 1 .77 .02 
Diabetes .34b 1 .56 .04 
PVD .00b 1 1.0a -.01 
Periph neuro .18b 1 .67a .04 
Skin complaints .56b 1 .45a .07 
Inflamm cond .01b 1 .91 -.02 
Previous Ca ∆ .57b 1 .45 .33 
Prev DXT 3.53b 1 .06 .11 
Performance status 3gps 5.02 2 .08 .15 
Tumoursite3gps 7.47 2 .02 .14 
Met spread 6.68b 1 .01 -.14 
PPE with prev chemo 18.47 2 <.001a .23 
Regime3gps 73.17 2 <.001 .45 
Aim of Rx2gps 3.64b 1 .06 -.11 
Start season 4.14b 1 .03 .11 
CrClC13gps 4.34 2 .11 .11 
aat least 1 cell has expected count of less than 5 
byate’s correction for 2 x 2 table 
 Indicates variables p < .05 and included in multivariate regression 
 Indicates additional variables p < .25 included in multivariate regression  
Table 4-8 Chi-square test for association between variables and 
development of PPE before cycle 4 retrospective data 
 
A chi-square test for independence (with Yate’s correction for 2 x 2 tables) 
indicated a significant association between; 
 
 the development of PPE prior to cycle 4 and metastatic spread X 2  
(1, n = 265) = 6.68 p = .01.  
The association between metastatic spread and PPE showed that for those 
whose cancer had not metastasised there were more cases of PPE than 
would have been expected (observed = 51 cases versus expected = 40.2) 






p = .01 
Metastatic spread 
Total No Yes 
PPE prior to Cycle 4  No Count 127 154 281 
Expected Count 137.8 143.2 281.0 
Yes Count 51 31 82 
Expected Count 40.2 41.8 82.0 
 % of Total 49.0% 51.0% 100.0% 
Table 4-9 Crosstabulation Chi-square metastatic spread 
 
 PPE with previous chemotherapy X 2 (1, n = 265) = 18.47 p = <.001. 
The association between PPE with previous chemotherapy and PPE with 
current treatment showed that for those who did not develop PPE with 
previous treatment there were more cases of PPE than would have been 
expected (observed = 36 cases versus expected = 29). Participants who 
developed PPE with previous treatment there were more case of PPE than 
would have been expected (observed = 7 cases versus expected = 2.3) (table 
4.10). The accuracy of this finding may be unreliable since the expected count 
in the latter is less than 5 breaching one of the assumptions of a chi square 
test. 
Crosstab 
p < .001 








PPE prior to Cycle 4  No Count 181 92 3 276 
Expected Count 169.3 99.0 7.7 276.0 
Yes Count 38 36 7 81 
Expected Count 49.7 29.0 2.3 81.0 
 % of Total 61.3% 35.9% 2.8% 100.0% 
Table 4-10 Cross tabulation Chi square PPE with previous 
chemotherapy 
 
 Regime divided into 3 groups (capecitabine monotherapy; other 
capecitabine containing agents; infusional 5FU) X 2 (1, n = 265) = 
73.17 p = <.001.  
The association between the regime and PPE showed that for those receiving 
capecitabine monotherapy there were more cases of PPE than would have 
been expected (observed = 63 cases versus expected = 31). Interestingly for 
those receiving infusional 5FU there were far less cases of PPE than would 







p = < .001 
regime3gp 
Total Other Cap Cap SA Inf 5FU 
PPE prior to Cycle 4  No Count 74 75 134 283 
Expected Count 68.2 107.0 107.8 283.0 
Yes Count 14 63 5 82 
Expected Count 19.8 31.0 31.2 82.0 
 % of Total 24.1% 37.8% 38.1% 100.0% 
Table 4-11 Cross tabulation Chi square regime 
 
 Tumour site divided into 3 groups (Colorectal cancer; Breast 
cancer; other) X 2  (1, n = 265) = 7.47 p = .02  
The association between tumour site and PPE showed that for those who had 
breast or colorectal cancer there were more cases of PPE than would have 
been expected (observed = 10 cases versus expected = 6.7 and observed = 
63 cases versus expected = 58.2 respectively) (figure 4.12). 
  
Crosstab 
p = .02 
tumour site 3 gps 
Total Other Breast Colorectal 
PPE prior to Cycle 4  No Count 67 20 196 283 
Expected Count 58.9 23.3 200.8 283.0 
Yes Count 9 10 63 82 
Expected Count 17.1 6.7 58.2 82.0 
 % of Total 20.8% 8.2% 71.0% 100.0% 
Table 4-12 Cross tabulation Chi square Tumour site 
 
 The season during which the treatment commenced X 2 (1, n = 265) 
= 4.14 p = .03  
The association between the season at the start of treatment and PPE 
showed that for those whose started their treatment in the winter months there 
were more cases of PPE than would have been expected (observed = 57 
cases versus expected = 48.5) (figure 4.13) 
 
Crosstab 
p = .03 
Seasonstart 
Total Summer Winter 
PPE prior to Cycle 4  No Count 124 159 283 
Expected Count 115.5 167.5 283.0 
Yes Count 25 57 82 
Expected Count 33.5 48.5 82.0 
 % of Total 40.8% 59.2% 100.0% 





A small effect was detected for tumour site 3gps, Cramer’s V = .14, start 
season, phi = .11 and metastatic spread, phi = -.14. A medium effect was 
detected for PPE with previous chemotherapy, Cramer’s V = .23 and a large 
effect for regime 3gps, Cramer’s V = .45.  
 
4.2.2.2 Summary of findings from Chi-square tests 
Findings from the chi-square tests (p < .05) show that those more likely to 
develop PPE within the first 3 cycles are participants; 
 Whose tumour had not metastasised 
 Who had been previously treated with chemotherapy but not 
necessarily had previous episodes of PPE 
 Who received capecitabine monotherapy for breast or colorectal 
cancer 
 Who commenced their treatment during the winter months 
 
The results of the comparison of the means from the independent samples t-
test for age and laboratory values (continuous data) prior to treatment 
commencing are shown in table 4.14. Independent-samples t-test were 
conducted to compare PPE incidence prior to commencing cycle 4 of the 
treatment for Body Surface Area (BSA), Body Mass Index (BMI), creatinine, 
creatinine clearance, Alanine Aminotransferase (ALT) and Bilirubin. No 
significant differences were observed in any of these variables between those 
who developed PPE and those who did not. The same test applied to age 
showed a significant difference between those who did not develop PPE (  
= 64.18, SD = 10.66) and those that did (  = 67.13, SD = 11.54); t (363) = -
2.17, p = .03 and applied to Alkaline Phosphatase (ALP) showed a significant 
difference between those who did not develop PPE (  = 163.03, SD = 
174.68) and those that did (  = 111.75, SD = 102.39); t (226) = 3.31, p = 
.001 The magnitude in the difference of the means ( ) (mean difference) for 
age = -2.96 (95% CI, -5.64 to -.27) was small (eta squared = 0.01) and ALP = 





4.2.2.3 Summary of the findings from the t-tests 
The mean of each group in the t-tests (p < .05) was examined, with the higher 
mean indicating the direction of association. Older participants and those with 
a lower pre treatment ALP level were more likely to develop PPE within the 
first 3 cycles. 
 
Although this analysis is useful in showing any association of individual 
variables with the development of PPE, clinically, variables are not present in 
isolation and it is therefore more useful to apply multivariate tests to the data 
to establish the performance of the variables when in combination with each 
other. A multivariate analysis using logistic regression will now be described. 
 
Variable Ma PPE 
Yb 
SD Ma PPE 
Nc 
SDd t p Mean 
diffe 
CIf ETA2g 
Age 67.13 11.54 64.18 10.66 -2.17 .03 -2.96 -5.64 to 
-.27 
0.01 
BSA 1.82 .19 1.82 .22 .16 .87 .004 -.05 to 
.06 
0.00 
BMI 25.81 4.15 25.65 5.05 -.26 .79 -.16 -1.36 to 
1.04 
0.001 
Creatinine  76.51 17.99 74.89 21.33 -.62 .53 -1.62 -6.71 to 
3.47 
1.00 
CrCl 85.20 29.88 91.52 31.66 1.61 .11 6.32 -1.39 to 
14.04 
1.00 
ALT 29.96 43.47 30.32 32.12 .082 .93 .36 -8.33 to 
9.05 
1.00 
ALP 111.75 102.39 163.03 174.68 3.31 .001 51.28 20.77 to 
81.78 
0.99 
Bilirubin 7.96 4.77 4.77 9.12 1.42 .15 1.50 -.56 to 
3.57 
1.00 
a M = mean ( ) 
b PPE Y = subjects who developed PPE prior to commencing cycle 4 
c PPE N = subjects who did not develop PPE at any cycle 
d SD = standard deviation 
e Mean diff = Mean difference between the groups 
f CI = 95% confidence interval 
g ETA2 = effect size 
 Indicates variables p < .05 included in multivariate regression  
 Indicates variables p < .25 included in multivariate regression 






4.2.2.4 Multivariate analysis 
Variables that had a p value of < .25 but had less than 5 cases in any cell in 
the chi-square test were not included in the logistic regression as there were 
insufficient cases in such variables to reliably estimate odds ratios in the 
logistic regression. The two variables that this applied to were PPE with 
previous chemotherapy and tumour3gps (Colorectal cancer, Breast cancer 
and other). Tumour 3gps had been collapsed to reduce the number of 
categories within the variable, leaving both tumour3gps and PPE with 
previous chemotherapy with the minimum number of categories felt to be 
clinically relevant. 
 
A multicollinearity diagnostics test was applied to the selected variables to 
identify any correlation between them. All variables had a tolerance value of   
> 0.1 indicating that there was no high correlation between any of the 
variables. However, clinically there may be an association between variables. 
From the variables tested for correlation a further chi-square test was applied 
to two variables thought to be clinically associated; metastatic spread and aim 
of treatment X 2 (2, n = 390) = 229.04 p = < .001. Based on this result only one 
of these two variables, metastatic spread, was included in the logistic 
regression based on its significance in the bivariate analysis; p = .01 versus p 
= .06 for the variable aim of treatment. These two variables are clinically 
associated since participants with metastatic spread most frequently receive 
palliative treatment which is given without curative intent, but to decrease 
tumour load and increase life expectancy. 
 
Table 4.15 provides a summary of variables that were significant in the 
bivariate analyses. It shows those variables significant at both the 
conventional alpha level of p < .05 and the relaxed level p < .25 included in 
the regression model. It excludes those variables with insufficient numbers to 






Variable P < .05 P < .25 
Age .03  
Recent weight loss  .12 
Previous radiotherapy  .06 
PS 3 groups  .08 
Metastatic spread  .01  
Regime 3 groups < .001  
Start season .03  
CrCl 3 groups  .11 
Bilirubin  .15 
ALP .001  
Table 4-15 Variables from bivariate analysis entered into regression 
model 
 
4.2.2.5 Purposeful entry and model reduction  
10 variables (table 4.15) were entered into the logistic regression analysis and 
5 removed. Logistic regression, which consisted of 8 steps, was performed for 
the research sample (n = 392) with 40 missing cases not included in the 
model. 27 of these were participants who developed PPE after commencing 
cycle 4 and the remaining 13 consisted of small numbers from several other 
predictor variables (appendix 4.2). 
 
The omnibus tests of model coefficients revealed a Chi-square statistic of 
111.16 (df, 9) p < .001 indicating that the model performs well compared to 
the baseline model before the variables were added. The Hosmer-Lemeshow 
statistic was applied to the data revealing a Chi-square statistic of 5.68 (df, 8) 
p = 0.68 which indicates that the observed numbers who develop PPE are not 
significantly different from those expected by the model and that the overall fit 
of the model is good. The Nagelkerke R2 (.41) value shows about 41% of the 
variation in the outcome variable (PPE) is explained by the logistic regression 
model. This model correctly predicted 84.6% of the cases. 
 
As illustrated in table 4.16 the outcome of the logistic regression analysis 
produced a model containing 3 predictors which were significantly related to 
PPE development; the regime the patient received, ALP level prior to 




There were a further 2 confounding predictors, performance status and 
metastatic spread. Performance status and metastatic spread were 
considered confounders since their removal, at different steps in the model 
building strategy, caused a greater than 20% change in the beta value of the 
variable ALP in both instances. It is possible that this effect could be 
explained by the fact that metastatic spread to the bones causes a raise in 
serum ALP and participants with metastatic spread are more likely to have 
poor performance status. Therefore it follows that those with poor 
performance status are more likely to have a raised ALP level. Factors had 
variable ability to predict the development of PPE. Participants who had 
received capecitabine monotherapy were nearly 6 times more likely to 
develop PPE than those who had received other capecitabine containing 
regimes (OR = 5.88; 95% CI 2.87 – 12.03, p < .001). The risk of PPE in those 
who commenced their treatment in the winter was just over twice as great 
compared to those who commenced in the summer (OR = 2.24; 95% CI 1.19 
– 4.18, p = .01). In participants receiving infusional 5FU, they were less likely 
to develop PPE compared to those receiving other capecitabine containing 
agents (OR = .18; 95% CI .06 - .54, p = .002). For every unit increase in the 
ALP level taken prior to commencing treatment (OR = .99; 95% CI .99 – 1.0,  
p = .05) the risk of developing PPE was reduced. Performance status 
although a confounding variable and not achieving statistical significance 
showed a trend that as performance status worsened, the risk of developing 
PPE was reduced (OR = .97; 95% CI .44 – 2.14, p = .95). The other 
confounding variable, metastatic spread, again although not achieving 
statistical significance showed a trend that participants who did not have 
metastatic spread were one and a half times more likely to develop PPE than 
those who had metastatic spread (OR = 1.53; 95% CI .81 – 2.92, p = .19).  
 
A logistic regression test was applied to regime3gps with infusional 5FU as 
the reference category to establish the odds ratio for capecitabine in 
combination regimes (other cap) when compared with 5FU, as this was not 
possible when the variable other cap was the reference category. For 




compared with the one selected as the reference category, hence the 
rationale for the change in reference category (the output for both models with 
the different reference categories are presented in table 4.16).  
 
Predictor variable (n = 356) Β Wald X 2 p* value OR (exp β) 95% CI 
Regime3gps  
Other cap (ref cat) (85) 
Cap SA (133) 






















Inf 5FU (ref cat) (138) 
Other cap (85) 





















ALPC1 (356) -.003 3.79 .05 .99 .99-1.0 
Seasonstart   




































PS 0 (112) 
PS 1 (80) 






















* significant at p < .1 (2-tailed)  a Confounder 
Table 4-16 Logistic regression output purposeful entry model 
retrospective data 
 
Participants who received capecitabine monotherapy were 32 times more 
likely to develop PPE compared to those who received infusional 5FU (OR = 
32.12, 95% CI 11.95 - 86.37, p < .001) and those who received other 
capecitabine containing regimes were over 5 times more likely to develop 
PPE than those who received infusional 5FU (OR = 5.47; 95% CI 1.85 - 
16.15, p = .002). These findings added strength to the decision to focus on 
participants receiving capecitabine monotherapy only during the prospective 
data collection phase. 
 
Variables that were not included in the original model containing the 10 
variables were added one at a time and logistic regression applied. Out of the 




.25 therefore these were added to the final model and reduced as before. 
Diabetes was removed leaving alcohol and gender, both of which achieved 
significance (using an alpha level of p < .1). Men were nearly twice as likely to 
develop PPE than women (OR = 1.83; 95% CI .95 – 3.53, p = .07) and 
participants that drank alcohol regularly were less likely to develop PPE than 
those that did not drink or only drank occasionally (OR = .53; 95% CI .23 – 
1.23, p = .05) (table 4.17).  
 
Predictor variable  
(n = 356) 








Inf 5FU (ref cat) (138) 
Other cap (85) 





















ALPC1  -.003 3.69 .05 .99 .99-1.00 
Seasonstart   




































PS 0 (ref cat) (112) 
PS 1 (80) 


























































* significant at p < .1 (2-tailed) 
a Confounder 
Table 4-17 Logistic regression output purposeful entry model plus 
additional non-significant variables 
 
4.2.2.6 Forward and backward conditional entry model 
The same 10 variables included in the purposeful reduction model were 




forward entry method and 7 removed in 8 steps in the backward entry 
method. 
 
The assessment of the ‘goodness of fit’ is shown in table 4.18 demonstrating 
a good fit in both entry methods with the 38% variance explained by the 
model in both the forward entry and backward entry methods. The ability of 
the model to correctly predict which category each case fits into was 82.4% in 
both stepwise entry methods. 
 
Test Forward entry Backward entry 












Nagelkerke R2 .39 .38 












Table 4-18 Goodness of fit automated entry method retrospective data 
 
As shown in table 4.19 the outcomes of the automated entry methods of the 
logistic regression analysis showed predictive models containing 4 variables 
in the forward entry strategy and 3 variables in the backward entry strategy. 
Variables that were significantly related to PPE development; the regime the 
patient received, the season during which the participant commenced their 
treatment in and ALP level prior to commencing treatment were common in 
both models with weight loss an additional variable in the forward entry model. 
Factors had variable ability to predict the development of PPE but were 
similar in the forward and backward entry methods. The risk of developing 
PPE was more than 5 times greater in participants who received capecitabine 
containing regimes compared to those who had received infusional 5FU (OR 
= 5.75; 95% CI 1.93-17.10, p = .002 OR = 5.31; 95% CI 1.82-15.55, p =.002 
respectively) and over 30 times greater in those who received capecitabine 
monotherapy compared with infusional 5FU (OR = 30.19; 11.29-80.69, p < 




commenced their treatment in the winter were more than twice as likely to 
develop PPE than those who commenced in the summer (OR = 2.25; 95% CI 
1.21-4.18, p = .01 OR = 2.25; 95% CI 1.18-4.05, p = .01) and for each unit 
increase in the ALP level taken prior to commencing treatment there was a 
reduced risk of developing PPE (OR = .99; 95% CI .99-.99 in both forward 
and backward entry models p = .006 and p = .003 respectively). In the forward 
entry model participants who had recently lost weight were less likely to 
develop PPE than those who had not lost weight recently (OR = .61; 95% CI 
.20-1.79, p = .21) although did not achieve statistical significance. 
 
 Predictor variable  
(n = 352) 








Forward entry method 
Regime3gps 
Inf 5FU (137) (ref cat) 
Other cap (85) 





















ALPC1 -.004 7.62 .006 .99 .99-.99 
Seasonstart  

















Weight loss  

















Backward entry method 
Regime3gps 
Inf 5FU (137) (ref cat) 
Other cap (85) 





















ALPC1 -.005 8.71 .003 .99 .99-.99 
Seasonstart  


















* significant at p < .1 (2-tailed) 
Table 4-19 Logistic regression output automated entry methods 
retrospective data 
 
The differences in the odds ratios for each variable between the different entry 




variables in each model, thereby reflecting the influence exerted on each 
variable when in combination with different variables. 
 
Comparison of models using different variable entry methods (forward, 
backward and purposeful) was made using the area under the curve figure 
obtained by applying Receiver Operator Characteristics (ROC) tests to 
establish which method proved to be the better predictor of PPE. 
 
4.2.2.7 Receiver operating characteristic (ROC) curves 
ROC curves were applied to the predicted probabilities created in each of the 
logistic regression entry methods to compare the accuracy of the models in 
terms of their sensitivity and specificity in predicting participants who 
developed PPE within the first 3 cycles and those that did not develop PPE.  
 
The model with 5 variables remaining following purposeful entry and retention 
provides a slightly more accurate prediction of participants who are likely to 
develop PPE and those who will not AUC = .85 (95% CI .81-.90) than the 
models with 4 and 3 variables remaining using the forward and backward 
entry methods respectively AUC = .84 (95% CI .80-.89) (figure 4.1). From the 
ROC curve applied to the purposeful entry model, the most favourable values 
for sensitivity and specificity are 82% and 76% respectively. The positive and 
negative predictive values calculated from the logistic regression output were 
69.0% and 88.2% respectively. 
 
A comparison of the final model with the same model including the two 
variables that were non-significant in the bivariate analysis (figure 4.2) 
showed that the latter model provided a more favourable ability to predict the 
development of PPE AUC = .87 (95% CI; .83 - .92) with a sensitivity = 78% 
and specificity 1 - 0.22 = 78% The positive and negative predictive values 
calculated from the logistic regression output were 70.6% and 88.5% 




PPE correctly diagnosed. The negative predictive value is the proportion of 
subjects without PPE who are correctly diagnosed. 
 
 





Figure 4-2 ROC curves comparing purposeful entry models 
retrospective data 
 
Test Result Variable(s) from figure 
4.7 
Area 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
Purposeful entry .852 .806 .898 
Forward entry .845 .798 .892 
Backward entry .845 .798 .892 
Test Result Variable(s) from figure 
4.8 
Area 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
Purposeful entry final model .851 .805 .897 
Final model with non-sig variables .872 .827 .917 
 
Since the confidence intervals are wide and overlap between the models, this 
would indicate that there is very little difference between the models and that 
the automated entry methods produce a model that is not significantly 
different in predicting development of PPE within the first 3 cycles of treatment 
compared to the purposeful entry methods. Purposeful selection and retention 




confounders. This is particularly so if one is interested in risk factors modelling 
rather than simply prediction. 
 
4.2.2.8 Summary of findings from logistic regression 
To summarise the findings from the richer purposeful model (final model with 
non-significant variables added), those most at risk of developing PPE were 
participants; 
 
 Who were male  
 Who did not drink alcohol regularly 
 With good performance status 
 Whose tumour had not metastasised 
 Who received capecitabine monotherapy 
 With a lower pre treatment ALP level 





4.3  Retrospective data capecitabine monotherapy sample 
As previously stated, the data analysis of the retrospective sample showed 
that participants who received capecitabine monotherapy had a higher 
incidence of PPE than those who received capecitabine in combination 
regimes or infusional 5-FU. The results of the analysis of the 151 subjects 
who received capecitabine monotherapy are presented in this section. 
4.3.1 Descriptive statistics 
4.3.1.1 Sample characteristics 
A total of 151 participants of which men totalled 80 (53.0%) and women 71 
(47.0%), were included in the analysis. The median age across the sample 
was 69 (range 39-85 yrs) with men slightly older than women with a median 
age of 71yrs (range 47-84 yrs) compared to a median age of 65 yrs (39-85 
yrs). The sample characteristics are presented in table 4.20. 
 
All participants received more than one cycle of chemotherapy, unless the 
treatment was stopped following the first cycle due to severe toxicities 
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a patients who developed PPE of any grade 
b patients who did not develop PPE during treatment 
c other tumour sites = Pancreas; Ovary  








In relation to toxicity from capecitabine monotherapy, mild to severe adverse 
events were reported for 102 of the 151 (67.5%) participants. Diarrhoea was 
the most common adverse effect. The incidence of each toxicity is listed in 
table 4.21, the figures reflecting the development of multiple toxicities in many 
participants.  
 
Toxicity Sample With 
PPEa 









Number (%) 151 (100) 76 (50.3)  63 (82.9) 13 (17.1) 75 (49.7) 
Diarrhoea 67 (44.4) 43 (56.6) 39 (61.9) 4 (30.8) 24 (32.0) 
Mucositis 34 (22.5) 22 (28.9) 20 (31.7) 2 (15.4) 12 (16.0) 
N & Vc 36 (23.8) 23 (30.3) 18 (28.6) 5 (38.5) 13 (17.3) 
Rash 4 (2.6) 2 (2.6) 1 (1.6) 1 (7.7) 2 (2.7) 
Fatigue 29 (19.2) 22 (28.9) 17 (27.0) 5 (38.5) 7 (9.3) 
a patients who developed PPE of any grade 
b patients who did not develop PPE during treatment 
c Nausea and vomiting 
Table 4-21 Incidence of toxicity retrospective data capecitabine 
monotherapy 
 
Gastrointestinal adverse events were observed most frequently. 67 
participants reported diarrhoea (44.4%) and nausea and/or vomiting were 
observed in 36 participants (23.8%). PPE developed in 76 participants 
(50.3%) with 63 (82.9%) of these developing PPE during the first three cycles 
of their treatment.  
 
A chi-square test for independence (with Yates continuity correction) indicated 
an association between diarrhoea and PPE, X 2 (1, n = 151) = 8.27 p = .004, 
showing that for those who did not develop diarrhoea there were more cases 
of PPE than would have been expected (observed = 20 cases versus 






p = .004 
Diarrhoea 
Total No Yes 
PPE before Cycle 4 No Count 188 95 283 
Expected Count 189.9 93.1 283.0 
Yes Count 20 7 27 
Expected Count 18.1 8.9 27.0 
Total Count 208 102 310 
Expected Count 208.0 102.0 310.0 
% of Total 67.1% 32.9% 100.0% 
Table 4-22 Cross tabulation Chi square diarrhoea 
 
 There was a statistically significant association between fatigue and PPE, X 2 
(1, n = 151) = 8.14 p = .004, showing that for those who reported fatigue there 
were more cases of PPE than would have been expected (observed = 11 
cases versus expected = 7) (figure 4.23). 
Crosstab 
p = .004 
Fatigue 
Total No Yes 
PPE before Cycle 4 No Count 214 69 283 
Expected Count 210.0 73.0 283.0 
Yes Count 16 11 27 
Expected Count 20.0 7.0 27.0 
Total Count 230 80 310 
Expected Count 230.0 80.0 310.0 
% of Total 74.2% 25.8% 100.0% 
Table 4-23 Cross tabulation Chi square fatigue 
 
There was a small to moderate effect size detected with phi = .25 in both 
instances. The test showed no association between mucositis, nausea and 
vomiting or rash and development of PPE at any cycle (table 4.24).  
 
Variable X 2a df
b p Phic 
Diarrhoea 8.27 1 .004 .25 
Mucositis 2.92 1 .087 .15 
N & Vd 2.80 1 .094 .15 
Rash  .00 1 1.00a -.001 
Fatigue 8.14 1 .004 .25 
a X 2 differences between observed and expected frequencies 
bdf extent to which values are free to vary given a specific number of subjects and a total score 
(in 2 x 2 table always 1) 
cphi strength of any association (effect size or risk) 0-1 higher values indicate a stronger 
association (small effect = .10, medium effect = .30, large effect = .50 (Cohen 1988)) Can be 
+ve or -ve 
dNausea and vomiting 
Table 4-24 Other toxicity effects with PPE incidence any cycle (n = 151) 





Since PPE is the toxicity of interest in this study, a more detailed description 
of the severity of PPE will now be presented. 
 
4.3.1.3 Severity and time course of PPE 
For analysis of the severity of PPE, the grade and cycle at first presentation of 
PPE was recorded and the most severe episode of PPE experienced. The 
grade distribution, cycle of presentation and the worst episode is presented in 
table 4.25. Of the 151 participants who received capecitabine monotherapy 76 
(50.3%) developed PPE at any cycle, 63 (82.9%) presented with PPE before 
starting cycle 4 and 13 (17.1%) after starting cycle 4 of their treatment. PPE 
was evaluated at the time of the development of the first episode. Of the 76 
participants who had PPE, 15 participants (19.7%) had their first episode after 
the first cycle, 34 (44.8%) after the second cycle, 14 (18.4%) after the third 
cycle and 13 participants (17.1%) had their first episode following the fourth or 
more cycles. Of the 43 participants whose first presentation of PPE at any 
cycle of PPE was grade 1, 20 developed grade 2 (11 participants) or grade 3 
(9 participants) following subsequent cycles. 24 participants (31.6%) had 
grade 1 PPE, 23 participants (30.3%) had grade 2 PPE and 29 participants 
(38.1%) had grade 3 PPE as their most severe episode. 
 
Toxicities of chemotherapy can impact on the patient’s ability to continue with 
their normal activities and some can be life-threatening resulting in delays in 
treatment and sometimes a reduction in the dose prescribed. Some toxicities 
may influence the patient’s tolerance of treatment, therefore, details of 






Description Capecitabine monotherapy 
 
Number (%) 
No with PPE (%) 































































a cycle in which the first episode of PPE developed number and percentage of 
those with PPE 
b grade that participants presented with at first episode of PPE number and 
percentage of those with PPE 
c worst grade for each participant developing PPE number and percentage of 
those with PPE 
Table 4-25 Severity and time course of PPE retrospective capecitabine 
monotherapy data 
 
4.3.1.4 Treatment Outcome 
81 (53.6%) out of 151 participants completed all planned cycles. Details of 
completion rates including deferral of treatment and dose reductions are 
provided in table 4.26.  
 
70 participants (46.3%) among the 151 discontinued treatment before 
completion of 6 cycles. Of these 70 participants the reasons for the 
discontinuation of treatment were PPE in 11 (15.7%), other toxicities or 
adverse events 23 (32.9%), disease progression or deteriorating performance 
status 13 (18.6%), patient request 5 (7.1%), died during treatment 10 (14.3%) 
or no reason given 5 (7.1%). The remaining 3 (4.3%) were changed to 
alternative treatment due to toxicities from capecitabine; 2 of the 3 had PPE 





The 5 participants who chose to discontinue their treatment did so as they 
were feeling generally unwell due to the effects of the treatment. None of the 
participants met the usual threshold to stop based on manufacturer’s 
recommendations. Of the 10 that died during their treatment, 6 died following 




Number (%) 151 (100) 
Completed all cycles  81 (53.6) 
Discontinued treatment  
due to PPEa 
due to other toxicities/adverse eventsa 
Dis prog/poor PSa 
Patient requesta 
Dieda 
No reason givena 









Deferred due to PPE 35 (23.2) 
Deferred due to other toxicities 26 (17.2) 
Dose reduction at cycle 1 41 (27.2) 
Dose reduction due to PPE 34 (22.5) 
Dose reduction due to other toxicities 30 (19.9) 
a% of total no who discontinued treatment 
Table 4-26 Completion rates n(%) retrospective data capecitabine 
monotherapy 
To enable comparison with studies in the literature a further analysis was 








Number (%) 79 (52.7) 71 (47.3) 
Completed all cycles 54 (68.4) 27 (38.0) 
Discontinued treatment due to PPE 6 (7.6) 5 (7.0) 
Discontinued treatment due to other toxicities 9 (11.4) 4 (5.6) 
Dose reduction at cycle 1 13 (16.5) 28 (39.4) 
Dose reduction due to PPE 24 (30.4) 10 (14.1) 
Dose reduction due to other toxicities 15 (19.0) 15 (21.1) 




There is similarity between the percentage of the sample receiving treatment 
with adjuvant/neoadjuvant intent compared with metastatic/palliative intent. A 
higher proportion completed all 6 cycles in the adjuvant group. More 
participants receiving treatment for palliative intent had a dose reduction at 
the start of treatment. There were similar percentages in each group who had 
treatment discontinued due to PPE or a dose reduction due to other toxicities. 
Dose reduction as a result of PPE occurred more frequently in the adjuvant 
group. 
 
As in the model using the whole sample from the retrospective notes review, 
the sample used for inferential statistical analysis was restricted to 
participants who developed PPE within the first 3 cycles and those who did 
not develop it. 
  
4.3.2 Inferential statistics 
4.3.2.1 Bivariate analysis 
The findings from the chi-square test for all variables are shown in table 4.34 
(page 140). A chi-square test for independence (with Yate’s correction for 2 x 
2 tables) indicated a significant association between the development of PPE 
prior to cycle 4 and; 
 
 Gender X 2 (1, n = 138) = 4.47 p = .03.  
The association between gender and PPE showed that for men there were 
more cases of PPE than would have been expected (observed = 40 cases 
versus expected = 33.3) (table 4.28). 
Crosstab 
p = .03 
Sex 
Total Male Female 
.=those with PPE C4 onwards .00 Count 33 42 75 
Expected Count 39.7 35.3 75.0 
1.00 Count 40 23 63 
Expected Count 33.3 29.7 63.0 
 % of Total 52.9% 47.1% 100.0% 





 Tumour site 2 groups (Colorectal and other) X 2 (1, n = 138) = 7.28 
p = .01  
The association between tumour site and PPE showed that for those with 
colorectal cancer, there were more cases of PPE than would have been 
expected (observed = 54 cases versus expected = 46.6) (table 4.29). 
Crosstab 
p = .01 
tumour2gps 
Total Other Colorectal 
.=those with PPE C4 onwards .00 Count 27 48 75 
Expected Count 19.6  55.4 75.0 
1.00 Count 9 54 63 
Expected Count 16.4 46.6 63.0 
 % of Total 26.1% 73.9% 100.0% 
Table 4-29 Cross tabulation Chi square tumour type 
 
 Metastatic spread X 2 (1, n = 138) = 12.50 p = <.001  
The association between metastatic spread and PPE showed that for those 
whose cancer had not metastasised there were more cases of PPE than 
would have been expected (observed = 43 cases versus expected = 32.2) 
(table 4.30). 
Crosstab 
p < .001 
Metastatic spread 
Total No Yes 
.=those with PPE C4 onwards .00 Count 27 47 74 
Expected Count 37.8 36.2 74.0 
1.00 Count 43 20 63 
Expected Count 32.2 30.8 63.0 
 % of Total 51.1% 48.9% 100.0% 
Table 4-30 Cross tabulation Chi square metastatic spread 
 
 PPE with previous chemotherapy X 2  (2, n = 138) = 6.46 p = .04  
The association between PPE with previous chemotherapy and PPE showed 
that for those who had not had previous chemotherapy, and those who had 
PPE with previous chemotherapy there were more cases of PPE than would 
have been expected (observed = 28 cases versus expected = 24 and 
observed = 5 cases versus expected = 2.8). The accuracy of this finding may 
be unreliable since the expected count in the latter is less than 5 breaching 






p = .04 








.=those with PPE C4 onwards .00 Count 23 47 1 71 
Expected Count 27.0 40.8 3.2 71.0 
1.00 Count 28 30 5 63 
Expected Count 24.0 36.2 2.8 63.0 
 % of Total 38.1% 57.5% 4.5% 100.0% 
Table 4-31 Cross tabulation Chi square PPE with previous 
chemotherapy 
 
 Treatment intent X 2 (1, n = 138) = 15.29 p = <.001  
The association between treatment intent and PPE showed that for those who 
were receiving adjuvant capecitabine, there were more cases of PPE than 
would have been expected (observed = 45 cases versus expected = 33.1) 
(table 4.32). 
Crosstab 
p < .001 
Aimofcurrentregime2gps 
Total Adj or neoadj 
metastatic or 
palliative 
.=those with PPE C4 onwards .00 Count 27 47 74 
Expected Count 38.9 35.1 74.0 
1.00 Count 45 18 63 
Expected Count 33.1 29.9 63.0 
 % of Total 52.6% 47.4% 100.0% 
Table 4-32 Cross tabulation Chi square treatment intent 
 
 The season during which the treatment commenced X 2 (1, n = 138) 
= 5.12 p = .02  
The association between the season in which treatment started and PPE 
showed that for those who commenced their treatment during the winter 
months, there were more cases of PPE than would have been expected 
(observed = 44 cases versus expected = 37) (table 4.33). 
 
Crosstab 
p = .02 
Seasonstart 
Total Summer Winter 
.=those with PPE C4 onwards .00 Count 38 37 75 
Expected Count 31.0 44.0 75.0 
1.00 Count 19 44 63 
Expected Count 26.0 37.0 63.0 
 % of Total 41.3% 58.7% 100.0% 
Table 4-33 Cross tabulation Chi square season in which treatment 
started 
A small to medium effect size was detected for gender, phi = .19; tumour site, 




Medium effects were seen for metastatic spread, phi = -.32, treatment intent, 
phi = .35 and PPE with previous chemotherapy cramer’s V = .22.  
 
Variable X 2 df p  value Phi/Cramer’s V 
Gender 4.47b 1 .03 -.19 
Maritalstatus2gps .12 b 1 .73 .05 
Ethnic2gps 3.23b 1 .07a -.23 
Job2gps .00 b 1 1.00 -.01 
Smoker .10 b 1 .76 .06 
Alcohol .14 b 1 .71 -.06 
Recent wt loss .68 b 1 .41 -.18 
BMI2gpsM .00 b 1 1.00 -.01 
BMI2gpsF .00 b 1 1.00 -.01 
Diabetes .01 b 1 .93 .03 
PVD .67 b 1 .24a -.10 
Periph neuro .01 b 1 .93 a -.04 
Skin complaints .01 b 1 .92a .09 
Inflamm cond 2.05 b 1 .15 -.14 
Previous Ca ∆ 3.47 b 1 .06a .18 
Prev DXT .51 b 1 .48 -.08 
PPE with prev chemo 6.46 2 .04a .22 
Tumoursite2ps 7.28 b 1 .01 .25 
Met spread 12.50 b 1 <.001 -.32 
Aim of Rx2gps 15.29 b 1 <.001 -.35 
PS3gps 3.92 2 .14 a .27 
Start season 5.12 b 1 .02 .21 
CrClC13gps 3.16 2 .21 .15 
a at least 1 cell has expected count of less than 5 
b yate’s correction for 2 x 2 table 
 Indicates variables p < .05 and included in multivariate regression analysis 
 Indicates additional variables p < .25 and included in multivariate regression 
analysis 
Table 4-34 Chi-square test for association between variables and 
development of PPE before cycle 4 retrospective data capecitabine 
monotherapy 
Other analyses were performed to allow comparison with findings in the 
literature and include; 
 Treatment intent and treatment outcome 
 Treatment intent and dose reduction 
 PPE and age ≥ 65 years compared to > 65 years  
 PPE and age > 79 years 
 PPE and age and gender combined 




 Performance status and dose reductions 
 PPE and hormone status of breast cancer 
 Grade 3 PPE and creatinine clearance 3 groups 
 PPE and gender and alcohol combined 
 Metastatic spread and dose reduction 
 
 
 Treatment intent and treatment outcome X 2 (4, n = 150) = 32.35 p < 
.001  
The association between treatment intent and treatment outcome showed that 
for those who received their treatment with adjuvant/neoadjuvant intent, there 
were more cases who completed all cycles than would have been expected 
(observed = 43 cases versus expected = 42.7). For those who received 
treatment with palliative intent, there were more cases who stopped treatment 
for other reasons than would be expected (observed = 35 cases versus 
expected = 19.9) (table 4.35). A large effect size was seen phi = .46. 
 






























































% of total 54.0 7.3 8.7 28 2.0 100 
Table 4-35 Cross tabulation treatment intent and treatment outcome 
 
 Treatment intent and dose reduction 
o At start of treatment X 2 (1, n = 150) = 8.82 p = .003 
 
The association between treatment intent and dose reduction at the start of 
treatment showed there were more cases who received treatment for 




expected = 19.4) (table 4.36). A medium to large effect size was seen phi = 
.26. 
 
Dose reduction at cycle 1 
 No Yes 
Adj or neoadj    Count 





Met or pall 
    Count 





% of total 72.7 27.3 
Table 4-36 Cross tabulation treatment intent and dose reduction cycle 1 
 
o Due to PPE X 2 (1, n = 150) = 4.77 p = .03 
The association between treatment intent and dose reduction due to PPE 
showed there were more cases who received treatment for 
adjuvant/neoadjuvant intent than would have been expected (observed = 24 
cases versus expected = 17.9) (table 4.37). A small effect size was seen phi = 
.19 
 
Dose reduction due to PPE 
 No Yes 
Adj or neoadj    Count 





Met or pall 
    Count 





% of total 77.3 22.7 
Table 4-37 Cross tabulation treatment intent and dose reduction due to 
PPE 
o Due to other toxicities X 2 (1, n = 150) = .12 p = .94 
The association between treatment intent and dose reduction due to other 
toxicities showed that the proportion receiving treatment for 
adjuvant/neoadjuvant intent is not significantly different from the proportion 
receiving treatment for palliative intent. 
 
 PPE and age ≤ 65 years compared to > 65 years X 2 (1, n = 150) = < 
.001 p = 1.00 
The association between the two age groups and PPE showed that the 




grade or grade 3 as their worse grade is not significantly different from the 
proportion of participants older than 65 years who developed PPE. 
 
 PPE and age > 79 years 
Since there were only 20 participants aged over 79 years a cross tabulation 
was not possible and therefore only frequency data are presented here (table 
4.38) 
 
Participants aged over 79 years n = 20 (100%) 
PPE within the first 3 cycles 12 (60) 
Grade 2 or 3 at presentation (% of total with PPE) 8 (66.7) 
Grade 3 PPE as the worst grade (% of total with PPE) 6 (50) 
Completed all planned cycles 11 (55) 
Stopped due to PPE 3 (15) 
Deferred due to PPE 5 (25) 
Deferred due to other toxicities 2 (10) 
Dose reduction at cycle 1 




Dose reduction due to PPE 5 (25) 
Dose reduction due to other toxicities 2 (10) 
Table 4-38 Frequency data participants aged over 79 years (n = 20) 
 
 PPE and age and gender combined X 2 (3, n = 138) = 5.63 p = .13 
Age and gender were combined into four groups; men < 65yrs; men > 64yrs; 
women < 65yrs; and women > 64yrs. 
The association between the age and gender combined and PPE showed that 
the proportion of participants in any of the 4 groups who developed PPE of 
any grade is not significantly different from the proportion of participants who 
did not develop PPE. 
 
When the same variable was entered into a regression analysis, older women 
were more likely to develop PPE compared with younger women (OR = 1.41, 
95% CI .50 – 3.97 p = .51) with the opposite among males, younger men were 
more likely to develop PPE compared with older men (OR = 1.05, 95% CI .40 








B Wald Sig Exp (B) 95% C.I for Exp (B) 
Lower Upper 
F < 65 (ref cat) 
M < 65 
F > 64 

























M > 64 (ref cat) 
F < 65 
M < 65 

























Table 4-39 Logistic regression output age and gender combined and 
PPE retrospective sample 
 
 Age and gender combined and treatment intent X 2 (3, n = 150) = 20.04 
p < .001 
The association between treatment intent and age and gender combined 
showed there were more men aged < 65 or > 64 years who received 
treatment for adjuvant/neoadjuvant intent than would have been expected 
(observed = 21 and 31 cases versus expected = 15.3 and 26.9 respectively) 
and there were more women aged < 65 who received treatment for palliative 
intent than would be expected (observed = 27 cases versus expected = 16.1) 
(table 4.40). A large effect size was seen phi = .37. 
 
 Treatment intent 
 Adj or neoadj Met or pall 
F < 65   Count 





M < 65   Count 





F > 64   Count 





M > 64   Count 





% of total 52.7 47.3 
Table 4-40 Cross tabulation treatment intent and age and gender 
combined 
 
 Performance status and dose reductions 
o At start of treatment X 2 (2, n = 92) = .57 p = .75 
The association between performance status and dose reduction at the start 
of treatment showed that the proportion that had a dose reduction at the start 
of treatment is not significantly different from the proportion that did not have a 




o Due to PPE X 2 (2, n = 92) = 5.22 p = .07 
The association between performance status and dose reduction due to PPE 
showed that the proportion that had a dose reduction due to PPE is not 
significantly different from the proportion that did not have a dose reduction 
due to PPE for any grade of performance status. 
o Due to other toxicities X 2 (2, n = 92) = 2.89 p = .24 
The association between performance status and dose reduction due to other 
toxicities showed that the proportion that had a dose reduction due to other 
toxicities is not significantly different from the proportion that did not have a 
dose reduction due to other toxicities for any grade of performance status. 
 
 PPE and hormone status of breast cancer 
Of the 30 participants with breast cancer, 13 (43.3%) were oestrogen positive 
(ER) and 9 (30.0%) progesterone receptor (PR) positive. Due to this smaller 
number it was not possible to apply this data to a chi square test. 
 
 Grade 3 PPE and creatinine clearance 3 groups X 2 (4, n = 76) = 2.54 p 
= .64 
The association between grade 3 PPE and creatinine clearance showed that 
the proportion that had mild renal impairment (CrCl 50.01 – 80.00) is not 
significantly different from the proportion that had moderate renal impairment 
(CrCl < 50.01) or normal renal function (CrCl > 80.00). Of the 76 participants 
who developed PPE, 29 developed grade 3 as their worst grade. 3 had 
moderate renal impairment; 12 mild renal impairment and 14 normal renal 
function.  
 
A logistic regression applied to creatinine clearance and PPE any cycle or 
PPE within the first 3 cycles showed that the risk of developing PPE increases 
for every point decrease in CrCl (OR = .99, 95% CI .99 – 1.01). 
A logistic regression applied to CrCl 3 groups showed that participants with 
mild renal impairment were twice as likely to develop PPE at any cycle and 
within the first 3 cycles compared with those with moderate renal impairment 




 OR 95% CI 
Mild renal impairment compare with moderate renal 
impairment PPE any cycle 
2.10 .72 – 6.10 
Mild renal impairment compare with moderate renal 
impairment PPE within the first 3 cycles 
1.77 .60 – 5.21 
Mild renal impairment compare with normal renal 
function PPE any cycle 
1.78 .88 – 3.61 
Mild renal impairment compare with normal renal 
function PPE within the first 3 cycles 
1.93 .92 – 4.06 
Table 4-41 Logistic regression applied to creatinine clearance 3 groups 
 
 PPE and gender and alcohol combined X 2 (1, n = 51) = <.001 p = 1.00 
The association between PPE and gender and alcohol combined showed that 
the proportion that developed PPE at any cycle is not significantly different 
from the proportion that did not develop PPE for both men and women who 
drank alcohol.  
A chi square could not be applied to gender and alcohol combined and PPE 
within the first 3 cycles due to insufficient number of cases to meet the 
assumption that there is a minimum of 5 cases per cell. 
 
 Metastatic spread and dose reductions 
o At start of treatment X 2 (1, n = 150) = 5.28 p = .02 
The association between metastatic spread and dose reduction at the start of 
treatment showed there were more participants whose tumour had 
metastasised and had a dose reduction at the start of treatment than would 
have been expected (observed = 27 cases versus expected = 20.2) (table 
4.42). A small to medium effect size was seen phi = .20. 
 
 Dose reduction at cycle 1 
 No Yes 
Metastatic spread No Count 





Metastatic spread Yes Count 





% of total 72.7 27.3 
Table 4-42 Cross tabulation metastatic spread and dose reduction at 





o Due to PPE X 2 (1, n = 150) = 4.23 p = .04 
The association between metastatic spread and dose reduction due to PPE 
showed there were more participants whose tumour had not metastasised 
and had a dose reduction due to PPE than would have been expected 
(observed = 23 cases versus expected = 17.2) (table 4.43). A small effect size 
was seen phi = .18. 
 
 Dose reduction due to PPE 
 No Yes 
Metastatic spread No Count 





Metastatic spread Yes Count 





% of total 77.3 22.7 
Table 4-43 Cross tabulation metastatic spread and dose reduction due 
to PPE 
 
o Due to other toxicities X 2 (2, n = 150) = 2.14 p = .34 
The association between metastatic spread and dose reduction due to other 
toxicities showed that the proportion that had a dose reduction due to other 
toxicities is not significantly different from the proportion that did not have a 
dose reduction due to other toxicities. 
 
4.3.2.2  
Summary of findings from chi-square 
Findings from the X 2 tests (p < .05) show that those more likely to develop 
PPE were participants; 
 Who were male 
 With colorectal cancer 
 Whose tumour had not metastasised 
 Who had PPE with previous chemotherapy or had not had previous 
chemotherapy 
 Receiving capecitabine monotherapy as adjuvant therapy 





The results of the comparison of the means from the independent samples t-
test for age and laboratory values (continuous data) prior to treatment 
commencing are shown in table 4.44. Independent-samples t-tests were 
conducted to compare PPE incidence prior to commencing cycle 4 of the 
treatment for age, BSA, BMI, creatinine, creatinine clearance, and ALT and no 
significant differences were observed, in any of these variables, between 
those who developed PPE and those that did not. The same test applied to 
ALP, albumin and bilirubin (bili) showed a significant difference between those 
who did not develop PPE (ALP; = 223.04, SD = 211.04, ALB; = 40.15, SD 
= 4.38, bili; = 10.01, SD = 10.77) and those that did (ALP; = 105.45, SD = 
58.80, ALB; = 41.85, SD = 2.98, bili; = 7.92, SD = 4.61) t (132) = 4.53, p = 
<.001 t (132) = 1.50, p = 0.01. The magnitude in the difference in the means (
) (mean difference) for ALP = 117.59 (95% CI, 65.94 to 169.23) was small 
(eta squared = 0.13), for albumin = -1.70 (95% CI, -2.97 to -.43) and bilirubin 
















Age 67.98 11.03 65.84 11.54 -1.10 .27 -2.14 -5.96 to 
1.68 
0.008 
BSA 1.79 .20 1.77 .20 -.58 .56 -.02 -.08 to .05 0.002 
BMI 25.10 4.00 25.37 4.85 .35 .73 .27 -1.25 to 
1.79 
0.0009 
Creat  76.51 17.33 76.00 25.01 -.14 .89 -.51 -7.89 to 
6.87 
0.0001 
CrCl 80.79 27.63 85.86 31.08 1.00 .32 5.06 -4.95 to 
15.08 
0.007 
ALT 32.89 49.02 38.39 49.38 .64 .52 5.50 -11.36 to 
22.37 
0.003 







Bili 7.92 4.61 10.01 10.77 1.50 .009 2.90 -.68 to  
-4.87 
0.02 
ALB 41.85 2.98 40.15 4.38 -2.66 .009 -1.70 -2.97 to  
-.43 
0.05 
a M = mean  
b PPE Y = subjects who developed PPE prior to commencing cycle 4 
c PPE N = subjects who did not develop PPE at any cycle 
d SD = standard deviation 
e Mean diff = Mean difference between the groups 
f CI = 95% confidence interval 
g ETA2 = effect size 
 Indicates variables p < .05 and included in multivariate regression analysis 
Table 4-44 Effects within PPE incidence pre cycle 4 (n = 138) 
retrospective data capecitabine monotherapy 
 
To enable comparison with findings in the literature, logistic regression was 
applied to BMI and showed that for every point increase in BMI the risk of 
PPE increased OR = 1.02, 95% CI .95 – 1.09 although this suggested an 
effect this was not confirmed statistically p = .64 
A logistic regression applied to BSA showed that for every unit increase in 
BSA the risk of developing PPE increased OR = 2.37; 95% CI .48 – 11.57, p = 





4.3.2.3 Summary of findings of t-test 
The mean of each group in the t-tests (p < .05) was examined, with the higher 
mean indicating the direction of association. Those with a lower pre treatment 
ALP level or bilirubin level or raised albumin level (only slightly) were more 
likely to develop PPE. 
 
Although this analysis is useful in showing any association of individual 
variables with the development of PPE, clinically, variables are not present in 
isolation and it is therefore more useful to apply multivariate tests to the data 
to establish the performance of the variables when in combination with each 
other. A multivariate analysis using logistic regression will now be described. 
 
4.3.2.4 Multivariate analysis 
The modelling technique used with the whole of the retrospective notes 
sample was applied to the capecitabine monotherapy sample. 
 
Variable P < .05 P < .25 
Gender .03  
Inflammatory conditions  .15 
Tumour site 2 groups .01  
Metastatic spread < .001  
Season start .02  
CrCl 3 groups  .21 
Bilirubin .009  
ALP < .001  
ALB .009  
Table 4-45 Variables from bivariate analysis entered into regression 
model 
 
Table 4.45 provides a summary of variables that were significant in the 
bivariate analysis. It shows those variables significant at both the conventional 
alpha level of p < .05 and the relaxed level p < .25 included in the regression 
model. It excludes those variables with insufficient numbers to be included in 





4.3.2.5 Purposeful entry and model reduction  
9 variables were entered into the logistic regression analysis and 4 removed. 
Logistic regression, which consisted of 5 steps, was performed for the 
research sample (n = 151) with 20 missing cases not included in the model. 
13 of these were participants who developed PPE after commencing cycle 4 
and the remaining 7 consisted of small numbers from several other predictor 
variables. (Appendix 4.2). 
 
The omnibus tests of model coefficients revealed a Chi-square statistic of 
36.05 (df, 4) p < .001 indicating that the model performs well compared to the 
baseline model before the variables were added. The Hosmer-Lemeshow 
statistic was applied to the data indicating a good fit ( p = > .05) for all steps 
until the final step where gender was removed. As this test now showed a 
poor fit gender was put back into the final model to ensure a good fit, 
assuming that gender is a confounder and important to the model 
construction. The Nagelkerke R2 (.34) value shows about 34% of the variation 
in the outcome variable (PPE) is explained by the logistic regression model 
and the percentage correctly predicted to have PPE in this model was 75.0%. 
 
As illustrated in table 4.46 the outcome of the logistic regression analysis 
produced a model containing 4 predictor variables and 1 confounding variable 
(gender) which were significantly related to PPE development; absence of pre 
existing inflammatory conditions, ALP level prior to commencing treatment, 
the season in which the treatment commenced and metastatic spread. 
Factors had variable ability to predict the development of PPE. Participants 
who did not have a pre existing inflammatory condition such as arthritis were 
two and a half times more likely to develop PPE (OR = 2.59; 95% CI .80 – 
8.85, p = .10). The risk of PPE in participants who commenced their treatment 
in the winter was just over two and a half times as great compared to those 
who commenced in the summer (OR = 2.75; 95% CI 1.21 – 6.24, p = .02). 
The absence of metastases made the chances of developing PPE over twice 




5.31, p = .06) and for every unit increase in the ALP level taken prior to 
commencing treatment (OR = .99; 95% CI .98 - .99, p = .02) the risk of 
developing PPE was reduced. Men were almost twice as likely to develop 
PPE than women (OR = 1.91; 95% CI .85 – 4.32), however, this difference did 
not achieve statistical significance (p = .12) since this is a confounding 
variable.  
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ALPC1 -.006 5.75 .02 .99 .98-.99 
Metastatic spread 


















* significant at p < .1 (2-tailed) 
Table 4-46 Logistic regression output. Predictors of PPE development 
purposeful entry model 
 
Variables that were not included in the original model were added one at a 
time and logistic regression applied. Out of the 16 variables that had p > .25 in 
the bivariate tests, 3 became significant at p < .25 and were added to the 
model and reduced as before. All 3 were retained in the model, 1 (smoker) 
became significant at p < .01, and the other 2 (alcohol and weight loss) were 
retained as confounding variables (table 4.47). Participants who smoked were 
nearly twice as likely to develop PPE as those who did not smoke (OR = 1.65; 
95% CI .46-5.95, p = .08). Conversely participants who did not drink alcohol 
regularly were more likely to develop PPE (OR = .51; 95% CI .17-1.54, p = 
.17). Participants who had lost weight prior to commencing treatment were 




95% CI .07-1.95, p = .24). The latter two variables failed to achieve statistical 
significance but remained as confounders. 
 
Retrospective data capecitabine monotherapy 






























































ALPC1 -.006 3.82 .05 .99 .98-1.00 
Metastatic spread 








































































* significant at p < .1 (2-tailed) 
Table 4-47 Logistic regression output purposeful entry model with 
additional non-significant variables 
 
Different entry methods were applied to the same variables as those used in 
the purposeful entry model building process and the retention strategy was 
based on the same rationale as stated previously. 
 
4.3.2.6 Forward and backward conditional entry model 
The same 9 variables included in the purposeful reduction model were 




forward entry method and 4 removed in 5 steps in the backward entry 
method. 
 
The assessment of ‘goodness of fit’ is shown in table 4.48 demonstrating a 
good fit in both entry methods with 28% variance explained by the model in 
the forward entry method and 31% in the backward entry method. The ability 
of the model to correctly predict which category each case fits into was 68% in 


















Nagelkerke R2 .28 .31 












Table 4-48 Goodness of fit automated entry methods retrospective 
capecitabine monotherapy data 
 
As shown in table 4.49 the outcomes of the automated entry methods of the 
logistic regression analysis showed predictive models containing 3 variables 
in the forward entry strategy and 4 variables in the backward entry strategy 
which were significantly related to PPE development. The season that the 
participant commenced their treatment in, metastatic spread and ALP level 
prior to commencing treatment were common in both models with 
inflammatory conditions an additional variable in the backward entry model. 
Factors had variable ability to predict the development of PPE but were 
identical in the forward and backward entry methods for the 3 common 
variables. The variables in both automated models showed similar odds ratios 
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Forward entry method 
Season start 

















ALPC1 -.006 5.31 .02 .99 .98-.99 
Metastatic spread 

















Backward entry method 
Inflammatory 
conditions 








































ALPC1 -.006 5.58 .02 .99 .98-.99 
Metastatic spread 


















* significant at p < .1 (2-tailed) 
Table 4-49 Logistic regression output predictors of PPE in the 
automated entry methods 
 
4.3.2.7 Receiver operating characteristic (ROC) curves 
ROC curves were applied to the predicted probabilities created in each of the 
logistic regression entry methods to compare the accuracy of the models in 
terms of their sensitivity and specificity in predicting those that develop PPE 
within the first 3 cycles and those that do not.  
 
The model with 5 variables remaining following the purposeful entry and 
retention strategy provides a slightly more accurate prediction of those who 
are likely to develop PPE and those who will not AUC = .80 (95% CI .72-.88) 
than the models with 4 variables remaining in the backward entry method and 
3 variables remaining using the forward entry method AUC = .77 (95% CI .70-




curve applied to the purposeful reduction model, the most favourable values 
for sensitivity and specificity were 75% and 65% respectively. The positive 
and negative predictive values calculated from the logistic regression output 
were 70.6% and 79.7% respectively. However, since the confidence intervals 
are wide and overlap between the models, this would indicate that there is no 
statistically significant difference between the models. 
 
 
Figure 4-3 ROC curve comparison of purposeful and automated entry 
methods 
 
Test Result Variable(s) 
from figure 4.24 
Area 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
 
Purposeful entry .800 .724 .876 
Forward entry .765 .686 .845 
Backward entry .777 .699 .856 
 
A comparison of the final model with the same model including the three 
variables that were non-significant in the bivariate analysis (figure 4.4) 




development of PPE AUC = .84 (95% CI; .78 - .91) with a sensitivity = 79% 
and specificity 1-.29 = 71%. The positive and negative predictive values 




Figure 4-4 ROC curve comparing purposeful entry model with model 
containing non-significant variables 
 
Test Result Variable(s) 
from figure 4.25 
Area 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
Purposeful entry .800 .724 .876 
With non-sig added .843 .777 .909 
 
As previously stated, the purposeful selection and retention of variables is, 
however, worthwhile to produce a richer model including confounders. This is 






4.3.2.8 Summary of findings of logistic regression model 
To summarise the findings from the purposeful selection and retention model, 
those most at risk of developing PPE were participants; 
 
 Who were male 
 Who smoked 
 Who did not drink alcohol regularly (confounder) 
 With no history of an inflammatory condition 
 Who did not lose weight prior to commencing treatment (confounder) 
 Whose tumour had not metastasised 
 Who commenced their treatment during the winter months 
 With a lower pre treatment ALP level 
 
Four variables (smoking, alcohol, inflammatory conditions and weight loss) 
must be treated with some caution due to the large number of missing data for 





4.4  Prospective data 
4.4.1 Descriptive statistics 
4.4.1.1 Sample characteristics 
The sample was drawn from patients commencing capecitabine monotherapy 
11th June 2009 to 31st December 2010. A total of 125 participants of which 
men totalled 49 (39.2%) and women 76 (60.8%) were included in the analysis. 
The median age was 65 (range 36-83yrs) with no difference between men 
and women whose median ages were 65yrs (range 36-83yrs) and 64.5 yrs 
(44-83yrs) respectively. 
 
The sample characteristics are presented in table 4.50. All participants 
received more than one cycle of chemotherapy, unless the treatment was 






Description Sample With PPEa 
n (%)  
PPE  




4a n (%) 
No PPEb 
n (%) 
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a patients who developed PPE of any grade 
b patients who did not develop PPE during treatment 
c other tumour sites = Pancreas; Cholangiocarcinoma, unknown primary  
Table 4-50 Patient characteristics prospective data 
 
4.4.1.2 Toxicity 
Mild to severe adverse events were reported for 101 (80.8%) of the 125 
participants. Fatigue and diarrhoea were the most common adverse side 
effects. The incidence of toxicity is listed in table 4.51, the figures reflecting 




the toxicities was similar except for the development of a rash which was 
infrequent and seen in only 7 participants (5.6%). PPE developed in 83 
participants (66.4%) with 70 (84.33%) of these developing PPE during the first 
three cycles of their treatment.  
 
Toxicity Sample With PPE a  
n (% with 
PPE) 
PPE pre cycle 
4a 
n (% with PPE) 
PPE after cycle 
4a 
n (% with PPE) 
No PPEb 




125 (100) 83 (66.4) 70  (84.3) d 13 (15.7)d 42 (33.6) 
Diarrhoea 55 (44.0) 41 (49.4) 36 (51.4) 5 (38.5) 14 (33.3) 
Mucositis 43 (34.4) 34 (41.0) 31 (44.3) 3 (23.1) 9 (21.4) 
N & Vc 49 (39.2) 39 (47.0) 31 (44.3) 8 (61.5) 10 (23.8) 
Rash 7 (5.6) 6 (7.2) 6 (8.6) 0 1 (2.4) 
Fatigue 56 (44.8) 38 (45.8) 34 (48.6) 4 (30.8) 18 (42.9) 
a patients who developed PPE of any grade 
b patients who did not develop PPE during treatment 
cNausea and vomiting 
d% of those who developed PPE 
Table 4-51 Incidence of toxicity n (%) prospective data 
 
A chi-square test for independence (with Yates continuity correction) indicated 
an association between mucositis and PPE, X 2 (1, n = 125) = 3.89 p = .05, 
showing that for those with mucositis there were more cases of PPE than 
would be expected (observed = 41 cases versus expected = 36.5) (table 
4.52).  
Crosstab 
p = .05 
Mucositis 
Total No Yes 
PPE No Count 33 9 42 
Expected Count 27.6 14.4 42.0 
Yes Count 49 34 83 
Expected Count 54.4 28.6 83.0 
 % of Total 65.6% 34.4% 100.0% 
Table 4-52 Cross tabulation Chi Square Mucositis 
 
The only other toxicity where an association was seen was between nausea 
and vomiting and PPE, X 2 (1, n = 125) = 5.35 p = .02, showing that for those 
who reported nausea and vomiting there were more cases of PPE than would 







p = .02 
Nausea or Vomiting 
Total No Yes 
PPE No Count 32 10 42 
Expected Count 25.5 16.5 42.0 
Yes Count 44 39 83 
Expected Count 50.5 32.5 83.0 
 % of Total 60.8% 39.2% 100.0% 
Table 4-53 Cross tabulation Chi Square Nausea or Vomiting 
 
A small to medium effect size was detected in both cases with phi = .19 and 
phi = .22 respectively. The test showed no association between diarrhoea, 
fatigue or rash and development of PPE at any cycle (table 4.54).  
 
Variable X 2b df
c p phid 
Diarrhoea 2.30 1 .13 .15 
Mucositis 3.89 1 .05 .19 
N & Ve 5.35 1 .02 .22 
Rash  .49 1 .48a .10 
Fatigue .01 1 .90 .03 
a at least 1 cell contained less than 5 cases 
b X 2 differences between observed and expected frequencies 
c df extent to which values are free to vary given a specific number of subjects and a total 
score (in 2 x 2 table always 1) 
d phi strength of any association (effect size or risk) 0-1 higher values indicate a stronger 
association (small effect = .10, medium effect = .30, large effect = .50 (Cohen 1988)) Can be 
+ve or -ve 
e Nausea and vomiting 
Table 4-54 Other toxicity effects with PPE incidence any cycle (n = 125) 
prospective data 
 
Since PPE is the toxicity of interest in this study, a more detailed description 
of the severity of PPE will now be presented. 
 
4.4.1.3 Severity and time course of PPE 
For analysis of the severity of PPE, the grade and cycle at first presentation of 
PPE was recorded as well as the most severe episode of PPE experienced. 
The grade distribution, cycle of presentation and the worst episode are 
presented in table 4.55. Of the 125 participants who received capecitabine 




presented with PPE before starting cycle 4 and 13 (15.66%) after starting 
cycle 4 of their treatment. PPE was evaluated at the time of the development 
of the first episode. Of the 83 participants who had PPE, 20 participants 
(24.1%) had their first episode after the first cycle, 32 (38.5%) after the 
second cycle, 18 (21.7%) after the third cycle and 13 participants (15.7%) had 
their first episode following the fourth or more cycles. Of the 56 participants 
whose first presentation of PPE at any cycle was grade 1, 23 went on to 
develop more severe PPE; grade 2 (17 participants) or grade 3 (6 
participants) following subsequent cycles. 34 participants (40.96%) had grade 
1, 34 (40.96%) grade 2, and 15 participants (18.1%) had grade 3 PPE as their 
most severe episode. 
 
Description Capecitabine monotherapy 
 
Number (%) 
No with PPE (%) 



























Grade at 1st episodeb   































a cycle in which the first episode of PPE developed number and percentage of those 
with PPE 
b grade that patients presented with at first episode of PPE number and percentage of 
those with PPE 
c worst grade for each patient developing PPE number and percentage of those with 
PPE 
Table 4-55 Summary data of PPE prospective data 
 
An incidental finding during this phase was that some patients may not reveal 
that they have developed PPE unless specifically questioned. An example of 
this is a female participant in her 50s had a consultation with a doctor and was 




the tablets, it is usual for the nurse or pharmacist to check that the patient is 
taking the tablets correctly, they have no toxicities and that they are aware of 
symptoms to report. It would be easy to assume, that as this was the patient’s 
fifth cycle, she would have a full understanding of these. However, from 
observation of the patient’s hands and further questioning, she revealed that 
both her hands and feet had been very painful and had developed open 
cracks in the folds of her fingers which had improved. She thought this was 
due to the cold weather even though she had not experienced this in past 
winters. On examination, there was erythema of the palms, the healed cracks 
were evident, and she also stated that her feet were still quite painful but with 
no broken areas of skin. The concern here was that her PPE had not resolved 
completely to grade 1 and that if she was to continue with her capecitabine 
she would rapidly present with grade 3 PPE which may require 
hospitalisation. This opportunity was used to emphasise to the patient the 
importance of reporting any symptoms and the implications if they are not 
reported. A doctor was asked to review the patient who agreed that the 
treatment should be deferred for one week to allow the PPE to resolve.  
 
As mentioned in chapter 2 (page 24), presentation of PPE may differ in 
people with dark skin. An example seen in this study was a 61 year old lady 
from the Philippines with breast cancer who developed grade 3 PPE after 
cycle 2 of capecitabine treatment. She presented with hyperpigmentation 
particularly highlighting the creases on the palms of her hands, with blisters 
and desquamation causing pain and affecting her ability to carry out activities 
(figure 4.5). She had received previous chemotherapy regimes and had 
developed PPE at that time. 
   





Toxicities of chemotherapy can impact on the patient’s ability to continue with 
their normal activities and some can be life-threatening resulting in delays in 
treatment and sometimes a reduction in the dose prescribed. Some toxicities 
may influence the patient’s tolerance of treatment, therefore, details of 
treatment outcome for this sample are presented in the following section. 
 
4.4.1.4 Treatment Outcome 
72 (57.6%) out of 125 participants completed all planned cycles. Details of 
completion rates including deferral of treatment and dose reductions are 
provided in table 4.56.  
 
53 (42.4%) participants  among the 125 discontinued treatment. Of these  53 
participants the reasons for the discontinuation of treatment were PPE in  5 
(9.4%), other toxicities or adverse events  29 (54.7%), disease progression or 
deteriorating performance status  17 (32.1%), patient request  2 (3.8%), and 
died during treatment  4 (7.5%). The 3 (5.7%) participants who had received 
FOLFOX regime and changed to capecitabine did not require 6 cycles of 
capecitabine and therefore stopped treatment before the sixth cycle. 3 (5.7%) 
participants developed other serious illnesses and 2 (3.8%) moved home to 
another location in the country and transferred their care to that region. The 
remaining participant was changed to alternative treatment due to toxicities 
from capecitabine, including PPE grade 1. The 2 participants who chose to 
discontinue their treatment did so as they were feeling generally unwell due to 
the effects of the treatment. Neither of these two participants met the usual 
threshold to stop based on the manufacturer’s recommendations. The 4 
participants who died during treatment were all receiving capecitabine for 
palliation, 3 for breast cancer and 1 for colorectal cancer. Three of these died 








Number 125 (100) 
Completed all cycles  72 (57.6) 
Discontinued treatment  
due to PPEa 
due to other toxicities/adverse eventsa 
Dis prog/poor PSa 
Patient requesta 
Dieda 
Had previous cycles of folfoxa 
Changed to other treatmenta 
Developed other illnessa 











Deferred due to PPE 35 (28.0) 
Deferred due to other toxicities 32 (25.6) 
Dose reduction at cycle 1 27 (21.6) 
Dose reduction due to PPE 33 (26.4) 
Dose reduction due to other toxicities 23 (18.4) 
a % of total number who discontinued treatment 
Table 4-56 Completion rates n (%) prospective data 
 
To enable comparison with studies in the literature a further analysis was 








Number (%) 60 (100) 65 (100) 
Completed all cycles 40 (66.7) 32 (49.2) 
Discontinued treatment due to PPE 3 (5.0) 2 (3.1) 
Discontinued treatment due to other toxicities 8 (13.3) 2 (3.1) 
Dose reduction at cycle 1 9 (15.0) 19 (29.2) 
Dose reduction due to PPE 18 (30.0) 15 (23.1) 
Dose reduction due to other toxicities 10 (16.7) 14 (21.5) 
Table 4-57 Comparison of completion rates n(%) and treatment intent 
 
There is similarity between the percentage of the sample receiving treatment 
with adjuvant/neoadjuvant intent compared with metastatic/palliative intent. A 
higher proportion completed all 6 cycles in the adjuvant group. More 
participants receiving treatment for palliative intent had a dose reduction at 




treatment discontinued due to PPE. dose reduction due to PPE or a dose 
reduction due to other toxicities.  
 
As in the previous analysis of the retrospective sample and the participants 
receiving capecitabine monotherapy taken from that sample, inferential 
statistical tests were applied to those who developed PPE within the first 3 
cycles and those who did not develop it. 
 
4.4.2 Inferential statistics 
4.4.2.1 Bivariate analysis 





Variable X 2 df P value Phi/Cramer’s V 
Gender .58b 1 .45 -.08 
Maritalstatus2gps .00b 1 1.00 .005 
Ethnic2gps .13b 1 .72a -.06 
Job2gps .83b 1 .36 -.1 
Smoker .01b 1 .90a -.04 
Alcohol 1.54b 1 .21 .13 
Recent wt loss .29b 1 .59 -.07 
Diabetes 2.52b 1 .11 -.16 
PVD .57b 1 .45a -.11 
Periph neuro .00b 1 .99a .03 
Skin complaints .05b 1 .83 .04 
Inflamm cond 3.87b 1 .05 .19 
Previous Ca ∆ .14b 1 .71 .06 
Prev DXT .96b 1 .33 -.10 
Perf status 3 gps 6.56 2 .04 .23 
PPE with prev chemo .65 2 .72 .07 
Tumoursite3gps 1.04b 2 .59 .09 
Met spread 4.83b 1 .03 -.21 
Aim of Rx2gps 5.22b 1 .02 -.22 
Start season .51b 1 .48 -.08 
CrClC13gps 2.85 2 .24 .15 
Sunburn .49 b 1 .49 .09 
Hobbies .30 b 1 .58 .07 
Hot water 1.05 b 1 .30 -.12 
Dry skin .65 b 1 .42 .10 
Cool hands 3.83 b 1 .05 -.22 
Cool feet 2.79 b 1 .09 -.19 
Sweaty hands .02 b 1 .89 -.04 
Sweaty feet .02 b 1 .89 .04 
Hand cream .00 b 1 1.00 -.002 
Skin type 2gps .00 b 1 1.00 -.013 
aat least 1 cell has expected count of less than 5 
byate’s correction for 2 x 2 table 
 Indicates variables p < .05 and included in multivariate regression 
analysis 
 Indicates additional variables p < .25 included in multivariate 
regression analysis 
Table 4-58 Chi-square test for association between variables and 
development of PPE before cycle 4 prospective data 
 
A chi-square test for independence (with Yate’s correction for 2 x 2 tables) 
indicated a significant association between the development of PPE prior to 




 Presence of a pre-existing inflammatory condition X 2 (1, n = 125) = 
3.87 p = .05  
The association between inflammatory conditions and PPE showed that for 
those who had a pre-existing inflammatory condition there were more cases 
of PPE than would have been expected (observed = 25 cases versus 
expected = 19.6) (table 4.59). 
Crosstab 
p = .05 
Inflammatory conditions 
Total No Yes 
PPE before C4 No PPE or post C4 Count 45 10 55 
Expected Count 39.6 15.4 55.0 
PPE pre C4 Count 45 25 70 
Expected Count 50.4 19.6 70.0 
 % of Total 72.0% 28.0% 100.0% 
Table 4-59 Cross tabulation Chi Square Inflammatory conditions 
 
 Treatment intent (aim of treatment 2gps) X 2 (1, n = 125) = 5.22 p = 
.02  
The association between treatment intent an PPE showed that for those who 
were receiving capecitabine as adjuvant therapy, there were more cases of 
PPE than would have been expected (observed = 41 cases versus expected 
= 34.2) (table 4.60). 
Crosstab 
p = .02 






PPE before C4 No PPE or post C4 Count 20 35 55 
Expected Count 26.8 28.2 55.0 
PPE pre C4 Count 41 29 70 
Expected Count 34.2 35.8 70.0 
 % of Total 48.8% 51.2% 100.0% 
Table 4-60 Cross tabulation Chi Square Treatment Intent 
   
 Metastatic spread X 2 (1, n = 125) = 4.83 p = .03  
The association between metastatic spread and PPE showed that for those 
whose cancer had not metastasised there were more cases of PPE than 







p = .03 
Metastatic spread 
Total No Yes 
PPE before C4 No PPE or post C4 Count 20 34 54 
Expected Count 26.6 27.4 54.0 
PPE pre C4 Count 41 29 70 
Expected Count 34.4 35.6 70.0 
 % of Total 49.2% 50.8% 100.0% 
Table 4-61 Cross Tabulation Chi Square Metastatic Spread 
  
 Performance status X 2 (2, n = 121) = 9.31 p = .05  
The association between performance status and PPE showed that for those 
whose performance status was 0. There were more cases of PPE than would 
have been expected (observed = 33 cases versus expected = 26) (table 
4.62). 
p = .05 Perfstatus3gps Total 
0 1 2 & 3 
PPE before C4 No PPE   Count 









  PPE pre C4  Count 









Total     % of total 38.8% 51.2% 9.9% 100% 
Table 4-62 Cross Tabulation Chi Square Performance Status 
  
 Cool hands X 2 (1, n = 125) = 3.83 p = .05  
The association between cool hands and PPE showed that for those who had 
a tendency to have warm hands, there were more cases of PPE than would 
have been expected (observed = 42 cases versus expected = 21) (table 
4.63). 
Crosstab 
p = .05 
Cool hands 
Total No Yes 
PPE before C4 No PPE or post C4 Count 17 21 38 
Expected Count 22.2 15.8 38.0 
PPE pre C4 Count 42 21 63 
Expected Count 36.8 26.2 63.0 
 % of Total 58.4% 41.6% 100.0% 
Table 4-63 Cross Tabulation Chi Square Cool Hands 
 
A small effect size was detected for pre-existing inflammatory conditions, phi 
= .19 and a small to medium effect size for metastatic spread, treatment 
intent, performance status and a tendency to have warm hands (phi = .21, 





A case from this prospective sample highlights the potential link between 
peripheral vascular disease and PPE. A 68 year old white skinned male 
commenced adjuvant capecitabine following a right hemicolectomy for 
colorectal cancer. The retired gentleman, who lives alone, stopped smoking 
20 years ago and who drinks one and a half litres of whisky per week and has 
a past medical history of a previous high grade non-Hodgkin’s lymphoma 
which had been treated with chemotherapy (CHOP). In addition he had 
received radiotherapy to his right eye 12 years previously. Co-morbidities 
include Rheumatoid Arthritis currently treated with methotrexate; 
Dermatomyocitis treated with prednisolone 7.5mg daily and Reynaud’s 
Disease. Other medications taken were amlodipine and ibandronic acid. Folic 
acid was stopped prior to commencing capecitabine.  
 
This gentleman was commenced on 75% of the standard capecitabine regime 
of 1250 mg/m2 twice a day for 2 weeks with 1 weeks rest due to the 
concomitant methotrexate. He tolerated his first cycle well with PPE grade 1 
as the sole toxicity and the capecitabine was increased to the full dose. 
Following cycle 2 he went on to present with grade 3 PPE with erythema, 
pain, swelling and sores on his fingers significantly affecting his daily activities 






        
Figure 4-6  PPE grade 3 following cycle 2 of capecitabine monotherapy 
 
His treatment was deferred for 2 weeks with improvement in some of the 
lesions. However, one lesion had become infected for which he was 
prescribed antibiotics. Two weeks later this lesion had shown no improvement 
(figure 4.7), and he was subsequently referred to a dermatologist who 
prescribed a further course of antibiotics. The capecitabine was stopped. 
  
 
Figure 4-7 Infected lesion following a course of antibiotics 
 
People commencing capecitabine in the presence of dermatological toxicities 
from previous chemotherapy treatment may experience a delay or even a 
deterioration in symptoms as was the case in a young female in the current 
study. This lady previously received docetaxel, but unfortunately her disease 
progressed during this treatment and she was changed to capecitabine. She 
had lost her finger nails due to the effect of docetaxel which failed to heal 






Figure 4-8 Nail toxicity from docetaxel 
 
Other analyses were performed to allow comparison with findings in the 
literature and include; 
 Treatment intent and treatment outcome 
 Treatment intent and dose reduction 
 PPE and age ≥ 65 years compared to > 65 years  
 PPE and age > 79 years 
 PPE and age and gender combined 
 Age and gender combined and treatment intent 
 Performance status and dose reductions 
 Performance status and hobbies 
 PPE and hormone status of breast cancer 
 Grade 3 PPE and creatinine clearance 3 groups 
 PPE and gender and alcohol combined 







 Treatment intent and treatment outcome X 2 (3, n = 125) = 14.33 p < 
.002  
The association between treatment intent and treatment outcome showed that 
for those who received their treatment with adjuvant/neoadjuvant intent, there 
were more cases who completed all cycles than would have been expected 
(observed = 40 cases versus expected = 34.8). For those who received 
treatment with palliative intent, there were more cases who stopped treatment 
for other reasons than would be expected (observed = 28 cases versus 
expected = 19.1) (figure 4.64). A large effect size was seen phi = .34. 
 



















































% of total 58.1 4.0 8.1 29.8 100 
Table 4-64 Cross tabulation treatment intent and treatment outcome 
 
 Treatment intent and dose reduction 
o At start of treatment X 2 (1, n = 125) = 3 13 p = .08 
The association between treatment intent and dose reduction at the start of 
treatment showed that the proportion receiving treatment for 
adjuvant/neoadjuvant intent is not significantly different from the proportion 
receiving treatment for palliative intent. 
o Due to PPE X 2 (1, n = 125) = .39 p = .53 
The association between treatment intent and dose reduction due to PPE 
showed that the proportion receiving treatment for adjuvant/neoadjuvant intent 
is not significantly different from the proportion receiving treatment for 
palliative intent. 
o Due to other toxicities X 2 (3, n = 125) = 2.30 p = .51 
The association between treatment intent and dose reduction due to other 




adjuvant/neoadjuvant intent is not significantly different from the proportion 
receiving treatment for palliative intent. 
 
 PPE and age ≤ 65 years compared to > 65 years X 2 (1, n = 125) = 5 47 
p = .02 
The association between the two age groups and PPE showed there were 
more participants aged ≤ 65 years who developed PPE of any grade than 
would have been expected (observed = 47 versus expected = 40.3) (table 




Age ≤ 65   Count 





Age > 65   Count 





% of total 33.9 66.1 
Table 4-65 Cross tabulation age 2 groups and PPE any grade 
 
 PPE by grade and age ≤ 65 years compared to > 65 years X 2 (3, n = 
125) = 8 97 p = .03 
The association between the two age groups and PPE showed that more 
participants aged ≤ 65 years old developed grade 1 PPE than would have 
been expected (observed 23 versus expected = 16.7) (table 4.66) A medium 
to large effect size was seen phi = .27  
 
 Worst grade of PPE 
1 2 3 N/A 
Age ≤ 65   Count 









Age > 65   Count 









% of total 27.4 26.6 12.1 33.9 
Table 4-66 Cross tabulation age 2 groups and worst grade of PPE 
 
The proportion of participants who developed PPE grade 3 as their worse 





 PPE and age > 79 years 
Since there were only 6 participants aged over 79 years a cross tabulation 
was not possible and therefore only frequency data are presented here (table 
4.67) 
 
Participants aged over 79 years n = 6 (100%) 
PPE within the first 3 cycles 2 (33.3) 
Grade 3 PPE as the worst grade 1 (16.7) 
Completed all planned cycles 3 (50) 
Stopped due to PPE 1 (16.7) 
Deferred due to PPE 2 (33.3) 
Deferred due to other toxicities 1 (16.7) 
Dose reduction at cycle 1 
(1 due to moderate renal failure who did not subsequently develop PPE. 1 of 




Dose reduction due to PPE 2 (33.3) 
Dose reduction due to other toxicities 1 (16.7) 
Table 4-67 Frequency data participants aged over 79 years (n = 6) 
 
 PPE and age and gender combined X 2 (3, n = 125) = 5.01 p = .17 
Age and gender were combined into four groups; men < 65yrs; men > 64yrs; 
women < 65yrs; and women > 64yrs. 
The association between the age and gender combined and PPE showed that 
the proportion of participants in any of the 4 groups who developed PPE of 
any grade is not significantly different from the proportion of participants who 
did not develop PPE. 
 
When the same variable was entered into a regression analysis, younger 
women were more likely to develop PPE compared with older women (OR = 
1.38, 95% CI .56 - 3.41 p = .48) with a similar finding among males, (OR = 
3.55, 95% CI 1.04 – 12.06 p = .04). However, only the male sample achieved 




B Wald Sig Exp (B) 95% C.I for Exp (B) 
Lower Upper 
F < 65 .32 .49 .48 1.38 .56 3.41 
M < 65 1.27 4.12 .04 3.55 1.04 12.06 
Table 4-68 Logistic regression output age and gender combined and 





 Age and gender combined and treatment intent X 2 (3, n = 125) = 42.58 
p < .001 
The association between treatment intent and age and gender combined 
showed there were more men aged < 65 or > 64 years who received 
treatment for adjuvant/neoadjuvant intent than would have been expected 
(observed = 20 and 18 cases versus expected = 11.0 and 11.6 respectively) 
and there were more women aged < 65 who received treatment for palliative 
intent than would be expected (observed = 34 cases versus expected = 19.1) 
(table 4.69). A large effect size was seen phi = .59. However, since there are 
less than 5 cases in two cells this result may not be reliable. 
 
 Treatment intent 
 Adj or neoadj Met or pall 
F < 65   Count 





M < 65   Count 





F > 64   Count 





M > 64   Count 





% of total 48.4 51.6 
Table 4-69 Cross tabulation treatment intent and age and gender 
combined 
 
 Performance status and dose reductions 
o At start of treatment X 2 (2, n = 125) = 5.50 p = .06 
The association between performance status and dose reduction at the start 
of treatment showed that the proportion that had a dose reduction at the start 
of treatment is not significantly different from the proportion that did not have a 
dose reduction at the start of treatment for any grade of performance status. 
o Due to PPE X 2 (2, n = 125) = 4.78 p = .09 
The association between performance status and dose reduction due to PPE 
showed that the proportion that had a dose reduction due to PPE is not 
significantly different from the proportion that did not have a dose reduction 
due to PPE for any grade of performance status. 




The association between performance status and dose reduction due to other 
toxicities showed that the proportion that had a dose reduction due to other 
toxicities is not significantly different from the proportion that did not have a 
dose reduction due to other toxicities for any grade of performance status. 
 
 Performance status and hobbies X 2 (2, n = 125) = 6.22 p = .04 
The association between performance status and hobbies showed that there 
were more cases of those with performance status 0 who had hobbies that 
could cause friction or pressure to the hands or feet than would be expected 
(observed = 25 versus expected = 20.9) (table 4.70). A medium effect size 
was seen phi = .25. Since there are less than 5 cases in one expected count 




PS 0  Count 





PS 1  Count 





PS 2 & 3 Count 





Total % 43.4 56.6 
Table 4-70 Cross tabulation performance status and hobbies 
 
 PPE and hormone status of breast cancer 
Of the 45 participants with breast cancer, 23 (51.1%) were oestrogen positive 
(ER) and 13 (28.9%) progesterone receptor (PR) positive.  
o Oestrogen receptor status and PPE X 2 (1, n = 40) = 7.37 p = 
.007 
The association between oestrogen receptor status and PPE showed that 
there were more cases developing PPE that were oestrogen receptor positive 
than would be expected (observed = 20 versus expected = 15.5) (table 4.71). 








PPE No  Count 





PPE Yes  Count 





Total % 42.5 57.5 
Table 4-71 Cross tabulation oestrogen receptor status and PPE 
 
o Progesterone status and PPE 
The association between progesterone status and PPE showed that the 
proportion that were progesterone positive is not significantly different from 
the proportion that were progesterone negative. 
 
 Grade 3 PPE and creatinine clearance 3 groups X 2 (6, n = 83) = 14.40 
p = .03 
The association between grade 3 PPE and creatinine clearance showed that 
there were more cases that had mild renal impairment (CrCl 50.01 – 80.00) 
and grade 3 PPE than expected (observed = 10 versus expected = 6.4) (table 
4.72). A medium to large effect size was seem phi = .34 However the 
assumption that there should be 5 cases in all expected count cells was 
violated, therefore the result may be unreliable. 
 
CrCl Worst grade of PPE 
1 2 3 
<50.00   Count 







50.01-80.00   Count 







>80.01   Count 







Total % 41 41 18 
Table 4-72 Cross tabulation CrCl 3 groups and worst grade of PPE 
 
 Of the 15 participants who developed PPE grade 3 as their worst grade; 1 





A logistic regression could not be applied to CrCl 3 groups since there were 
less than 10 cases in one category. 
 
 PPE and gender and alcohol combined  
o Men and alcohol X 2 (1, n = 45) = .65 p = .42 
The association between men and alcohol and PPE showed that the 
proportion that drank alcohol regularly and developed PPE is not significantly 
different from the proportion that did not drink alcohol regularly and developed 
PPE. 
o Women and alcohol X 2 (1, n = 71) = .02 p = .89 
 The association between women and alcohol and PPE showed that the 
proportion that drank alcohol regularly and developed PPE is not 
significantly different from the proportion that did not drink alcohol 
regularly and developed PPE. 
 
 Metastatic spread and dose reductions 
o At start of treatment X 2 (1, n = 125) = 3.30 p = .11 
The association between metastatic spread and dose reduction at the start of 
treatment showed that the proportion whose tumour had metastasised was 
not significantly different from the proportion whose tumour had not 
metastasised.  
o Due to PPE X 2 (1, n = 125) = 4.82 p = .09 
The association between metastatic spread and dose reduction due to PPE 
showed that the proportion whose tumour had metastasised was not 
significantly different from the proportion whose tumour had not metastasised.  
o Due to other toxicities X 2 (2, n = 123) = 2.35 p = .50 
The association between metastatic spread and dose reduction due to other 
toxicities showed that the proportion whose tumour had metastasised was not 





4.4.2.2 Summary of findings from the chi-square tests 
Findings from the chi-square tests (p < .05) show that those more likely to 
develop PPE were participants; 
 Who had a history of inflammatory conditions 
 Whose tumour had not metastasised 
 Who received capecitabine monotherapy as adjuvant treatment 
 With a good performance status 
 Who reported having warm hands most of the time 
 
The results of the comparison of the means from the independent samples t-
test for age and laboratory values (continuous data) prior to treatment 
commencing are shown in table 4.73. Independent-samples t-tests were 
conducted to compare PPE incidence prior to commencing cycle 4 of the 
treatment for age, BSA, BMI, creatinine,  creatinine clearance, ALT, ALP, 
Bilirubin and Albumin and no significant difference was observed in any of 
these variables between those who developed PPE and those that did not.  
 
To allow comparison with findings in the literature, logistic regression was 
applied to BSA to establish any risk of developing PPE. This showed that for 
every unit increase in BSA the risk of developing PPE increased OR = 4.43; 







Variable Ma   
PPE 
Yb 
SD Ma   
PPE 
Nc 




Age 62.39 10.12 66.22 11.92 1.93 .06 3.83 -.09 to 
7.75 
.03 
BSA 1.79 .21 1.72 .21 -1.70 .09 .27 -.14 to .01 .02 





73.61 17.64 70.47 16.37 -1.01 .31 -3.14 -9.25 to 
2.98 
.01 
CrClC1 89.78 28.95 83.01 32.54 -1.22 .22 -6.77 -17.71 to 
4.17 
.01 
ALTC1 29.54 24.38 29.44 22.21 -.02 .98 -.09 -8.63 to 
8.45 
<.001 
ALPC1 139.92 151.52 160.83 140.38  .77 .44 20.91 -32.54 to 
74.36 
.005 
BiliC1 7.38 3.22 8.19 5.00 1.05 .29 .80 -.70 to -
2.30 
.01 
ALB C1 43.28 4.14 42.00 3.70 -1.72 .09 -1.28 -2.76 to 
.199 
.02 
a M = mean 
b PPE Y = subjects who developed PPE prior to commencing cycle 4 
c PPE N = subjects who did not develop PPE at any cycle 
d SD = standard deviation 
e Mean diff = Mean difference between the groups 
f CI = 95% confidence interval 
g ETA  squared = effect size             
 Indicates variables with p < .25 included in multivariate regression analysis 
Table 4-73 Effects within PPE incidence pre cycle 4 (n = 138) prospective 
data 
 
4.4.2.3 Multivariate analysis 
The modelling technique used is the same as that applied to the retrospective 
data.  
 
Table 4.74 provides a summary of variables that were significant in the 
bivariate analysis. It shows those variables significant at both the conventional 
alpha level of p < .05 and the relaxed level p < .25 included in the regression 
model. It excludes those variables with insufficient numbers to be included in 





Variable P < .05 P < .25 
Age  .06 
Alcohol  .21 
BMI  .07 
Diabetes  .11 
Inflammatory conditions .05  
Performance status 3 groups .04  
Metastatic spread .03  
CrCl   .22 
Albumin   .09 
Cool hands .05  
Table 4-74 Variables from bivariate analysis entered into regression 
model 
 
4.4.2.4 Purposeful entry and model reduction  
11 variables were entered into the logistic regression analysis and 3 removed. 
Logistic regression, which consisted of 6 steps, was performed for the 
research sample (n = 125) with 13 missing cases (those that developed PPE 
after the third cycle of treatment) not included in the model. (Appendix 4.2) 
 
The omnibus tests of model coefficient revealed a Chi-square statistic of 
35.29 (df, 10) p < .001 indicating that the model performs well compared to 
the baseline model before the variables were added. The Hosmer-Lemeshow 
statistic was applied to the data revealing a Chi-square statistic of 4.77 (df, 8) 
p = .78 which indicates that the observed numbers who develop PPE are not 
significantly different from those expected by the model and that the overall fit 
is good. The Nagelkerke R2 (.36) value shows about 36% of the variation in 
the outcome variable (PPE) is explained by the logistic model and the 
percentage correctly predicted in this model was 72.6% 
 
As illustrated in table 4.75 the outcome of the logistic regression analysis 
produced a model containing 6 predictors and 2 confounding variables. The 
predictors which were significantly related to PPE development included; pre 
existing inflammatory conditions, metastatic spread, cool hands, age, BMI and 
CrCl prior to commencing treatment. The 2 confounding variables were 




were considered confounders since their removal, at different steps in the 
model building strategy, caused a greater than 20% change in the beta value 
of other variables. The removal of alcohol from the model caused a change in 
the beta value of the variables performance status and creatinine clearance. 
The removal of performance status caused a change in the beta value of the 
variable alcohol. Factors had variable ability to predict the development of 
PPE. Participants who had a pre existing inflammatory condition such as 
arthritis were nearly 3 times more likely to develop PPE prior to cycle 4 (OR = 
2.60; 95% CI .89 – 7.59, p = .08) The risk of PPE in participants who did not 
have metastatic spread was just over 3 times as great compared to those who 
had metastatic spread (OR = 3.18; 95% CI 1.17 – 8.61, p = .02). The 
tendency to have warm hands made the chances of developing PPE nearly 
twice as likely than those with a tendency to have cool hands (OR = 1.90; 
95% CI .72 – 5.02, p =.06) and for every unit increase in age (OR = .93; 95% 
CI .88 - .99, p = .01) the risk of developing PPE was reduced. For every unit 
increase in BMI the risk of developing PPE increased (OR = 1.13; 95% CI 
1.00 – 1.29. p = .04), conversely the risk of PPE decreased with every unit 
increase in creatinine clearance (OR = .98; 95% CI .96 – 1.00, p = .07). 
Although non-significant as confounding variables participants who drank 
alcohol regularly were twice as likely to develop PPE (OR = 2.18; 95% CI .77 
– 6.12, p = .14) and participants with a performance status of 0 were nearly 
twice as likely to develop PPE compared to those with poorer performance 






Predictor variable Β Wald X 2 p* value OR (exp β) 95% CI 
Alcohol 
















.77 - 6.12 
Inflammatory conditions 
















.89 – 7.59 
Metastatic spread 
















1.17 – 8.61 
Cool hands 
















.72 – 5.02 
Performance status 






















.30 – 8.83 
.12 – 2.98 
Age -.07 6.03 .01 .93 .88 - .99 
BMI .13 4.03 .04 1.13 1.00 – 1.29 
CrCl C1a -.02 3.10 .07 .98 .96 – 1.00 
Notes 
*significant at p < .1 (2-tailed) 
aCreatinine clearance cycle 1 
Table 4-75 Logistic regression output predictors of PPE purposeful 
entry model prospective data 
 
Variables that were not included in the original model were added one at a 
time and logistic regression applied. Out of the 22 variables that had p > .25 in 
the bivariate tests, one (previous radiotherapy) became significant at p < .1 in 
this process. This variable was therefore added to the final model and 
reduced in the same way as before. Participants who had not had previous 
radiotherapy treatment were more likely to develop PPE than those that had 






Predictor variable  
(n = 356) 
Β Wald X 2 p* value OR (exp β) 95% CI 
Alcohol 





































































































Age -.09 7.84 .005 .91 .86-.97 
BMI .16 5.46 .02 1.17 1.03-1.33 
CrCl C1a -.03 4.12 .04 .97 .95-.99 
Previous radiotherapy 


















* significant at p < .1 (2-tailed) 
a Creatinine clearance cycle 1 
Table 4-76 Logistic regression output predictors of PPE purposeful 
entry model with additional non-significant variables prospective data 
 
Different entry methods were applied to the same variables as those in the 
purposeful strategy based on the rationale stated in section 4.2.2.3. 
 
4.4.2.5 Forward and backward conditional entry model 
The same 11 variables included in the purposeful reduction model were 
entered into the logistic regression analysis. 9 variables were removed in 2 






The assessment of ‘goodness of fit’ is shown in table 4.77 demonstrating a 
good fit in both entry methods with 18% variance explained by the model in 
the forward entry method and 30% in the backward entry method. The ability 
of the model to correctly predict which category each case fits into was 65.1% 


















Nagelkerke R2 .18 .30 












Table 4-77 Goodness of fit automated entry methods prospective data 
 
As shown in table 4.78 the outcomes of the automated entry methods of the 
logistic regression analysis showed predictive models containing 2 variables 
in the forward entry strategy and 6 variables in the backward entry strategy 
which were significantly related to PPE development; alcohol consumption 
and cool hands were common in both models with metastatic spread, age, 
BMI, and CrCl level prior to commencing treatment in the backward entry 
model. Factors had variable ability to predict the development of PPE and 







Predictor variable Β Wald X 2  p* value OR (exp β) 95% CI 
Forward entry method 
Alcohol  



































Backward entry method 
Alcohol 





















































Age -.07 6.11 .01 .93 .88-.99 
BMI .14 4.69 .03 1.15 1.01-1.30 
CrCl -.02 4.10 .04 .98 .95-.99 
Notes 
* significant at p < .1 (2-tailed) 
Table 4-78 Logistic regression output predictors of PPE automated entry 
methods prospective data 
 
Participants who consumed alcohol regularly were more than twice as likely to 
develop PPE as those who did not drink alcohol or only occasionally drank; 
(OR = 2.45; 95% CI 1.02 – 5.85, p = .04) forward entry and (OR = 2.88; 95% 
CI 1.03 – 8.04, p = .04) backward entry. Those who had a tendency to have 
warm hands were just over twice as likely to develop PPE than those with 
cool hands (OR = 2.30; 95% CI .96 – 5.40, p = .06) forward entry model and 
(OR = 1.87; 95% CI .73 – 4.76, p = .03) in the backward entry model. In the 
backward entry model which contained an additional 4 variables, the absence 
of metastatic disease made it almost 3 times as likely that PPE would develop 
(OR = 2.84; 95% CI 1.07 – 7.54, p = .04). Increasing age showed a reduced 
risk of PPE (OR = .93; 95% CI .88 - .99, p = .01), and for each unit increase in 
CrCl level prior to commencing treatment, the risk of developing PPE 
decreased (OR= .98; 95% CI .95 - .99, p = .04). Finally, for each unit increase 
in BMI the risk of developing PPE increased (OR = 1.15; 95% CI 1.01 – 1.30, 





4.4.2.6 Receiver operating characteristic (ROC) curves 
ROC curves were applied to the predicted probabilities created in each of the 
logistic regression entry methods to compare the accuracy of the models in 
terms of their sensitivity and specificity in predicting those that develop PPE 
within the first 3 cycles and those that do not.  
 
The model with 8 variables remaining following the purposeful entry and 
retention strategy provides a slightly more accurate prediction of those who 
are likely to develop PPE and those who will not with AUC = .79 (95% CI .72-
.88) compared to the models with 2 variables remaining in the forward entry 
method and 6 variables remaining using the backward entry method AUC = 
.71 (95% CI .61-.80) and AUC = .77 (95% CI .69-.86) respectively (figure 4.9). 
From the ROC curve applied to the purposeful reduction model, the most 
favourable sensitivity = 75% and specificity = 1 – 0.29 = 71% which is 
supported by the positive and negative predictive values calculated from the 
logistic regression output 74.3% and 69.7% respectively. However, since the 
confidence intervals are wide and overlap between the models, this would 






















.798 .717 .879 
Forward 
entry 
.710 .615 .805 
Backward 
entry 
.771 .686 .857 
 
A comparison between the final model and the same model including one 
variable that was non-significant in the bivariate analysis added (figure 4.10) 
showed that the latter model provided a more favourable ability to predict the 
development of PPE AUC = .81 (95% CI .73-.89) with a sensitivity = 77% and 
specificity = 1 – 0.23 = 76% The positive and negative predictive values 
calculated from the logistic regression output was 76.12% and 69.6% 
respectively. Since the confidence intervals are wide and there is overlap 




could be suggested that the automated entry methods produce a model that 
adequately predicts the development of PPE within the first three cycles of 
treatment, the finding that the purposeful entry models showed a more 
favourable ability to predict the development of PPE in all three samples is of 
interest. This would indicate that the purposeful selection and retention 




Figure 4-10 ROC curve comparing purposeful entry model with the same 
plus additional non-sig variables prospective data 
 










Purposeful entry .798 .717 .879 
With non-sig 
variable 




4.4.2.7 Summary of findings of logistic regression model 
To summarise the findings from the purposeful selection and retention 
models, those most at risk of developing PPE were participants; 
 
 Who were younger 
 Who drank alcohol regularly 
 Who were overweight or obese 
 Who had a history of inflammatory conditions 
 With a good performance status 
 Who had not previously been treated with radiotherapy 
 Whose tumour had not metastasised 
 With a low pre treatment creatinine clearance level 
 Who reported having warm hands most of the time 
 
4.4.3 Comparison of retrospective data capecitabine monotherapy 
predictor variables in the purposeful entry and retention model with 
the prospective data  
A comparison of the results of the purposeful entry and retention models 
between the retrospective capecitabine monotherapy sample and the 
prospective sample revealed the following (table 4.79). Of the 8 variables in 
the final model applied to the retrospective capecitabine monotherapy data, 3 
also remained in the prospective data model containing 9 variables. The 3 
variables were; metastatic spread; inflammatory conditions; and alcohol. 
Whilst the absence of metastatic spread was consistent in both samples, the 
other 2 variables were contradictory. In the retrospective sample the absence 
of a pre-existing inflammatory condition was associated with an increased risk 
of PPE. Conversely, in the prospective sample, participants with a pre-existing 
inflammatory condition had an increased risk of PPE. Participants who did not 
drink alcohol regularly had an increased risk of PPE in the retrospective 
sample, whereas, participants in the prospective sample who drank alcohol 




be the underreporting of past medical history and alcohol consumption in the 
retrospective sample or may have occurred by chance. The third variable 
related to weight of a participant, demonstrated conflicting results. In the 
retrospective sample, weight loss as a confounding variable carried an 
increased risk of PPE. However, in the prospective sample an increased BMI 
demonstrated an increased risk of developing PPE.  
 













Gender .12 1.91 .85-4.32 .50 1.37 .54-3.45 
Inflammatory 
conditions 
.07 2.83 .91-8.85 .05 2.40 .99-5.77 
Seasonstart .02 2.63 1.18-5.89 .33 1.48 .67-3.26 
ALPC1 .02 .99 .98-.99 .99 1.00 .99-1.00 
Metastatic spread .04 2.47 1.06-5.75 .03 2.71 1.07-6.84 
Note 
*significant at p < .1 (2-tailed) 
Table 4-79 Logistic regression output purposeful entry model variables 
applied to prospective data 
 
Contradictory results also presented in two other variables; gender and the 
season in which the treatment started. Men were more likely to develop PPE 
in the retrospective sample, but women had an increased risk in the 
prospective sample, however, the differences were not significant. There was 
a more even distribution between males and females in the retrospective 
sample (M = 53%, F = 47%) than in the prospective sample (M = 39.2%, F = 
60.8%) which may partially explain this discrepancy. The difference between 
the samples seen in the variable season in which the treatment started 
(retrospective = winter, prospective = summer) cannot be explained by any 
difference in distribution. Since the prospective sample is the smaller of the 
two samples, it may be that there is insufficient power to detect differences 
and this association would need to be further tested in larger samples. A 
summary of the variables retained in each model described in each of the 
three sections of this chapter is presented in table 4.80 to allow easy 




























































































































































This chapter has presented the findings from data collected from the 3 
samples (retrospective – whole sample and capecitabine monotherapy 
sample and prospective). Bivariate statistical tests were applied to each 
sample to examine any association between the dependent variable (PPE) 
and each independent variable. Variables that were significant at the defined 
alpha levels were then entered into a logistic regression model where different 
entry and retention strategies were employed. The probabilities from the 
models were entered into a ROC test to establish which model demonstrated 
the most favourable ability to predict the development of PPE during the first 
three cycles of treatment. Finally the regression model containing variables 
from the retrospective capecitabine monotherapy sample was applied to the 
same variables in the prospective sample. The purpose of this final step was 
to compare the effect each variable had in the two samples and to validate the 
findings from the retrospective sample. 
  
Table 4.80 demonstrates that a comparison between the retrospective and 
prospective capecitabine monotherapy samples showed little consistency and 
was therefore unable to validate the findings. However, from the ROC results 
there is concurrence that using a purposeful algorithm including confounders  
to build a risk factor model is worthwhile. 
   
The differences between the purposeful entry and retention models for the 
retrospective and prospective capecitabine monotherapy samples will be 
discussed in chapter 5.  
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CHAPTER  5   DISCUSSION OF FINDINGS 
5.1  Introduction 
The aim of this exploratory study was to identify factors that may increase the 
risk of developing PPE, focusing on PPE prior to cycle 4 of capecitabine 
monotherapy. The findings have the potential to be used by nurses, who, 
either inform and educate patients about their treatment or assess the 
patient’s fitness for their next cycle of treatment.  
 
In this chapter comparisons will be made between the findings from the 
retrospective (capecitabine monotherapy only) and prospective samples in 
this study with findings of studies reported in the literature. The incidence and 
severity of PPE will be discussed followed by the impact of PPE on tolerance 
of treatment. An analysis of any association between PPE and other toxicities 
from capecitabine is preceded by a discussion of potential risk factors for the 
development of PPE. Bar charts and tables are used to illustrate and enhance 
the text. 
 
Where reference is made to “this current study”; “retrospective sample”; or 
“prospective sample” these allude to the study on which this thesis is based. 
As a reminder to the reader statistical significance is inferred in the bivariate 
analysis using the conventional alpha level of p < .05. A relaxed alpha level 
was used in the logistic regression modelling algorithm, p <.25 for selection of 
variables into the model and p < .1 for retention of the variables. Therefore 
variables are deemed as achieving statistical significance in the regression 
model if they are p < .1. Page numbers are provided to enable the reader to 
cross reference with chapter 4 (findings). 
 
The chapter concludes with comparison of the logistic regression models 
applied to the two samples from this study, a summary of the key findings and 
the unique contribution this study makes to the current body of knowledge. 




5.2  Incidence and severity 
5.2.1 Incidence 
Initial clinical trials revealed an incidence of PPE, of any grade or at any cycle, 
of 60% (Roche 2010), 53.0% from pooled data of two trials (Saif 2009), 68.3%  
(Abushullaih et al 2002) and 55.0% from pooled data of three trials 
(Koukourakis et al 2008). In the current study, the incidence of PPE of any 
grade or at any cycle was greater in the prospective sample compared with 
the retrospective data (66.4% versus 50.3%) (pages 160 and 131).  The 
overall incidence of PPE in this current study mirrors the studies summarised 
in appendix 5.1 (shaded red) where, although the range was 16% (Barrios et 
al 2010) to 87.7% (Brearley et al 2010) the majority had an incidence of 
between 50-69% (Blum et al 1999, 2001, Cassidy et al 2002, Reichardt et al 
2003, Scheithauer et al 2003, Hong et al 2004, Pierga et al 2004, Van Cutsem 
et al 2004, Twelves et al 2005, Lee et al 2008, Kusama et al 2010). 
Sometimes the incidence was reported as grade 3, some as grade 2 and 3 
and others gave no indication of their definition of severe PPE. The wide 
range of figures seen in these studies is possibly due to either the sample size 
or the difficulties in the way the incidence of PPE is reported. It is often 
unclear whether the figures refer to all grades of PPE or just to grades 2 and 
3. 
  
Blum et al’s (1999) findings indicated a gradual increase in the incidence of 
first episodes of PPE over the period, although, contrary to this Abushullaih et 
al (2002) found that 92.9% of those who developed PPE did so within the first 
two cycles of treatment and suggests that Blum et al’s findings are due more 
to a slower onset than a true cumulative effect. Other authors (Pierga et al 
2004) support Blum et al’s findings, stating that dose and treatment duration 
are linked to PPE, and while they state that there is a higher incidence of 
severe PPE in higher doses (20% versus 2%), no detail is provided of the 
presentation of PPE by cycle. Similar to Abushullaih et al (2002), the findings 
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in the current study showed that 82.9% of those who developed PPE did so 
within the first 3 cycles in the retrospective sample and 84.33% in the 
prospective sample. This finding is further supported by Heo et al (2004) who 
found that 86.2% of the patients in their study developed PPE within the first 3 
cycles. The high incidence of PPE developing within the first 3 cycles would 
indicate that there are factors other than accumulation of the drug that causes 
PPE. This is supported by Lipworth et al (2009) in their review article where 
they presented contradictory findings. They found one retrospective study that 
demonstrated a statistically and clinically significant dose correlation with PPE 
incidence. However, a second prospective study found no correlation between 
dose accumulation and PPE incidence or severity. Lipworth et al (2009) 
referred to two further studies where PPE occurred mostly within the first 3 
cycles of treatment, further suggesting that PPE rates are not affected solely 
by total cumulative dose of capecitabine. 
 
5.2.2 Severity  
The incidence of grade 3 PPE in initial trials was 11–24% (Roche 2010), 
17.0% from pooled data of two trials (Saif 2009) and 11% (Abushullaih et al 
2002). Despite a lower incidence overall in the retrospective sample of the 
current study, the incidence of grade 3 PPE at presentation was higher than in 
the prospective sample (21.0% versus 8.4% respectively) (pages 135 and 
163). There was some difficulty in interpreting data from many studies, as it 
was unclear if the percentage given for each grade was that of the whole 
sample or purely the sample that developed PPE. It was also unclear at what 
point the development of grade 3 PPE was reported; whether it was the first 
presentation of PPE or the worst grade experienced. In studies of patients 
receiving capecitabine monotherapy 1250mg/m2 BD where the incidence of 
grade 3 PPE was reported as a percentage of the whole sample, this ranged 
from 9.9% (Blum et al 1999) to 24.2% (Miller et al 2005). The samples in both 
studies were all female with metastatic breast cancer. A third study using a 
similar sample reported the incidence as 16.0% (Pierga et al 2004). In two 
other studies that included both men and women with colorectal cancer 
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receiving the same capecitabine dose as above, the incidence of grade 3 PPE 
were similar 17.0% (Twelves et al 2005) and 18.1% (Hoff et al 2001). When 
the percentage of grade 3 PPE is reported as a percentage of only those who 
developed PPE there appears to be more similarity between findings with 
comparable samples (female, metastatic breast cancer). Kaufmann et al 
(2005) reported an incidence of 20.0%; Fumoleau et al (2005) 21.0% and 
Venturini et al (2007) 21.9%. Similarly with samples containing both men and 
women with colorectal cancer, 29.0% (Scheithauer et al 2003) and 33.3% 
(Van Cutsem et al 2001). The variability shown in the studies is summarised 
in appendix 5.1 (shaded red and blue). A further difficulty arose in that 
different toxicity criteria were used in these studies; NCI-CTCAE (NCI 2006), 
NCIC-CTG (National Cancer Institute of Canada clinical trials group 1991), or 
World Health Organisation (WHO 1979). One example is that skin changes 
with pain interfering with function are equated with grade 3 in the NCI criteria 
but as grade 2 in the NCIC criteria. It is these difficulties that may explain 
some of the variability. The differences in incidence of particularly grade 3 
PPE in the current study may be attributed to improved patient education, 
patient monitoring and early recognition of PPE by practitioners who have 
developed experience over time in using oral capecitabine.  
 
Personal clinical experience has led to the questioning of whether patients 
who develop grade 1 PPE between cycles of chemotherapy are at risk of 
developing more severe grades with subsequent cycles. Unless questioned 
specifically about symptoms of PPE between cycles, the patient will not 
mention it as they either do not understand its significance or they are worried 
that their treatment will be delayed or stopped. An example of this was 
provided in chapter 4 pages 163-164 where one participant had not revealed 
to the doctor during the consultation that she had developed sore hands and 
feet with open cracks which had not yet healed completely. This was identified 
when supplying the capecitabine tablets to the participant. The opportunity 
was taken to educate the participant about the implications of not reporting 
toxicities. Action was taken to have the participant reviewed by the doctor who 
deferred the treatment by a week. 




From the copious amount of literature retrieved which either made reference 
to PPE within the text or specifically contained PPE in the title, it was found 
that although there was the occasional mention that the onset of PPE 
between cycles was possibly under reported, only one study was identified 
that specifically collected and analysed this type of data (Tebbutt et al 2003). 
They demonstrated that more than half of the patients who developed grade 1 
PPE did go on to develop grade 2 or worse in subsequent cycles. 
 
The findings from the current study support this, although the proportions who 
developed grade 2 or worse PPE following the first presentation of grade 1 
were slightly less than Tebbutt et al's study. Of the 43 participants 
(retrospective sample) who developed grade 1 PPE as their first presentation, 
20 (46.5%) developed grade 2 or 3 PPE in subsequent cycles (page 134). 
Similarly in the prospective sample, 56 developed grade 1 PPE as their first 
presentation, with 23 (41%) subsequently developing grade 2 or 3 PPE (page 
163).  
 
As explained in chapter 3 section 3.2.2, the data obtained from the 
participant’s diaries, which were maintained by approximately 50% of the 
sample, were transferred to the interview schedule. Those who did not 
maintain the diary were questioned about any signs or symptoms of PPE 
since the previous cycle. It was therefore difficult to present data to answer 
the question whether the development and resolution of PPE between cycles 
results in more severe PPE with subsequent cycles. The data from those who 
did not complete a diary could be unreliable as it relied on recall of the timing 
of the development of PPE. 
 
5.2.3 Completion of treatment 
Completion rates were analysed during this study to examine the effect of 
PPE on tolerance of treatment. The proportion of participants who complete 
the whole course of treatment were similar between the retrospective and 
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prospective samples (53.6% versus 57.6%) (pages 156 and 166). This 
compares well with a 45.7% completion rate in Brearley et al’s study (2010), 
whereas, Son et al (2009) report a much higher rate of 90.5%, although, the 
reason for this is not apparent from scrutinising the sample characteristics.  
 
There have been suggestions that the development of PPE may be a marker 
of the efficacy of treatment in patients receiving capecitabine, either as 
monotherapy or in combination with other agents. Five year data from the X-
ACT (bolus 5FU versus oral capecitabine as adjuvant therapy for early-stage 
colon cancer) trial suggested increased efficacy in those who developed PPE 
compared with those who did not (Twelves et al, 2008). This finding has been 
replicated in a study of patients taking capecitabine for metastatic breast 
cancer (Kaufmann et al, 2010) and in a meta-analysis of 13 retrospective 
studies of patients receiving capecitabine monotherapy for colon, gastric and 
breast cancer (Roche, 2010). Others have developed this notion further and 
suggested that the severity of PPE, particularly grade 3, may be a predictor of 
efficacy (Chua et al 2003, Kurt et al 2006). Furthermore Han et al (2005) have 
reported a significant association between high levels of thymidine 
phosphorylase (TP) (the key enzyme involved in the conversion of 
capecitabine to 5-FU) in tumour cells and the development of PPE (p=0.01) 
and with tumour response (p=0.004). This poses the question of whether it is 
the TP level in tumour cells (which is not routinely measured) that influences 
the efficacy of the treatment and that PPE is merely a clinical sign of these 
raised levels.  
 
This question warrants further research to compare TP levels and efficacy 
with the incidence of PPE. Yun et al (2010) compared the outcome of 
treatment after dose reduction or cessation of capecitabine in 173 Korean 
patients with colorectal cancer. Of the whole sample 114 (65.9%) developed 
PPE, with 45 of these assessed as grade 2 or above. The relapse rate 
between patients who completed all 8 cycles and patients who had an 
interruption in their treatment was 10.3% and 27.8% respectively. The 3-year 
survival rate for each group was 90.7% and 70.9% respectively. Patients who 
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completed 8 cycles of treatment had an improved recurrence rate (p = 0.05) 
and 3-year survival (p = 0.03) compared to those whose treatment was 
stopped before completion of the 8 cycles. This further supports the argument 
to maintain treatment as much as possible and also demonstrates that a 
reduced dose is effective in terms of outcome. Yun et al (2010), however, 
identify limitations of their study and question whether the difference in 
prognosis is solely due to dose reduction or interruption since the sample size 
is small (no details of power given), and that other factors such as 
performance status, age and gender may affect the outcome and are difficult 
to analyse. The group who received a dose reduction also contained an 
increased number of older patients. 
 
Dose reduction is recommended by the manufacturer in the management of 
severe toxicities, including PPE, from capecitabine and in cases where there 
is moderate renal impairment. Few studies have reported figures for the 
proportion who received a dose reduction, mainly reporting the median 
number of cycles received. 
 
Abushullaih et al (2002) in their review of the literature suggested that the 
incidence of dose reduction at any cycle was between 12 and 50%, and in 
their own study stated that 16 of 41 (39%) patients received a dose reduction 
due to PPE. However, this study included patients receiving 5FU and the true 
incidence for those taking capecitabine is unclear. Dose reduction for any 
reason was 32% in Pierga et al’s (2004) study with 19% due to PPE. Venturini 
et al (2007) reported 13.6% received a dose reduction due to PPE. In the 
current study dose reduction due to PPE was similar between the 
retrospective and prospective samples (34 (22.5%) (page 136) and 33 
(26.4%) (page 166)) respectively, not too dissimilar to the studies above. 
 
Reducing the dose of capecitabine for any reason in the current study 
produced similar rates between the two samples with 42.4% (64) in the 
retrospective sample and 44.8% (56) in the prospective sample. A similar 
picture was noted for dose reduction due to toxicities other than PPE, 19.9% 
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(30) in the retrospective sample (page 136) and 18.4% (23) in the prospective 
sample (page 166) were recorded. Pierga et al (2004) only reported dose 
reductions due to gastrointestinal toxicity in 10.0% of the sample. 
 
Variable rates of dose reduction were reported in other studies, 20.2% (35) 
(Cox et al 1999), 27% (81) (Twelves et al 1999), 32% (63) (Pierga et al 2004), 
33.9% (202) (Cassidy et al 2002) and 40% (121) (Yun et al 2010), although, 
details of specific reasons for these reductions were not provided. Figure 5.1 
provides a graphical comparison of the percentage of dose reductions from 
studies in the literature to enable comparison between those and the rates in 
the current study. The data in these studies was collected prospectively in 
these studies with the exception of Pierga et al (2004) which evaluated data 
retrospectively from two phase III trials. Therefore the limitations of 
retrospective analysis apply. All of the studies mentioned above collected data 
from a large number of patients. The smallest sample size (n = 173) in Yun et 
al (2010) study and the largest (n = 596) (Cassidy et al 2002), although the 
latter was a combination of data from two phase III trials. The greatest 
proportion that had a dose reduction for any reason (Yun et al 2010) was 
seen in patients receiving capecitabine as adjuvant therapy for colorectal 
cancer. Twelves et al (1999) study based on the same criteria yielded a lower 
proportion having a dose reduction. Cox et al (1999) and Cassidy et al (2002) 
collected data from patients receiving capecitabine for metastatic colorectal 
cancer and had comparable proportions that had a dose reduction for any 
reason. Cultural or ethnic disparity between these studies may have 
influenced the differences in incidence, since Yun et al’s (2010) study was 
restricted to a single country (Korea), and Pierga et al (2004) to France, 
whereas, the rest were international studies. 
  




Notes; Cox = Cox et al 1999, Twe = Twelves et al 1999, Pie =  Pierga et al 2004, Cas = 
Cassidy et al 2002, Yun = Yun et al 2010, Ret = Retrospective sample, Pro = Prospective 
sample  
Figure 5-1 Percentage of dose reduction for any reason 
 
Treatment was discontinued for any reason in 70 (46.3%) in the retrospective 
sample (page 136) and 53 (42.4%) in the prospective sample (page 166) in 
the current study. Of those who had their treatment discontinued, 11 (15.7%) 
(7.3% of whole sample) participants in the retrospective sample (page 136) 
and approximately half that number in the prospective sample 5 (9.4%) (4.0% 
of whole sample) (page 166) were due to PPE.  Few studies reported 
numbers discontinued due to PPE and those that did varied from none 
(Abushullaih et al 2002), just 1 (Hyodo et al 2006, Son et al 2009), 5 (1.7%) 
(Van Cutsem et al 2001), 39 (6.2%) (Venturini et al 2007), with the largest 
proportion of 22 (11.0%) reported by Pierga et al (2004). The small numbers 
seen in the first three studies are based on data from small samples 41; 60 
and 84 respectively although all were treated for metastatic colorectal cancer. 
Similarly a small number were reported in Van Cutsem et al (2001), although 
the sample size was larger, n = 301 and data were gathered from multiple 
centres compared with the previous three studies which were single institute 
studies. The two studies that found a larger proportion of patients having their 
treatment discontinued due to PPE were both based on a sample containing 
only females. Venturini et al (2007) and Pierga et al (2004) collected data 
from pre treated patients with advanced breast cancer. Vasey et al (2003) 
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(1 in each of three different dose groups) were reported to have discontinued 
due to grade 3 PPE in a study by Van Cutsem (2000). 
 
In the current study, 3 participants from the retrospective sample (page 136) 
and 1 from the prospective sample (page 166) were changed to alternative 
treatment due to toxicity including grade 3 PPE. Figure 5.2 provides a 
graphical comparison of the percentage of patients who had their treatment 
stopped due to PPE from studies in the literature to enable comparison 
between those and the rates in the current study.  
 
 
Notes; Van = Van Cutsem et al 2001. Ven = Venturini et al 2007, Vas = Vasey et al 2003, Pie = 
Pierga et al 2004, Ret = Retrospective sample, Pro = Prospective sample 
NB the figures for the Ret & Pro samples are given as a % of the whole sample here contrary to 
those given in the text above which gives the % of those who stopped their treatment for any 
reason, to allow direct comparison with other studies. 
Figure 5-2 Percentage of treatment stopped due to PPE 
 
The rates of discontinuation of treatment due to other toxicities reported in the 
literature was relatively low, ranging from 4.9% to 13.5% (Van Cutsem et al 
2000, Abushullaih et al 2002, Venturini et al 2007, Brearley et al 2010, Yun et 
al 2010), although it was not clear if the figures included all toxicities or just 
gastrointestinal toxicities.  
 
In this current study there was a higher rate of discontinuation of treatment 
due to other toxicities in the prospective sample, 29 (54.7%) (page 166), 
compared with 23 (32.9%) in the retrospective sample (page 136). The 
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the prospective sample receiving capecitabine for palliation. With this group of 
participants the aim is to ensure that the treatment does not cause more 
symptoms than the disease. In an attempt to confirm this notion, further 
analysis was carried out examining any association between treatment intent 
(aim of Rx2gps) and dose modification or cessation. In both the retrospective 
and prospective samples in the current study, more participants receiving 
treatment for palliation had a dose reduction at the start of their treatment. 
However, statistical significance was achieved only in the retrospective 
sample (p = .003) (pages 141 and 174). Dose reduction may have led to a 
reduced incidence of toxicities including PPE. Interestingly a higher proportion 
had a dose reduction due to PPE in the adjuvant group than the palliative 
group in both samples, whereas, the percentage receiving a dose reduction 
due to other toxicities was higher in the palliative group in the prospective 
sample but similar in the retrospective sample (pages 142 and 174). This 
difference may be due to under reporting in the latter sample. A higher 
number of participants completed all cycles in the adjuvant group, and there 
was no difference in the number who stopped treatment due to PPE between 
the adjuvant and palliative groups or between the two samples. As with dose 
modification, treatment was more likely to be stopped in the palliative group 
for other reasons, mostly disease progression (p = <.001 retrospective and p 
= .002 prospective) (pages 141 and 174). This confirms that participants 
receiving capecitabine for palliative intent are more likely to have their 
treatment modified to enable them to continue with treatment, either because 
the toxicities of capecitabine caused more symptoms than the disease or 
because of disease progression. 
 
Evidence shows that since PPE is not life threatening, if it is managed with 
deferring a cycle and dose reduction, few patients require cessation of 
treatment as a result of PPE. It is the presence of other toxicities particularly 
diarrhoea or persistent bone marrow depression that result in cessation of 
treatment. 
 
Discussion of Findings 
Page 207 
 
5.3  Other toxicities 
The literature showed a great deal of variability in the incidence of 
capecitabine induced toxicities other than PPE (shaded pink in appendix 5.1). 
The incidence of diarrhoea range from 12% (Chua et al 2003) to 93.1% (Yun 
et al 2010) The incidence report by Chua et al (2003) was however based on 
a small sample of 17, whereas Yun et al (2010) had a larger sample of 173. 
Mucositis was reported as occurring in 8% (Barrios et al 2010) to 93.6% (Yun 
et al 2010). It is unclear why there is such a difference in the incidence of 
mucositis between these two studies. In both, sample size was similar 240 
and 173 respectively and the same toxicity assessment tool was used. They 
both reported mucositis of any grade and in neither study were mucositis of 
grade 2 or above experienced by the participants. The only differences 
between the studies was that one was a single centre study on patients with 
colorectal cancer receiving capecitabine as adjuvant treatment (Yun et al 
2010). The other was a multicenter study on females with previously treated 
HER2-negative advanced breast cancer (Barrios et al 2003). Data were 
collected retrospectively in the Yun et al study and prospectively in the Barrios 
et al one. Since the incidence of mucositis was lower in the latter study the 
limitations of retrospective data collected cannot explain the difference.  
 
Nausea and/or vomiting ranged from 7.5% (Martinez-Trufero et al 2010) to 
86.1% (Yun et al 2010) and fatigue 9% (Venturini et al 2010) to 99.4% (Yun et 
al 2010). It is interesting to note that of all the studies detailed in appendix 5.1 
the incidence of these toxicities was markedly greater in Yun et al's (2010) 
study the reason for this remains unclear. This wide variability in the incidence 
made it difficult to make a comparison. As mentioned previously this wide 
variation is probably due to the methods of reporting the incidence. 
Interestingly the lowest incidence of diarrhoea was reported in 4 out of 5 
studies carried out in China (Chua et al 2003, He et al 2011) or Japan (Hyodo 
et al 2006, Osako et al 2007, Kusama et al 2010), with wider variability in 
other Asian populations such as Taiwan and Korea. The reason for this is 
unknown but could be due to other factors, for example diet or under reporting 
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by patients. Possible confounding factors for diarrhoea in those with colorectal 
cancer are surgery or previous radiotherapy which may account for some 
reported diarrhoea. 
 
The incidence in the current study of diarrhoea (44.4% vs 44.0%), and rash 
(2.6% vs 5.6%) were similar between the retrospective and prospective 
samples. However, there was an increased incidence of mucositis (22.5% vs 
34.4%), nausea and/or vomiting (23.8% vs 39.2%) and fatigue (19.2% vs 
44.8%) in the prospective sample (pages 132 and 161). This difference can 
probably be attributed to the under reporting of mild mucositis or nausea in 
the retrospective sample. Since fatigue is not viewed as a side effect that can 
be treated with medication it is often not explored by the healthcare 
practitioners despite its impact on the patient’s quality of life. Extreme fatigue 
can be the side effect that influences the patient’s motivation to continue with 
their treatment. This view is supported by Saif et al (2008) who state that 
many patients receiving capecitabine report fatigue as the side effect that 
causes the most disruption to their everyday lives, often continuing long after 
treatment has ended. Further research to explore the impact of fatigue on 
quality of life is warranted and could lead to strategies to help patients 
manage this effect. Figure 5.3 presents the comparison of toxicities other than 
PPE between the retrospective and prospective samples in the current study. 
 
Notes: D = diarrhoea, R = rash, M = mucositis, N/V = nausea and/or vomiting, F = fatigue 
Figure 5-3 Comparison of incidence of toxicities other than PPE from the 
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A favourable comparison can be made between the current study and the 
data provided in the manufacturers prescribing information (Roche 2011). A 
phase III trial of capecitabine versus 5FU/leucovorin for colorectal cancer and 
a second pooled data of two phase III trials of capecitabine versus 
5FU/leucovorin as first line therapy in metastatic colorectal cancer showed an 
incidence of diarrhoea (47.0 and 55.0%), mucositis (22.0 and 25.0%), Nausea 
and/or vomiting (34.0 and 43.0%) and fatigue (16.0 and 42.0%) respectively 
(Roche 2011). 
 
Application of a chi-square test to these toxicities in the current study revealed 
a statistically significant association between diarrhoea and fatigue and PPE 
development (p = .004) at any cycle in the retrospective sample (page 133). 
An increased incidence of PPE was seen in those who did not develop 
diarrhoea or were fatigued. While this trend was replicated in the prospective 
sample for fatigue despite the higher incidence it did not achieve statistical 
significance. The opposite trend was seen for diarrhoea. Those who 
developed diarrhoea also developed PPE more frequently. However, there 
was no statistically significant association. A statistically significant 
association between mucositis (p = .05) and nausea and/or vomiting (p = .02) 
and PPE at any cycle was seen in the prospective sample (pages 161-162), 
both of which showed no association in the retrospective sample. Differences 
may be due to the small numbers in some cells in the chi-square test, 
although all were greater than 5. Other reasons for this difference may be the 
under reporting of mild toxicities or may simply be due to chance. 
 
Studies examining any association between PPE and other toxicities were 
limited with 3 studies identified. A retrospective study (n = 330) found that 
mucositis (42.0%) was three times more likely in those who developed PPE (p 
= .0001), whereas the incidence of vomiting was lower in those who 
developed PPE (p = .045) (Tanyi et al 2009). While these results both support 
(mucositis) and refute (vomiting) those found in the current prospective 
sample, the sample in Tanyi’s study received pegylated liposomal doxorubicin 
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for gynaecological cancers and would therefore have a gender bias and a 
different toxicity profile to capecitabine. Thereafter the usual deficiencies of 
retrospective analysis have to be taken into account. Heo et al (2004), in their 
study of patients receiving capecitabine-containing regimes, found that prior 
occurrence of oral mucositis was associated with the development of PPE p = 
0.029. However, a similar association was not seen with other toxicities. Again 
this association between mucositis and the development of PPE supports the 
findings from the current study; although whether the mucositis appeared prior 
to PPE or vice versa was not tested. The third study by Tebbutt et al (2003) 
found that early grade 1 diarrhoea was predictive of grade 2 or worse PPE in 
subsequent cycles in patients receiving infusional 5FU with or without 
mitomycin. 
 
The only toxicity that shows consistent association with the development of 
PPE appears to be oral mucositis and further examination of this association 
may confirm this toxicity to be a predictor of PPE.  
 
5.4  Age and gender 
5.4.1 Age 
 Over 60% of cancers occur in the over 65 age group and this group present 
unique challenges due to age-related changes that may affect their tolerance 
to treatments for cancer particularly chemotherapy (Hurria & Lichtman 2008).  
 
Age related changes include; 
 Changes to gastrointestinal tract 
 Reduction in total body water 
 Declining glomerular filtration rate  
 Delays in DNA repair  
 Reduced Dihydropyrimidine Dehydrogenase (DPD) enzyme 
production. 
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Many changes occur as a result of the ageing process. Changes to 
gastrointestinal tract may affect drug absorption (Hurria & Lichtman 2008). A 
reduction in total body water changes the volume distribution of water soluble 
drugs. With the decrease in serum albumin and haemoglobin seen in the 
elderly, this further affects the volume distribution of these drugs and 
increasing the risk of toxicities in drugs bound to albumin and haemoglobin 
(Balducci & Extermann 2000, Hurria & Lichtman 2008). Declining glomerular 
filtration rate leads to increased toxicity due to reduced excretion of the drug 
or its metabolites via the kidneys (Balducci & Extermann 2000). Since age 
forms part of creatinine clearance calculations and age appears to be a risk 
factor for toxicities, older patients taking capecitabine may require a reduced 
starting dose and careful monitoring (Balducci & Extermann 2000, Cassidy et 
al 2002). Although, serum creatinine which also forms part of creatinine 
clearance calculations is a poor indicator of renal function in the elderly due to 
their reduced muscle mass (Hurria & Lichtman 2008). Although reduced renal 
excretion of drugs is seen in the elderly the same effect is not seen with 
plasma clearance indicating that there is an alternative method of drug 
disposition when glomerular filtration reduces; therefore reducing drug dosage 
based on renal function in the elderly cannot be recommended (Balducci & 
Extermann 2000). These authors go on to suggest that other mechanisms 
that may increase the risk of toxicity in elderly patients receiving 
chemotherapy comprise delays in DNA repair, and more relevant to 
capecitabine is delayed drug catabolism due to reduced DPD enzyme 
production. 
 
Two key age milestones have been suggested to be linked with toxicities from 
chemotherapy agents; 70 and 85 years. Age-related changes follow a flat line 
trend but increase markedly between 70 and 75 with an even sharper 
increase after 85 years (Balducci & Extermann 2000). 
 
In this current study, the median age and range were similar in both the 
retrospective and prospective samples 69 (39-85) and 65 (36-83) respectively 
(pages 131 and 160), and is comparable with other studies (appendix 5.1 
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shaded purple). Independent samples t-test revealed no statistical association 
between age and the development of PPE at any grade in both the 
retrospective and prospective samples (p = .27 and p = .06 respectively) 
(page 149 and 182). This result did not achieve significant in the bivariate 
analysis taking an alpha level of p < .05. As previously explained a more 
liberal alpha level of p < .25 was used as the inclusion criterion for candidate 
variables into the multivariate analysis. Only data from the prospective sample 
achieved this level of significance. In this multivariate logistic regression 
model younger participants were more at risk of developing PPE than older 
participants (p = .01) (page 184).  
 
A statistically significant association between older patients and development 
of PPE has been see with the use of 5FU (Meta-analysis Group 1998), but 
has not been clearly seen with capecitabine, although, when given in 
combination with other agents, age ≥ 52 years was shown to be associated 
with PPE (Heo et al 2004).  A single institute study in America of 41 patients 
with colorectal cancer receiving capecitabine monotherapy found no 
association between age and PPE (Abushullaih et al 2002). Scheithauer et al 
(2003) examined the difference in PPE between ages ≥ 65 years and < 65 
years and found similar incidence of any grade between the two groups (63% 
versus 61% respectively), and of grade 3 PPE (20% versus 16%), although 
no statistical test was applied to determine any significance.  
 
This current study supports these findings in the retrospective sample. 
However, the opposite trend was seen in the prospective sample, with 
younger participants having an increased risk of PPE at any cycle, with a 
similar incidence of grade 3 PPE. In the retrospective sample comparing the 
two groups ≥ 65 years and < 65 years, a similar incidence was found of PPE 
between the groups (50.6% and 50.0% respectively), and grade 3 PPE 
(40.9% and 34.4% respectively). In the prospective sample an incidence of 
55.6% and 77.0% respectively p = .02 with a higher proportion of those < 65 
developing PPE of any grade but similar incidence of grade 3 PPE between 
the two age groups 12.7% and 11.5% respectively (pages 143 and 175). 




Figure 5.4 shows a graphical representation of the findings from the 
retrospective and prospective samples from the current study. 
 
 
Figure 5-4 Comparison of the incidence of PPE between 2 age groups 
from the retrospective and prospective samples 
 
In the past there has been an under use of adjuvant treatment for elderly 
patients with cancer. Studies of anti-neoplastic agents which demonstrated a 
survival advantage were often restricted to the under 70s (Reddy et al 2007). 
In the past there were concerns about the ability of elderly patients to tolerate 
capecitabine treatment, but more recently treatment in the elderly has become 
the focus of several research studies. Two small studies by Zamora et al 
(2004) and He et al (2011) concluded that capecitabine is tolerable in older 
patients and toxicity is reduced if treated with a reduced dose of 1000mg/m2 
without loss of efficacy. 
 
Similar toxicities were found in patients older than 70 years compared to 
younger patients in two studies (Feliu et al 2005, Diaz-Rubio et al 2007). Feliu 
et al (2005) found that there was no relationship between grade 3 toxicity and 
age comparing the age groups 70-79 versus ≥ 80 years. However, with only a 
small number who developed grade 3 toxicity and the small sample size of 51 
there was insufficient power to definitely rule out any potential relationship. 
Conversely, Cassidy et al (2002) analysed pooled data from two multi-centre 
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grade 3 PPE was 64 (17.1%) for the whole sample of 596, being especially 
high in those aged 80 or above 13 (15%). Furthermore, they stated that this 
might be explained by age-related renal function. When age was entered into 
a multivariate regression analysis, adjusting for creatinine clearance, showed 
that age in isolation was not an independent predictor of toxicity of 
capecitabine (p = 0.72).  
 
In women with breast cancer receiving capecitabine, patients aged 80 and 
above had an increased incidence of grade 3 or 4 toxicities (Blum 1999), 
although the proportion of the sample who fell into this age group and which 
toxicities this applied to were not identified. A more recent trial (Focus 2) 
evaluating treatment of elderly patients receiving capecitabine 1250mg/m2 
and bevacizumab revealed 54% developing grade 3 or 4 toxicities with an 
increased rate of these in patients with reduced renal function (Feliu et al 
2010).  
 
A retrospective single institution study evaluating toxicity and overall survival 
in octogenarians (80-89) and nonagenarians (90-99), found that all 25 
patients who received chemotherapy (all but one regime contained 5FU or 
capecitabine) where given a reduced starting dose. Despite this initial 
reduction 82% developed grade 3 or 4 toxicities requiring further dose 
reduction and treatment delay. PPE incidence was 18%, however, no patient 
received capecitabine alone. This study suggests that patients greater than 80 
years old behave differently to septuagenarians who appear to tolerate full 
doses, and that the older population require substantially reduced doses of 
chemotherapy (Reddy et al 2007). They did however, acknowledge the 
limitations of this study particularly due to its retrospective nature; in that co-
morbidities or other confounding variables may have been missed and 
toxicities wrongly attributed to chemotherapy.  
 
An analysis of data from the retrospective sample of the current study 
revealed 20 (13.2%) participants aged more than 79yrs with 12 (60%) 
developing PPE prior to cycle 4, 8 (66.7%) developed grade 2 or 3 for their 
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first presentation and 6 (50%) grade 3 as their worst episode. 11 (55%) of the 
20 completed all planned cycles with only 3 (15%) stopping due to PPE. 7 
(35%) were deferred due to any toxicity and all 7 (35%) had a dose reduction, 
5 (25%) due to PPE and 2 (10%) for other toxicities, although they also had 
grade 1 PPE. 11 (55%) of the 20 started on a reduced dose of capecitabine, 9 
(45%) of these had moderate renal failure (CrCl of 30-50mls/min). 6 (30%) of 
these participants still went on to develop PPE, 5 (25%) at grades 2 or 3 
(page 143). In the prospective sample, only 6 (4.8%) were aged over 79 years 
with 2 (33.3%) developing PPE and 1 (16.7%) participant developing grade 3 
as their worst episode. 3 (50%) of the 6 completed all planned cycles with 
only 1 (16.7%) stopping due to PPE. 4 (66.7%) out of 6 participants aged > 79 
years, 4 (66.7%) started on a reduced dose with 1 (16.7%) developing grade 
1 PPE for which a delay in treatment occurred with a further reduction in the 
dose of Capecitabine (page 176). 
  
Figures 5.5 and 5.6 present this data in graphical form, with separate graphs 
for the retrospective and prospective samples. 
 
 
Notes: G = grade of PPE, Com = completed all planned cycles, SPPE = stopped due to PPE, 
DPPE = deferred due to PPE, DRPPE = dose reduction due to PPE, Drother = dose reduction 
due to other toxicities, DRS = dose reduction at start of treatment 
Figure 5-5 Retrospective sample age > 79 years n = 12 incidence of PPE 
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Notes: G = grade of PPE, Com = completed all planned cycles, SPPE = stopped due to PPE, 
DRS = dose reduction at start of treatment 
Figure 5-6 Prospective samples age > 79 years n = 6 incidence of PPE 
and impact (page 176) 
 
In both the retrospective and prospective samples statistical significance 
could not be tested, since with only such small numbers, no firm conclusions 
can be drawn, and there were no nonagenarians in either sample to allow 
comparison with other studies. 
 
5.4.2 Gender 
There was a difference in the gender distribution with the prospective sample 
(page 160) weighted towards females (60.8%) compared with 47% in the 
retrospective sample (page 131). Although summary figures may be slightly 
altered by a ratio other than 50:50, the statistical tests used to analyse this 
data allows for different ratios in the categories. Having said that, both 
samples showed that men were more likely to develop PPE than women 
(figure 5.7). However, the association achieved statistical significance (p = 
.03) only in the retrospective sample (page 137). When gender was combined 
with other variables from the retrospective sample in the multivariate 
regression model, men were almost twice as likely as women to develop PPE 
(OR = 1.91), although it was not confirmed statistically (p = .12), but remained 
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Retro = Retrospective sample 
Prosp = Prospective sample 
Figure 5-7 Percentage of males and females with PPE from both 
samples 
 
Studies (Abushullaih, et al 2002, Sun, et al 2009) have shown no difference in 
frequency or relationship between gender and PPE, with a similar finding in 
the over 70s (Feliu et al 2005). Conversely Park et al (2009) found a 
statistically significant difference (p = .04) with men more likely to develop 
PPE than women. This may be explained by the small sample size (n = 17) 
and the imbalance of gender in the sample, with only 3 women included. 
Since this small number would have resulted in less than 5 cases in the 
expected count in half the cells of the cross tabulation, no firm conclusion can 
be drawn from this study. 
 
5.4.3 Age and Gender combined 
As previously alluded to, age alone does not appear to be a predictor of 
toxicity. It is acknowledged that large prospective studies are needed to 
confirm this since in the past there has been a reluctance to administer 
chemotherapy to older patients. Age and gender were combined into four 
groups; men < 65yrs; men > 64yrs; women < 65yrs; and women > 64yrs to 
examine the influence of gender on age and the incidence of PPE. A chi 
square test applied to this variable showed no statistically significant 
association in either the retrospective sample (page 143) or the prospective 
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analysis, younger men were more likely to develop PPE than older men in the 
prospective sample (OR = 3.55, p = .04) (page 176). However, although this 
trend was replicated in the retrospective sample it did not achieve statistical 
significance (OR = 1.05, p = .92) (page 144), therefore this finding cannot be 
confirmed.  
 
This raised the question of whether younger men were receiving capecitabine 
as adjuvant treatment and therefore less likely to have delays or dose 
reductions to maintain dose intensity, leading to a higher incidence of toxicity. 
A chi square test applied to the variables age and gender combined and 
treatment intent achieved statistical significance association (p < .001) in both 
samples (pages 144 and 177). The question posed above was refuted since 
both age groups of men had a higher proportion receiving adjuvant treatment. 
In both samples there were higher proportions of younger women receiving 
capecitabine with palliative intent for breast cancer.  
 
Trials of older patients receiving capecitabine show that this can be 
administered to people over 70 years as long as they wish to receive 
aggressive therapy and accept the higher rate of toxicities (Feliu et al 2005, 
Diaz-Rubio et al 2007). There is some controversy over the role of renal 
function and drug dosage in the elderly with some (Cassidy et al 2002) 
suggesting that this should be taken into account for dose adjustments and 
others (Balducci & Extermann 2000) disagreeing. However, there appears to 
be consensus that drugs with overlapping toxicities should be avoided in 
these patients. Emerging evidence also suggests that the very elderly, i.e. 
aged over 80 yrs, appear to respond differently and should receive a dose 
reduction from the start of capecitabine therapy (Blum 1999, Reddy et al 
2007, Feliu et al 2010). The effect of age on the incidence of PPE is 
contradictory in the literature and replicated between the two samples in this 
current study. This may be due in part to the different proportions of each age 
group within study samples, the tumour type, ethnicity and other co-
morbidities or performance status that may not have been accounted for.  
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5.5  Ethnicity 
5.5.1 Incidence 
The incidence of PPE of any grade in non-white ethnic groups was 
appreciably higher (greater than 85%) than in the white skinned population in 
both samples in the current study. The incidence of PPE in white skinned 
participants differed between the samples, with 41 of 95 (43.1%) in the 
retrospective sample and 73 of 113 (27.4%) in the prospective sample. This 
difference can possibly be attributed to the fact that ethnicity was unknown in 
31.8% of the retrospective sample, with 58.33% of these participants 
developing PPE at any cycle. In a chi-square analysis, ethnicity confirmed the 
trend of non-whites having an increased risk of developing PPE at any cycle 
but did not achieve statistical significance in either sample (p = .07 and p = 
.72 respectively) (pages 140 and 168). While the increased incidence of PPE 
in the non-white population is interesting to note, firm conclusions cannot be 
drawn. This is due to the small numbers of non-white participants in the 
samples, and the reason that ethnicity was not included as a variable in the 
logistic regression model. Further research is warranted in order to examine 
more closely the role of ethnicity in the development of PPE.  
 
The majority of studies in the literature do not provide details on the ethnicity 
of the sample, and of those that do, few test any association between ethnic 
origin and toxicity. From the studies presented in appendix 5.1 on first 
reading, it would appear that there is similar variability in the incidence of PPE 
between countries in the western world and those in the far east. However, on 
closer inspection the incidence of PPE of any grade appears to be higher in 
studies carried out in Korea than in other countries. Firm conclusions cannot 
be drawn from this observation, since, it is based on the assumption that the 
samples in the Korean studies consisted of participants indigenous to that 
country, whereas, populations in many western countries may be more 
ethnically diverse.  Two studies (Hyodo et al 2006, Yun et al 2010) reported a 
higher incidence of PPE in Japanese and Korean patients (73% and 65.9% 
respectively), but a lower incidence of grade 3 PPE (13% and 10.4% 
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respectively) and found the tolerability of treatment to be similar to the 
western patient population. Lee et al (2008) also suggested that there is a 
lower incidence of grade 3 PPE in Asian patients (6-13%) compared with a 
multinational phase III trial (17%). Komamura et al (1995) suggest that the 
increased incidence of PPE in Japanese patients may be explained by the  
usage of G-CSF more frequently than other countries. In chapter 2 section 
2.7.4 (page 33) evidence was presented that pegylated G-CSF is associated 
with an increased incidence of PPE (Burnstein et al 2005, Bardia et al 2006, 
Lee & Lynch 2007). It is unclear in Komamura et al’s (1995) paper whether 
they are referring to pegylated G-CSF or nonpegylated G-CSF. 
 
A meta-analysis of 18 trials (1 UK, 1 multi-national and 16 china) comparing 
toxicities of capecitabine with infusional 5FU found an increased incidence of 
grade 3 PPE in both Caucasian [sic] and Asian patients taking capecitabine 
compared with 5FU, although this difference achieved a statistically significant 
association only in the Caucasian [sic] group (p = 0.005 and p = 0.06 
respectively) (Ma et al 2011). A word of caution in the interpretation of these 
findings was given, since the comparison was based on data from different 
trials for the two ethnic groups and would benefit from a larger international 
trial. In another retrospective study of three phase III trials by Haller et al 
(2008) a comparison was made of the incidence of toxicities between USA 
populations and non-USA populations, split into east Asia and the rest of the 
world. However, specific details of ethnicity were not provided. The study 
found that the incidence of any grade 3/4 toxicity was higher in the USA than 
the non-USA samples, with the lowest incidence in the east Asian group. This 
supports previous studies demonstrating a lower incidence of grade 3 PPE in 
non-Caucasian [sic] populations. However, the overall incidence was not 
provided making it unclear whether the east Asian group had a higher or 
lower incidence of PPE of any grade to allow comparison with the other 
studies. Haller et al (2008) suggested that regional variations may be due to 
ethnic factors such as, genetics, physiological or pathological conditions, 
cultural factors such as diet, or different trial methodology.  
 




A phenomenon linked to ethnicity, that appears to be gaining interest, is the 
different presentation that is seen in dark skin. Although the country where 
studies were carried out can be identified, the lack of data on the ethnicity of 
the samples developing PPE is a weakness of the literature. Most examples 
have been single or series case studies and describe hyperpigmentation of 
the skin on the hands and feet. Sometimes this hyperpigmentation presented 
with an odd distribution appearing on the dorsum of the hands particularly 
over the knuckles and in the creases of the palms. Many also developed 
keratoderma-like thickening of the skin (Narasimhan et al 2004, Lee et al 
2007, Saif & Elfiky 2007a, Vasudevan 2010 & Akash & Bhounsule 2011).  It 
has been suggested that hyperpigmentation may be a different entity to PPE 
(Vasudevan 2010) and that the grading of PPE be adapted to include 
hyperpigmentation in grade 1 and keratoderma-like thickening in grade 2 (Lee 
et al 2007, Saif 2011) (Table 5.1). 
 
Grade Manifestations of PPE in white 
patients 
Manifestations of PPE in non-white 
patients 
1 Minimal skin changes or dermatitis 
(e.g., erythema) without pain     
  
Hyperpigmentation of palms and soles 
without pain 
2 Skin changes (e.g., peeling, blisters, 
bleeding, oedema) or pain, not 
interfering with function   
Thickening of skin of palms and soles 
with pain and no loss of function 
3 Ulcerative dermatitis or skin changes 
with pain interfering with function 
Ulceration, dermatitis or desquamation 
(with pain interfering with function) 
Table 5-1 New staging proposed by Saif (2011 p164) in non-white 
patients 
 
In the current study darkening of the palms was seen in those of Indian or 
Philippino origin (8 participants) who developed PPE with one female also 
revealing a similar hyperpigmentation of the tongue, comparable to the one 
reported by Vasudevan (2010). Chapter 4 section 4.4.1.3 (page 64) described 
one case to support the different presenting features of PPE in participants 
with dark skin. This hyperpigmentation was clearly evident in the creases of 
the palms and fingers with blistering on some of the finger tips. 




It would appear that ethnic variation may influence the overall incidence of 
PPE. On the other hand, severe PPE does not appear to be as much of a 
problem in the non-white population compared with white skinned people. 
There is some uncertainty concerning the grading of PPE in people with dark 
skin or if indeed the hyperpigmentation is a separate entity unique to these 
populations. Larger scale studies would be required to confirm any link 
between ethnicity and PPE and to exclude other factors. 
 
5.6  Past Medical History 
The risk of developing PPE in the presence of other co-morbidities, past 
illness or previous treatment has not been analysed in any large scale studies 
and only a few single case reports suggest any association. 
 
5.6.1 Peripheral vascular disease 
 
The single case from the current study reported in chapter 4 page 171-172 
appears to be the first case reported anywhere in the literature of PPE 
possibly due to peripheral vascular impairment as a result of Reynaud’s 
Disease. PPE developed early (grade 1 after cycle 1 and grade 3 during cycle 
2) despite a dose reduction on commencement of capecitabine.  It 
demonstrates the need for careful assessment and monitoring of patients 
taking capecitabine since this participant did not contact the hospital when he 
started to show worsening signs of PPE. Whilst his Reynauds disease 
appears to be a plausible risk factor for PPE, other factors may also have 
contributed, such as a synergistic effect of methotrexate, alcohol 
consumption, and regular activities that exposed his hands to heat and 
friction. Statistical analysis of data in the current study showed no significant 
association between PPE and peripheral vascular disease. However, in the 
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retrospective sample there were insufficient numbers to produce reliable 
results. 
 
5.6.2 Previous chemotherapy treatment 
There is some evidence to suggest that people who had developed PPE with 
previous chemotherapy treatment have a recurrence with subsequent 
treatment with PPE inducing chemotherapy (Chiara et al 1997). This is 
supported by the findings in the current study of capecitabine monotherapy 
However, the association only achieved significance in the retrospective 
sample p = .04 (page 138). With such small numbers (only 6 had developed 
PPE with previous chemotherapy regimes, with 5 developing PPE with 
capecitabine), and with the limitations of retrospective sampling this result 
may not be reliable. Conversely Fabian et al (1990) found that 10 (71%) of 
previously untreated patient developed moderate to severe PPE compared 
with 3 (27%) of previously treated patients. They suggested that this may be 
due to longer total infusion time (continuous infusion of 5FU) in the former 
group 7.3 months versus 4.5 months. Their findings were however based on 
small numbers and would need confirming in a large study. 
 
Heo et al (2004) reported a significant association between docetaxel induced 
nail toxicity and PPE. One case from the prospective sample reported in 
chapter 4, who although did not develop PPE, demonstrated how nail loss 
following previous chemotherapy with docetaxel may not resolve when 
commenced on capecitabine.  
 
5.6.3 Diabetes 
Two case reports in the literature have mentioned diabetes and PPE. One 
(Narasimhan et al 2004) reported a black [sic] patient with diabetes who 
developed grade 3 PPE, which resulted in amputation and concluded that this 
group of patients may be more at risk of severe PPE. However, this 
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suggestion is based on a single case of a patient who had already had a 
previous amputation due to his diabetes. No assumptions can be made and 
begs the questions whether the diabetes or ethnicity were predictive factors or 
indeed the combination of the two. The second report was of a 71 year old 
white male with type II diabetes who, following his fourth cycle of 
capecitabine, was referred to a burns unit with severe blistering of lesions on 
the palms of his hands and soles of his feet, which healed within 7 days with 
treatment and discontinuing capecitabine (Goutos et al 2009). No suggestion 
was made in this article that diabetes was linked to the development of PPE 
and is therefore an area where further evidence is required to confirm or 
refute any significant link between diabetes and the risk of developing PPE. It 
is probable that it is not diabetes per se that is a risk factor, rather the 
consequences of this co-morbidity such as cardiovascular disease and 
neuropathy, which may prevent the patient from recognising the early signs of 
PPE.   
 
In this current study only 18 out of a sample of 150 were reported to have a 
history of diabetes in the retrospective sample. Similarly 17 out of a sample of 
125 in the prospective sample had diabetes. No association between diabetes 
and PPE was observed in either sample (p = .93 and p = .11 respectively) 
(pages 140 and 168). The variable diabetes in the prospective sample met the 
relaxed alpha level (p < .25) for inclusion in the logistic regression model. This 
was removed according to the algorithm described in chapter 3 and therefore 
was not included in the final model. 
  
5.6.4 Inflammatory diseases 
A significant association between PPE and other inflammatory diseases such 
as rheumatoid arthritis or asthma (p = .05) was found in the prospective 
sample of the current study (page 169). This variable was subsequently 
included in the multivariate logistic regression model. Participants with a pre-
existing inflammatory condition were almost three times more likely to develop 
PPE than those who did not suffer from any inflammatory conditions (pages 
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184-185). The hypothesis that people with a predisposition towards 
inflammatory diseases would also be more prone to developing PPE is 
supported by the suggestion that PPE is thought to be caused by an 
inflammatory response. However this finding would need to be tested in a 
larger sample that the one in the current study. 
 
As previously alluded to in chapter 2, Palmar Plantar Keratoderma (PPK) is 
associated with pre-existing inflammatory conditions. PPK becomes 
progressively worse when signs of PPE are seen (Do & Kim 2001). 
Keratoderma has also been suggested as a presenting feature of PPE in non-
white patients (Narasimhan et al 2004, Schellens et al 2005, Hood and Reeck 
2006, Saif & Elfiky 2007). This appears to lend support to the findings in the 
current study that there is an association between the presence of 
inflammatory conditions and the development of PPE. 
 
The link between peripheral vascular or sensory insufficiency and the 
increased risk of PPE points to the need for careful history taking to identify 
patients with compromised peripheral and autonomous nervous system. 
Regular monitoring and patient education is needed to avoid an 
underestimation of severe PPE in these patients. 
 
5.7  Performance status 
Performance status provides an indication of the patients’ functional ability in 
relation to everyday activities, and can be used to assess a patient’s response 
to treatment and the impact of disease. There are two scales that are 
commonly used the Eastern Co-operative Oncology Group (ECOG) (Oken et 
al 1982) (sometimes also known as WHO or Zubrod) & Karnofsky (Karnofsky 
and Burchenal 1949) (Appendix 2.1).  
 
Unlike other toxicities, PPE has been reported to have a higher incidence in 
patients with good performance status receiving 5FU (Chiara et al 1997, 
Meta-analysis group 1998, Abushullaih et al 2002). Conversely Comandone 
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et al (1993) and Heo et al (2004) found no association between performance 
status and PPE. The current study supports a statistically significant 
association between the development of PPE at any cycle or prior to cycle 4 
and performance status 0 or 1 (ECOG) but only in the prospective sample (p 
= .04) (page 170). In the retrospective sample there were 58 missing cases 
and less than 5 cases in more than one cell in the chi-square test, questioning 
the reliability of the finding. Performance status was included in the 
multivariate regression (page 184) as a variable from the prospective data 
and while non-significant when combined with other variables, it remained in 
the model as a confounder, since it affected a change in another variable, 
alcohol, when removed (see chapter 3 pages 69-70 for details on selection of 
variables for the logistic regression model). Neither of the two studies (Chiara 
et al 1997, Abushullaih et al 2002) performed a multivariate analysis although 
Abushullaih et al (2002) did provide a rationale for not carrying this out, which 
was the small numbers in each category. 
 
One might consider that this association between performance status and 
PPE could be attributed to dose, in that those with poor performance status 
may receive a reduced dose or have more delays in treatment. However, this 
detail was not provided in either study to enable these conclusions to be 
drawn. A chi square test applied to the two samples in the current study to 
test for any association between performance status and dose reduction at 
the start of treatment showed no association p = .75 in the retrospective 
sample (page 144) and p = .06 in the prospective sample (page 177), thereby 
refuting the notion above. If it is true that PPE can be a result of trauma and 
friction then it would seem logical that people with a good performance status 
are more likely to develop it, since, they are more likely to be engaged in 
activities that cause the trauma or friction. This is a personal opinion and is 
unsubstantiated in the literature. 
 
Since the removal of performance status from the logistic regression model 
affected a change in the variable alcohol, chi-square was applied to test any 
association between these two variables. This showed that those with a good 
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performance status were more likely to drink alcohol regularly than those with 
poor performance status, although this association did not achieve 
significance p = .23. 
 
Although there are contradictory findings in the literature concerning any 
association between performance status and the development of PPE, there 
were no studies identified that tested this association in patients receiving 
capecitabine monotherapy. The findings in the current study may be the first 
report of such an association, and while firm conclusions cannot be drawn 
from the retrospective sample due to the number of missing cases, the fact 
that the association was confirmed in the prospective sample adds support to 
this relationship. Further work may explore how PPE affects quality of life in 
those with good performance status compared with those with poor 
performance status to ascertain if performance status is an important factor to 
consider in the management of PPE.  
 
5.8  Hormones and breast cancer 
An analysis of hormone status in both samples in this current study revealed 
insufficient numbers to draw any conclusions in the retrospective sample. In 
the prospective sample there was a significant association between oestrogen 
receptor positive tumours and the development of PPE (p = .007) (page 178) 
but no difference in progesterone receptor status (page 176). These findings 
are contradictory to those in Kurt et al (2006) study, who found a significant 
association between progesterone positive tumours and PPE. These 
opposing findings may be due to the different characteristics of the sample, 
particularly ethnicity, with Kurt et al’s (2006) study based on a sample of 94 
women in Turkey. The prospective sample in this current study was based on 
a sample of 44 women in England. Details of the ethnicity of Kurt et al’s 
(2006) sample were not provided therefore it would be a assumption to 
deduce that the majority were Turkish. Of the 44 women from England in this 
current study 40 (91%) were white. 
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5.9  Nutritional deficits and weight 
A risk factor identified in the literature which could include both drug and 
patient factors is the role that malnutrition plays in the development of PPE. 
Particular factors that have been implicated are albumin or folate levels, 
weight loss and body mass index. 
 
5.9.1 Albumin bilirubin and folate 
Many drugs are bound to albumin as a carriage mechanism and any reduction 
in the serum albumin level, or raised level of other molecules which are 
protein bound e.g. bilirubin, may result in an increased level of circulating drug 
and therefore greater risk of toxicity (Jansman et al 2000). It was for this 
reason that albumin and bilirubin levels were analysed as part of the current 
study. Independent t-test applied to the data demonstrated a statistically 
significant association between pre-treatment serum albumin levels and the 
development of PPE in the retrospective sample (p = .009) (page 149), 
though this association was not replicated in the prospective sample (p = .09) 
(page 182). This variable was then entered into a regression analysis and in 
both samples, it failed to achieve statistical significance. Similarly pre-
treatment bilirubin levels demonstrated a statistically significant association 
with the development of PPE only in the retrospective sample (p = .009) (page 
149), although interestingly, participants with a raised bilirubin level were less 
likely to develop PPE. These findings indicate that in this study the hypothesis 
that pre-treatment serum albumin or bilirubin levels have an influence on the 
development of PPE cannot be supported. 
 
One dietary constituent, folate, has been linked to the incidence of toxicities. 
Raised folate levels prior to commencing treatment showed an increased 
incidence of capecitabine-induced toxicity during the first cycle and over the 
whole treatment period (Hurria & Lichtman 2008).  
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Careful questioning of the patient prior to commencing treatment on the use of 
supplements bought over the counter or concurrent folic acid administration is 
required to identify this potential synergistic effect. Folate levels were not 
collected during either the retrospective or prospective parts of the current 
study, and may be an interesting factor to analyse in future work. 
 
5.9.2 Weight loss 
An increased incidence of PPE has been seen in patients who had lost weight 
prior to a diagnosis of cancer, similarly these patients were more likely to 
develop severe PPE (Andreyev et al 1998). Weight loss cross-tabulated with 
PPE in the two samples in the current study revealed no statistically 
significant association between these two variables (p = .41 retrospective 
sample, p = .59 prospective sample) (pages 140 and 168). In the 
retrospective sample weight loss was not recorded in the majority of cases 
(108 out of 151) and similar to other studies, weight loss was subjectively 
reported by patients. Future studies would benefit from analysing the 
influence of the percentage of weight lost prior to treatment on the 
development of toxicities which may help clinicians in deciding the appropriate 
dose of chemotherapy for people who have lost weight, rather than an 
arbitrary reduction in starting dose.  
 
5.9.3 Body Mass Index (BMI) and Body Surface Area (BSA) 
Sparreboom et al (2007) evaluated data from studies of eight different 
chemotherapy drugs comparing BMI > 30 with BMI < 25 (WHO definition of 
obesity 2008) and found no evidence to support the practice of reducing or 
capping the dose (at 2.0m2) in obese patients There are several physiological 
changes that occur in overweight individuals that may affect the way drugs 
are processed by the body. These include, alterations in lean body mass, 
adipose tissue mass, organ size, blood volume and cardiac output. However, 
prospective pharmacokinetic studies are required to demonstrate whether 
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increased body weight is a risk factor for toxicities from chemotherapy agents 
(Baker et al 1995, Jansman et al 2000).  
 
Individual patient chemotherapy doses are based on calculated body surface 
area (BSA). An independent samples t-test was applied to BSA in the current 
study and revealed no association between BSA and the development of PPE 
(p = .56 retrospective sample and p = .09 prospective sample). Logistic 
regression showed that for every unit increase in BSA the risk of developing 
PPE increased, but once again failed to achieve significance. Although these 
findings indicate a trend towards a higher BSA increasing the risk of 
developing PPE, since they did not achieve statistical significance, no firm 
conclusions can be drawn. 
 
Alternative suggestions to BSA include a fixed dose for all sizes, however, this 
showed wide variations in drug exposure and toxicity and those with a low 
BSA were particularly vulnerable to an increase in toxicity. This suggestion 
was refined to recommending fixed dose for BSA clusters ≤ 1.65m2; 1.66 – 
2.04m2 and ≥ 2.05m2, which needs testing in clinical trials (Loos et al 2006). 
There is also a growing body of evidence that lack of chemotherapy-induced 
toxicity is associated with a worse outcome in terms of time to disease 
progression and overall survival. Toxicity-adjusted dosing is suggested as a 
way to provide individualised treatment schedules (Gurney 2005 & 2006). 
Indeed Hénin et al (2009) agree with this suggestion and are currently 
developing a dose-toxicity model specifically to attempt to reduce the duration 
of grade 2/3 PPE and maintain patients on capecitabine. 
 
There have been few studies investigating the effects of obesity on anticancer 
drugs (Baker et al 1995). Gordinier et al (2006) tested any difference between 
BMI and PPE in a retrospective analysis of patients records over 7 years (n = 
103) and found that there was no significant difference between those that 
had PPE and those that did not. This finding was replicated by Tanyi et al 
(2009) in a study of 330 patients, thus suggesting that Body Mass Index (BMI) 
is not a risk factor for PPE in patients receiving pegylated liposomal 
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doxorubicin. No similar analysis was found in studies of capecitabine. In the 
current study no significant association was found in either sample in a 
bivariate independent samples t-test (retrospective sample p = .73 and 
prospective sample p = .07) (pages 149 and 182). Regression analysis was 
applied to BMI and PPE and showed a trend that for every unit increase in 
BMI the risk of PPE increased, though only confirmed statistically in the 
prospective sample (OR = 1.09, p = .05). In the prospective sample BMI was 
included in the purposeful entry and retention multivariate regression model. 
BMI achieved significance p < .1 in combination with other variables entered 
and reduced in the model as detailed in chapter 3 and remained significant at 
p = .04 (pages 185). Since BMI demonstrated no significant association in the 
bivariate analysis this would show support for the findings in the studies by 
Gordinier et al (2006) and Tanyi et al (2009). However, when in combination 
with other variables it did affect the chances of developing PPE. It is unclear 
whether age or pre-treatment creatinine clearance (CrCl) levels, also included 
in the final model, in combination with BMI caused this effect. The rationale for 
this notion is that BMI generally decreases with age and age and weight are 
factors used to calculate creatinine clearance. A multicollinearity diagnostics 
test applied to BMI and age and BMI and CrCl showed no high correlation 
between them. A linear regression applied to BMI and CrCl showed a 
statistically significant association p < .0001 suggesting that it is probable that 
CrCl in combination with BMI are predictors for the development of PPE. 
 
5.10  Renal function 
It is well established that renal impairment is a risk factor associated with 
severe toxicities of capecitabine. 
 
However, creatinine clearance calculated using the Cockroft-Gault formula 
has been criticized for its lack of precision and accuracy in that the dose 
reductions recommended by the manufacturers of capecitabine based on 
CrCl discriminates against individuals with lower weight, older age and raised 
serum creatinine, the variables used to calculate CrCl with this formula. The 
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other factor used in this formula is gender, for which it reduces the CrCl by 
15% in females, which may result in smaller women being under-dosed 
compared to larger men (Ratain 2002). Baracskay et al (1997) also supports 
the opinion that this mathematical formula to calculate CrCl in the elderly does 
not give accurate results since serum creatinine may remain normal as renal 
function declines with age.  
 
During the data collection phase of the current study, observations suggested 
that among the participants receiving capecitabine monotherapy, those with a 
CrCl between 50-80mls/min appeared to develop PPE more frequently.    
Tests were applied to CrCl at baseline to ascertain any influence on the 
development of PPE at any cycle and any grade, and PPE development 
within the first 3 cycles of capecitabine monotherapy. Logistic regression 
applied to the retrospective data, PPE at any cycle or grade and CrCl, 
identified that for every point increase in CrCl the risk of developing PPE 
decreases (OR = .99, 95% CI .99-1.01). The same result was found when 
applied to PPE developing within the first three cycles of treatment.  
 
CrCl was categorized using the same parameters described by Poole et al 
(2002); 
Normal renal function = > 80.01 mls/min 
Mild renal impairment = 50.01-80 mls/min 
Moderate renal impairment = 30-50 mls/min 
 
Logistic regression was repeated using these categories (page 146), with the 
findings from the retrospective sample showing that participants with mild 
renal impairment were twice as likely to develop PPE at both any cycle (OR = 
2.10) and within the first 3 cycles (OR = 1.77) than those with moderate renal 
impairment. This finding is perhaps not surprising since a 25% dose reduction 
is recommended for a CrCl of 30-50mls/min, which may reduce the risk of 
developing PPE and other toxicities. The logistic regression also showed that 
participants with mild renal failure were almost twice as likely to develop PPE 
at any cycle (OR = 1.78) and within the first 3 cycles (OR 1.93) than those 
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with normal renal function confirming the personal observation mentioned 
above.  
 
Poole et al (2002) found that people with mild renal impairment and those with 
normal renal function had a similar probability of developing grade 3 or 4 
adverse events from capecitabine. Of the 29 participants in the retrospective 
sample of the current study who developed grade 3 PPE, 15 had a base line 
CrCl between 50.01 and 80.00 and 14 had a CrCl greater than 80.00, thus 
agreeing with Poole et al’s (2002) findings of similar patterns of grade 3 
toxicity between the groups. A Chi-square test applied to the retrospective 
data confirmed the lack of statistical significance between baseline CrCl and 
grade 3 PPE (p = .64) (page 145). When the prospective data from the current 
study were examined, 15 participants had grade 3 PPE. Of these 15, 10 had a 
baseline CrCl between 50.01 and 80.00 and 4 had a CrCl greater than 80.00 
A Chi-square test showed a statistical difference between baseline CrCl and 
grade 3 PPE X 2 (6, n = 125) = 14.40 p = .03 with a medium to large effect phi 
= .34 (page 179). A logistic regression test was not subsequently applied to 
baseline CrCl (collapsed into the 3 groups) and PPE from the prospective 
sample, since there were very small numbers in one category. Pre-treatment 
CrCl, in the prospective sample, showed no statistically significant association 
with the development of PPE (p = .22) in a bivariate independent samples t-
test (page 182). However, this alpha value met the criteria for inclusion into 
the logistic regression model and in conjunction with the other variables 
achieved significance (p = .07) and remained in the final model (page 185). It 
is possible that the presence of age and BMI as other variables in the same 
model may have affected the behaviour of CrCl in the model, since both are 
used to calculate CrCl as already stated above. However, multi-collinearity 
diagnostics did not reveal a high correlation between these variables. 
 
From the findings of the current study and from studies reviewed in the 
literature, the role of CrCl as a predictor of PPE seems well established. 
Although the manufacturers recommend a dose reduction for patients with 
moderate renal failure, there are no recommendations for those with mild 
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renal failure. Although there are similarities between the incidence of grade 3 
PPE in those with normal renal function and mild impairment, the overall 
incidence of PPE was higher in those with mild renal failure. This would need 
confirming in large scale studies, it is a factor worth considering when 
monitoring patients receiving capecitabine.  
 
5.11  Patient activities 
As identified in chapter 2, many authors (Baer et al 1985, Vukelja et al 1989, 
Arias et al 1997, Mrozek-Orlowski & Sanborn 1999, Lassere & Hoff 2004) 
make reference to the increased risk of PPE when there is increased 
vascularisation of the hands and feet caused by increased temperature, 
pressure, friction and long-term alcohol intake. These studies suggest that 
educating patients to avoid activities that cause these, to reduce their risk of 
developing PPE is needed. There appears to be consensus based on 
anecdotal evidence, and case reports, since studies providing any statistical 
analysis of these risk factors could not be found during the search of the 
literature. This is supported by Gualandi et al (2009) who carried out a search 
of the literature up to May 2008 to examine scientific evidence for non-
pharmacological management of side effects of chemotherapy. They found no 
scientific evidence (using the levels of evidence from the Oxford Centre for 
evidence-based medicine) for any non-pharmacological management of PPE.  
 
The findings in the current study are discussed below in the context of those 
presented in the literature. Since it was impossible to obtain data from the 
retrospective sample on these activities, with the exception of the season in 
which the treatment started and alcohol intake, the findings are from the 
prospective sample only.  
 




The body has a temperature gradient from trunk to extremities. Drug eruptions 
over distal surfaces may be attributed to the effect of temperature on antigen-
antibody reactions since the metabolites of a drug are recognised by the 
immune system as potential harmful antigens (Bhasin et al 2005).  
 
Participants were questioned on whether they had a tendency to have cool or 
warm hands and feet; if they wore socks and gloves to keep warm, and 
activities where they exposed their hands and feet to hot water such as hand 
washing crockery and cutlery or clothes and taking baths or showers that 
were as hot as they could stand. 
 
Participants who reported a tendency to have warm hands was significantly 
associated with PPE (p = .05) (page 170) whereas, warm feet did not achieve 
significance p = .09 (page 168). The alpha value for cool feet fell below the 
threshold (p < .25) for inclusion in the purposeful selection logistic regression 
model. It was not included, since a multi-collinearity diagnostic test revealed a 
high correlation between cool hands and feet. The association in the bivariate 
test of cool hands was confirmed in the logistic regression model showing a 2-
fold risk of PPE in those with warm hands compared to those with cool hands 
(OR = 1.95 p = .03) (page 186).  
 
Whilst the association between warm hands and the development of PPE 
appears initially to support the suggestion that temperature does influence the 
incidence of PPE, the results should be viewed with caution. There was no 
significant association between regular exposure to hot water and 
development of PPE p = .30 (page 168); the limitations of self reported 
measures; and a simple yes or no answer may make this finding difficult to 
replicate. It is a difficult factor to measure since it would change depending on 
the time of day and activities being undertaken. No scale measure was used 
to assess the immersion in hot water and future studies would need to include 
a more detailed measure of the frequency of immersion and possibly the 
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temperature of the water. Despite these limitations, this is an important finding 
since it is the first study to confirm that increased temperature is a risk factor 
for PPE.  
 
Some authors have suggested active cooling to reduce the risk of PPE. Baer 
et al (1985) suggests cooling measures during the period when peak drug 
levels are reached. Molpus et al (2004) evaluated the effect of regional 
cooling on the incidence of PPE caused by PLD, which consisted of ice packs 
applied to the wrists and ankles, and drinking iced liquids during the infusion 
of PLD and for 24 hours after completion of the infusion. They found a higher 
incidence of severe PPE in those who did not use regional cooling methods 
compared to those that did (67% versus 6%) p = .047, indicating that cooling 
may reduce the incidence of PPE induced by PLD. Conversely, Tanyi et al 
(2009) in a study of 330 patients receiving PLD for gynaecological cancers 
reported an incidence of PPE in 30.9% and tested for any association 
between active cooling and the development of PPE. The cooling regime 
consisted of the application of ice packs to the wrists and ankles during the 
infusion of PLD. They found an increased incidence of PPE in those who used 
cooling (48/123; 39%) compared to those that did not (54/207; 26%) p = .014 
which is a surprising finding since cooling is intended to prevent PPE. Both of 
these were retrospective studies and they stated that if cooling was not 
mentioned in the medical notes it was assumed that it was not used, which 
may have affected the results. Also in Molpus et al’s (2004) study the sample 
size was very small with 17 women using regional cooling measures and only 
3 who did not use these measures, thus bringing into question the reliability of 
the results. To date there have been no published studies on the affect of 
cooling on the incidence of PPE in patient receiving capecitabine 
monotherapy. Capecitabine is taken every day either for 14 days or 
continuously making active cooling difficult and could be unbearable for the 
individual. Education to avoid excessive exposure to heat may be more 
appropriate for patients receiving capecitabine. 
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Another area connected to temperature is the role of sweat in the 
development of PPE that has been studied in patients receiving PLD. A 62 
year old female with angiosarcoma had measurements of PLD or its 
metabolites taken using laser scanning microscopy, prior to treatment, then 
half hourly intervals up to 4.5 hours post infusion and at 24 hours. 
Measurements were taken from the forearms, palms, soles, axilla and 
forehead. There was no detection of PLD prior to treatment, but PLD was 
detected after 1 hour on the forehead and axilla confined to the furrows and 
sebum around hair. After 2 hours and lasting for 2-3.5 hours reducing in 
intensity PLD was detected on the palms and soles over the whole skin area, 
demonstrating that sweat and sebaceous glands may be a pathway for the 
release of PLD or its metabolites onto the skin (Jacobi et al 2004). A later 
study by the same lead author confirmed these findings, although again 
measurements were only taken on one patient (Jacobi et al 2005). 
 
In the current study, participants were questioned whether they had a 
tendency to sweat on their hands and/or feet. No statistically significant 
association was found between those who reported sweaty hands and/or feet 
and developed PPE and those that did not p = .89 (for both hands and feet) 
(page 168). The accuracy is difficult to determine as this was a self reported 
factor with no measurement of the frequency or amount of sweat produced. 
This is the first documented analysis of any association between sweating 
and the incidence of PPE in patients receiving capecitabine monotherapy. 
This finding indicates that capecitabine is not carried to the surface of the skin 
by sweat in the same way as PLD, therefore refuting the theory suggested in 
the literature by Gressett et al (2006). 
 
The time of year and the external temperature could also affect the 
temperature exposure to the hands and feet and subsequent sweating. To 
examine the influence of the time of year on the development of PPE, initially 
the month during which the treatment was started was cross-tabulated with 
PPE. However, with only small numbers in some months the results would be 
questionable. This variable was then collapsed into the four quarters of the 
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year (January – March; April – June; July – September and October – 
December), but again there were still too few in some cells to be able to trust 
the results. Finally, this was collapsed into two categories; Summer and 
Winter, with April – September classed as summer and the rest as winter. The 
rationale for examining the influence of the time of year was that since the 
temperature is generally higher in the summer, one would assume that the 
incidence would be higher during this season.  
 
The effects of the season in which treatment started may differ from year to 
year depending on whether we have a hot summer or very cold winter. This 
may partly explain the contradictory findings between the retrospective data 
and the prospective data. An association (p = 0.2) was found in the 
retrospective sample, with those commencing their treatment in the winter 
more likely to develop PPE (page 139). Conversely, in the prospective sample 
those who commenced their treatment in the summer were more likely to 
develop PPE but did not achieve significance (p = .48) (page 168). The 
season in which treatment commenced was included in the multivariate 
regression model applied to the retrospective data. This revealed that those 
who started their treatment in the winter were just over 2.5 times more likely to 
develop PPE than those who started in the summer (OR = 2.75; p = .02) 
(page 152). The latter finding disproves the assumption made above and 
following consideration would appear rational. In normal circumstances during 
the summer months active measures are taken to cool down, while in the 
winter months active measures are taken to keep warm, for example, by 
wearing socks and gloves, taking hotter baths or showers, having the heating 
higher in the house and warming hands on hot drinks by encircling the cup or 
mug.  
 
Suggestions have been made that PPE is more common in the summer 
because of the theory that PPE is caused by the elimination of capecitabine 
via the eccrine glands of which large numbers are found on the hands and 
feet (Mrozek-Orlowski et al 1999). However, changes to the skin, making it 
more sensitive to damage are more likely in the winter (Son et al 2009). There 
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is often less humidity in the winter coupled with the low humidity of indoor 
heating resulting in drying of the skin (winter xerosis) which becomes more 
vulnerable to flaking or cracking at the finger tips (Harvard Health Publications 
2012). It would therefore seem logical to have an increased risk of PPE in the 
winter.  
 
There are few studies that have tested any association between PPE and the 
time of year in which treatment is administered. In a retrospective review of 
330 patients notes Tanyi et al (2009) found no association between the 
season in which the first dose of PLD was administered and the development 
of PPE, with 22% in the summer versus 28% at other times of the year p = 
.21. The authors did not state their definition of summer months. In a 
Japanese study of 47 patients receiving capecitabine for colorectal cancer 
grade 2 or 3 PPE was seen in 10 patients (21.7%). However this incidence 
increased to 15 (32.6%); 5 of these were cherry farmers with the increase in 
incidence attributed to friction of the hands and legs thus supporting the 
investigation of patient activities as important factors to predict the 
development of PPE (Suto et al 2010). Although the assumption made in that 
study was that the increased incidence was due to friction, it may not be 
friction per se but may be associated with the combination of other factors 
such as higher temperatures of the summer. 
 
Another chemotherapy-induced phenomenon thought to be a consequence of 
PPE caused by capecitabine is onycholysis (detachment of the nail from the 
nail bed). One study reported onycholysis in 5 out of 21 patients who received 
more than 6 cycles of weekly paclitaxel. In all 5 patients it developed during 
the summer months (not defined) but was not seen in those who received less 
than 6 cycles of 3-weekly paclitaxel or doxorubicin. The authors stated that 
onycholysis is exclusive to anthracycline and taxanes and recommend 
protecting nails from sunlight (Hussain et al 2000). In opposition, in a second 
report of 36 patient receiving irinotecan/capecitabine, 2 patients developed 
onycholysis, however it developed during the winter (not defined) in covered 
toenails (Muñoz et al 2003). Personal experience has not been that 
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onycholysis in patients receiving capecitabine monotherapy is a common 
occurrence, with a more frequent appearance of paronychia in the great toe. 
Paronychia refers to an infection around the nail (US National Library of 
Medicine 2012a), and often results in a delay in treatment to allow healing to 
take place. Records have not been made of the true incidence and whether it 
is more prevalent at different times of the year. Figure 5.8 shows an example 
of a toe nail with a fungal infection seen in one participant after 5 cycles of 
capecitabine and who had developed grade 3 PPE prior to this which was 
resolving.  
 
Figure 5-8 Fungal infection of the great toe 
 
There have been a few reports of nail toxicity with capecitabine monotherapy 
including paronychia as well as onycholysis and onychomadesis, although 
seen in a minority of cases (Chen et al 2001 and 2003, Maino et al 2003, 
Vaccaro et al 2008). 
  
Contradictory findings have been found when examining any association 
between the time of year that treatment is received and the development of 
PPE. Findings have been based on small numbers or retrospectively collected 
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data. Large prospective studies are required to examine this association 
further. 
 
5.11.2 Sunburn and radiation recall 
In this current study no significant association was found in either sample 
between PPE and previous radiotherapy treatment (p = .48 retrospective 
sample, p = .33 prospective sample) (pages 140 and 168). This variable was 
not included in the initial logistic regression models. In the prospective sample 
when this variable was added to the final model (as described in chapter 3) it 
became significant p = .04 and remained in the model as a confounder (page 
186). When in combination with other variables, participants who had not 
received radiotherapy previously were nearly three times more likely to 
develop PPE than those who had received previous radiotherapy (OR = 2.93; 
95% C.I 1.04 – 8.25) (page 186). 
 
Initial thoughts were that participants who had previously received 
radiotherapy were more likely to be prescribed capecitabine with palliative 
intent. They were therefore more likely to have a dose reduction due to mild to 
moderate toxicities than those receiving capecitabine with curative intent. 
Descriptive analysis demonstrated that 58.6% of the participants who had 
previously been treated with radiotherapy had breast cancer and 92.9% of 
these participants had received previous radiotherapy. Less than 25% had a 
dose reduction either at the start of their treatment or at any subsequent 
cycles, indicating there must be some other reason for this finding.  
 
Many cytotoxic agents sensitize the skin to sunlight making the patient more 
vulnerable to sunburn. Participants in the prospective sample of the current 
study were questioned on any history of sunburn in the past and their skin 
type, and were tested by cross tabulation to examine any association with the 
development of PPE. Of the 18 participants who had reported sunburn in the 
past, more developed PPE (13) than did not (5) but with no statistically 
significant association seen p = .49 (page 168). With such a small sample, the 
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dependence on recall from the past, and no degree of sunburn given, firm 
conclusions cannot be drawn about the relationship between sunburn or 
radiation exposure and the development of PPE. However, this is the first 
report of a study to examine any association between a history of sunburn 
and the development of PPE. Since there were small numbers in this study, a 
multi-centre study would recruit a larger sample to be able to establish 
whether an association exists. 
 
Due to small numbers of participants with some skin types, data were 
collapsed into two group (Type I & II and III-VI table 5.2) based on the 
definitions that types I and II have an increased risk of sunburn and therefore 
may have increased risk of PPE. This hypothesis was rejected since more 
type III-VI developed PPE (34) than types I and II (29) p = 1.0 although both 
groups of skin type had a higher incidence of participants who developed PPE 
than those who did not. 
 
SKIN TYPE 
Type I Often burns, rarely tans. Tends to have freckles, red or fair hair, blue or green eyes 
Type II Usually burns, sometimes tans. Tends to have light hair, blue or brown eyes 
Type III Sometimes burns, usually tans. Tends to have brown hair and eyes 
Type IV Rarely burns, often tans. Tends to have dark brown eyes and hair. 
Type V Naturally black-brown skin. Often has dark brown eyes and hair. 
Type VI Naturally black-brown skin. Usually has black-brown eyes and hair. 
Ref: Cancer Research UK. Sunsmart. www.cancerresearchuk [Accessed 14.10.08] 
Table 5-2 Skin type 
 
Of the 18 participants who stated they had been sunburnt in the recent past or 
when they were younger, some participants at the same time as developing 
PPE, developed non painful erythema over sites where they had been 
sunburnt in the past (3 participants), or over old scars and blemishes making 
them more prominent (3 participants). One participant developed erythema 
over a previous irradiated site and another developed erythema where a 
dressing was applied to a central venous catheter site, this effect also being 
reported by Zimmerman et al (1995). One of the 3 who developed erythema 
over previous sunburnt sites was an 83 year old man who had been 
diagnosed with Actinic Keratosis, also known as solar keratosis which 
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presents as small rough areas on skin exposed sun, usually the hands, face, 
scalp, back of hands and chest (US National Library of Medicine 2012b). 
These are precisely the areas where the erythema developed in this 
participant. He has also been diagnosed with Lentigo Maligna, a non-invasive 
melanoma which presents initially as blue/black in colour (US National Library 
of Medicine 2012c), although these lesions did not change during treatment. 
 
This occurrence appears akin to radiation recall dermatitis, the development 
which is similar to acute radiation reaction, of a previously irradiated area. 
This recall can be as a result of receiving certain drugs and has been reported 
with 5FU, although the cause and incidence are unknown (Camidge & Price 
2001). Zimmerman et al (1995) report two cases in patients receiving 
docetaxel. One patient developed erythema at a site of recently applied 
electrocardiograph (ECG) pads, and the other, erythema on the back of the 
neck and a V-shaped area on the chest, where previously exposed to the sun. 
Another case reported a 65 year old man taking capecitabine 1000mg twice a 
day who developed a rash over his upper trunk and arms after the second 
cycle which became worse after the third. He also developed PPE at the 
same time which also worsened at each cycle. On questioning he reported 
working in his garden bare-chested, although he wore a hat and applied 
sunscreen to his face (Peramiquel et al 2006). A final report by Markman et al 
(2004) described a female patient who received PLD for ovarian cancer and 
who became badly sunburnt (severe erythema without blistering) a few days 
before she was due to start cycle 2. Treatment was delayed for a week to 
allow the sunburn to resolve with the dose reduced by 25%. One week after 
the start of cycle 2, she developed severe redness, swelling and blistering of 
both hands and similar but less severe on both soles of the feet. With steroid 
creams and pyridoxine the PPE gradually resolved over a period of 5 weeks. 
These cases lend support to the notion of photo-recall phenomenon, and also 
highlight that skin almost recovered from injury, such as sunburn, is sensitive 
to further damage if exposed to another toxin. 
 




A case study (Vukelja et al 1989) reports a 63 year old man with metastatic 
pancreatic cancer who received bolus 5FU 900mg per week increased to 
1150mg per week. He developed severe PPE after 11 weeks of treatment but 
which was not felt to be due to drug accumulation. The patient had a history of 
alcohol abuse, however had recently stopped drinking. The PPE in this case 
was suggested to be similar to neuritis caused by isoniazid in chronic 
alcoholism as described by Goldman and Braman (1972) and Pellock et al 
(1985). Vukelja et al (1989) go on to suggest that patients with long term 
alcohol abuse should be commenced on pyridoxine at the outset of treatment 
to prevent or reduce the severity of PPE. 
 
In the current study, no association with the development of PPE was found in 
the bivariate analysis applied to each sample, between those that drank 
alcohol regularly and those that did not. In the retrospective sample 64 
(42.4%) had no mention of alcohol consumption in the notes and therefore 
were recorded as missing, leaving just 87 cases to analyse. It was unclear 
from the information available whether the intake of alcohol was regular or not 
in the 51 participants where this was recorded and therefore the limitations of 
a retrospective review can be applied. The remaining 36 participants were 
reported as not consuming alcohol or only occasionally. 
 
Participants in the prospective sample were questioned about their alcohol 
intake. However, it was difficult to record the actual number of units consumed 
in a week, since many merely responded “regularly” or “occasionally”. The 
findings revealed that of the 50 participants who drank alcohol regularly 36 
developed PPE compared with 14 who did not develop PPE, but did not 
achieve significance in the bivariate analysis p = .21 (page 168). Alcohol was 
included in the multivariate regression model which demonstrated that those 
who drank alcohol regularly were more likely to develop PPE than those who 
did not (OR = 2.18; p = .14) (page 185). Alcohol remained as a confounder, 
as it altered the beta value of other variables by more than 20% as described 
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in chapter 3. To test any association between gender, alcohol and PPE, cross 
tabulation of these variables was applied using only the participants who 
stated they drank alcohol regularly. This demonstrated that men who drank 
alcohol regularly were more likely to develop PPE than women who drank 
regularly, although the association did not achieve statistical significance p = 
.21. Another cross tabulation was applied to the development of PPE and 
alcohol consumption taking each gender individually. This showed that twice 
as many men who drank alcohol regularly developed PPE than those who did 
not drink regularly, whereas, the opposite was found for women. Twice as 
many women who did not drink regularly, developed PPE compared to those 
who drank regularly, but neither achieved statistical significance (p = .42 and 
p = .89 respectively) (page 180). 
 
Although these results were not significant it is interesting to note since an 
association between men and the development of PPE was shown in the 
retrospective sample. Thus it may be that male gender in combination with 
regular alcohol consumption increase the risk of developing PPE. 
 
5.11.4 Hobbies and activities causing friction 
Studies providing results from statistical analysis of patient factors, other than 
biographical and laboratory data, have not be found in the literature searched 
so far. Confirmation of the value of exploring this subject is supported by Von 
Moos et al (2008) in a review of PLD-associated PPE who also identified that 
there is currently no validated predictive model identifying the risk of 
developing PPE. 
 
Participants were questioned about activities such as regular walking, 
dancing, gardening, DIY, playing musical instruments, sewing, knitting, 
rubbing hands with moisturising cream regularly or any other activities that 
may cause friction to the hands or feet. No statistically significant association 
was found between those who developed PPE and those who did not and 
those who regularly performed activities that caused friction and those who 
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did not. The incidence of PPE was higher in both groups with 38/58 in the 
activity group and 25/43 in the non-activity group but no statistical association 
was found p = .58 (page 168).  
 
Moisturising the hands and feet regularly is recommended by the 
manufacturer to reduce the severity of PPE however, which emollient to use 
has not been established by scientific evidence. The very action of rubbing 
the cream into the hands and feet may cause the very friction that has been 
suggested to increase the risk of PPE. There were similar numbers of those 
who developed PPE and used hand cream regularly (33) and those who 
developed PPE but did not use hand cream (30) with no difference between 
the groups found p = 1.00 (page 168). While these findings would indicate that 
friction causing activities alone have no association with the development of 
PPE, no scale measurements were used. Yes/no was assigned based on 
personal judgement, which, although providing consistency in this study as 
the researcher was the sole data collector and analyser, would prove difficult 
for others to replicate.  
 
Participants were also asked whether they worked or not and the type of work 
they did. Initially the variable was coded with four categories, with insufficient 
numbers in each category to apply any statistical tests. When collapsed into 
three categories a cross tabulation revealed an association between the 
variables job3gps and the development of PPE p = .05. However, there were 
less than 5 cases in one of the cells and this variable could therefore not be 
included in a multivariate regression. Finally the data were collapsed into two 
categories (working and not working) and cross tabulation applied. When 
analysed using PPE development at any cycle an association was seen p = 
.04 with an increased incidence in those who were in employment. When 
analysed using PPE development prior to cycle 4 no association was seen p = 
.36 but still with a higher incidence of PPE in those who were working (page 
168). Table 5.3 shows the categories that this variable contained as it was 
collapsed from its original state. While firm conclusions cannot be drawn, in 
this exploratory study there is a trend to suggest that those who continue to 
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work while receiving capecitabine, regardless of whether it is manual or non-
manual labour, have an increased risk of developing PPE and is worth 
considering when advising patients on how to reduce the risk of developing 
PPE. 
 
Job Job3gps Job2gps 
Manual work 18 (14.7%) Manual work 18 (14.7%) Working 45 (36.9%) 
Non-manual work  
27 (22.2%) 
Non-manual work  
27 (22.2%) 
Not working 77 (63.1%) 
Retired 70 (57.4%) Not working 77 (63.1%)  
Unemployed 7 (5.7%)   
Table 5-3 Categories within the variable job and when collapsed 
 
This again is the first reported study examining any association between 
friction causing activities and the development of PPE. Since this indicates no 
association between activities and PPE, advising patients to avoid these has 
not evidence base. People who continue to work during treatment do however 
appear to have an increased risk of PPE. This would indicate that it may be 
the exposure of hands and feet to regular general activities that increase the 
risk. Advising patients receiving capecitabine to avoid activities or hobbies 
that they enjoy has no evidence base and may affect their psychological well-
being. A more sensible approach would be to advise those who develop early 
PPE to avoid these activities to prevent progression to more severe PPE. 
 
One variable that could possibly influence the participant’s ability to carry out 
friction causing activities would be their performance status, since it could be 
argued that those with a poorer performance status by its definition would be 
unable to carry out these activities on a regular basis, and would be less likely 
to be currently working. An investigation of any association between these 
activities and performance status did indeed reveal a statistically significant 
association p = .04 showing more participants assessed as performance 
status 0 engaged in friction causing activities (page 178). 
 
There have been no large scale studies to evaluate patient factors that cause 
increased temperature, trauma or friction to the hands and feet to test the 
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suggestions in the literature that these may increase the risk of developing 
PPE. Hence the lack of discussion in this section regarding these variables. 
The current study is the first of its kind to do so and although confirmed the 
link between temperature indicated by warm hands, the season in which the 
treatment started and PPE, it refuted others, i.e. temperature indicated by 
exposure to hot water, hyperhydrosis, regular alcohol intake and friction 
causing activities. This study also tested and demonstrated no association 
between previous sunburn, skin type or the regular use of hand cream and 
the development of PPE. Limitations of the data collection tools have been 
identified and would need to be addressed in future research. However, this 
does not detract from the usefulness of the findings from this first large scale 
study of patient factors and PPE and would indicate that these factors alone 
may not be predictive of PPE. It may be that in combination with other 
variables they are predictive, hence the rationale for performing multivariate 
regression analysis.  
 
5.12  Comparison of logistic regression models 
The rationale for the use of a purposeful entry model was provided in chapter 
3, and the ROC curve results demonstrated that there was little difference 
between the purposeful entry method and the automated entry methods. 
Despite this result the purposeful model may provide a richer one in terms of 
range of risk factors and it is for that reason that it will be discussed here.  
 
This is the first study to use this method to develop a model that predicts the 
development of capecitabine induced PPE particularly prior to cycle 4. 
Although, several studies have applied logistic regression to the data it has 
often been bivariate with only the occasional mention of multivariate analysis. 
Even then, the models did not include patient factors such as friction causing 
activities and exposure to high temperatures. 
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Table 5.4 provides a reminder of the variables that remained in the final 
purposeful entry and retention logistic regression models applied to the two 
samples in this study. 
 
Retrospective sample Prospective sample 
Absence of pre-existing inflammatory 
condition 
Commenced treatment during the winter 
Absence of metastases 
Pre treatment ALP value within normal limits 
Smoker 
Male gender (confounder) 
No regular alcohol (confounder) 
No weight loss prior to treatment (confounder) 
 
Presence of pre-existing inflammatory 
condition 




Pre treatment CrCl below normal limits 
particularly 50.01-80mls/min 
Drinking alcohol regularly (confounder) 
Good performance status (confounder) 
No previous radiotherapy treatment 
(confounder) 
Table 5-4 Final models of purposeful entry and retention logistic 
regression 
 
Comparisons between the final purposeful entry models from both samples 
revealed only one similarity. Participants whose tumour had not metastasised 
had an increased risk of developing PPE. There was also two contradictory 
findings between the two samples. In the retrospective sample, participants 
who did not have a history of inflammatory conditions had an increased risk of 
developing PPE. Conversely, in the prospective sample, those with a pre-
existing inflammatory condition had an increased risk. In the retrospective 
sample those who did not drink alcohol regularly had an increased risk of 
developing PPE. However, in the prospective sample, those who drank 
alcohol regularly had an increased risk. The remaining variables in the 
retrospective sample that were risk factors for PPE were not present in the 
prospective sample and vice versa. Therefore these findings could not be 
validated as risk factors for the development of PPE. Out of the additional 
variables in the prospective model that were not present in the retrospective 
model, 1 (warm hands) was not tested in the latter sample. 
 
The inclusion of age and BMI in the prospective model but not in the 
retrospective model may be due to type I error (where the null hypothesis is 
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rejected when it is in fact true) and may be as a result of the difference in 
numbers in each group. For example there was a difference in the age range 
between the two samples with a more equal number between those less than 
65 years and those 65 years or older in the prospective sample than in the 
retrospective sample (49.2% and 50.8% and 40.6% and 59.4% respectively). 
The addition of alcohol and performance status in the prospective sample 
may be due to the number of missing data in the retrospective sample for 
these two variables. It is not clear why the pre treatment ALP value was a risk 
factor for the development of PPE in the retrospective sample but not in the 
prospective one. Participants with breast cancer were more likely to have a 
raised ALP level due to the presence of bone metastases. There is a larger 
variation between numbers of participants with breast cancer and colorectal 
cancer in the two samples (30 and 110 in the retrospective sample vs 45 and 
70 in the prospective sample), this may partly explain the reason.    
 
Contradictions between the retrospective and prospective data were most 
likely not due to sample size. The prospective data are likely to be richer and 
more accurate, since they were directly collected from participants and there 
may have been under-reporting in the retrospective sample. Another 
explanation that these differences occurred by chance is a possibility. 
  
In the prospective model comparing the automated entry methods, there are 
differences in the odds ratios for alcohol and cool hands. This is probably 
because of the additional variables retained in the backward entry model. 
Thereby reflecting the influence exerted on these variables when in 
combination with the other variables. 
 
Two of the variables in the model from the prospective sample, metastatic 
spread and performance status were suspected as being clinically associated. 
A cross-tabulation of metastatic spread and performance status did indeed 
reveal an association (p = .04) showing as expected that those with poor 
performance status were more likely to have metastatic spread than those 
with good performance status. Based on this finding it was assumed that 
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there would be an increased likelihood of those with metastatic spread having 
a dose reduction of capecitabine, at the start of treatment or as a result of 
toxicities. Any association between performance status and a dose reduction 
prior to commencing treatment was discussed earlier, finding no association. 
Similarly when a chi-square test was applied to performance status and dose 
reduction due to toxicities of capecitabine no statistically significant 
association was found. The same tests applied to metastatic spread and dose 
reduction found a statistically significant association between participants with 
metastatic spread and a dose reduction at the start of treatment in the 
retrospective sample but not the prospective sample. Conversely, participants 
whose tumour had not metastasised were more likely to have a dose 
reduction due to PPE. There was no association between metastatic spread 
and a dose reduction due to other toxicities. As there was no association 
found between performance status and dose reduction, the former cannot be 
considered a confounder as was first thought. It is more difficult to state the 
same with metastatic spread and dose reduction since there are contradictory 
findings between the samples. If we believe the prospective data to be more 
reliable as previously stated, then the notion of metastatic spread being a 
confounding variable can also be refuted with both performance status and 
metastatic spread considered as risk factors of the development of PPE in 
patients receiving capecitabine.  
 
Conclusions that may be drawn from the multivariate logistic regression model 
applied to the prospective sample are that patients receiving capecitabine 
monotherapy are more likely to develop PPE, if they are less than 65 years 
old; have a good performance status and absence of metastatic spread; 
presence of a pre-existing inflammatory condition; have a tendency to have 
warm hands, drink alcohol regularly; are overweight or obese and have a pre 
treatment creatinine clearance level of 50.01-80.00 millilitres/minute. Having 
said this, further study would be required to categorise some of these 
variables more accurately, particularly, warm hands, units of alcohol 
consumed per week, and degree of excess weight. 
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5.13  Summary 
The aim of this exploratory study was to identify factors that may increase the 
risk of developing PPE, focusing on PPE prior to cycle 4 of capecitabine 
monotherapy therapy. Risk factors have been discussed. Comparing the 
findings from the retrospective (capecitabine monotherapy only) and 
prospective samples in this study with others in the literature has 
demonstrated that findings are comparable for some risk factors, while for 
others there is contradiction.  
 
In this study more than 50% of participants developed PPE of any grade, with 
more than three quarters of these developing PPE during the first three cycles 
of treatment. 59% of participants who developed PPE had grade 2 or 3 as 
their worst episode. As stated above PPE is more likely to occur in people 
who are less than 65 years old; with good performance status and absence of 
metastatic spread; presence of a pre existing inflammatory condition; have a 
tendency to have warm hands (and feet); drink alcohol regularly; are 
overweight or obese and have a pre treatment creatinine clearance level of 
50.01-80.00 millilitres/minute. These factors would seem reasonable given the 
evidence presented in the discussion in this chapter. Raising awareness 
through the dissemination of these findings will provide nurses with a basis on 
which to identify patients more at risk of developing PPE. Other factors to 
consider are hormone receptor status of women with breast cancer; ethnicity; 
time of year when treatment is given; employment; history of sunburn and 
presence of other capecitabine induced toxicities. In this study, women with 
oestrogen receptor positive tumours were more likely to develop PPE. 
Participants whose ethnicity was described as non-white were more likely to 
develop PPE and given the evidence that presentation of PPE differs in this 
population it is worthy of further study. Comparisons between the time of year 
that treatment is commenced and the development of PPE have not been 
studied in large samples. There were contradictory results between the two 
samples in this study, but this may have been due to under reporting of mild 
PPE in the retrospective sample.  




Participants who continue to work during treatment with capecitabine were 
more likely to develop PPE. This variable could be linked with performance 
status, since those with poor performance status were unlikely to be in 
employment. There were only a small number of participants who admitted to 
being sunburnt in the past. The link between previous sunburn and the 
recurrence of erythema at these sites would seem logical, since radiation 
recall is a known phenomenon with some chemotherapy agents. The 
association between previous sunburn and PPE is interesting and would 
warrant further exploration. Patients who developed capecitabine induced 
diarrhoea, mucositis or nausea and vomiting appear to develop PPE more 
frequently. Whether the development of these other toxicities increases the 
risk of PPE or whether the development of PPE increases the risk of 
developing the other toxicities is unclear. Further examination of this would be 
required to accurately record the onset of symptoms of these toxicities. 
Having said that, awareness of this association is useful to identify patients 
who may require increased monitoring to recognise early development of 
these toxicities and prompt management. This may avoid the development of 
severe toxicities which would result in delays in treatment. 
 
The individual case reports add to the body of knowledge on unusual features 
of PPE. The modelling algorithm used for selection and retention of variables 
in multivariate logistic regression and application of statistical tests to 
establish association between patient activities and the development of PPE 
are the distinct features that demonstrate the uniqueness of this study. The 
findings from this study demonstrate the impact of PPE on participants and 
the importance of thorough questioning and examination to identify PPE 
particularly its early occurrence, which may develop into a more severe form 
later.  
 
The following chapter will draw together the conclusions from the findings of 
this study, reflect on study design, identify the contribution to current 
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knowledge on capecitabine-induced PPE and recommend areas for future 
work. 
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CHAPTER  6 CONCLUSIONS AND RECOMMENDATIONS  
6.1  Introduction 
Although PPE is said to be rarely serious and never life-threatening, it can 
cause severe pain and interfere with everyday activities. There have, 
however, been reports of serious consequences of PPE, such as, increasing 
the risk of infection via breaks in the skin, which in some cases has led to 
amputation of a digit or limb. Interest in this toxicity of chemotherapy has 
increased, particularly since the introduction of more PPE-inducing agents 
into clinical practice. 
 
While there is sufficient evidence to show that the dose and schedule of 
capecitabine plays a large role in the development of PPE, the fact that many 
patients still go on to develop severe PPE following a dose reduction would 
indicate that there are other factors which influence the risk of developing 
PPE. 
 
Many studies have analysed biographical characteristics, such as age, gender 
and ethnicity to assess any association with the incidence of PPE. Other 
factors that have been explored as predictors of PPE are performance status, 
co-morbidities and renal function. The findings from these studies have been 
contradictory with the exception of renal function where there is agreement 
that a reduction in creatinine clearance increases the risk of developing PPE. 
 
No study has previously collected data to specifically assess the potential of 
patient activities as risk factors of PPE. The aim of this study was to identify 
factors, other than the drug itself that may influence the development of PPE. 
The statistical analysis focused on those who developed PPE within the first 3 
treatment cycles of capecitabine monotherapy. This was based on the 
assumption that PPE developing in later cycles is more likely to be due to 
accumulation of the drug.  




This chapter starts with a summary of the research and the key findings which 
answer the research questions. It presents the implications of these findings 
to nursing practice as well as the methodological implications, and the 
contribution it makes to the current body of knowledge. The chapter 
concludes by describing the limitations of the study and recommendations for 
future research. 
 
Risk factors that have previously been studied were analysed. In the majority 
of cases these were from clinical trials of the drug, to assess its effectiveness 
in terms of survival, in particular phase III trials. Only a few studies were 
specifically designed to explore the relationship between factors and the 
incidence of PPE. Factors that had been analysed in the literature included 
age, gender, ethnicity, performance status, nutritional deficits and weight loss, 
organ function, co-morbidities and genetics. These findings were often 
contradictory, with many based on small samples or case reports. All but 
genetics were included in the current study to enable comparison of the 
findings from this study with those in the literature. An examination of 
strategies employed to minimise the severity or to manage PPE demonstrated 
some interesting and promising potential agents requiring larger prospective 
randomised trials to confirm their effect on PPE. A review of the literature 
concluded that there is a lack of empirical evidence to support the advice 
given to patients to avoid certain activities that have been suggested as 
potential risks for developing PPE.  
 
The review of the literature influenced the focus of this study, in terms of the 
sample group and the data collection tools with two purposes in mind. Firstly 
to compare the findings from this study with those in other studies, adding to 
the growing knowledge of PPE and to support or refute those findings.   
Secondly to analyse risk factors previously based on consensus but 
unsubstantiated by empirical evidence. 
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Chapter 3 provides detail of the methods utilised to collect and analyse the 
data and the rationale for the selection of the algorithm used in the modelling 
process. Chapters 4 and 5 presented the analysis and discussions of the 
findings in response to the research questions. The next section answers the 
research questions summarising the findings.   
 
6.2  Answering the research questions 
This section discusses the responses to the two questions this study set out 
to answer. The responses will be taken from the prospective analysis of 
participants receiving capecitabine monotherapy to reflect the refined study 
aim. The prospective data are likely to be richer and more accurate since they 
were directly collected from participants and there may have been under-
reporting in the retrospective sample in addition to the large number of 
missing data in some variables in the latter sample. A brief summary to 
compare findings from the retrospective sample and the prospective sample 
will be included to show where similarities exist. 
 
1. Can risk factors be identified to predict the development of PPE? 
 
In order to answer this question the study formulated a number of hypotheses 
to be tested. There were 31 hypotheses tested in both samples (one for each 
variable) details of which can be found in chapter 3. 
  
The bivariate analysis examined any association between other capecitabine-
induced toxicities which revealed that participants who developed mucositis or 
nausea and/or vomiting were more likely to develop PPE than those who did 
not develop these other toxicities. No association was seen between 
diarrhoea, fatigue or a rash and PPE.  
 
Biographical data which included age, gender and ethnicity found that age 
alone showed no association, but when age was broken down into two groups 
(≤ 64 and ≥ 65) an increased risk of PPE of any grade was seen in the < 65 
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age group, but no difference between the age groups for severe PPE. While 
men were more likely to develop PPE than women in this sample it was not 
confirmed statistically. When age and gender were combined, younger men 
had an increased risk of PPE possibly explained by the fact that older men 
were more likely to commence treatment on a reduced dose than younger 
men. Ethnicity revealed an increased risk of PPE in the non-white population. 
This was an interesting finding and although the small numbers of non-white 
participants meant that no firm conclusions could be drawn, it is worthy of 
further attention. 
 
No association was found between the variables related to social history and 
the development of PPE. These included marital and employment status, 
smoking and alcohol consumption. These factors were examined based on 
the notion that those who lived alone or worked would be undertaking more 
activities that expose the hands and feet to high temperature and friction. The 
incidence of PPE as expected was higher in those who did work than in those 
who did not work. Smoking and alcohol both have an effect on vascularisation 
and although neither achieved significance in the bivariate analysis, alcohol 
was included in the regression model since it met the criteria for inclusion and 
remained in the final model as a confounder. 
 
Co-morbidities have been reported in the literature as linked to the 
development of PPE. Data were collected on those co-morbidities that had 
been linked to PPE, namely, diabetes and peripheral vascular disease (PVD). 
Others were included because of possible clinical relevance. The presence of 
peripheral neuropathy (PN) would reduce sensation which would prevent the 
patient from recognising early signs of PPE. Since PPE is a cutaneous 
toxicity, a history of skin complaints such as eczema may make the skin more 
sensitive to chemical insult. PPE has been purported to be due to an 
inflammatory response, therefore it would seem logical that if an individual 
has a pre-existing inflammatory condition such as arthritis, they may be more 
likely to develop PPE. No association was seen between PPE and diabetes, 
PVD, PN or skin conditions, although with only small numbers with PVD or PN 
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these findings are unreliable. An association was seen between the presence 
of an inflammatory condition and the development of PPE. 
 
The performance status of each participant was assessed and illustrated an 
association with the development of PPE. Those with a good performance 
status (0 or 1) were more likely to develop PPE than those with poor 
performance status (2 or 3). At first it was thought that this may be related to 
those with poor performance status having a dose reduction at the start of 
treatment. When this potential link was explored by statistical testing, no 
association was found thereby refuting this initial thought. No studies were 
found in the literature which tested the association between performance 
status and PPE and this may be the first report of such an association. 
Although firm conclusions could not be drawn from the retrospective sample 
due to the number of missing cases, the fact that the association was 
confirmed in the prospective sample adds support to this relationship. 
 
Tumour related factors were examined and included; the tumour site, 
presence of metastases, treatment intent and previous radiotherapy 
treatment. An association was seen between PPE and participants who did 
not have metastatic spread and were receiving capecitabine as adjuvant 
treatment. Although a multicollinearity test showed no correlation between 
performance status, metastatic spread or treatment intent, clinically one could 
assume an association. Cross tabulation confirmed this clinical assumption 
showing that participants with a good performance status were less likely for 
their tumour to have metastasized and more likely to receive capecitabine as 
adjuvant therapy. 
 
No association between albumin levels or weight loss prior to commencing 
treatment and PPE were found. However, being overweight or obese 
appeared to increase the risk of developing PPE. The logistic regression 
indicated that for every unit increase in BMI the risk of developing PPE 
increased. This finding, that BMI in combination with other variables increases 
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the risk of PPE, adds to the debate on the value of using BSA to calculate 
chemotherapy dosage. 
  
Organ function can affect the clearance of drugs and increase the risk of 
toxicities. Pre-treatment laboratory data collected included; creatinine, 
creatinine clearance (CrCl), ALT, ALP, bilirubin and albumin. None of these 
variables reached significance in the bivariate analysis. Creatinine clearance 
and albumin met the criteria for inclusion in the regression model. Albumin 
was removed, but CrCl was retained as a significant variable and 
demonstrated that for every unit decrease in CrCl the risk of PPE increased. 
During the data collection phase observations suggested that participants with 
a CrCl of between 50 and 80mls/min (mild renal impairment) had an 
increased incidence of PPE. This observation was confirmed in a logistic 
regression containing just CrCl and PPE. 
 
The effects of the season in which treatment started may differ from year to 
year depending on whether we have a hot summer or very cold winter. This 
may partly explain the contradictory findings between the retrospective data 
and the prospective data. An association was found in the retrospective 
sample, that participants commencing their treatment in the winter were more 
likely to develop PPE than those commencing their treatment in the summer. 
Conversely, in the prospective sample participants who commenced their 
treatment in the summer were more likely to develop PPE, however, this was 
not confirmed statistically. 
 
One of the study aims was to utilise the prospective data to validate the 
findings from the retrospective sample. When applying the conventional alpha 
level of p < .05, there were only two variables that were significantly 
associated with the development of PPE in the retrospective sample that also 
achieved significance in the prospective sample. The two variables were 
participants whose cancer had not metastasized and were receiving 
capecitabine monotherapy as adjuvant treatment. When the relaxed alpha 
level of p < .1 was applied to both samples an additional two variables 
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achieved significance. There was consensus between the two samples of the 
creatinine clearance level (50.01-80.00) associated with an increased risk of 
developing PPE. However, a co-morbidity of an inflammatory condition 
indicated contradiction between the samples. Participants in the prospective 
sample whose medical history included the presence of an inflammatory 
condition were more likely to develop PPE. Conversely in the retrospective 
sample those with no history of inflammatory conditions were more likely to 
develop PPE. This difference may be due to under reporting of this medical 
history in the latter sample. 
 
2. Do individual activities that cause friction or exposure to heat 
increase the risk of developing PPE? 
 
The same 31 hypotheses tested in the retrospective sample were re-tested in 
the prospective sample with an additional 10 hypotheses related to individual 
activities.  
 
The 10 additional variables included; history of previous sunburn, regular 
engagement in friction-inducing activities or exposure to hot water, a tendency 
to have dry skin, cool or sweaty hands and feet, regular application of hand 
cream and skin type.    
 
Participants who reported a tendency to have warm hands had an increased 
risk of PPE than those who reported having a tendency to having cool or cold 
hands. No association was found between participants who reported sweating 
on their hands and feet regularly and PPE. Similarly no association was found 
in those who regularly exposed their hands and feet to hot water. Self 
reported measures (simple yes or no answer) and lack of any scale 
measurement make this difficult to replicate. Future studies would need to 
address this and include measures of, for example, the frequency of 
immersion and temperature of the hot water. 
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No association was seen between friction-inducing activities or regular 
application of hand cream, despite consensus advice to moisturise regularly 
and avoid activities that cause friction. In this exploratory study self reported 
measures were taken. To make the findings generalisable, scale measures 
would need to employed to include the type, frequency, and amount of activity 
and moisturisers. 
 
The skin type of the participants showed no association with PPE, and 
interestingly those who had skin types more sensitive to sunburn had a 
reduced risk of developing PPE. Despite a few reported cases of radiation 
recall in areas that had previously been sunburnt, a history of sunburn 
showed no association with PPE.  
 
There have been no large scale studies in the literature to evaluate patient 
factors that cause increased temperature, trauma or friction to the hands and 
feet to test the suggestions that these may increase the risk of developing 
PPE. The current study is the first of its kind to do so and in bivariate analysis 
confirm a link between temperature indicated by warm hands and PPE. The 
study however, refuted others such as temperature indicated by exposure to 
hot water, hyperhydrosis, and friction causing activities. This study also tested 
and demonstrated no association between previous sunburn, skin type or the 
regular use of hand cream and the development of PPE. Limitations of the 
data collection tools have been identified and would need to be addressed in 
future research. This does not detract from the usefulness of the findings from 
this first large scale study of patient factors and PPE and would indicate that 
these factors alone may not be predictive of PPE and it may be that in 
combination with other variables they are predictive, hence the rationale for 
performing multivariate regression analysis. 
 
Variables, from the prospective data, to answer both research questions were 
entered into the regression model based on the purposeful algorithm 
described in chapter 3. A number of entry methods were employed in 
regression modelling and applied to the data to compare the conclusions or to 
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validate the model results. Following this analysis the probabilities generated 
in each model were tested using ROC curve to assess which model provided 
the most accurate prediction of PPE. The purposeful selection model 
containing one additional variable that was not significant in the bivariate 
analysis achieved the highest score. This model contained 6 significant 
variables (p < .01) and 3 confounders (caused a > 20% change in the beta 
coefficient of another variable when removed from the model).  
 
Table 6.1 lists the categories that were included in the final model and 
established those that were predictive of PPE. The greater the odds ratio the 
more important that variable may be as a risk factor of PPE. It seems 
accepted that renal impairment is a risk factor for toxicity of capecitabine. One 
might question whether some of the variables might be associated with a 
dose reduction and therefore influence their effect on the development of 
PPE. These variables are participants with metastatic spread, older age, have 
received previous radiotherapy treatment (particularly breast cancer) and 
assessed as poor performance status. These all showed a reduced risk of 
developing PPE. To test this notion bivariate tests were applied and no 
association was found between each variable and dose reduction at the start 
of treatment, or at any time due to PPE or other toxicities. This would indicate 
other reasons why these variables may act as risk factors.  
 
Significant category Odds ratio 
Absence of metastatic spread 3.18 
Pre-existing inflammatory condition 2.60 
Warm hands 1.90 
Overweight or obese 1.13 
Renal impairment .98 
Younger age .93 
Confounders Odds ratio 
No previous radiotherapy treatment  2.93 
Regular alcohol intake 2.18 
Good performance status 1.64 
Table 6-1 Variable categories in final regression model predictive of PPE 
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One might also question the link between BMI, age and renal function, since 
weight and age form part of the equation to calculate CrCL. A multicollinearity 
diagnostic test revealed no correlation between these variables.  
 
Conclusions that may be drawn from the multivariate logistic regression model 
applied to the prospective sample are that participants receiving capecitabine 
monotherapy are more likely to develop PPE, if they have a good 
performance status and absence of metastatic spread. Others include a 
tendency to have warm hands, drink alcohol regularly, and be overweight or 
obese. Finally a pre treatment creatinine clearance level of 50.01-80.00 
millilitres/minute. Having said this, further study would be required to 
categorise some of these variables more accurately, particularly, warm hands, 
units of alcohol consumed per week, and degree of excess weight. 
 
In an attempt to validate the findings from the retrospective sample, the 
variables from this sample that were entered into the regression model were 
applied to the prospective data. This model was reduced according to the 
same purposeful algorithm as before. Only two out of the variables entered 
remained significant, namely the absence of metastatic spread and the 
presence of pre existing inflammatory conditions, with no confounders. This 
between samples comparison could not validate all variables as risk factors of 
PPE. This may be due to the limitations of retrospectively collected data and 
validation of the findings from the prospective sample would need to be 
confirmed by further prospective studies. 
 
6.3  Contributions to research and practice  
The unique contributions of this study to research include the modelling 
algorithm applied to the data, the uniqueness of certain data collected and 
analysed and the valuable information that has been provided to support 
future research and development. 
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Stepwise regression models depend on statistical criteria to reduce and fit the 
final model. The advantage of purposeful selection of variables is that the 
analyst makes the decision at each step based on statistical and clinical 
relevance. This results in a model containing confounders in addition to the 
significant variables. The use of this modelling technique as a unique 
contribution of this study adds to the current literature. It is the first study to 
use this type of purposeful selection algorithm to fit a regression model to 
analyse risk factors of capecitabine-induced PPE. The results from the ROC 
tests show that it is worthwhile and gives a potentially richer model with the 
inclusion of confounders, although statistically there was little difference 
between the various entry methods. 
 
This research explored numerous potential risk factors of PPE. The findings 
will add to the current evidence of biographical data, performance status, co-
morbidities and renal function as risk factors of PPE. Since this is the first time 
that individual activity related factors have been studied, this is the unique 
contribution made by this research. The findings raise questions about the 
current advice given to patients receiving capecitabine to avoid activities that 
cause friction or exposure to high temperatures. Whilst it is acknowledged that 
the findings need validating by further research they have implications for 
nursing practice. 
 
Current practice with patients commencing capecitabine involves advising 
them to avoid activities that cause friction, pressure or high temperature. The 
evidence base for this is based on consensus and case reports. There are no 
previous large studies to validate this advice. This study is the first that has 
tested any association between activities that cause friction, pressure or high 
temperature and PPE. 
 
The advice to avoid exposure to heat and keeping the hands cool has been 
confirmed in this study. All other activities were not confirmed statistically as 
having any association with the development of PPE. Whilst these findings 
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will need validating in further large prospective studies, they do suggest that 
avoidance of some activities is unnecessary unless PPE develops. 
 
The prospective purposeful entry model indicates that participants who drink 
alcohol regularly, are overweight and have an inflammatory condition as co-
morbidity have an increased risk of developing PPE. With the possible 
exception of having a pre existing inflammatory condition, the other two 
variables were not supported by the retrospective model and therefore have 
to be treated with caution until these are confirmed or refuted in other studies.  
 
Other findings in the literature and supported in this study that increase the 
risk of PPE is that patients with mild renal impairment (CrCl 50 – 80 mls/min) 
should be monitored closely for early signs of PPE and may require a dose 
reduction. Nurses should also be aware that older patients and those with 
poor performance status are not necessarily at risk of PPE, although they may 
be for other toxicities. Careful assessment should be made of patients over 
the age of 80 receiving capecitabine since they appear to respond differently 
to the drug and may be at more risk of toxicity. Implementation of a risk 
assessment tool such as the CRASH tool presented by Extermann et al 
(2010) may increase confidence in treating older patients with chemotherapy. 
Awareness amongst nurses who educate or monitor patients receiving 
capecitabine should be raised to ensure they can advise patients and 
recognise the different presentation of PPE in people with dark skin. 
 
Until such a time that the evidence base for avoiding friction or pressure 
causing activities is established, the focus should be on careful monitoring, 
questioning and assessment. There is evidence that early onset of grade 1 
PPE results in an increased risk of developing more severe PPE in 
subsequent cycles. Careful questioning of patients to identify PPE developing 
between cycles which has resolved, may identify those who would benefit 
from early dose reduction to avoid delays in treatment due to severe PPE. 
This is particularly important in light of the emerging evidence that PPE may 
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be a marker of efficacy of treatment. This would indicate that those who 
develop PPE and the ones most likely to benefit from continuing treatment. 
 
Another recommendation would be to ensure men receiving agents that are 
known to cause PPE are educated about the possibility of penile and scrotal 
involvement, giving them permission to report this, which, if identified early, 
may reduce its severity. 
 
The evidence for strategies to prevent or manage PPE once it develops is 
weak. The only agent that has been subjected to randomised controlled trials 
is pyridoxine demonstrating that the findings cannot support its use to avoid or 
manage PPE. The use of emollients has not been subjected to rigorous 
testing. However, since one of the early symptoms of PPE is dryness and 
flaking, the use of emollients would seem logical. Since it a safe and 
uncontroversial substance its use can be recommended without ill effects. 
 
6.4  Limitations 
Every effort is made to use the best available data to answer the research 
questions. Despite this it is inevitable that there will be factors that affect the 
findings of the study. These factors include limitations of the study design or 
other factors within the study that may affect the findings. The following 
limitations apply to this study; 
 
Collection of data retrospectively is easy and inexpensive but can be limited in 
its accuracy. There can be operational difficulties in collecting retrospective 
data. In this study, this included; difficulties in obtaining several sets of notes 
and large amounts of missing data from some variables. This can affect the 
external validity of the findings and could not be recommended for use in 
clinical practice without further validation in prospective studies. The 
prospective data collection phase of this study set out to validate these 
findings and also to collect data about individual participant activities which 
were not available from retrospective notes. 




Randomisation was not appropriate in this study since comparison was not 
being made between those who received an intervention and those who did 
not. Stratification, the process of dividing members of the population into 
homogeneous subgroups before sampling (Marston 2010) may have 
produced different results. However, this would have required a much larger 
sample from which to randomly select subjects from each group.  
 
Data collection restricted to one geographical site lacks generalisability. 
Similarly data collection restricted to a single chemotherapy agent cannot be 
generalised to other agents. Although, if we accept the notion that there may 
be different pathophysiological mechanisms and risk factors for PPE between 
different agents, this may in fact be the study’s strength. Large scale studies 
focusing on each different drug would enable comparison of data to test 
commonality or variability. 
 
The analysis was not definitive, since it was not possible to consider all 
covariates due to a limited number of participants per category within a 
variable. 
 
The analysis described has certain disadvantages. It has been performed in a 
series of participants and the results applied to this particular series only. 
Even if the validity were tested and confirmed in another similar series, it 
would not necessarily be applicable to a different group of patients because of 
the probable presence or absence of other known risk factors. 
 
Although the logistic regression analysis discussed had some limitations, it 
was undertaken in the spirit of a preliminary investigative study and was a 
worthwhile exercise. 
 
Some variables lack scale measurement such as friction-inducing activities, 
exposure to high temperature and alcohol consumption. Responses were 
coded based on the judgement of the researcher. Since there was a single 
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investigator collecting and analysing the data there was consistency in the 
definition for this sample but would prove difficult to replicate by other 
investigators.  
 
The study was restricted by time which resulted in occasions where 
information had to be gathered from other staff or patient records. 
  
Despite these limitations, this study was worthwhile in that it has contributed 
to the existing body of knowledge and demonstrated the usefulness of an 
algorithm that produces a richer risk factor model. It has succeeded in 
providing the first steps in providing an evidence-base for education delivered 
by nurses to patients receiving capecitabine by nurses. Based on these 
preliminary findings planning a prospective and a much larger study for testing 
the discrimination of the independent variables would be a meaningful 
venture.  
 
6.5  Future research 
From the study outcomes in response to the research questions, and 
emerging literature during this study a number of supplementary areas worthy 
of prospective research are identified. The following are suggestions for future 
research; 
 
There is a dearth of literature examining any association between other 
toxicities of capecitabine and PPE. Further exploration of these may identify if 
the advent of toxicities such as diarrhoea or stomatitis predict the subsequent 
emergence of PPE. Alternatively whether the advent of PPE predicts for other 
toxicities of capecitabine. This would enable nurses to identify patients that 
may require more vigilant monitoring, education and support.  
 
Fatigue was identified in this study to occur in almost 50% of participants in 
the prospective sample. Participants often described this as the one side 
effect that they found most difficult to cope with. It does not appear to be a 
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transient effect, that is, it does not resolve completely with treatment delay or 
dose reduction. Personal clinical experience has shown that fatigue can 
persist for up to a year after treatment and sometimes never resolves 
completely. A study to examine the onset and severity of capecitabine-
induced fatigue and its impact on quality of life would demonstrate the scale of 
the problem. This may then lead on to identifying and testing strategies to 
manage fatigue. 
 
One of the limitations of this study was that the variables related to friction-
inducing activities and those that exposed the hands and feet to high 
temperatures lacked reproducibility. Development of measurement scales and 
further testing of these variables would provide a basis for other researchers 
to replicate and make comparisons 
 
Since PPE is not life-threatening, it has rarely been examined in terms of its 
impact on quality of life. This and other studies have demonstrated an 
association between good performance status and PPE. Personal clinical 
experience is that some patients decide to stop their capecitabine treatment, 
even when it is given as adjuvant therapy, because of the impact of fatigue on 
their everyday lives. A study to further examine the association between PPE 
and performance status would confirm the findings from this study. Inclusion 
of well recognised tools such as the Hospital Anxiety and Depression Scale 
(HADS) and other quality of life assessment tools would clearly show the 
impact of PPE on patients.  
 
This study found an association between BMI and PPE, with participants that 
were overweight or obese having an increased risk of PPE. Arguments were 
presented suggesting that LBM may be a more appropriate measurement on 
which to calculate chemotherapy doses. A study to compare LBM, BMI and 
capecitabine-induced toxicities may add to this ongoing debate. 
 
Small scale studies have examined a link between serum folate levels and 
severe PPE. A large scale prospective study to explore any influence of pre-
Conclusions and Recommendations 
Page 271 
 
treatment folate levels and dietary folate intake on toxicities of capecitabine 
would refute or confirm these findings. This in turn would provide evidence for 
nurses and dieticians to educate patients on how to reduce their folate intake 
during treatment with capecitabine.  
 
Studies have suggested that PPE may be a predictor of efficacy of 
capecitabine (TTP and OS) with one study suggesting that Thymidine 
Phosphorylate (TP) levels in tumour cells are associated with efficacy of 
capecitabine (TTP and OS) and PPE. This raises questions of whether it is 
the TP level in tumour cells that influences the efficacy of the treatment and 
whether PPE is a clinical sign of these raised levels and would warrant further 
research to compare TP levels and efficacy with the incidence of PPE. 
 
Evidence in the literature suggests that the older adult may be at increased 
risk of toxicities from chemotherapy. Studies of patients over 70 years old, 
incorporating a geriatric assessment with clinical and treatment variables, 
produced a validated risk assessment tool. This Chemotherapy Risk 
Assessment Scale for High-Age Patients (CRASH) was validated in patients 
receiving many different chemotherapy regimes and tumour types in the 
samples studied (Extermann et al 2010). The next step would be to develop 
this further by studying its use in specific regimes such as capecitabine 
(Feurst 2010).  
 
This study showed that there is an association between having warm hands 
and PPE. There is contradictory evidence that regional cooling reduces the 
risk of PPE in patients receiving PLD. An investigation into the usefulness of 
regional cooling to reduce the incidence and/or severity of capecitabine-
induced PPE would add to the evidence-base to support advice given to 
patients. This could be developed as either a randomised controlled trial or 
applying regional cooling to just one hand, thereby using the other as a 
control. This may present some difficulties, given that capecitabine is taken 
twice a day for 14 days. The timing and length of cooling would need to be 
carefully planned based on the pharmacological knowledge of capecitabine. 




Chapter 2 presented the evidence for several agents that have been 
suggested to either prevent or manage PPE. Further randomised double-
blinded trials are required on several of these to establish their efficacy. These 
agents include cod liver oil; hempseed oil; Vitamin E and henna. 
 
Since this was an exploratory study examining many factors future research 
may concentrate on individual factors to ensure detailed measurements which 
could then be replicated. 
 
The future studies suggested above provide a real opportunity for nurses to 
be engaged in multi-professional research. Collaboration could be between 
nurses and physiotherapists, occupational therapists, dieticians, scientists, as 
well as doctors.   
 
6.6  Conclusion 
A summary of the study and the findings to answer the research questions 
has been presented. The unique contributions to research and to nursing 
practice were identified. These include the unique application of the 
purposeful selection algorithm, where the analyst not the computer makes the 
decisions at each step. This produces a richer and more controlled model 
containing significant variables in addition to confounders. The contribution to 
nursing practice adds cumulative evidence to current knowledge and new 
evidence which may support patient education and monitoring strategies.  
 
PPE appears to be a problem of multi-factorial nature where it is difficult to 
report and collect reliable data. This is evidenced by the conflicting reports in 
the literature and perhaps explains some of the differences between the two 
samples in this study. There were difficulties in interpretation of the findings in 
the literature due to the different toxicity measurement tools and ways of 
presenting the data.  Many of the differences in this study, however, could be 
explained by the limitations of the retrospective nature of the first sample.   




The limitations of this study were described and despite these the study was 
worthwhile because of its unique contribution. Finally suggestions were made 
for further studies to answer different questions about risk factors for PPE and 
to confirm or refute agents to prevent or manage PPE. 
 
This thesis commenced by stating that PPE is not life-threatening, although 
serious consequences have been reported. It was also suggested that the 
impact of PPE on a patient’s quality of life sometimes results in refusal to 
continue with treatment because of the pain and discomfort it causes. Being 
able to identify those at most risk in order to initiate preventative measures 
including appropriate education would reduce the severity and thereby 
prevent delays in treatment or cessation of treatment. This would seem a 
fitting place to finish and to take forward the implementation of the following 
recommendations for nursing practice. 
 
6.7  Summary of recommendations 
The following recommendations provide guidance to nurses who manage 
patients receiving capecitabine 
 Patients should be educated prior to commencing capecitabine; 
o Emphasise the importance of reporting all signs and symptoms 
of PPE as soon as they appear. This will ensure that PPE is 
managed appropriately, in a timely manner and reduce delays in 
subsequent treatment. 
o To keep hands cool as much as possible 
o That PPE can occur in areas other than the hands and feet such 
as areas previously irradiated or sunburnt and inter-triginous 
areas such as the scrotum in men and under the breast in 
women.  
 Careful monitoring of patients who may have an increased risk of PPE; 
o Those who develop early grade 1 PPE, since they are at risk of 
developing more severe PPE at subsequent cycles. 
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o Aged under 65 years, have a good performance status, no 
metastatic spread from their primary cancer and who continue to 
work during their treatment. 
o Aged 80 years or above and consider implementing an older 
persons risk assessment tool. 
o Are over weight or obese. 
o Those with a history of diabetes, peripheral vascular disease or 
peripheral neuropathy, as they may have a reduced ability to 
feel the early onset of pain associated with PPE. 
o Patients with other inflammatory conditions such as rheumatoid 
arthritis. 
o Have mild renal impairment (CrCl 50-80 mls/min) 
o Ethnic minority groups with dark skin. Include the toxicity 
grading suggested by Saif (2011) and described on page 221 
into local toxicity assessment tools 
o Patients who develop mucositis and/or diarrhoea should be 
assessed for signs of PPE. 
 At each visit  prior to receiving the next cycle of treatment the nurse 
should; 
o Question the patient carefully about any signs and symptoms of 
PPE that occurred between cycles which have resolved. This 
should include questioning any redness or soreness in areas 
other than the hands and feet. 
o Examine the hands and feet at each visit to identify and signs of 
PPE which the patient may not have revealed. 
o Patients who develop PPE should be questioned about any 
symptoms of mucositis and diarrhoea. 
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CHAPTER  8     APPENDICES 
APPENDIX 2.1 PERFORMANCE STATUS 
 
ECOG PERFORMANCE STATUS* 
Grade ECOG 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work 
2 Ambulatory and capable of all selfcare but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited selfcare, confined to bed or chair more than 
50% of waking hours 
4 Completely disabled. Cannot carry on any selfcare. Totally confined 
to bed or chair 
5 Dead 




Page 310  
KARNOFSKY PERFORMANCE STATUS SCALE DEFINITIONS RATING 
(%) CRITERIA 
Able to carry on normal activity and to 
work; no special care needed. 
  100   
Normal no complaints; no 
evidence of disease. 
90 
Able to carry on normal activity; 
minor signs or symptoms of 
disease. 
80 
Normal activity with effort; 
some signs or symptoms of 
disease. 
Unable to work; able to live at home 
and care for most personal needs; 
varying amount of assistance needed. 
70 
Cares for self; unable to carry 




assistance, but is able to care 
for most of his personal needs. 
50 
Requires considerable 
assistance and frequent 
medical care. 
Unable to care for self; requires 
equivalent of institutional or hospital 
care; disease may be progressing 
rapidly. 
40 
Disabled; requires special care 
and assistance. 
30 
Severely disabled; hospital 
admission is indicated although 
death not imminent. 
20 
Very sick; hospital admission 
necessary; active supportive 
treatment necessary. 
10 
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APPENDIX 2.2    PPE GRADING SYSTEMS 
  NCI criteria for PPE (NCI CTCAE v 3.0 2006) 
Grade Definition  
1 Minimal skin changes 
or dermatitis without 
pain (e.g. erythema, 
peeling) 
 
2 Skin changes (e.g. 
peeling, blisters, 
bleeding, oedema) or 
pain, not interfering with 
function 
 
3 Ulcerative dermatitis or 
skin changes with pain, 
interfering with function 
 
National Cancer Institute Common Toxicity Criteria of Adverse Events 
version 3.0 (NCI 2006) 
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Grade  
1 Dysesthesia/ paraesthesia, tingling in the hands and feet 
2 Discomfort in holding objects and upon walking, painless 
swelling or erythema 
3 Painful erythema and swelling of palms and soles, Periungual 
erythema and swelling 
4 Desquamation, ulceration, blistering, severe pain 
WHO Toxicity criteria (WHO 1979) 
 
 
Grade Clinical domain Functional domain 
1 Numbness, dysesthesia/ 
paraesthesia, tingling, painless 
swelling or erythema 
Discomfort that does not 
disrupt normal activities 
2 Painful erythema, with swelling Discomfort that affects 
activities of daily living 
3 Moist desquamation, ulceration, 
blistering, severe pain 
Severe discomfort, unable 
to work or perform 
activities of daily living 
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APPENDIX  3.1     MEDICAL NOTES DATA EXTRACTION FORM 
Trial Id no:     
 
Unit no:     RTD no: 
 







Ethnic group (Optional) 
British  Irish  White & Asian  
White & Black Caribbean  White & Black African  Pakistani  
Any other mixed 
background 
 Indian  Caribbean  
Bangladeshi  Any other Asian 
background 
 Chinese  
African  Any other Black 
background 
 Not stated  
Any other ethnic group  Any other White 
background 
   
 
Past medical history; 
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Restricted in physically strenuous activity but ambulatory and able to carry 




Ambulatory and capable of all self care but unable to carry out any work 













Site and cell type of tumour (e.g. 
adenocarcinoma of the rectum)  
 
 
Stage & Grade 
 
 
Metastatic spread (where) 
 
 





Previous chemotherapy  YES/NO 
 
If Yes state regime(s) 
 
PPE with previous chemo YES/NO Worse grade of PPE 
 
Other toxicities with previous chemo (Please state) 
Previous radiotherapy  YES/NO Site: 
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MOST RECENT CHEMOTHERAPY REGIME 






    
 




HEIGHT (cms) WEIGHT (Kg) BSA (M2) BMI 







Smoker  YES/NO  No per day   
 
Recent smoking history (if stopped) 
 
 
Alcohol  YES/NO  Type   Units/week 
 
 
Recent weight loss? (amount) 
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PRE TREATMENT BLOOD RESULTS 
Urea  ALP  
Creatinine  Bilirubin  
Cr clearance  Albumin  
Neutrophils  ALT  
 
 
GCSF support  YES/NO 
 
Name of GCSF prescribed 
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Is PPE present?   YES/NO 
 
Grade (see below)  1   2   3 
 
Grade Clinical domain Functional domain 
1 Numbness, 
dysesthesia/paraesthesia, 
tingling, painless swelling or 
erythema 
Discomfort that does not disrupt 
normal activities 
2 Painful erythema with 
swelling 
Discomfort that affects normal 
daily activities 
3 Moist desquamation, 
ulceration, blistering, severe 
pain 
Severe discomfort, unable to 
work or perform normal daily 
activities 
 




PRE TREATMENT BLOOD RESULTS 
Urea  ALP  
Creatinine  Bilirubin  
Cr clearance  Albumin  
Neutrophils  ALT  
 
GCSF support  YES/NO 
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APPENDIX 3.2  CODING OF INDEPENDENT VARIABLES  
(before collapsing categories with small numbers) 
 
VARIABLE CATEGORIES 
Gender Male = 0; Female = 1 
Age Actual age 
Marital status Single = 1; Married/cohabiting = 2; 
Divorced/separated = 3; Widow(er) = 
4 
Ethnic origin White British = 1; White & Black 
Caribbean = 2; Any other mixed 
background = 3; Bangladeshi = 4; 
African = 5; Irish = 6; White & Black 
African = 7; Indian = 8; Any other 
Asian background = 9; Any other 
black background = 10; White & 
Asian = 11; Pakistani = 12; Caribbean 
= 13; Chinese = 14 
Diabetes No = 0; Yes = 1 
Peripheral Vascular disease No = 0; Yes = 1 
Peripheral neuropathy No = 0; Yes = 1 
Skin complaint No = 0; Yes = 1 
Inflammatory condition No = 0; Yes = 1 
Previous cancer diagnosis No = 0; Yes = 1 
NSAID No = 0; Yes = 1 
Steroids No = 0; Yes = 1 
Cox-2 inhibitors No = 0; Yes = 1 
Other anti-inflammatory drugs No = 0; Yes = 1 
Performance status Actual figure 0 – 4 
Tumour site Colon = 1; Rectal = 2; Oesophageal = 
3;Breast = 4; Gastric = 5; Unknown 
primary = 6; Cholangiocarcinoma = 7; 
Pancreas = 8; Pseudomyxoma 
peritonei = 9; Neuroendocrine = 10; 
Ovary = 11 
Metastatic spread No = 0; Yes = 1 
Previous chemo No = 0; Yes = 1 
PPE with previous chemo No = 0; Yes = 1 
Previous radiotherapy No = 0; Yes = 1 
Aim of current treatment Adjuvant = 1; Neoadjuvant = 2; 
Palliative = 3 
Regime Capecitabine SA = 1; 
Capecitabine/Radiotherapy = 2;  
ECX = 3; Folfox = 4; Capox = 5; 
Cisp/Cap/RTD = 6; Cap/Docetaxel = 
7; Bev/Cap = 8; Folfiri = 9; Gem/Cap 
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= 10; Cap sa trial = 11; EOX = 12 
BSA Actual figure 
BMI Actual figure 
Employment No = 0; Yes = 1 
Smoker No = 0; Yes = 1 
Alcohol No = 0; Yes = 1 
Recent weight loss No = 0; Yes = 1 
Cycle of 1st presentation of PPE Actual figure 1 – 6 
Grade at 1st presentation of PPE Actual figure 1 – 3 
Worst grade Actual figure 1 – 3 
Other toxicities No = 0; Yes = 1 
Outcome Completed all planned cycles = 1; 
Stopped due to PPE = 2; Stopped 
due to other toxicities = 3; Stopped 
for other reason = 4; Changed to 
other treatment due to PPE = 5 
Deferred due to PPE No = 0; Yes = 1 
Deferred due to other toxicities No = 0; Yes = 1 
Dose reduction at 1st cycle No = 0; Yes = 1 
Dose reduction due to PPE No = 0; Yes = 1 
Dose reduction due to other toxicities No = 0; Yes = 1 
Creatinine cycle 1 Actual figure 
CrCl cycle 1 Actual figure 
ALP cycle 1 Actual figure 
ALT cycle 1 Actual figure 
Bilirubin cycle 1 Actual figure 
Albumin cycle 1 Actual figure 
No. of cycles received Actual figure 
Month at start of treatment Actual figure 
Additional variables in prospective sample 
Recent sunburn No = 0; Yes = 1 
Hobbies with friction No = 0; Yes = 1 
Hot water No = 0; Yes = 1 
Skin type Actual figure 1 – 6 
Dry skin No = 0; Yes = 1 
Cool hands No = 0; Yes = 1 
Cool feet No = 0; Yes = 1 
Sweaty hands No = 0; Yes = 1 
Sweaty feet No = 0; Yes = 1 
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IDENTIFICATION OF RISK FACTORS THAT PREDICT THE 
DEVELOPMENT OF PALMAR-PLANTAR ERYTHEMA (PPE) 
 















This sheet is used to enable the research team to identify which patient this 
document refers to during the data collection stage to prevent data from 
patients being mixed up. 
 
This sheet will be shredded immediately after the 6th cycle of chemotherapy 








Please stick label here 
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PATIENT INTERVIEW SCHEDULE 
 
Check consent form has been signed. 
 
Date:      Trial Id no: 
 
Unit no:     RTD no: 
 







Ethnic group (Optional) 
British  Irish  White & Asian  
White & Black Caribbean  White & Black African  Pakistani  
Any other mixed 
background 
 Indian  Caribbean  
Bangladeshi  Any other Asian 
background 
 Chinese  
African  Any other Black 
background 
 Not stated  
Any other ethnic group  Any other White 
background 
   
 
Past medical history; 
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Restricted in physically strenuous activity but ambulatory and able to carry 




Ambulatory and capable of all self care but unable to carry out any work 













Site and cell type of tumour (e.g. 


















Previous chemotherapy  YES/NO 
If Yes state regime(s) 
PPE with previous chemo YES/NO Worse grade of PPE 
Other toxicities with previous chemo (Please state) 
 
 
Previous radiotherapy  YES/NO Site: 
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CURRENT PROPOSED CHEMOTHERAPY REGIME 






    
 




HEIGHT (cms) WEIGHT (Kg) BSA (M2) BMI 






Smoker  YES/NO  No per day   
 
Recent smoking history (if stopped) 
 
Alcohol  YES/NO  Type   Units/week 
 
Recent weight loss? (amount) 
 































Hand washing clothes 
 
 
Bath/Shower (please circle) 
Temperature (please circle) 
Cool  Warm  Hot 
 
 
Number of hot drinks per day 
 
 
Kneeling or leaning on elbows (e.g. 
cleaning floors etc) 
 
 







Skin type (see description below) 
 
I II III IV V VI 
Patient’s own description (please 
circle) 
Dry  Moist  Sensitive 
Patient’s hands normally Cool  Warm  Hot 
Patient’s feet normally Cool  Warm  Hot 
Is the patient prone to sweaty 
palms in warm weather or when 
stressed/anxious? 
 
YES   NO 
Is the patient prone to sweaty feet 
in warm weather or when 
stressed/anxious? 
 
YES   NO 
Does the patient use hand cream 
regularly? 
 




Type I Often burns, rarely tans. Tends to have freckles, red or fair 
hair, blue or green eyes 
Type II Usually burns, sometimes tans. Tends to have light hair, blue or 
brown eyes 
Type III Sometimes burns, usually tans. Tends to have brown hair and eyes 
Type IV Rarely burns, often tans. Tends to have dark brown eyes and hair. 
Type V Naturally black-brown skin. Often has dark brown eyes and hair. 
Type VI Naturally black-brown skin. Usually has black-brown eyes and hair. 
Ref: Cancer Research UK. Sunsmart. www.cancerresearchuk [Accessed 
14.10.08] 
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PRE TREATMENT BLOOD RESULTS 
Urea  ALT  
Creatinine  ALP  
Cr clearance  Bilirubin  
Neutrophils  Albumin  
 
 
GCSF support  YES/NO 
 
Name of GCSF prescribed 
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CYCLE 2 (There will be sheets for cycles 3 – 6) 
Date: 
 
Any symptoms of PPE between cycles? 
 
YES/NO (if YES complete table) 
 
When did it 
occur? 
Which symptoms? Which part of the body was 
affected? 
 Tingling  Palms of hands  
Itching  Soles of feet  
Burning sensation  Armpits  
Redness  Groin area  
Flaking skin  Mouth  
Swelling  Other parts of the body 
(please state) 
 
Small blisters    
Small sores    
Other (please state)    
 
Is PPE current present?   YES/NO 
Grade (see below)  1   2   3 
 
Time after treatment to onset: 
 
How does PPE affect daily activities; (please circle) 
 
Not at all  A little  Moderately  a lot 
 
Which activities are affected? (please state) 
 
Grade Clinical domain Functional domain 
1 Numbness, 
dysesthesia/paraesthesia, 
tingling, painless swelling or 
erythema 
Discomfort that does not disrupt 
normal activities 
2 Painful erythema with 
swelling 
Discomfort that affects normal 
daily activities 
3 Moist desquamation, 
ulceration, blistering, severe 
pain 
Severe discomfort, unable to 
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PRE TREATMENT BLOOD RESULTS 
Urea  ALP  
Creatinine  Bilirubin  
Cr clearance  Albumin  
Neutrophils  ALT  
 
 
GCSF support  YES/NO 
 


















    
 
 
Comments: (e.g. any change in activities, performance status etc) 
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Trial Id no: 
 






















Frequency of treatment; 
 
 




Please remember to contact the chemotherapy suite or oncology wards if you 
have any of the side effects listed on your yellow chemotherapy card or if you 
feel unwell in any way. 
 
If you are taking chemotherapy tablets and suffer from any of the side effects, 
do not take any more tablets until you have contacted the hospital. Contact 










Please record any symptoms you have of Hand Foot Syndrome (HFS) or 
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Have you had any symptoms of HFS between treatment cycles?
 YES/NO 
 





Painless Swelling  
Redness with no pain  
Redness with pain  
Burning sensation  
Flaking skin  
Small blisters  
Small sores  
Severe pain of hands or feet  
Other (please state)  
 
Which part of your body was affected? 
 
 Tick 
Palms of your hands  
Soles of your feet  
Armpits  
Groin area  
Mouth  
Other parts of the body (please state)  
 
 




When did it disappear? 
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No problems with hands or feet  
Discomfort that does not disrupt normal activities  
Discomfort that affects normal daily activities  
Severe discomfort, unable to work or perform 








NONE MILD MODERATE SEVERE 
 
Diarrhoea 
    
 
Mouth ulcers 
    
 
Fever 
    
 
Feeling sick 
    
 
Being sick 




    
 
Did you have to contact the hospital about any side effects? YES/NO 
 
If YES which side effect? 
 
Have you suffered with sun burn? 
 
Any other notes or comments: (e.g. any change in activities that you do 
using your hands and feet) 
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APPENDIX 3.5  PATIENT INFORMATION SHEET (Version 3.0) 
 
IDENTIFICATION OF RISK FACTORS FOR PALMAR-PLANTAR 
ERYTHEMA (PPE)  
 




You will have attended a consultation with your specialist chemotherapy nurse 
to discuss the chemotherapy treatment that has been recommended for your 
type of cancer. 
The type of chemotherapy you will receive can, in some patients, cause a 
condition known as Palmar-Plantar erythema (PPE), also known as ‘Hand-
foot syndrome’. This is a known side effect of the type of chemotherapy you 
will receive and usually disappears once the chemotherapy treatment is 
discontinued. You are invited to take part in a research study. 
Before you decide whether to participate in the study it is important for you to 
understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with your 
family and friends if you wish. Please ask Annie, or your chemotherapy 
specialist sister if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part, you will 
be asked for your decision when you attend for your first chemotherapy 
treatment. 
 
Some questions you may have about this study:~ 
 
1. What is PPE? 
 
PPE is a side effect of some (not all) chemotherapy drugs, and mostly 
affects your hands and feet but can occur in other areas of the body. 
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The first sign is usually redness of the affected area, which can then 
develop into cracks and small blisters followed by peeling of the skin if 
not picked up at the first signs. It can cause pain and discomfort 
making it difficult to carry out day to day activities.  
 
The treatment for PPE is to delay the next dose of chemotherapy by a 
week or two until the PPE has resolved or to reduce the dose of 
chemotherapy. In severe cases the chemotherapy treatment may need 
to be stopped. 
 
2. What is the purpose of this study? 
 
You are invited to participate in this study to help find out if there are 
any particular factors that may make it more likely for people to develop 
PPE. 
 
3. What is the purpose of this study? 
 
PPE is a side effect of some chemotherapy drugs and can cause pain 
and discomfort and affect your ability to carry out day to day activities. 
The treatment for this is to delay the next dose of chemotherapy by a 
week or two until the PPE has resolved or to reduce the dose of 
chemotherapy. In severe cases the chemotherapy treatment may need 
to be stopped. 
In order to learn more about this side effect and to identify if there are 
any particular factors that may make it more likely for people to develop 
PPE you are invited to participate in this study.  
 
4. Why have I been approached? 
 
All patients commencing chemotherapy that contains 5-Fluorouracil, 
Capecitabine, Caelyx or Docetaxel will be invited to take part in the 
study as these are the drugs that commonly cause PPE. During the 
period of the study 200 patients will be asked to take part in the study. 
 
Appendices 
Page 334  
5. Do I have to take part? 
 
No, the study is entirely voluntary. If you decide to take part you will be 
given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw at any time 
and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you 
receive. 
 
6. What is involved in the study? 
 
When you attend the chemotherapy suite for your first treatment you 
will be asked a series of questions about yourself and activities 
involving your hands and feet such as work and hobbies. 
Many of these questions would be asked routinely of all people 
commencing chemotherapy treatment, therefore the additional 
questions should not extend your visit by more than a few minutes. 
 
You will be asked to keep a record of any symptoms of PPE that you 
may experience between treatments. If you are unable or prefer not to 
keep a record to keep a record, you will be telephoned once a week 
between treatments and be asked about any symptoms of PPE. 
 
Each time you attend the hospital for chemotherapy treatment you will 
be assessed for any side effects of the treatment (this is carried out 
with all patients whether participating in the study or not). You will be 
asked questions specific to PPE by a member of the research team or 
your chemotherapy specialist sister either during the visit or by 
telephone following your visit, but this should not extend the length of 
your visit. Your participation in the study will end once you have had 6 
courses of chemotherapy. 
If you develop any signs of PPE a photograph will be taken (with your 
permission) of the affected area (e.g. your hands or feet) to enable the 
research team to build up a catalogue of pictures to show how PPE 
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appears and if it varies in different individuals. Some photos may be 
included in the final report, in articles in medical or nursing journals and 
presentations at conferences. It will not be possible to identify you from 
the photo. 
   
7. Will the information obtained in the study be confidential? 
 
The fact that you are helping us with this study will be recorded in your 
medical notes and all information will be treated with the usual degree 
of confidentiality under the Data Protection Act. You GP will be notified 
that you are taking part in this study. 
 
At the time of entering the study you will be allocated a specific study 
number and it is only this study number which will be recorded on the 
documents used to collect information. No one will be able to identify 
you from the study. 
 
Only the researcher, the researcher’s supervisor and a statistician will 
have access to the data 
 
Sensitive data under the terms of the Data Protection Act 1998 on 
Ethnicity is being collected. You have a choice whether you want to 
reveal this information. If you choose not to answer this question the 
other information gathered will still result in a valid set of data. 
 
However, if you disclose any information that indicates someone may 
be at risk of harm, is against the law, unprofessional behaviour or 
unsafe practice, this will have to reported to the appropriate authorities. 
 
 
8. What happens to the information? 
 
The information obtained will be put into a computer to be analysed. 
The computer will be kept in a secure location and accessible by a 
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password. All written information obtained will be stored in a locked 
office at the university or hospital and only the researcher will have 
access to it. At the end of the study any features that could be used to 
identify an individual will be removed. 
 
9. Who has reviewed the study? 
 
This study has been reviewed by the De Montfort University and the 
Leicestershire, Northamptonshire and Rutland Research Ethics 
Committees. 
 
All research that involves NHS patients or staff, information from NHS 
medical records or uses NHS premises or facilities must be approved 
by an NHS Research Ethics Committee before it goes ahead. Approval 
does not guarantee that you will not come to any harm if you take part. 
However, approval means that the committee is satisfied that your 
rights will be respected, that any risks have been reduced to a 
minimum and balanced against possible benefits and that you have 
been given sufficient information on which to make an informed 
decision. 
 
10. What if something goes wrong? 
 
If you are harmed by taking part in this research project, there are no 
special compensation arrangements. If you are harmed due to 
someone’s negligence, then you may have grounds for a legal action 
but you may have to pay for it. Regardless of this, if you wish to 
complain, or have any concerns about any aspects of the way you 
have been approached or treated during the course of this study, the 
normal National Health Service complaints mechanisms would be 
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11. What will happen to the results of the study? 
 
The results from this study will be analysed to identify factors that 
appear to be linked with the development of PPE. These factors will be 
used to develop an assessment tool with a score given to each factor. 
This tool will then be tested on a further sample of patients receiving 
the chemotherapy drugs listed in point 2 to check that it can predict 
those patients that are most likely to develop PPE. 
  
While data collected, once analysed, may be used in a report of the 
research being undertaken and published, no information will be made 
available in the report or publication that identifies individuals directly or 
indirectly. 
 
The results will be made available following the completion of the 
study.  A summary will be provided and you will be able to receive a 
copy of this if you wish. 
 
12. Who is organising and funding the study? 
 
The study is organised by the researcher at the hospital and university. 
The study is funded by the Smith & Nephew Foundation. The Smith & 
Nephew Foundation funds nurses to carry out research into areas of 
tissue damage. http://www.snfoundation.org.uk/ 
 
13. Where can I get further information? 
 
If you would like any further information about the study please contact  
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APPENDIX 3.6  CONSENT FORM 
Title of project: Identification of risk factors for Palmar-Plantar Erythema (PPE) 
Name of researcher: Mrs Annie Law 
Initials 
1. I confirm that I have read and understand the information sheet (Version 3.0) 
for the above study. I have had the opportunity to ask questions and have had 
these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw 




3. I give permission for the researcher to look at my medical records to get 




4. I give permission for my General Practitioner to be informed I am taking part 
in this study. 
 
 
5. I agree to be interviewed by the researcher or specialist chemotherapy sister 
prior to commencing my chemotherapy treatment and at each treatment visit 
for 6 cycles, or to be telephoned following the visit, and to keep a record of 
symptoms for this period. If I am unable or prefer not to maintain a record I 
agree to a weekly phone call between treatments. 
 
 
6. I understand that I will not benefit financially if this research leads to the 
development of a new treatment or medical test. 
 
 
7. I agree to a photograph being taken of any area of skin affected by the 
chemotherapy which will be used to illustrate the findings of the research. I 
understand that I have the right to decline to have a photograph taken. 
 
 
8. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from regulatory authorities 
or from the NHS trust, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records. 
 
 
9. I know how to contact the researcher if I need to and how to get information 
about the results of the research 
 
10. I agree to take part in the above study  
Name of Participant  Date 
Name of person taking consent (if different 
from researcher) 
 Date 
Researcher  Date 
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APPENDIX 3.8  NHS ETHICS APPROVAL 
Leicestershire, Northamptonshire & Rutland Research Ethics Committee 2 





Telephone: 0115 8839428  
Facsimile: 0115 9123300 
16 March 2009 
 
 
Mrs Annie Law 
Practitioner/Lecturer 
University Hospitals of Leicester NHS Trust 
Cancer Services 





Dear Mrs Law, 
 
Full title of study: Identification of risk factors for Palmar-Plantar 
erythema. This research is in 2 phases;1. 
Identification of risk factors for Palmar-Plantar 
erythema.2. Develop and validate a PPE risk 
assessment tool. This application is for phase 1 and 
further ethical approval will be made for phase 2. 
REC reference number: 09/H0402/12 
 
Thank you for your letter of 09 March 2009, responding to the Committee’s 
request for further information on the above research, and enclosing the 
following revised documents: 
  
Document    Version    Date      
Confirmation of access to medical records    04 March 2009    
Student Annual Review    09 October 2008    
Statement regarding identifiable data    09 March 2009    
Response to Request for Further Information   09 March 2009    
Participant Consent Form  2.0  04 March 2009    
Participant Information Sheet  3.0  04 March 2009    
 
The further information and revised documentation has been considered on 
behalf of the Committee by the Chair. 
 
The Committee was satisfied with the responses to: 
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Points clarified at the meeting: 
 The Committee asked whether the participants would understand the 
abbreviation ‘PPE’ and asked if a lay explanation could be included in 
the information sheet. You explained that patients would have been 
informed about PPE as a possible side effect of the chemotherapy agent 
at their meeting with the nurse but she would be happy to explain it in the 
information sheet. 
 The Committee noted that the information sheet refers to emotional 
distress, and asked for further clarification as to the potential risk. You 
explained that there is very little potential risk from the study but patients 
are often distressed, especially when they first attend for treatment and it 
is this distress not specifically because of PPE that they may need 
further support with. 
 The Committee asked why the application states that the participant’s 
GP will be informed but there is no mention of informing their consultant. 
You explained that the consultants and clinical director have given 
permission for patients to be contact and so are already aware of the 
study. 
 The Committee asked for further details as to what information will be 
collected from the medical notes and how eligible patients will be 
identified. You explained that you will use the note review form 
submitted. A pharmacist will provide a list of patients who have had the 
chemotherapy agents in the last year. You will review 100 -200 patients’ 
notes looking for threads. This will be done concurrently with the 
interviews and the patients interviewed will not be the same people as 
those whose notes are reviewed. There will be a master list of patient’s 
whose notes have been accessed to prevent duplication. 
 
Requests for changes / further clarification: 
1. The Committee require confirmation that you have gained Trust 
permission to access patient medical notes for the research without 
taking consent to do so.  
2. The master list with identifiable patient data must be securely stored 
separately to the study data. Confirmation that this will be done in 
accordance with Trust policy is required. 
3. The Committee require a copy of the written feedback from the annual 
review carried out in October 2008. 
4. The Committee request the following changes / amendments to the 
patient information sheet: 
a. A lay explanation of the abbreviation PPE must be included. 
b. Under ‘What is involved in the study?’ the use of photographs must 
be explained. 
c. As discussed under ‘What is involved in the study?’ the sentence ‘If 
you are unable or unwilling to keep a record, you will be telephone 
once a week between treatments…’ should be reworded. The 
Committee advise that anyone unwilling to carry out the study 
requirements should be excluded. It would be more appropriate to 
offer the option of telephone calls if the patient prefers it to keeping a 
diary. 
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5. The Committee request the following changes / amendments to the 
consent form: 
a. The standard statement allowing audit of the research should be included 
(amended as appropriate, for example remove ‘and company name’ if 
access is not required outside of the NHS) 
I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from [company name], 
from regulatory authorities or from the NHS Trust, where it is relevant to my 
taking part in this research. I give permission for these individuals to have 
access to my records. 
b. Statement one should be updated to refer to the revised version number 
and date of the information sheet. 
 
However, the Committee would be grateful for a more complete response on 
the following points: 
 
 At the meeting the Committee asked how the statistics had been 
decided. You explained that you have held discussions with a statistician 
who had advised on the type of tests she will need to do and the number 
of participants that would be required. The Committee asked if any 
written feedback had been given. You explained that you had written 
feedback from the annual review which was carried out in October 2008.  
The Chair noted the annual review form submitted, but did not think that 
it answered the statistical elements queried by the Committee. The 
statistics are mentioned briefly but there did not seem to be any evidence 
of discussion with the University. Please submit further evidence of 
statistical review, for example a letter from the Statistician who has 
advised you. 
 
 The consent form should have a box next to each statement for the 
participant to initial.  
Please note, that this was not included in the Committee’s previous letter 
and is therefore not a mandatory requirement for approval. However, is 
being suggested as it is considered best practice. 
 
Any further revised document submitted should be given a revised version 
number and date 
The 60 day clock for issue of a final ethical opinion on this application will re-
start when the Committee has received a response on the outstanding points. 
 









Copy to: Prof Paul Whiting, De Montfort University 
R&D Department for NHS care organisation at lead site - UHL 
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APPENDIX 3.10  AMENDMENT TO PROTOCOL 
Mrs Annie Law 
Practitioner/Lecturer 
Directorate of Cancer Services & Clinical Haematology 
Leicester Royal Infirmary 
University Hospitals of Leicester NHS Trust 
Leicester, LE1 5WW 
Tel: 0116 2586178 
Email: annie.law@uhl-tr.nhs.uk 
 
Date: 17th February 2010  
 
Re: Amendments to protocol following initial data collection 
 
Committee name: Leicestershire, Northamptonshire & Rutland No 2 
Ref no:  09/H0402/12 
 
During the data collection phase and following further discussions with 
colleagues, a few minor amendments to the protocol are required. The overall 
aims and objectives of the research have not changed. 
 
1. Retrospective notes review 
Following a review of the numbers of patients in one calendar year who 
received each type of chemotherapy detailed in the sample group, 
namely, Capecitabine, 5FU, Docetaxel or Caelyx and discussion with 
colleagues on the incidence of PPE in each group, a decision was 
made to restrict the notes review to patients who had received 
Capecitabine or infusional 5FU only. The number of notes reviewed 
has to be increased to 400 to capture a full calendar years data. 
 
2. Prospective data collection 
The sample group for the prospective data will be reduced to include 
patients receiving Capecitabine monotherapy only. 
The rationale for this change is that from the retrospective data 50% of 
patients who received this regime developed symptoms of PPE, with 
approximately 25% at grade 3. In patients receiving Capecitabine in 
combination with radiotherapy or other cytotoxic agents, and those 
receiving infusional 5FU the incidence of PPE was less than 10% and 
mostly only mild in nature. 
Since the principal investigator is the sole data collector, redefining the 
focus of the sample group would ensure the amount of data being 
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collected at one time remains manageable within the time frame 
allocated to the study.  
 
This communication is to keep the ethics committee informed of 
developments in this study which is progressing as planned with these 
amendments. It is also to seek agreement of these amendments by the chair 
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APPENDIX 4.1  CAPECITABINE DOSE MODIFICATION  
  MANUFACTURERS RECOMMENDATIONS  
 
Toxicity NCI grades Dose changes within a 
treatment cycle 
Dose adjustment 
for next cycle/dose 
(% of starting dose) 
• Grade 1 Maintain dose level Maintain dose level 
• Grade 2 
-1st appearance Interrupt until resolved to 
grade 0-1 
100% 
-2nd appearance 75% 
-3rd appearance 50% 
-4th appearance Discontinue treatment 
permanently 
Not applicable 
• Grade 3 
-1st appearance Interrupt until resolved to 
grade 0-1 
75% 
-2nd appearance 50% 
-3rd appearance Discontinue treatment 
permanently 
Not applicable 
• Grade 4 
-1st appearance Discontinue permanently 
or 
If physician deems it to be in 
the patient's best interest to 
continue, interrupt until 
resolved to grade 0-1 
50% 
-2nd appearance Discontinue permanently Not applicable 
NB For hand-foot syndrome grade 4 does not apply. 
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APPENDIX 4.2  VARIABLES ENTER INTO LOGISTIC 
REGRESSION MODELS AND REMOVED. DETAILS OF MISSING 
CASES 
Purposeful entry and model reduction retrospective data PPE pre cycle 
4 all data 
Variables entered Variables remaining Missing cases 
Metastatic spread CrCl 3gps PPE after cycle 4 = 27 
Regime 3gps Bilirubin Bilirubin = 5 
CrCl 3gps Previous radiotherapy ALP = 5 
Bilirubin Age CrCl = 3 
Previous radiotherapy Weight loss  
Age  Total = 40 
ALP    
Performance status   
Weight loss   
Season start   
Notes; gps = groups; CrCl = creatinine clearance; ALP = alkaline phosphatase 
 
Purposeful entry and model reduction retrospective data PPE pre cycle 
4 Capecitabine monotherapy 
Variables entered Variables remaining Missing cases 
Gender Gender PPE after cycle 4 = 13 
Inflammatory conditions Inflammatory conditions Bilirubin = 3 
Tumour 2gps Season start ALP = 3 
Season start ALP CrCl = 1 
CrCl 3gps Metastatic spread  
ALP  Total = 20 
Metastatic spread   
Bilirubin   
Albumin   
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Purposeful entry and model reduction prospective data PPE pre cycle 4 
Variables entered Variables remaining Missing cases 
Alcohol Alcohol PPE after cycle 4 = 13  
Diabetes Inflammatory conditions  
Inflammatory conditions Metastatic spread Total = 13 
Metastatic spread Cool hands  






Season start BMI  
Age CrCl  
BMI   
ALB   
CrCl   
Notes; gps = groups; BMI = Body mass index; ALB = albumin; CrCl = creatinine clearance;   
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APPENDIX 5.1 SUMMARY OF CAPECITABINE MONOTHERAPY TRIALS 
NB when the trial is a comparison of Capecitabine monotherapy and another agent only the sample who received Capeci tabine are 
reported here. 
 




N TS Age M 
Range 

























et al (2002) 
Observational 
study of data 








7 days rest 
41 CRC 63 
25-79 
M = 30 




























7 days rest 
10 MBC 47 
NR 





























7 days rest 
1000mg/m
2








F = 240 NCI 146  
(16) 












Blum et al 
(1999) 
Multicentre 
single arm phase 
II trial 25 centres 






7 days rest 



























Phase II trial 11 
centres North 







7 days rest 
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N TS Age M 
Range 





































7 days rest 










M = 29 
F = 52 
 
NCI 71  
(87.7) 













Cassidy et al 
(2002) 
Evaluation study 
of safety from 2 







7 days rest 


















Chua et al 
(2003) 








7 days rest 
17 MNPC 46 
29-71 
M = 12 



















Phase II single 







7 days rest 
57 MBC 48 
Mean 
20-73 
F = 57 NCI 17 
32 










Feliu et al 
(2005) 
Study to assess 








7 days rest 
51 CRC 76 
Mean 
71-89 
M = 31 




























7 days rest 
126 MBC 54 
30-80 























500mg bd for 28 
days 7 days rest 
45 AGC 74.5 
71-81 
M = 33 



















et al (2005) 
Retrospective 














113 MBC 52.5 
26-77 
M = 1 









46 28 42 
40.0 








302 CRC 64 
23-86 
M = 181 
F = 121 
NCI
C 




NR NR NR NR NR 
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phase III study 
61 centres. 48 
USA, 9 Canada, 
2 Brazil, 2 
Mexico 
14 days 
7 days rest 




N TS Age M 
Range 
























Hoff et al 
(2004) 









7 days rest 
23 CRC 63 
44-75 
M = 18 
















Hong et al 
(2004) 
Phase II single 








7 days rest 
44 MGC 62 
25-72 
M = 35 



















phase II trial 







7 days rest 
60 CRC 60 
34-71 
M = 33 
F = 27 
NCI 44 
73.0 












Jakob et al 
(2002) 
Open-label 








7 days rest 
14 MBC 45.5 
35-60 











Jenkins et al 
(2005) 
Single centre 







7 days rest 




























M = 1 
F = 160 
NCI 60 
37.3 





















7 days rest 
20 CRC 59 
31-83 
M = 14 
F = 6 






NR NR NR 
Koizumi et al 
(2003) 










7 days rest 
31 AGC NR M = 22 









NR NR NR NR 
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N TS Age M 
Range 




































7 days rest 
50 MBC 52.5 
35-75 






























7 days rest 
51 CRC 57 
32-73 
M = 31 


























7 days rest 
46 AGC 71 
66-78 
M = 30 
F = 16 
NCI 26 
59.1 



















7 days rest 
102 MBC 53 
30-95 
M = 3 
F = 99 
NCI 37 
36.0 





















7 days rest 
37 MBC 52 
47-84 
F = 37 NCI 7 
19.0 




















NR NR NR 0 0 0 0 0 0 0 NR NR 
Martinez-
Trufero et al 
(2010) 







7 days rest 
40 HNC 58.4 
Mean 
40-75 














Miller et al 
(2005) 
Randomized 







7 days rest 
230 MBC 52 
Mean 
30-77 




57 11 NR NR NR 















7 days rest 
25 MPC 70 
54-85 
M = 25 NCI
C 
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N TS Age M 
Range 
























Muller et al 
(2010) 
Phase I pilot 













































































































7 days rest 










G 3 & 4 
3 
1.0 





G 3 & 4 
15 
5.0 









days 1-5 of 
weeks 5-8 
30 MRC 60 
38-73 
M = 24 




























7 days rest 
102 MBC 56.1 
Mean 
29-85 































7 days rest 
62 MBC 69 
54-83 































7 days rest 
27 Meso 70 
40-81 
M = 19 
F = 7 















Pagliaro et al 
(2006) 








7 days rest 
15 MRC 59 
38-75 
M = 13 





G 1 & 2 























7 days rest 





M = 24 
F = 14 
WH
O 
NR NR NR 17 
44.7 
NR NR NR NR 13 
34.2 
Appendices 
Page 357  




N TS Age M 
Range 







































M = 37 
F = 26 
NR 23 
37.0 






















7 days rest 
197 MBC 56 
31-88 
M = 2 
F = 195 
NCI 96 
54.0 




















7 days rest 
136 MBC 56 
32-77 



























7 days rest 
35 OC 58 
26-76 


























7 days rest 
603 NR NR NR NR NR NR NR 102 
17.0 
NR NR NR NR NR 





Phase 1 study 








¼ of the dose 
0800hrs, ¼ of 
the dose 
1800hrs and ½ 
dose 2300hrs 
for 14 days 








M = 9 





















et al (2003) 
Open-label 
randomized 








7 days rest 
993 CRC 62 
25-80 
M = 536 



































7 days rest 
115 CRC 73 
49-84 
M = 68 
F = 47 
NR NR NR 24 
21.0 
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N TS Age M 
Range 
























Sharma et al 
(2006) 










7 days rest 
55 CRC 72 
42-86 
M = 35 
F = 20 
NCI NR NR 12 
22.0 





G2 & 3 
8 
15.0 
G2 & 3 
6 
11.0 
G2 & 3 
15 
27.0 
G2 & 3 
16 
29.0 














7 days rest 
84 CRC 62 
29-78 
M = 51 

















Spicer et al 
(2005) 








7 days rest 
14 MPC 68 
Mean 
41-82 
M = 14 WH
O 
NR NR 7 
50.0 






























M = 14  

































7 days rest 
22 MBC 52 
33-67 











































7 days rest 
995 CRC 62 
25-80 
M = 537 
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N TS Age M 
Range 











































for 14 days, 7 
days rest 




14 days, 7 days 
rest + 
leucovorin 60mg 
A  39 
B 34 
C 35 







M = 26 
F = 13 
B 
M = 24 
F = 10 
C 
M = 22 














































7 days rest 
297 CRC 64 
29-84 
M = 169 
















et al (2004) 
Integrated data 









7 days rest 
603 CRC 64 
23-86 
M = 362 












Vasey et al 
(2003) 
Phase II open-







7 days rest 
29 OC 57 
38-78 
F = 29 NCI 18 
62.0 






















7 days rest 
631 MBC 54 
47-91 
































7 days rest 
26 RCC 58 
47-76 
M = 19 






























7 days rest 
48 MBC 55 
35-74 
F = 48 NCI
C 





NR NR NR  
29.0 
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N TS Age M 
Range 




















































Yun et al 
(2010) 
Evaluation study 










7 days rest 











M = 92 
F = 46 
B 
M = 22 
F = 13 
C 
M = 105 





















TS = tumour site, AGC – Advanced Gastric Cancer, CBT – Cancer of the biliary tree CRC – Colorectal Cancer, EBC – Early Breast Cancer, FTC – Fallopian tube 
Cancer, GUT – Genitourinary tumours, HCC – Hepatocellular Cancer, HNC – Head & Neck cancer, MBC – Metastatic Breast Cancer, Meso – Mesothelioma, MGC – 
Metastatic gastric cancer,  MNPC – Metastatic Nasopharyngeal Cancer, MPC – Metastatic Prostate Cancer, MRC – Metastatic Renal Cancer, OC – Ovarian Cancer, 
PC – Pancreatic cancer, PerC – Peritoneal Cancer, RCC – Renal Cell Carcinoma 
Age M = age median 
G = gender 
TSC = Toxicity scoring system, NCI – National Cancer Institute common toxicity criteria for adverse events, NCIC – National Cancer Institute of Canada common 
toxicity criteria for adverse events 
D = Diarrhoea 
S = Stomatitis 
NV = Nausea and/or vomiting 
F = Fatigue 
DR = Dose reduction due to adverse events 
NR = not reported 
 
